The occurrence of feline neoplasia; a comparison between Danish and NorthAmerican cats by Børresen, Betina et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
The occurrence of feline neoplasia; a comparison between Danish and NorthAmerican
cats
Børresen, Betina; Heden, Martin Anker; Kent, Michael S.; Kristensen, Annemarie Thuri
Published in:
Journal of Veterinary Internal Medicine
DOI:
10.1111/jvim.14858
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC
Citation for published version (APA):
Børresen, B., Heden, M. A., Kent, M. S., & Kristensen, A. T. (2018). The occurrence of feline neoplasia; a
comparison between Danish and NorthAmerican cats. Journal of Veterinary Internal Medicine, 32(1), 568.
https://doi.org/10.1111/jvim.14858
Download date: 03. Feb. 2020
ResearchCommunications
of the
27th ECVIM-CACongress
Intercontinental, Saint Julian’s, Malta, 14th to 16th September 2017
ORAL RESEARCH COMMUNICATIONS
ESVIM – European Society of Veterinary Internal Medicine
Thursday 14 September
09.00–09.15 ESVIM-O-1 Cuq Calibrated automated thrombography to evaluate thrombin generation in dogs with
immune-mediated hemolytic anaemia
09.15–09.30 ESVIM-O-2 Dandrieux Eﬀect of immune-suppressive treatment on cytokine production in healthy dogs
09.30–09.45 ESVIM-O-3 Hansson-Hamlin Identiﬁcation of antinuclear antibodies in dogs using immunodiﬀusion
Friday 15 September
14.40–14.55 ESVIM-O-4 Brown Short- and long-term morbidity and mortality in dogs and cats following
cardiopulmonary arrest
14.55–15.10 ESVIM-O-6 Darcy Feline primary erythrocytosis: a multicentre retrospective case series (18 cases)
15.10–15.25 ESVIM-O-7 Roels Investigation of a fungal aetiology in canine idiopathic pulmonary ﬁbrosis
15.25–15.40 ESVIM-O-8 Keegan Clinical features of 70 cases of canine idiopathic eosinophilic lung disease
15.40–15.55 ESVIM-O-9 Keegan Therapy and long-term follow-up of 70 cases of canine idiopathic eosinophilic lung
disease
16.30–16.45 ESVIM-O-10 Vientos-Plotts Development of respiratory dysbiosis as cats transition from healthy to asthmatic
airways
16.45–17.00 ESVIM-O-11 Grobman Documenting silent reﬂux and microaspiration events using nuclear scintigraphy in
healthy dogs
17.00–17.15 ESVIM-O-12 Canonne Diagnosis of pulmonary angiostrongylosis in dogs with negative non-invasive tests
(Baermann analysis and AngioDetectTM©)
17.15–17.30 ESVIM-O-13 Grobman Discrimination between cough and non-cough behaviours using acoustic wave
recordings
17.30–17.45 ESVIM-O-14 Robin Tracheal stent in dogs: outcome prediction and owner satisfaction assessment
17.45–18.00 ESVIM-O-15 Stengel Meticulous debridement as sole management for successful outcome in 6 dogs with
sinonasal aspergillosis (SNA)
ESVC – European Society of Veterinary Cardiology
Thursday 14 September
14.25–14.40 ESVC-O-1 Vitt Utility of VHS to predict echocardiographic EPIC Trial inclusion criteria in dogs
with myxomatous mitral valve disease: A retrospective multicentre study
14.40–14.55 ESVC-O-2 Rocchi Evaluation of continuous positive airway pressure in dogs with cardiogenic
pulmonary oedema secondary to severe mitral valve disease
14.55–15.10 ESVC-O-3 Rishniw Development of a simple algorithm for diagnosis of left-sided congestive heart failure
in dogs with mitral valve disease
15.10–15.25 ESVC-O-4 Lee Eﬀects of treatment with thromboxane A2 synthase inhibitor on pulmonary
hypertension: a pilot study
J Vet Intern Med 2018;32:525–609
15.25–15.40 ESVC-O-5 Vezzosi Echocardiographic evaluation of right ventricular dimension and systolic function in
dogs with pulmonary hypertension
15.40–15.55 ESVC-O-6 Merveille Caudal vena cava assessment in dogs with right-sided congestive heart failure: a pilot
study
15.55–16.10 ESVC-O-7 Blake Heart rate variability in dogs with intracranial disease
16.10–16.25 ESVC-O-8 Kiss Genetic background of focal junctional tachycardia with isorhythmic atrioventricular
dissociation in Labrador retrievers
16.25–16.40 ESVC-O-9 Oxford Immunoﬂuorescent localization of plakoglobin in endomyocardial biopsy samples to
diagnose arrhythmogenic right ventricular cardiomyopathy (ARVC) in the dog
Friday 15 September
08.00–08.15 ESVC-O-10 LeBlanc Right ventricular volume quantiﬁcation measured by real-time 3D echocardiography
and ECG-gated 64 slice MDCT in healthy dogs
08.15–08.30 ESVC-O-11 Damoiseaux Feasibility of intracardiac echocardiography in dogs: a pilot study
08.30–08.45 ESVC-O-12 Corda Use of two-dimensional speckle tracking echocardiography to assess left ventricular
systolic function in dogs with systemic inﬂammatory response syndrome
08.45–09.00 ESVC-O-13 Bree Major histocompatibility complex class II haplotypes associated with remodelling in
Cavalier King Charles spaniels with chronic valvular heart disease
11.20–11.35 ESVC-O-14 Traub MiRNAs in progressing canine myxomatous mitral valve disease
11.35–11.50 ESVC-O-15 Tims White coat eﬀect in client-owned dogs, as assessed by high deﬁnition oscillometry
(HDO)
11.50-12.05 ESVC-O-16 Mckeever Prevalence and murmur characteristics of incidentally detected heart murmurs and
heart disease in 12,958 young healthy shelter cats
12.05–12.20 ESVC-O-17 Szatmari When should we talk about tachypnoea in cats at the veterinarian’s consultation
room?
12.20–12.35 ESVC-O-18 Szatmari How often do primary care practitioners recognise innocent cardiac murmurs in
puppies during the ﬁrst veterinary health check?
12.35–12.50 ESVC-O-19 Connolly Towards cardiac stem cell therapy: characterisation and cryopreservation of canine
cardiosphere-derived cells
16.45–17.00 ESVC-O-20 Dutton Assessing the feasibility of allogeneic stem cell therapy for canine dilated
cardiomyopathy
17.00–17.15 ESVC-O-21 Ohad The association of clinical, laboratory and echocardiographic ﬁndings with survival in
108 dogs undergoing pericardiocentesis; a retrospective study
17.15–17.30 ESVC-O-22 Neves Usefulness of colour TDI at the level of lateral atrial tissue as a predictor of future
development of atrial ﬁbrillation in dogs
17.30–17.45 ESVC-O-23 Beijerink ECG-gated computed tomography angiography of patent ductus arteriosus in 25
dogs
17.45–18.00 ESVC-O-24 Szatmari Is prophylactic antibiotic therapy necessary to prevent infectious endocarditis in dogs
that undergo transcatheter embolisation of a patent ductus arteriosus?
Saturday 16 September
16.30–16.45 ESVC-O-25 Gomart Biological variability of N-terminal pro-B-type natriuretic peptide in ﬁfty-three
healthy Labrador retrievers over an 8 month period
16.45–17.00 ESVC-O-26 Glen Clinical use of a patient-side feline NT-proBNP ELISA test in 281 cats in general
practice
17.00–17.15 ESVC-O-27 Romito Diagnostic and prognostic utility of surface ECG in cats with left ventricular
hypertrophy
17.15–17.30 ESVC-O-28 Winter Notched QRS complexes in dogs with and without structural cardiac disease: 85
cases
526 ECVIM Abstracts
ESVNU – European Society of Veterinary Nephrology and Urology
Thursday 14 September
14.25–14.40 ESVNU-O-1 Sargent Fibroblast growth factor 23 and symmetric dimethylarginine in feline chronic kidney
disease
14.40–14.55 ESVNU-O-2 van den Broek Immunohistochemical staining of a-klotho protein in feline kidney tissue
14.55–15.10 ESVNU-O-3 Pelander Symmetric dimethylarginine (SDMA) compared to creatinine for detection of
decreased GFR in 97 dogs with stable kidney function
15.10–15.25 ESVNU-O-4 Buresova SDMA in hyperthyroid cats before and after treatment with radioiodine
15.25–15.40 ESVNU-O-5 Chen Interleukin 6 and Interleukin 18 as markers of kidney injury in dogs
15.40–15.55 ESVNU-O-6 Segev Application of novel kidney-speciﬁc biomarkers for canine kidney diseases
15.55–16.10 ESVNU-O-7 Lamoureux Prevalence of urinary tract infection in dogs with chronic kidney disease: a
retrospective study of 201 cases
16.10–16.25 ESVNU-O-8 Johnstone Whole genome sequencing of Escherichia coli isolated from the urinary tract of
individual dogs over time
16.25–16.40 ESVNU-O-9 Pomba Virulence and antimicrobial resistance of Escherichia coli Sequence Type 131 H30
and other human pandemic clones spreading in companion animals
Saturday 16 September
14.25–14.40 ESVNU-O-10 Russak Urinary biomarker concentrations in canine urinary tract infections
14.40–14.55 ESVNU-O-11 Garcia Evolution of ionised calcium concentration over time in cats with ureteral
obstruction: 39 cases
14.55–15.10 ESVNU-O-12 Crisi Urinary ﬁndings suggesting early renal involvement in cats with Feline Morbillivirus
infection
15.10–15.25 ESVNU-O-13 Reynolds Eﬀects of a non-absorbent litter on urinalysis results in cats
15.25–15.40 ESVNU-O-14 Garcia Determining the pH in canine urine: comparing visual and automated reading
variability of urine dipstick analysis within a small animal teaching hospital
15.40–15.55 ESVNU-O-15 van den Berg Assessment of kidney injury in canine parvoviral infection by comparing novel
urinary kidney injury biomarkers with routine renal functional parameters
ESVONC – European Society of Veterinary Oncology
Friday 15 September
09.30–09.45 ESVONC-O-1 Zandvliet Are protein kinase inhibitors of use in the treatment of canine lymphoma? A screening
in vitro study with multiple protein kinase inhibitors in canine lymphoid cell lines
09.45–10.00 ESVONC-O-2 Giuliano Masitinib treatment for advanced stage III and IV canine melanoma
10.00–10.15 ESVONC-O-3 Elliott Toceranib phosphate in ﬁfteen dogs with stage 4 anal sac apocrine gland
adenocarcinoma
10.15–10.30 ESVONC-O-4 Lyons Eﬀect of toceranib phosphate (Palladia) on outcome in dogs with anal sac
carcinoma
11.20–11.35 ESVONC-O-5 Børresen The occurrence of feline neoplasia; a comparison between Danish and North
American cats
11.35–11.50 ESVONC-O-6 Aghazadeh Expression of Felis catus gammaherpesvirus-1 ORF73, F7 and ORF50 in FIV-
associated lymphoma biopsies
11.50–12.05 ESVONC-O-7 Boye High pretreatment D-dimer concentraion is associated with poor prognosis in 48
dogs with high-grade lymphoma
12.05–12.20 ESVONC-O-8 Treggiari Eﬃcacy of chemotherapy and clinical outcome in primary, metastatic feline
pulmonary carcinomas: an observational study
12.20–12.35 ESVONC-O-9 Aupperle-
Lellbach
Ovarian tumours in the bitch – Pathological ﬁndings and AMH values
12.35–12.50 ESVONC-O-10 Bechtel Initial evaluation of gum arabic coated radioactive gold nanoparticles in canine
prostatic cancer
ECVIM Abstracts 527
SCH – Society of Comparative Hepatology
Friday 15 September
08.00–08.15 SCH-O-1 Bayton Prednisolone therapy for chronic hepatitis in the English Springer Spaniel: A
prospective study of 14 cases
08.15–08.30 SCH-O-2 Ullal Ciclosporin in the treatment of canine chronic hepatitis
08.30–08.45 SCH-O-3 Kortum Investigation into hepatocyte expression and prognostic signiﬁcance of senescence
marker p21 in canine chronic hepatitis
08.45–09.00 SCH-O-4 Sato Chronic portal vein thrombosis in eleven dogs
09.00–09.15 SCH-O-5 Allerton Breed predisposition to gall bladder mucocoeles in Border Terriers
09.15–09.30 SCH-O-6 Valiente Outcome of cats undergoing surgical attenuation of congenital extrahepatic
portosystemic shunts through cellophane banding: 23 cases
09.30–09.45 SCH-O-7 Neiger Transcutaneous ﬂuorometric measurement of indocyanine green clearance as dynamic
liver function test in dogs with congenital portosystemic shunt
ESCG – European Society of Comparative Gastroenterology
Friday 15 September
09.45–10.00 ESCG-O-1 Heilmann Serum S100/calgranulin concentrations in Miniature Schnauzers with idiopathic
hyperlipidemia
10.00–10.15 ESCG-O-2 Williams Serum tocopherol and retinol concentrations in dogs with exocrine pancreatic
insuﬃciency
10.15–10.30 ESCG-O-3 Schleifenbaum Eﬀect of mirtazapine on canine gastric emptying assessed by 13C-sodium acetate
breath test (13C-SABT)
11.20–11.35 ESCG-O-4 Botha Prevalence of Clostridium diﬃcile and Salmonella spp. in Juvenile Dogs Aﬀected
with Parvoviral Enteritis
11.35–11.50 ESCG-O-5 Albuquerque Risk factors for C. diﬃcile carriage in dogs and associations with clinical disease
11.50–12.05 ESCG-O-6 Manchester Long-term impact of tylosin on the faecal microbiota of healthy dogs
12.05–12.20 ESCG-O-7 Cartwright Vitamin D receptor expression in the dog and the eﬀect of intestinal inﬂammation
12.20–12.35 ESCG-O-8 Konstantinidis Serum circulating microRNAs as a marker for canine lymphocytic- plasmacytic
inﬂammatory bowel disease
12.35–12.50 ESCG-O-9 Allenspach Speciﬁc virulence factors in mucosa-associated E. coli of dogs with inﬂammatory
bowel disease (IBD) are associated with survival
Saturday 16 September
16.30–16.45 ESCG-O-10 Coddou Identiﬁcation of IgG4-related disease in the English Cocker Spaniel and dogs of other
breeds
16.45–17.00 ESCG-O-11 Allenspach Correlating gastrointestinal histopathologic ﬁndings to clinical disease activity in dogs
with inﬂammatory bowel disease
17.00–17.15 ESCG-O-12 Freiche Acquired oesophageal strictures: balloon dilatation or stenting? Outcome and
complications in 24 dogs and cats (2002–2017)
17.15–17.30 ESCG-O-13 Dominguez Ruiz Prevalence of gastric lymphoid follicular hyperplasia in French Bulldogs
17.30–17.45 ESCG-O-14 Woolhead A retrospective evaluation of ileocecocolic perforations associated with routine
diagnostic lower gastrointestinal endoscopy in dogs and cats
17.45–18.00 ESCG-O-15 Da Riz Acquired pyloric stenosis in cats: a prospective study of 15 cats (2015–2017)
ESVE – European Society of Veterinary Endocrinology
Saturday 16 September
08.15–08.30 ESVE-O-1 Sieber-Ruckstuhl Agreement of two prepill cortisol measurements in dogs with hypercortisolism treated
with trilostane
528 ECVIM Abstracts
08.30–08.45 ESVE-O-2 van Staalduinen Sterol-O-acyl transferase 1 (SOAT1) expression in canine cortisol-secreting
adrenocortical tumours: providing the basis for a future treatment option
08.45–09.00 ESVE-O-3 de Wit CYP17 inhibitor abiraterone acetate as a promising future treatment for canine
hyperadenocorticism: in vitro investigations
14.25–14.40 ESVE-O-4 Sanders Molecular prognostic markers in canine cortisol-secreting adrenocortical tumours
14.40–14.55 ESVE-O-5 Hanson The use of chromogranin A epitopes vasostatin and catestatin as biomarkers for
catecholamine-producing tumours in dogs
14.55–15.10 ESVE-O-6 Scudder Pilot study assessing the use of cabergoline in the management of diabetic
acromegalic cats
15.10–15.25 ESVE-O-7 Woolhead Serial changes in insulin-like growth factor 1 and impact on hypersomatotropism-
screening in feline diabetes mellitus
15.25–15.40 ESVE-O-8 Zini Ultrastructural characterisation of pancreatic beta-cells in cats with diabetes mellitus
15.40–15.55 ESVE-O-9 Niessen The diabetic clinical score (DCS): evaluation of a simple standardised quantiﬁcation
tool to allow rapid description of clinical signs in diabetic dogs
16.30–16.45 ESVE-O-10 Finch Thyroid and renal function in cats post low-dose radioiodine therapy
16.45–17.00 ESVE-O-11 Casado Diaz Evaluation of symmetric dimethylarginine (SDMA) in dogs with primary
hypoadrenocorticism under long-term mineralocorticoid replacement therapy
17.00–17.15 ESVE-O-12 Spence A comparison of the ACTH concentrations in dogs with stable hypoadrenocorticism
being treated with either ﬂudrocortisone or desoxycortone pivalate and prednisolone
17.15–17.30 ESVE-O-13 Hagblom Prevalence of hyperaldosteronism and hypertension in cats with chronic azotaemia
17.30–17.45 ESVE-O-14 Pijnacker The use of a TRH stimulation test, with measurement of plasma concentrations of
growth hormone and thyroid stimulating hormone, to diﬀerentiate between primary
hypothyroidism and non-thyroidal illness in dogs
17.45–18.00 ESVE-O-15 Scarpa Interrelation between thyroid function and sex hormones in female German Shepherd
Dogs
ESVCN – European Society of Veterinary Comparative Nutrition
Saturday 16 September
08.15–08.30 ESVCN-O-1 S€oder Plasma metabolomics reveals lowered carnitine concentrations in overweight
Labrador retriever dogs
08.30–08.45 ESVCN-O-2 Kiefer-Hecker Silica urolithiasis in a dog - a case report
08.45–09.00 ESVCN-O-3 Dobenecker Knowing the total amount of phosphorus in a diet is not enough – diﬀerent sources
have diﬀerent eﬀects
ESVCP – European Society of Veterinary Clinical Pathology
Saturday 16 September
09.15–09.30 ESVCP-O-1 Aroch Pre- and post-operative D-dimer concentration in dogs changes in D-dimer
concentration in dogs following soft tissue and orthopaedic surgery
09.30–09.45 ESVCP-O-2 Whitehead Evaluation of haemostatic changes in dogs with parvoviral enteritis before and after
ﬂuid resuscitation using thromboelastography
09.45–10.00 ESVCP-O-3 K€onig Analytical and clinical validation of a human enzyme-linked immunosorbent assay
(ELISA) for measurement of canine angiopoietin-2
10.00–10.15 ESVCP-O-4 K€onig Plasma angiopoietin-2 (Ang-2) is elevated in dogs with sepsis and/or systemic
inﬂammatory disease syndrome (SIRS) and is associated with severity of disease and
outcome
10.15–10.30 ESVCP-O-5 Neumann Investigation of Interleukin-6 (IL-6) as prognostic marker
11.20–11.35 ESVCP-O-6 Leynaud Comparison of serum amyloid A and ﬁbrinogen to other inﬂammatory biomarkers in
cats
11.35–11.50 ESVCP-O-7 Bremer Identiﬁcation of ILF2 autoantibodies as a promising biomarker for autoimmune
disease in dogs
ECVIM Abstracts 529
11.50–12.05 ESVCP-O-8 Aroch Serum histones as biomarkers of the severity of heatstroke in dogs
12.05–12.20 ESVCP-O-9 Zoia Pleural eﬀusion lactate dehydrogenase (LDHp) concentration and serum total protein
(TPs) concentration versus traditional veterinary classiﬁcation method in the
discrimination between transudates and exudates: a cross-sectional study in 100 dogs
with pleural eﬀusion
12.20–12.35 ESVCP-O-10 Burchell The site of bone marrow acquisition aﬀects the myeloid to erythroid ratio in
apparently healthy dogs
12.35–12.50 ESVCP-O-11 Cuq Acute myeloid leukemia in retrovirus-negative cats: a case series of 16 patients
ISCAID - International Society for Companion Animal Infectious Diseases
Saturday 16 September
11.20–11.35 ISCAID-O-1 Barrs Re-emergence of feline panleukopenia in Australia
11.35–11.50 ISCAID-O-2 Byrne Investigation of faecal parvovirus shedding in asymptomatic shelter housed cats in
Australia
11.50–12.05 ISCAID-O-3 Ferri Class A CpG oligonucleotides in cats with naturally occurring feline panleukopenia
infection: a prospective case-control study
12.05–12.20 ISCAID-O-4 Barrs Feral carnivores are reservoirs of Carnivore protoparvovirus 1 in Australia
12.20–12.35 ISCAID-O-5 de Luca Feline morbillivirus infection in domestic cats in Italy: epidemiological and
pathological aspects
12.35–12.50 ISCAID-O-6 Felten Evaluation of a discriminative realtime RT-PCR in cerebrospinal ﬂuid for the
diagnosis of feline infectious peritonitis
14.25–14.40 ISCAID-O-7 Duplan Screening for selected pathogens in ticks infecting cats in the United Kingdom: a
large-scale surveillance programme
14.40–14.55 ISCAID-O-8 Dvir The role of hypovitaminosis d in complicated canine babesiosis
14.55–15.10 ISCAID-O-9 Barash Is urine culture the poor man’s blood culture? Concordance between parallel canine
blood and urine cultures
15.10–15.25 ISCAID-O-10 Pomba Companion animals and humans with UTI share common uropathogenic Klebsiella
pneumoniae
15.25–15.40 ISCAID-O-11 Leutenegger Validation of a qPCR panel to aid in the diagnosis of dermatophytosis
VBPS - Veterinary Blood Pressure Society
16.30–16.45 VBPS-O-1 Glaus Eﬃcacy of telmisartan in hypertensive cats: results of a large European clinical trial
POSTER RESEARCH COMMUNICATIONS
ESVIM – European Society of Veterinary Internal Medicine
ESVIM_P_1 Paul Bronchoalveolar lavage analysis using urea dilution standardisation in diagnosis of respiratory
diseases in dogs
ESVIM_P_2 Huang Prevalence of degenerative joint disease in mature indoor cats
ESVIM_P_3 Rengaswamy
Baranidharan
Oral Carica papaya in the supportive care of infectious thrombocytopenia in bleeding dogs
ESVIM_P_4 Jaﬀey Methaemoglobinemia caused by cytochrome b5 reductase deﬁciency: genetic studies and long-
term treatment with oral methylene blue
ESVIM_P_5 Rohdin Prevalence of gait abnormalities in Pugs: a questionnaire based survey
ESVIM_P_6 Aromaa Comparing the submaximal exercise test results and severity of brachycephalic obstructive airway
syndrome in Pugs and French Bulldogs
ESVIM_P_7 Viitanen Bronchiectasis in Irish Wolfhounds with recurrent bacterial pneumonia
ESVIM_P_8 Roels Investigation of the nasal microbiota in healthy dolichocephalic dogs and dogs with sinonasal
aspergillosis (SNA)
530 ECVIM Abstracts
ESVIM_P_9 Clarke Retrospective study of clinical ﬁndings, treatment and outcome in dogs and cats diagnosed with
dysautonomia
ESVIM_P_10 Marchetti Retrospective study on 33 cases of canine primary IMHA: clinico-pathological features, follow-
up and prognostic factors
ESVIM_P_11 Benvenuti Diagnostic accuracy of the macro-endoscopic bronchial aspect for the diagnosis of eosinophilic
bronchitis
ESVIM_P_12 M€a€att€a Reﬂux aspiration can be detected in lungs of dogs with respiratory disease
ESVIM_P_13 Greci Clinical and laboratory alterations in 37 dogs diagnosed with lungworm infection: a retrospective
study (July 2010- April 2017)
ESVIM_P_15 Miglio Comparison of three diﬀerent guidelines for blood transfusion applied in a population of Italian
feline donors to reduce the risk of transfusion transmissible infections
ESVC – European Society of Veterinary Cardiology
ESVC_P_1 Caro-Vadillo Reliability of vena contracta for staging degenerative chronic mitral valve disease in dogs
ESVC_P_2 Vezzosi Retrospective analysis of pulmonary hypertension in cats with left-sided congestive heart failure
ESVC_P_3 Larsson Frequency of mitral valve prolapse in adult healthy Dachshund dogs
ESVC_P_4 Darnis Prevalence of pulmonary hypertension in dogs naturally infected with Angiostrongylus vasorum
ESVC_P_5 Berlanda Symmetric dimetyl-arginine in dogs with myxomatous mitral valve disease with and without
pulmonary hypertension
ESVC_P_6 Locatelli Left ventricular hypertrophy in dog: an echocardiographic study
ESVC_P_7 Patata Pulmonary vein to pulmonary artery ratio in healthy and cardiomyopathic cats
ESVC_P_8 Savarese Comparative analysis of a portable smartphone-based electrocardiograph (D-Heart) versus
standard 6-leads electrocardiograph in the canine patient
ESVC_P_9 Ward Use of graphic organisers in an elective veterinary cardiology course
ESVC_P_10 Itikawa Frequency of heart murmur in 69 healthy adult Dachshunds
ESVC_P_11 Levent Choline concentration as a new potential biomarker to distinguish pleural eﬀusions from heart
base tumours and cardiomyopathy in dogs
ESVC_P_12 Poissonnier Epidemiological, clinical, and echocardiographic features, and survival times of dogs with Ebstein
anomaly: 40 cases (2002-2017)
ESVC_P_13 Damoiseaux Utility of the SNAP feline n-terminal pro-b-type natriuretic peptide test in detecting
asymptomatic hypertrophic cardiomyopathy: a prospective study in 61 cats
ESVNU – European Society of Veterinary Nephrology and Urology
ESVNU_P_1 Maurey Guenec Eﬃcacy and safety of two new high protein-low carbohydrate dry diets in sterile, feline struvite
urolithiasis
ESVNU_P_2 Soerensen The eﬀect of storage temperature and boric acid preservation on quantitative bacterial culture for
diagnosing canine urinary tract infection
ESVNU_P_3 Falus Microalbuminuria in dogs infected with Diroﬁlaria repens
ESVNU_P_5 Zambarbieri Symmetric dimethylarginine (SDMA) and nephropathy in dog: diagnostic utility in clinical
practice
ESVNU_P_6 Codea Ultrasound-guided renal biopsy signiﬁcantly increases urinary n-acetyl-beta-d-glucosaminase
index activity in dogs with diﬀuse parenchimal nephropaties
ESVONC – European Society of Veterinary Oncology
ESVONC_P_2 Beguin Evaluation of infective and replicative properties of a replication-selective oncolytic Vaccinia
virus (VVTG17990) on canine, feline, porcine and human cell lines
ESVONC_P_3 Ruiz Multiple colorectal granular cell tumours in a dog
ESVONC_P_4 Pazzi Spirocerca lupi induced oesophageal neoplasia: predictors of surgical outcome
ECVIM Abstracts 531
ESVONC_P_5 Clares Moral Survival of dogs diagnosed with inﬂamatory mammary cancer treated with a multimodal therapy
ESVONC_P_6 Magalh~aes Eﬀect of radiation therapy on the treatment of intracranial tumours in dogs: meningioma and
glioma
ESVONC_P_7 Thiemeyer Ultrasound-guided ﬁne-needle aspiration of the canine prostate - a useful sampling method for
molecular biological analysis?
ESVONC_P_8 Elliott Histiocytic sarcoma is over-represented in Miniature Schnauzers in the United Kingdom
SCH – Society of Comparative Hepatology
SCH_P_1 Menard Validation of a blood score for non-invasive diagnosis of liver ﬁbrosis in dogs
SCH_P_2 Tabar Diagnostic value of paired serum bile acids in clinical practice in 484 samples
ESCG – European Society of Comparative Gastroenterology
ESCG_P_1 Hill Factors aﬀecting gastric mucosal barrier function in dogs
ESCG_P_2 Slovak Evaluation of the Hemoccult faecal occult blood test kit in cats
ESCG_P_3 Slovak Fecal occult blood testing in a presumed healthy population of cats
ESCG_P_4 Xenoulis Speciﬁcity of SNAP fPLTM for the diagnosis of pancreatitis in healthy cats and sick cats
without clinical suspicion of pancreatitis
ESCG_P_6 Hugonnard Metabolic and clinical follow-up of seven inappetent cats during enteral refeeding
ESCG_P_7 Hanifeh S100A12 and myeloperoxidase as possible biomarkers for intestinal inﬂammation in dogs
ESCG_P_8 Jolivet Fasting and postprandial variations of plasma TLI, cobalamin and folate concentration in
healthy beagle dogs
ESCG_P_9 Ioannidi Total serum magnesium and cobalamin concentration in 20 cats with inﬂammatory small bowel
disease or small intestinal neoplasia
ESCG_P_10 Fabres Megaesophagus associated with gastro-œsophageal junction neoplasia in dogs: 7 cases (2004-
2016)
ESCG_P_11 Heilmann Feasibility of measuring fecal calprotectin concentrations in dogs and cats by the fCAL turbo
immunoassay
ESCG_P_12 Watson Clinical features of English Cocker Spaniels with chronic pancreatitis mimic human IgG4RD
ESCG_P_13 Caivano Contrast-enhanced ultrasonography of the duodenum in dogs with inﬂammatory bowel disease:
preliminary ﬁndings
ESCG_P_14 Hill Utility of capsule endoscopy as a complement to traditional endoscopy
ESCG_P_15 Benvenuti Serum protein proﬁling of 100 cats with inﬂammatory bowel disease and lymphoma
ESVE – European Society of Veterinary Endocrinology
ESVE_P_1 Burchell Safety and eﬃcacy of dapagliﬂozin, a novel antidiabetic drug, in healthy cats
ESVE_P_2 Langner Evidence for regional variation of patient characteristics in dogs with hyperadrenocorticism
ESVE_P_3 Corsini Symmetric dimethylarginine (SDMA) in hyperthyroid cats
ESVE_P_4 Schmicke Low thyroxine concentrations after controlled feeding of bovine thyroid gland to dogs
ESVE_P_6 Lyngby C-reactive protein in dogs diagnosed with hypoadrenocorticism
ESVE_P_7 Garcıa San Jose Systemic hypertension in diabetic cats: does it really matters?
ESVE_P_8 Perez Alenza Systemic hypertension in dogs with diabetes mellitus
ESVE_P_9 Fowlie Canine electrolyte analysis in dogs with hypoadrenocorticism: a comparison of two in-house
analysers with a reference laboratory
ESVE_P_10 van Bokhorst Concurrent pituitary and adrenocortical tumors in dogs with spontaneous hypercortisolism
ESVE_P_11 Gonzalez Sanz Prevalence of neurological signs in hypothiroid dogs at diagnosis
ESVE_P_12 del Baldo Evaluation of one portable blood glucose meter and one portable glucose-ketones meter in dogs
532 ECVIM Abstracts
ESVE_P_13 Carotenuto Serum Symmetric Dimethylarginine (SDMA) in dogs with hypothyroidism
ESVE_P_14 Malerba Evaluation of one portable blood glucose meter and one portable glucose-ketones meter in cats
ESVCN – European Society of Veterinary Comparative Nutrition
ESVCN_P_1 Allaert A randomised double-blind, placebo controlled study evaluating the eﬀects of short-chain fructo-
oligosaccharides (scFOS) on cat stools odors
ESVCN_P_2 Jewell Increased dietary long-chain polyunsaturated fatty acids alter plasma fatty acid concentrations
and lower risk of urine stone formation in cats
ESVCN_P_3 Jewell Foods enriched with bioactive ingredients including ﬁsh oil increase circulating (n-3) fatty acid
concentrations, decrease PGE2, and increase lean body mass in cats
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SERUM S100/CALGRANULIN CONCENTRATIONS IN
MINIATURE SCHNAUZERS WITH IDIOPATHIC HYPER-
LIPIDEMIA. R.M. Heilmann1, P.G. Xenoulis2, K. M€uller1, E.
Stavroulaki2, J. Suchodolski3, J. Steiner3. 1College of Veterinary
Medicine, University of Leipzig, Leipzig, Germany, 2Small Animal
Clinic, University of Thessaly, Karditsa, Greece, 3Gastrointestinal
Laboratory, Texas A&M University, College Station, USA
Idiopathic hyperlipidemia (IH) is a common condition in Minia-
ture Schnauzers (MS), with more than 75% of dogs = 9 years old
being aﬀected and >45% of these dogs having moderate to severe
fasting hypertriglyceridemia (HTG) with or without combined
hypercholesterolemia (HCHOL). Severe HTG poses an increased
risk for the development of several conditions (e.g., pancreatitis,
insulin resistance). Recent studies in humans suggest IH to be
associated with low-grade inﬂammation involved in the pathogene-
sis of diseases associated with IH. The risk of such complications
decreases with medical control of IH. Given that biomarkers of
inﬂammation have not been investigated in MS with IH, the aims
of the study were to evaluate serum calprotectin and S100A12
concentrations (i) in healthy MS and in MS with IH, and (ii) in
MS with IH in response to dietary intervention for the manage-
ment of IH.
Serum samples were collected from 152 clinically healthy MS,
and a study questionnaire was completed for each dog to conﬁrm
the health status and medication history. Serum triglyceride,
cholesterol, calprotectin, and S100A12 concentrations were mea-
sured in all samples. Paired serum samples were obtained from 17
of the IH dogs after being placed on a commercial ultra-low fat
diet without any additional lipid-lowering medications. Statistical
analyses were performed using non-parametric (paired or
unpaired) group comparisons and Fisher’s exact or likelihood ratio
tests, with statistical signiﬁcance set at P < 0.05.
A total of 34%, 5%, and 11% of dogs had isolated HTG,
hypercholesterolemia (HCHOL), and combined hyperlipidemia,
respectively. Compared to MS without IH, both HTG and
HCHOL were associated with increased serum calprotectin
(P = 0.0007, odds ratio [OR] = 4.2 and P = 0.0051, OR = 4.1,
respectively) but not S100A12 concentrations (both P > 0.05).
There was no signiﬁcant diﬀerence in serum calprotectin or
S100A12 concentrations among MS with isolated HTG, HCHOL,
or combined hyperlipidemia. Presence and severity of HTG
decreased in MS with IH within 14–26 weeks after being placed
on an ultra-low fat diet (P = 0.0052 and P = 0.0032). Dietary
intervention also yielded a signiﬁcant decrease in serum cholesterol
(P = 0.0356) but neither serum calprotectin nor S100A12 concen-
trations changed signiﬁcantly during that time (both P > 0.05).
These results suggest that subclinical inﬂammation is present in
MS with HTG due to IH and that an ultra-low fat diet does not
reduce the concentrations of the inﬂammatory S100 proteins in
MS with HTG. Whether this presumable inﬂammatory phenotype
in MS with IH contributes to the development of pancreatitis,
insulin resistance, or other conditions warrants further research.
Disclosures: No disclosures to report.
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SERUM TOCOPHEROL AND RETINOL CONCENTRA-
TIONS IN DOGS WITH EXOCRINE PANCREATIC INSUFFI-
CIENCY. P.C. Barko, D.A. Williams. University of Illinois,
Urbana, USA
Exocrine pancreatic insuﬃciency (EPI) in dogs is diagnosed by
observing serum canine trypsin-like immunoreactivity (cTLI) to be
<2.5 µg/L; aﬀected dogs have severe fat malabsorption. Some dogs
with signs of EPI have marginally subnormal serum cTLI (3–6 µg/
L) and do not respond to enzyme replacement therapy (subclinical
EPI, SEPI), but given their clinical signs, abnormal serum cobal-
amin or folate, and absence of other detectable non-enteric disease
presumably have an idiopathic chronic enteropathy (ICE). Unpub-
lished preliminary data indicate decreased serum tocopherol con-
centrations in dogs with EPI that do not resolve after pancreatic
enzyme supplementation. The objectives of this study were to mea-
sure serum tocopherol and retinol in dogs with EPI and those with
subclinical EPI and ICE (SEPI/ICE).
Inclusion criteria for the EPI group (n = 8) were clinical signs
of EPI and serum cTLI concentrations <2.5 µg/L. Dogs in the
SEPI/ICE group (n = 9) had clinical signs of ICE and serum
cTLI concentrations in the 3.0–6.0 µg/L range. Diets of dogs in
both groups were supplemented with oral pancreatic enzyme
extract. Control samples were collected from 10 healthy dogs
before and after 10 days of pancreatic enzyme supplementation.
All samples were surplus from another study approved by our
institutional ethics committee, and stored at 80°C prior to
assay of tocopherol and retinol by high-performance liquid
chromatography.
Dogs with EPI and SEPI/ICE had signiﬁcantly lower serum
concentrations of tocopherol (means 14.02 and 16.66 lg/mL;
P = 0.015 and P = 0.0002 respectively) and retinol (means 509 and
673.78 ng/mL; P = 0.0003 and 0.004 respectively) than enzyme-
supplemented control dogs (means 41.6 lg/mL and 1124.86 ng/
mL respectively). Neither tocopherol nor retinol concentrations
were signiﬁcantly diﬀerent between the EPI and SEPI/ICE groups,
nor were there diﬀerences between the control dogs before and
after enzyme supplementation.
These ﬁndings indicate that dogs with EPI and SEPI/ICE have
relative deﬁciencies in tocopherol and retinol, likely reﬂecting fat
malabsorption, and may share a similar enteropathy that may pre-
cede the onset of EPI. The clinical signiﬁcance of these decreased
fat soluble vitamin concentrations is unknown though retinol has
been shown to inﬂuence enteric mucosal immune responses though
its eﬀects on T-cell diﬀerentiation, IgA secretion in GALT, and
homing of innate lymphoid cells to the gut. Tocopherol is an
important antioxidant and studies have revealed increased reactive
oxygen species in intestinal biopsies from humans with IBD.
Clinical trials to assess the value of tocopherol and retinol sup-
plementation in dogs with EPI and ICE are warranted.
Disclosures: Disclosures to report.
David Williams is a consultant with Idexx Laboratories and the
GI Laboratory at Texas A&M University, and is involved in a col-
laborative research study with Nestle-Purina. He is a member of
the Nestle-Purina Advisory Board.
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EFFECT OF MIRTAZAPINE ON CANINE GASTRIC EMPTY-
ING ASSESSED BY 13C-SODIUM ACETATE BREATH TEST
(13C-SABT). N. Schleifenbaum1, S. Salavati2, R. Neiger1. 1Small
Animal Clinic - Justus-Liebig-University Giessen, Giessen, Ger-
many, 2The Royal (Dick) School of Veterinary Studies and The R,
University of Edinburgh, Edinburgh, UK
Delayed gastric emptying is suspected to occur in several common
conditions in dogs, for example metabolic/ -endocrine disorders or
inﬂammatory bowel disease. It can also be a sequela in critical
care patients suﬀering from sepsis, peritonitis or pancreatitis.
Treating the underlying cause is indicated, but additional support-
ive treatment in the form of prokinetic drugs is scarce, especially
as 5-HT4 receptor agonists are not widely available. The antide-
pressant mirtazapine, routinely used at low dosages for its appetite
stimulating properties in small animals, has been reported to accel-
erate gastric emptying both in people and (at high dosages) in
experimental healthy dogs. The eﬀects of mirtazapine on gastric
emptying times using a non-invasive test have not been assessed.
Hence, assessing the eﬀect of diﬀerent dosages of this drug on
gastric half emptying times (G50%) in healthy dogs using the
13C-SABT was sought.
Six healthy Beagle dogs (3–5 years, 9.7–11.6 kg body weight)
were included. Mirtazapine was used at increasing dosages
(0.6 mg/kg = MLo, 2 mg/kg = MMe, 20 mg/kg = MHi). Initially,
MLo, placebo and prucalopride (1 mg/kg as a positive control)
were administered orally in a cross-over design. Subsequently,
MMe and MHi were administered and compared to a second and
third placebo treatment. This approach was chosen to enable
interim analysis of data, as ethical approval only allowed to pro-
gress to a higher mirtazapine dose if no eﬀect was seen with the
lower one. On day 4 of each treatment, a test meal consisting of
each dog’s half daily calorie requirement and 150 mg 13C-sodium
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acetate was fed after an overnight fast and a 13C-SABT was per-
formed. Breath samples were obtained with a facial mask before
(0 min) and 30, 60, 120, 180, 240, 300, and 360 min after test meal
ingestion. 12CO2/
13CO2 ratio in the breath was measured by non-
dispersive infrared spectroscopy and delta-over baseline (DOB)
values plotted against time. G50% was calculated for each treat-
ment based on cumulative non-linear curve ﬁtting of the DOB val-
ues. Median G50% was 78.3 min (range 48.4–93.3) with MLo,
84.4 min (69.2–109.6) with MMed and 106.4 min (range 83.1–
144.2) with MHi. Median G50% for Prucalopride and for placebo
was 61.9 min (43.1–159.0) and 67.1 min (38.1–146.1) respectively.
MLo (P = 0.75) and MMed (P = 0.12) had no eﬀect on G50%
compared to placebo. Unexpectedly, MHi prolonged gastric emp-
tying (P = 0.046). G50% was not signiﬁcantly diﬀerent between
Prucalopride and placebo (P = 0.75). In conclusion, mirtazapine
does not accelerate G50% in healthy dogs. In high dosages, it
might prolong gastric emptying, even though with borderline
signiﬁcance.
Disclosures: No disclosures to report.
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PREVALENCE OF CLOSTRIDIUM DIFFICILE AND SAL-
MONELLA SPP. IN JUVENILE DOGS AFFECTED WITH
PARVOVIRAL ENTERITIS. W.J. Botha1, J.P. Schoeman1, S.L.
Marks2, P.S. Morley3, Z. Whitehead1, C.H. Annandale1. 1Univer-
sity of Pretoria, Onderstepoort, South Africa, 2University of Cali-
fornia, Davis, Davis, USA, 3Colorado State University, Fort
Collins, USA
Clostridium diﬃcile (CD) is a common cause of hospital-acquired
diarrhea in humans and has been associated with diarrhea in dogs.
Salmonellosis is a major zoonotic disease but the transmission
pathway is unclear. It is thus important to evaluate the risk factors
that increase the likelihood of infection. Canine parvovirus (CPV)
is a prevalent and fatal cause of canine enteritis often exacerbated
by concurrent infection with other enteropathogens. Persistent iso-
lation of Salmonella spp. during hospital environmental surveys of
the isolation ward prompted further investigation. This study was
designed to determine the comparative prevalence of CD and Sal-
monella spp. in dogs with CPV and healthy dogs.
The study was approved by the ethics committee of the Univer-
sity of Pretoria and conducted from October 2015 to March 2017.
Fresh fecal samples were collected from dogs aged 6 weeks to
9 months diagnosed and admitted with CPV infection, and healthy
dogs presented for vaccination or routine hospital procedures.
CPV shedding was conﬁrmed using negative staining electron
microscopy. CD was detected via commercial fecal antigen enzyme
immunoassay for glutamate dehydrogenase (GDH), TcdA and
TcdB. In addition, feces was submitted for the isolation, antimi-
crobial susceptibility and serotyping of Salmonella spp.
Seventy-ﬁve dogs with CPV and 41 healthy dogs comprised the
study. The prevalence of CD was 2.7% and 5% in CPV and
healthy dogs, respectively, whereas the prevalence of Salmonella
spp. was 21.3% and 32.5% in CPV and healthy dogs, respectively.
No statistically signiﬁcant associations between Salmonella infec-
tion status and possible risk factors or continuous variables such
as age, weight and length of hospitalization were identiﬁed. Statis-
tical analysis was not performed on CD positive animals, because
only two animals in either groups tested positive. Moreover, all
the Salmonella spp. isolates (n = 32) were resistant to penicillin G,
lincomycin and tylosin. Nine of the isolates were resistant to lin-
cospectin and 21 showed intermediate (n = 20) or complete resis-
tance (n = 1) to doxycycline/oxytetracycline. Nine diﬀerent
serotypes of Salmonella spp. were identiﬁed.
In conclusion, the prevalence of Salmonella spp. in dogs with
CPV infection was not statistically diﬀerent from that in a healthy
cohort. However, the prevalence in both groups was considerably
higher than those previously reported (0–3.6%), yet similar to that
reported for shelter dogs or dogs fed a raw diet (30–69%). This is
the ﬁrst report of the prevalence of CD and Salmonella spp. in
dogs in South Africa.
Disclosures: No disclosures to report.
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RISK FACTORS FOR C. DIFFICILE CARRIAGE IN DOGS
AND ASSOCIATIONS WITH CLINICAL DISEASE. C. Albu-
querque, C. Millins, G. Douce, A. Ridyard, G. Mclaughlan. SAH
- University of Glasgow, Glasgow, UK
Clostridium diﬃcile is the most common cause of antimicrobial
and hospital-associated diarrhea in humans. Several risk factors
have been identiﬁed for development of community-associated C.
diﬃcile infection in humans. Information about prevalence, strain
types and risk factors for C. diﬃcile carriage in dogs is scarce.
This prospective study aimed at quantifying the prevalence and
strain types of C. diﬃcile in dogs with and without diarrhea pre-
sented to a small animal teaching hospital; and identifying risk
factors for C. diﬃcile carriage through retrospective analysis of
the clinical histories.
Stool samples were collected from 199 dogs within 48 h of
admission to the hospital. These included 52 dogs presented for
investigation of diarrhea and 147 dogs presented for reasons other
than diarrhea. At the time of sampling 24 of the dogs presenting
for reasons unrelated to diarrhea were found to have acute diar-
rhea and were moved to the diarrheal cohort. The prevalence of
C. diﬃcile carriage in dogs in the diarrheal cohort was 25% (95%
CI: 16.6–35.8%, 19/76 samples culture positive) and in the non-
diarrheal cohort was 13.8% (95% CI: 8.8–21%; 17/123 samples
culture positive). Dogs presented with chronic diarrhea had a
prevalence of C. diﬃcile carriage of 34.8% (95% CI: 18.8–55.3%,
8/23 samples culture positive) while dogs with acute diarrhea had
a prevalence of 17.2% (95% CI: 7.7–34.7%, 5/29 samples culture
positive). A number of ribotypes were detected and the predomi-
nate types identiﬁed. PCR testing of all ribotypes was carried out
to detect alpha and beta toxins which are associated with clinical
disease.
Epidemiological risk factors which were assessed included those
associated with the dog’s household environment including the
number of pets and presence of elderly people or infants, individ-
ual animal information including age, gender, neutering status and
clinical information on medical treatment including antibiotic
administration and visits to a veterinary practice in the previous
three months. This type of study has the power to provide evi-
dence-based data to support clinical decision making in evaluating
the signiﬁcance of detecting C. diﬃcile in a fecal sample in dogs
with acute and chronic diarrhea. It can also inform whether dogs
carry similar or diﬀerent ribotypes of C. diﬃcile to humans, and
their potential signiﬁcance as a reservoir for human infection.
Disclosures: No disclosures to report.
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LONG-TERM IMPACT OF TYLOSIN ON THE FECAL
MICROBIOTA OF HEALTHY DOGS. A.C. Manchester1, J.
Suchodolski2, J.M. Steiner2, C.B. Webb1, J.A. Lidbury2. 1Color-
ado State University, Fort Collins, USA, 2Texas A&M University,
College Station, USA
The intestinal microbiota is thought to play a major role in the
pathogenesis of intestinal disease. Antibiotics are commonly
employed in the treatment of acute and chronic enteropathy, in
some cases with the goal of eradicating speciﬁc pathogens. The
aim of this study was to prospectively evaluate the impact of tylo-
sin administration on speciﬁc bacterial components of the fecal
microbiota.
Sixteen healthy pet dogs were randomly assigned to one of two
groups in a double-blinded fashion: 8 dogs were given oral tylosin
at 20 mg/kg while the other 8 dogs were administered a placebo
capsule, each given q12 hr for 7 days. All dogs were maintained
on their usual diet and a standardized fecal score (range: 1–7) was
noted daily during drug administration. Fecal samples were col-
lected on day 0 prior to drug administration as well as on days 7,
10, 21, and 63. Fecal samples were assessed using quantitative
PCR for 7 bacterial taxa, belonging to the Firmicutes, Proteobac-
teria and Fusobacteria phyla. Relative abundance of Clostridium
perfringens was also assessed pre & post-treatment via qPCR.
Parameters were compared using a Friedman’s test, followed by
Dunn’s post-test. A P-value <0.05 was considered statistically
signiﬁcant.
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None of the dogs in either group developed diarrhea, though
signiﬁcant changes were seen in the abundance of various bacterial
taxa. Signiﬁcantly decreased Faecalibacterium, Clostridium hira-
nonis, Turicibacter and Fusobacterium were observed in the fecal
microbiota of dogs treated with tylosin at day 7. At 2 months
post-tylosin cessation, 5 and 4 of 6 dogs failed to have regained
their pre-treatment Faecalibacterium and C. hiranonis levels,
respectively. Tylosin administration was not associated with a sig-
niﬁcant decrease of C. perfringens (P = 0.38), but dogs in the pla-
cebo group had a signiﬁcant decrease in C. perfringens (P = 0.02).
There was no signiﬁcant change in relative abundance of E. coli in
dogs treated with tylosin (P = 0.64) or placebo (P = 0.38).
Tylosin leads to alterations in the fecal microbiota without pre-
dictable eﬀects of potential enteric pathobionts. Further studies
are warranted to determine the long-term eﬀects of antimicrobial-
induced changes as well as the eﬃcacy of recommended therapies
for bacterial enteritis.
Disclosures: Disclosures to report.
Some authors are employed by the Texas A&M GI lab which
oﬀers tests on a fee basis. The study was funded by grants from
the Comparative Gastroenterology Society and Naniboujou
Research Legacy.
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VITAMIN D RECEPTOR EXPRESSION IN THE DOG AND
THE EFFECT OF INTESTINAL INFLAMMATION. J.A. Cart-
wright, A.G. Gow, E. Milne, N. Macintyre, S. Smith, I. Handel,
R.J. Mellanby. University of Edinburgh, Edinburgh, UK
Vitamin D plays an important role in skeletal health in dogs. Due
to the inability to cutaneously produce vitamin D, dogs are heavily
reliant on dietary sources of vitamin D. We have previously shown
that dogs with a protein losing enteropathy have signiﬁcantly
lower concentrations of the major vitamin D metabolite, 25
hydroxyvitamin D (25(OH)D). Furthermore, we have shown that
serum 25(OH)D concentrations negatively correlate with extent of
inﬂammation in dogs with a chronic enteropathy (CE). In addi-
tion, low vitamin D status has been found to be a negative prog-
nostic marker in dogs with a CE.
Vitamin D inﬂuences cellular function by signaling through the
vitamin D receptor (VDR). Despite the growing awareness of the
potential impact gastrointestinal diseases have on vitamin D meta-
bolism in dogs, little is known about the sites of VDR expression
and whether intestinal inﬂammation inﬂuences VDR expression.
The aim of this study was to deﬁne the non-skeletal tissues which
express VDR in the dog and to investigate how extent of inﬂam-
mation correlated with VDR expression in the small intestine.
Twelve non-skeletal tissues were collected prospectively from 6
dogs, euthanized for non-health related problems. These included
stomach, duodenum, ileum, colon, skin, kidney, spleen, liver,
mesenteric lymph node, heart and lung. VDR expression was
assessed with immunohistochemistry using a Rat IgG VDR mono-
clonal antibody.
Thirty ﬁve dogs diagnosed with a chronic enteropathy were
prospectively enrolled and biopsies taken at endoscopy from the
duodenum were evaluated for VDR expression with both immuno-
histochemistry and quantitative polymerase chain reaction
(qPCR). Twenty three control dogs were also prospectively
enrolled without clinical signs of gastrointestinal disease.
The VDR was found to be highly expressed in the duodenum
of all 6 control dogs. It was also found in the skin of these 6 dogs
and in the majority of the kidney samples, and occasionally in
spleen and ileum.
There was no statistical diﬀerence in the relative expression, by
qPCR, of the VDR between dogs with chronic enteropathy and
dogs not clinically aﬀected. VDR expression was also not diﬀerent
between healthy and CE dogs when assessed by protein expression
via immunohistochemistry scoring.
Our study has deﬁned the tissues which express VDR in healthy
dogs. The lack of down regulation of VDR expression in intestinal
inﬂammation contrasts with humans and provides support for
future studies which aim to investigate whether vitamin D and its
analogues can be used to modulate intestinal inﬂammation in the
dog.
Disclosures: No disclosures to report.
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SERUM CIRCULATING MICRORNAS AS A MARKER FOR
CANINE LYMPHOCYTIC- PLASMACYTIC INFLAMMA-
TORY BOWEL DISEASE. A.O. Konstantinidis1, T.S. Rallis1, M.
Gazouli2, E. Legaki2, G.D. Brellou1, I. Savvas1, K.K. Adamama-
Moraitou1, D. Pardali1, A.E. Jergens3, K. Allenspach3. 1Aristotle
University of Thessaloniki, Thessaloniki, Greece, 2School of Medi-
cine, National and Kapodistrian University of Athens, Athens,
Greece, 3Iowa State University College of Veterinary Medicine,
Ames, IA, USA
MicroRNAs (miRs) are small, non-coding RNA molecules with
gene regulatory function. MiRs appear to play a critical role in
the pathogenesis of a variety of diseases in humans, including
inﬂammatory bowel disease (IBD). Furthermore, recent studies
suggest that miRs have altered expression proﬁles in the serum of
humans with IBD, suggesting they could be promising non-inva-
sive serum biomarkers.
The aim of the current study was to evaluate the expression of
a selection of serum circulating miR-16, miR-21, miR-122,
miR146a, miR-147, miR-185, miR-192 and miR-223 in canine
lymphocytic- plasmacytic (LP) IBD based on published data on
human IBD.
Serum samples were collected from 21 dogs diagnosed with
active LP IBD. All dogs had undergone upper and/or lower GI
endoscopy according to clinical signs, were diagnosed histopatho-
logically according to the guidelines of the WSAVA International
Gastrointestinal Standardization Group (Washabau et al. 2010)
and by clinical exclusion diagnosis. In addition, serum samples
were available from 14 clinically healthy control dogs for compari-
son. Total RNA from serum was isolated using Trizol, and reverse
transcribed into cDNA. The expression of serum miRs genes was
measured using real-time quantitative reverse transcriptase poly-
merase chain reaction (real-time qRT-PCR). Clinical disease activ-
ity was recorded for all dogs using the Canine Chronic
Enteropathy Clinical Activity Index (CCECAI; Allenspach et al.
2008). Endoscopies were performed and graded according to the
canine IBD endoscopic index (Slovak et al. 2014).
Compared to healthy controls, there was a signiﬁcantly
increased expression of the following miR in the serum of dogs:
miR-16 (IBD: median 1.56, range 1.24–1.89, P < 0.0005; controls:
median 1.4, range 0.89–1.64), miR-21 (IBD: median 1.85, range
0.87–6.89; controls: median 1.54, range 0.37–2.18; P = 0.009),
miR-122 (IBD: median 1.85, range 1.08–6.28; controls: median
1.49, range 1.02–2.21; P = 0.012), miR146a (IBD: median 1.86,
range 0.93–5.92; controls: median 1.575, range 1.33–2.33;
P = 0.016) and miR-147 (IBD: median 3.63, range 2.73–5.46,
P < 0.005; Controls: median 1.85, range 1.27–2.53, P < 0.0005), as
well as a signiﬁcantly decreased expression of miR-185 (IBD: med-
ian 0.86, range 0.44–1.53, P < 0.0005; Controls: median 1.68,
range 0.89–1.64, P < 0.0005), miR-192 (IBD: median 1.56, range
1.24–1.89, P < 0.0005; Controls: median 1.4, range 1.19–2.3,
P < 0.0005) and miR-223 (IBD: median 0.54, range 0.32–0.96,
P < 0.0005; Controls: median 0.9, range 0.62–1.68, P < 0.0005).
This study shows that some circulating miRs are diﬀerentially
expressed in the serum of dogs with LP IBD versus healthy dogs.
Further studies are needed to evaluate the usefulness of these
markers in the diagnosis and treatment of canine IBD.
Disclosures: No disclosures to report.
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SPECIFIC VIRULENCE FACTORS IN MUCOSA-ASSO-
CIATED E. COLI OF DOGSWITH INFLAMMATORY BOWEL
DISEASE (IBD) ARE ASSOCIATED WITH SURVIVAL. K.
Allenspach1, F. Vessieres2, Y. Du1, D.D. Kingsbury1, F. Procoli2,
C.M. Logue1, L.K. Nolan1, G. Li1, K.W. Simpson3, J.P. Mochel1,
A.E. Jergens1. 1Iowa State University, Ames, USA, 2Anderson
Moores Speciality Practice, Winchester, UK, 3Department of
Veterinary Clinical Sciences, Cornell University, Ithaca, USA
Growing evidence suggests that resident E.coli play an important
role in the pathogenesis of inﬂammatory bowel disease (IBD)
across species. Among the genes that may contribute to E. coli‘s
role in the development of IBD are those typical of Extraintestinal
Pathogenic E. coli (ExPEC). Here, we tested the hypothesis that
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mucosal E. coli harboring ExPEC virulence genes may drive
inﬂammation in the small intestine of dogs with lymphoplasma-
cytic IBD and contribute to a more severe clinical presentation.
A comprehensive investigation of virulence genes in E.coli
strains from dogs diagnosed with IBD was performed using a 17-
panel multiplex PCR, targeting for 8 genes typical for human
IBD-associated adherent and invasive E. coli [Group 1 genes:
eaeH, irp2, ﬁmH, ratA, fepC, usp, colV, dsbA] and 9 genes more
typically associated with ExPEC [Group 2 genes: cvaC, ompTp,
hlyF, etaB, iss, aerJ, ereA, papC] (Johnson, TJ, JMicrobiol 2008).
A cohort of 12 German Shepherd Dogs (GSDs) and 20 non-GSDs
diagnosed with lympho-plasmacytic IBD on the basis of clinical
signs, intestinal histopathology, and exclusion of other known
causes of chronic gastro-intestinal signs was enrolled. E. coli was
cultured from endoscopically collected biopsies using MacConkey
and Sheep Blood agar, and identiﬁed using API20E (BioMerieux).
Statistical analysis was performed using univariate linear mixed
eﬀect models and Fisher’s exact tests for continuous and categori-
cal variables, respectively. The following dependent variables were
considered: (i) clinical activity of disease (CCECAI; Allenspach K
2007), (ii) histological severity score (WSAVA index; Day M
2008)), (iii) use of immunosuppressive agents, and (iv) euthanasia
due to intractable IBD or survival within 1 year after diagnosis.
Results revealed that none of the tested virulence factors were sig-
niﬁcantly associated with the CCECAI index. However, one viru-
lence factor from group 1 [colV:colicin V, antimicrobial peptide;
P = 0.03) had a signiﬁcant eﬀect on the WSAVA index. Two of
the virulence genes typically associated with ExPEC (Group 2:
ompTP: inactivates antimicrobials, and cvaC: secreted toxin result-
ing in cytolysis) were signiﬁcantly associated with euthanasia due
to intractable IBD (ompTP: OR: 19, cvaC: OR: 30, P = 0.05), as
well as an increased likelihood of having been treated with
immunosuppressives (P = 0.03). These data are reminiscent of
reports on human ulcerative colitis cases harboring mucosal E. coli
with multiple ExPEC virulence factors that were associated with
clinical severity. Similarly, our data indicate that speciﬁc microbial
factors may be important determinants and predictors of disease
progression and survival in a sub-group of dogs with IBD.
Disclosures: No disclosures to report.
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IDENTIFICATION OF IGG4-RELATED DISEASE IN THE
ENGLISH COCKER SPANIEL AND DOGS OF OTHER
BREEDS. M.F. Coddou1, F. Constantino-Casas1, B. Blacklaws1,
T. Scase2, M.J. Day3, P.J. Watson1. 1University of Cambridge,
Cambridge, UK, 2Bridge Pathology Ltd., Bristol, UK, 3School of
Veterinary Sciences, University of Bristol, Bristol, UK
Chronic pancreatitis (CP) is common in the English Cocker Spa-
niel (ECS), and is characterized histologically by duct destruction,
interlobular ﬁbrosis and dense periductular and perivenous lym-
phocytic aggregates. These changes are characteristic of human
autoimmune pancreatitis type 1, part of a steroid-responsive, mul-
ti-organ syndrome, newly recognized as IgG4-Related Disease
(IgG4-RD). Human IgG4-RD aﬀects one or several organs, often
showing a predominance of IgG4+ plasma cells histologically, with
an IgG4+/total IgG+ plasma cell ratio >40%.
This study investigated whether ECSs with CP and inﬂamma-
tory disease in several organs show an increase in IgG4+ plasma
cells within aﬀected tissues. Histological sections of pancreas
(n = 12), liver (n = 10), kidney (n = 12), salivary gland (n = 4),
anal sacs (n = 9), and conjunctiva (n = 2) were obtained from 37
ECSs with idiopathic chronic inﬂammatory disease aﬀecting
those tissues. Control samples were identiﬁed from 18 age-
matched dogs of other breeds with chronic pancreatitis (n = 6),
chronic idiopathic hepatitis (n = 2), chronic nephritis (n = 6),
anal sacculitis (n = 5), chronic sialadenitis (n = 2) or chronic con-
junctivitis (n = 1). Eleven ECSs and 6 control dogs presented
with disease in more than one organ. Immunohistochemistry was
performed for canine total IgG and IgG subclasses (IgG2, IgG3,
and IgG4). Normal tissue sections were labeled as controls. The
number of plasma cells was counted in three high power ﬁelds
(9400). The number of IgG4+ cells and the percentage of total
IgG+ plasma cells were compared between groups using Mann-
Whitney U tests.
Nineteen sections from 17 ECSs and 11 sections from 10 con-
trols showed elevated numbers of IgG4+ plasma cells and IgG4+/
IgG+ ratios >40%. Individual dogs (ECSs and other breeds)
showed marked increases in IgG4+ cells. There were no signiﬁcant
diﬀerences in numbers of IgG4+ plasma cells between ECSs and
controls for aﬀected pancreas, liver, anal sacs, salivary glands and
conjunctiva. Anal sacs showed high numbers of total IgG and
IgG4+ plasma cells. Kidney sections had more IgG4+ cells in both
cases and controls than other organs. Dogs of other breeds had
signiﬁcantly more IgG4+ plasma cells in aﬀected kidneys.
In conclusion, several ECSs and dogs of other breeds fulﬁlled
the histological criteria for diagnosis of IgG4-RD, supporting the
existence of a multi-organ immune-mediated disease in ECS and
some other dogs. Strict inclusion criteria for controls with multi-
organ inﬂammatory disease likely selected for dogs of other breeds
with IgG4-RD. Anal sacculitis showed histological changes sug-
gesting an immune-mediated etiology. Future studies will focus on
the immunology and treatment of the disease.
Disclosures: Disclosures to report.
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CORRELATING GASTROINTESTINAL HISTOPATHO-
LOGIC FINDINGS TO CLINICAL DISEASE ACTIVITY IN
DOGS WITH INFLAMMATORY BOWEL DISEASE. K. Allen-
spach1, J. Mochel1, D. Yingzhou1, S. Priestnall2, F. Moore3, M.
Slaytor4, A. Rodrigues5, M. Day6, M. Ackermann1, M. Krocken-
berger7, J. Mansell5, W. Gi Standardization Group1, J. Suchodol-
ski5, N. Berghoﬀ8, N. Luckschander9, A. Jergens1. 1Iowa State
University, Ames, USA, 2Royal Veterinary College, London, UK,
3Marshﬁeld Clinic, Marshﬁeld, USA, 4IDEXX, San Diego, USA,
5Texas A&M University, College Station, USA, 6University of
Bristol, Bristol, USA, 7University of Sydney, Sydney, Australia,
8Michigan State University, Lansing, USA, 9University of Vienna,
Vienna, Austria
Diagnosis of canine inﬂammatory bowel disease (IBD) requires con-
ﬁrmation of histopathologic inﬂammation in intestinal biopsies. Dif-
ferent studies have found it diﬃcult to correlate histopathologic
ﬁndings with clinical disease severity due to a lack of consistency
between pathologists when describing histopathologic changes and
the questionable quality of specimens submitted for diagnostic eval-
uation. The WSAVA* GI standardization grading scheme (Day,
2008) was an attempt to rectify some of these problems but even it is
associated with poor agreement among pathologists. The aim of the
present study was to utilize a new grading scheme for improved con-
sistency of evaluation of GI histopathologic ﬁndings and to corre-
late these features to clinical disease activity in dogs with IBD.
Paraﬃn-embedded tissues from the stomach, duodenum, ileum,
and colon of 70 healthy dogs and 163 IBD dogs were evaluated
for histopathologic lesions using a simpliﬁed model for deﬁning
GI inﬂammation (Jergens, 2013). Morphologic/inﬂammatory fea-
tures were independently scored by 8 pathologists for total lesion
scores for each GI organ and sub-scores within each organ. Clini-
cal disease activity was calculated using CCECAI/CIBDAI scores.
Pearson’s correlation coeﬃcients were used to evaluate the associa-
tion between clinical and histopathologic scores.
The estimated correlation between CCECAI/CIBDAI and total
histology score was found to be signiﬁcant (P < 0.05) for duode-
num (r = 0.42, 95% CI = [0.08–0.65]) and colon (r = 0.33, 95%
CI = [0.04–0.57]). The correlation was borderline signiﬁcant for
ileum (P: 0.06, r = 0.29, 95% CI = [0.02 to 0.55]) but non-signiﬁ-
cant for stomach (P: 0.7, r = 0.05, 95% CI = [0.24 to 0.34]). In
evaluating the relationship between histopathologic sub-scores and
disease activity, the correlation was signiﬁcant for: (i) crypt dila-
tion (P < 0.001, r = 0.52), (ii) LP macrophages (P < 0.01,
r = 0.34), (iii) LP neutrophils (P: 0.03, r = 0.28), iv) mucosal ﬁbro-
sis (P < 0.001, r = 0.53), v) surface epithelium (P: 0.01, r = 0.34),
and (vi) villus stunting (P: 0.002, r = 0.43). The correlation to
CCECAI/CIBDAI for colonic goblet cells, intraepithelial lympho-
cytes, LP eosinophils, LP lymphocytes, and lacteal dilation was
non-signiﬁcant. There was agreement between pathologists for
total histology scores, while sub-scores for mucosal ﬁbrosis and
villus stunting diﬀered signiﬁcantly (P < 0.05).
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In conclusion, a simpliﬁed model for GI inﬂammation shows util-
ity in correlating histologic features to clinical disease activity. Gastric
biopsies would appear to be less clinically useful versus duodenal and
colonic biopsies for deﬁning intestinal inﬂammation in canine IBD.
Disclosures: No disclosures to report.
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ACQUIRED ESOPHAGEAL STRICTURES: BALLOON
DILATATION OR STENTING? OUTCOME AND COMPLI-
CATIONS IN 24 DOGS AND CATS (2002–2017). J.S. Beguin1,
M. Manassero1, M. Faucher2, V. Freiche1. 1Ecole nationale veteri-
naire d’Alfort, Universite Paris Est, Maisons-Alfort, France, 2Clin-
ique Veterinaire Alliance, Bordeaux, France
Balloon dilatation is the most commonly used therapy for esopha-
geal strictures. The objective of this study was to assess outcome
and complications of balloon dilatation and/or stenting for treat-
ment of acquired esophageal strictures in dogs and cats.
Medical records were reviewed from animals presented with eso-
phageal strictures that underwent endoscopic balloon dilatation or
stenting. All cases were managed by the same clinician (VF). Values
are expressed as percentage and median [interquartile range].
Twenty-four cases (19 dogs and 5 cats) were included. The med-
ian age was 6 years [2.7; 10.7] for dogs and 1 year [0.4; 4] for cats.
Strictures resulted from recent anesthesia in 11 cases (45.8%). Other
causes included foreign body (29%), toxic ingestion (10.4%), acute
vomiting (6.2%) and one benign neoplasia (4.2%). Clinical signs
reported by owners were regurgitation (24/24), vomiting (11/24),
dysphagia (13/23), dysorexia or anorexia (10/22), ptyalism (6/23)
and cough (6/24). Median duration of clinical signs prior to endo-
scopy was 15 days [10; 26]. Thirty-two strictures were identiﬁed at
initial esophagoscopy. Seventeen animals had one stricture, six had
two strictures and one had three strictures. Seven strictures (29.2%)
were located within the cervical esophagus, 10 of 32 (41.6%) were in
the mid-esophagus, and 15 of 32 (62.5%) were in the distal esopha-
gus. The median stricture diameter was 4 mm [3; 8]. Annular stric-
tures were observed in 21 of 32 stenosis (65.6%).
Balloon dilatation procedures were performed for 19/24 animals
using a dilatator (Olympus) with an inﬂated diameter of 10 to
12 mm. Median numbers of dilatation were 2 [1; 3]. Clinical
improvement was noted for 15 cases. Perforation of the esophagus
was the only complication (1/19). Stenting was considered for 6
animals (Boston Scientiﬁc “Ultraﬂex” half covered stent in 2
cases and “Symphony” nitinol uncovered stent in 4 cases). Stent
placement was considered for the last 4 refractory cases and as
ﬁrst-line treatment for 2 cases. Clinical improvement was observed
in 5 of 6 cases. Complications included discomfort (1/6) and stent
migration (1/6). Long-term follow up was available for 17 animals,
median survival time was 730 days [100.7; 1368.7].
The limited number of cases precluded statistical analysis to
determine the best treatment option. To the author’s opinion, bal-
loon dilatation remains a good ﬁrst-line therapeutic modality. Eso-
phageal stenting appears safe and eﬀective for refractory cases or
ductal strictures but needs to be compared to balloon dilatation in
a prospective study on a more substantial number of cases.
Disclosures: No disclosures to report.
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PREVALENCE OF GASTRIC LYMPHOID FOLLICULAR
HYPERPLASIA IN FRENCH BULLDOGS. T. Bienes, R. Oli-
veira Leal, M. Dominguez Ruiz, R. Elvas de Carvalho, N. Fer-
nandes Rodrigues, K. Le Boedec, J.L. Hernandez. CHV Fregis,
Arcueil, France
Gastric lymphoid follicular hyperplasia (GLFH) has been reported
as higher prevalent in French Bulldogs (FB). However, screening
for confounders was never performed. In humans and cats, an
association between Helicobacter/Helicobacter-like organism
(HLO) infection and GLFH is recognized.
This study aimed to (i) conﬁrm the association between GLFH and
FB and (ii) screen for confounders, especially regarding HLO presence.
A total of 288 client-owned dogs were included.
Medical records of dogs that underwent gastroscopy between
January 2013 and December 2015 were retrospectively reviewed.
Two univariate analyses were performed in order to identify the
association between signalment, clinical signs, endoscopic and
histopathologic variables with GLFH and FB respectively. Signiﬁ-
cant variables of both analyses were included in a multivariate
analysis. Backward elimination was used to select the ﬁnal model.
Variables associated with GLFH on univariate analysis
included: FB (P = 0.04), intact male (P = 0.03), age (P < 0.001),
vomiting (P = 0.03), discoloration (P = 0.02), hemorrhage
(P < 0.001), ulcerations (P = 0.004) on gastric endoscopy, and
epithelial and lamina propria lymphocyte invasion (P < 0.001) and
HLO presence (P < 0.001) on histopathology. Variables associated
with FB on univariate analysis included intact male (P = 0.005),
age (P < 0.001), vomiting (P < 0.001), discoloration (P = 0.001)
and hemorrhage (P = 0.01) on gastric endoscopy, and HLO pres-
ence (P = 0.001) on histopathology. Final model included FB, age,
vomiting, gastric hemorrhage and HLO presence. FB (P = 0.87)
and age (P = 0.18) were no longer associated with GLFH on mul-
tivariate analysis. HLO colonization was associated with young
age (P < 0.001) but not with FB (P = 0.1).
Although an association between HLO colonization and young
age was identiﬁed, this study shows that GLFH is not more fre-
quent in FB as it would be expected.
Disclosures: No disclosures to report.
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A RETROSPECTIVE EVALUATION OF ILEOCECOCOLIC
PERFORATIONS ASSOCIATED WITH ROUTINE DIAGNOS-
TIC LOWER GASTROINTESTINAL ENDOSCOPY IN DOGS
AND CATS. V.L. Woolhead1, J.C. Whittemore2, R. Geddes1, S.A.
Stewart1. 1Royal Veterinary College, North Mymms, UK,
2University of Tennessee, Knoxville, USA
Colonic perforation is a known complication of ileocolonoscopy in
human medicine. Most perforations are immediately detected dur-
ing endoscopy; however, up to 40% are diagnosed 24 h post-pro-
cedure. Recent veterinary studies documented that obtaining ileal
biopsies can increase the diagnostic yield of gastrointestinal [GI]
endoscopy for workup of diﬀuse intestinal diseases; therefore, this
procedure is being conducted more frequently. Currently, there are
no published cases in the veterinary literature documenting iatro-
genic ileocecocolic [ICC] perforations or delayed diagnosis of
endoscopic perforations. The purpose of the study was to identify
iatrogenic ICC perforations in dogs and cats associated with lower
gastrointestinal [LGI] endoscopy, including anatomical location of
perforation, timing of diagnosis, risk factors and outcome. Canine
and feline medical records from two university veterinary hospitals
between 2012 and 2017 were retrospectively evaluated for cases
with iatrogenic ICC perforation associated with diagnostic LGI
endoscopy. Cases were included if full medical records, including
histopathological reports, were available. Five ICC perforations
associated with canine LGI endoscopy were identiﬁed; no feline
endoscopic perforations were documented. All perforations
occurred adjacent to the ICC valve; two were ileal and three colo-
nic. Three perforations were immediately identiﬁed by visualiza-
tion of abdominal contents during endoscopy, and one perforation
was suspected intra-procedure due to excessive abdominal disten-
sion and conﬁrmed with demonstration of pneumoperitoneum on
plain radiographs. Pneumoperitoneum was detected on abdominal
ultrasound and radiographs in one dog 5 days post-endoscopy,
following evaluation for lethargy and anorexia post procedure. All
dogs underwent immediate surgical correction following diagnosis
of perforation, with four patients surviving beyond discharge.
Histopathology from the area of perforation revealed no signiﬁ-
cant underlying pathology. The patient with delayed diagnosis of
perforation died as a consequence of complications from septic
peritonitis following two surgical procedures. Patient signalment,
adequacy of colonic preparation and visualization, method of ileal
intubation (direct intubation vs. scope advancement over biopsy
forceps) and underlying GI pathology did not appear to contribute
to risk of iatrogenic perforation. Recent publications suggest that
ileal biopsies should be obtained in all patients undergoing diag-
nostic LGI endoscopy; however, clinicians should be aware that
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iatrogenic ICC perforation can occur in canine patients with mini-
mal underlying GI pathology. Delayed diagnosis of ICC perfora-
tion was associated with a negative outcome; if patients become
unwell within the days immediately following endoscopy, perfora-
tion should be rapidly excluded with abdominal radiography to
screen for pneumoperitoneum.
Disclosures: No disclosures to report.
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ACQUIRED PYLORIC STENOSIS IN CATS: A PROSPEC-
TIVE STUDY OF 15 CATS (2015–2017). F. Da Riz, E. Laloy, G.
Benchekroun, V. Freiche. Ecole Nationale Veterinaire d’Alfort,
Universite Paris Est, Maisons-Alfort, France
Pyloric stenosis (PSt) is a rare condition in cats and can be a diag-
nostic challenge as ultrasonography lacks speciﬁcity in this context.
Few reports describe congenital PSt in young cats presented for
chronic alimentary vomiting. A retrospective study conducted on 34
cases (Ecvim 2016) suggested that acquired PSt in cats, associated
with Inﬂammatory Bowel Disease (IBD) is probably an underdiag-
nosed feature. For the ﬁrst time, a prospective study conducted on
22 cats (Ecvim 2016) measured the pyloric diameter (PD) by per-
endoscopic assessment, using biocompatible graduated olives: PD
was reported to be between 9 to 10 mm in 22 healthy cats.
The aim of this prospective study was to describe a cohort of
cats with acquired PSt conﬁrmed by per-endoscopic measurement.
All procedures were performed by the same operator (VF), using a
GIF, Olympus 180 8.8 mm diameter video-gastroscope. Group A
included 15 cats with acquired PSt. Cats were included in group A
if PD was less than 9 mm. The control group (group B) included
12 cats presented during the same period with a normal PD. Gas-
trointestinal biopsies were submitted for histologic analysis in all
cats (including stomach, pylorus and duodenum, n = 14). Signal-
ment, clinical signs, endoscopic and histopathological ﬁndings
were compared between both groups.
Age, sex and weight were similar between groups. Chronic vom-
iting was the most frequent clinical complaint in both groups
(100% in group A, 67% in group B). Food vomiting occurred
more frequently in group A (12/15) than in group B (6/12) but this
was not statistically diﬀerent. Endoscopic ﬁndings were consistent
with mild gastritis in both groups. Edema and hyperemia were fre-
quently noted around the pylorus in group A (8/15), less in group
B (2/12). Median value of the PD in group A was 7 mm, which
was statistically diﬀerent from group B (9 mm; P < 0.05; Wil-
coxon/Mann-Whitney test). Histologic changes were non-speciﬁc
(lymphocytic-plasmacytic inﬁltration of the gastric mucosa in 6
cats in group A, in 3 cats in group B). Pyloric ﬁbrosis was found
in 11/15 cats from group A and in 4/9 cats from group B.
Our results conﬁrm that acquired pyloric stenosis can occur in
cats suﬀering from IBD. Pathogenic mechanisms are not clearly
understood but could imply mucosal scar pyloric ﬁbrosis. This
study should be pursued with inclusion of additional cases in each
group in order to increase statistical power.
Disclosures: No disclosures to report.
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UTILITY OF VHS TO PREDICT ECHOCARDIOGRAPHIC
EPIC TRIAL INCLUSION CRITERIA IN DOGS WITH MYX-
OMATOUS MITRAL VALVE DISEASE: A RETROSPECTIVE
MULTICENTRE STUDY. J.P. Vitt1, S. Gordon2, R.C. Fries1,
J.D. Rhinehart3, S.E. Achen4, I. Sosa5, A.H. Estrada6, J.A. Carl-
son7, R.L. Winter8, S. Kadotani1, K.E. Lamb9. 1University of Illi-
nois, Urbana, USA, 2Texas A&M University, College Station, TX,
USA, 3The Ohio State University, Columbus, OH, USA, 4Blue
Pearl Specialty and Emergency Pet Hospital, Southﬁeld, MI, USA,
5Massachusetts Veterinary Referral Hospital, Boston, MA, USA,
6University of Florida, Gainesville, FL, USA, 7Veterinary Emer-
gency and Referral Group, Brooklyn, NY, USA, 8Auburn Univer-
sity, Auburn, AL, USA, 9Lamb Consulting LLC, West Saint Paul,
MN, USA
The EPIC Trial reported three cardiac size inclusion criteria
including radiographic vertebral heart size (VHS) >10.5, and
echocardiographically derived normalized left ventricular internal
dimension in diastole (LVIDDN) ≥1.7 and left atrial to aortic
ratio (LA:Ao) ≥1.6 as measured by the Swedish method. However,
echocardiography may not always be available and, therefore,
there is interest in identiﬁcation of a VHS cutoﬀ that predicts
EPIC echocardiography inclusion criteria (EPIC-ECHO+) in dogs
with preclinical myxomatous mitral valve disease (MMVD). Medi-
cal records from 8 sites were searched for MMVD cases that had
contemporaneous thoracic radiographic and echocardiographic
studies. A total of 247 cases were identiﬁed and descriptive statis-
tics are reported as mean, median, and interquartile range for
VHS (11.4, 11.2, 10.8–11.9), LVIDDN (1.80, 1.79, 1.58–2.05), and
LA:Ao (1.78, 1.69, 1.42–2.06). Dogs that were EPIC-ECHO+
(N = 126) were identiﬁed and compared to the remaining popula-
tion (N = 121). Receiver operator curves were constructed for
VHS and performance was explored for optimal cutoﬀs. The per-
cent correct, sensitivity, speciﬁcity, false positive and negative rates
for a VHS of 11.1(72%, 0.730, 0.707, 12%, 16%), 11.7(60%,
0.439, 0.85, 6%, 34%) and 11.9(58%, 0.365, 0.90, 4%, 38%) were
determined. Based on these data, dogs with MMVD and a VHS
>11.7 have a high likelihood of meeting EPIC-ECHO+ (85%
speciﬁcity) and an acceptable false positive rate (6%), however
approximately 34% dogs with a VHS between 10.6–11.7 may meet
EPIC-ECHO+ and warrant further echocardiographic evaluation.
These results may help veterinarians apply the results of the EPIC
Trial to dogs with preclinical MMVD when an echocardiogram is
not readily available.
Disclosures: Disclosures to report.
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EVALUATION OF CONTINUOUS POSITIVE AIRWAY
PRESSURE IN DOGS WITH CARDIOGENIC PULMONARY
EDEMA SECONDARY TO SEVERE MITRAL VALVE DIS-
EASE. P.M. Rocchi, E. Cardone, L. Cagnazzo, S. Lugetti, A.
Ruggeri, F.S. Greco, P.M. Knafelz. Gregorio VII Veterinary
Hospital, Rome, Italy
The aim of this study was to evaluate the application, tolerability
and outcome of continuous positive airway pressure (CPAP) com-
pared to another non-invasive oxygen therapy (ﬂow-by), in dogs
diagnosed with cardiogenic pulmonary edema secondary to severe
mitral valve disease (MVD).
Records of dogs diagnosed with cardiogenic pulmonary edema
based on clinical ﬁndings, thoracic radiographs and echocardiogra-
phy were retrospectively evaluated. Newly diagnosed dogs with
MVD and dogs already in treatment for MVD were included in
the study.
Thirty dogs were included in the study between February 2016
and 2017. All dogs received medical treatment based on clinical
status and echocardiography results and were divided into 2
groups: group 1 (14 dogs) received oxygen administration by
CPAP-helmet at a positive expiratory pressure (PEP) of 5 cm H2O
and group 2 (16 dogs) received oxygen ﬂow-by (2–15 L/min).
Oxygen administration was discontinued based on clinical
improvement, decreased respiratory labor and RR (respiratory
rate), emogas-analysis parameters (PaCO2, or PaO2 and PaO2/
FiO2) and improvement of radiographic signs of pulmonary
edema.
In group 1 the mean age was 12.5 years (2–16) and mean body
weight was 6 kg (3–39). Eleven dogs (78%, 11/14) showed
improvement of RR, respiratory labor, blood gas parameters
within 30 min after CPAP treatment initiation; radiographic signs
of pulmonary edema improved within 8 h. Treatment with CPAP
was intermittent, mean wearing time of the CPAP-helmet was
13.4 h/day (3–12) for 50 h (3–23 h). Butorphanol was adminis-
tered only at the time of application of the CPAP-helmet. The
mortality rate was 35% (5/14).
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In group 2, the mean age was 11.3 years (8–15) and mean body
weight 8 kg (2–22). In seven dogs (43%, 7/16), RR, respiratory
labor and blood gas parameters improved within 30 min after oxy-
gen ﬂow-by administration. Radiographic signs of pulmonary
edema improved after a median of 19 h (12–26 h). Oxygen deliv-
ery was continuous. Butorphanol administration was necessary
more than three times per day. The mortality rate was 62% (10/
16).
Respiratory failure due to cardiogenic pulmonary edema sec-
ondary to MVD is a very common disease in dogs; in this study,
CPAP-helmet interface was a valid alternative to oxygen ﬂow-by
therapy. Though clinical improvement was similar in the ﬁrst
30 min, CPAP-helmet reduced the need for butorphanol adminis-
tration, quickened both clinical and radiographic signs of pul-
monary edema improvement and showed a decrease of the
mortality rate compared to oxygen ﬂow-by. CPAP-helmet was well
tolerated by all dogs.
Disclosures: No disclosures to report.
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DEVELOPMENT OF A SIMPLE ALGORITHM FOR DIAG-
NOSIS OF LEFT-SIDED CONGESTIVE HEART FAILURE IN
DOGS WITH MITRAL VALVE DISEASE. M. Rishniw1, D.
Dickson2, D. Caivano3, L.I. Vatne4, J. Harris5, E. Pavelkova6.
1Cornell University, Ithaca, USA, 2HeartVets UK, Portcawl, UK,
3University of Perugia, Perugia, Italy, 4AniCura Oslo, Oslo, Nor-
way, 5The Animal Hospital, Dursley, UK, 6Wright and Morten
Vets, Macclesﬁeld, UK
Clinicians in ﬁrst-opinion practice commonly diagnose congestive
heart failure (CHF) in small breed dogs with myxomatous mitral
valve disease (MMVD) that do not have CHF. To improve the
accuracy of CHF diagnosis, we developed an initial algorithm
based on historical, physical and radiographic ﬁndings that might
help a clinician in ﬁrst opinion practice to more accurately diag-
nose CHF in these dogs. We then sought to reﬁne and validate the
algorithm by determining which of these historical, physical and
radiographic ﬁndings help discriminate dogs with MMVD into
CHF and “not CHF” groups.
We collected the following historical and physical examination
information on 52 small-breed dogs presenting for evaluation of a
cough, murmur, or suspicion of CHF to the referral clinician:
presence or absence of coughing, duration of coughing, recent
worsening of cough, presence of loud crackles, murmur intensity,
presence of sinus arrhythmia, heart rate, in-clinic respiratory rate,
presence or absence of dyspnea, sleeping respiratory rate, response
to a diuretic trial (if considered necessary by the referral clinician)
and radiographic evaluation of left atrial size. Additionally, all
dogs underwent echocardiographic evaluation. The diagnosis of
“CHF” or “not CHF” was made by each investigator on their
own cases, using all required diagnostic tests and treatment, and
not validated by other investigators.
Historical and physical variables that excluded a diagnosis of
CHF included presence of a sinus arrhythmia (never identiﬁed
in CHF dogs), a murmur that was “less than loud”, a heart
rate <120 bpm, an in-clinic RR <35 breaths/min, less-than-mod-
erate left atrial enlargement on radiographs. A positive diuretic
trial which alleviated dyspnea conﬁrmed a diagnosis of CHF.
20/21 coughing dogs with CHF showed a recently worsening
cough.
Based on these ﬁndings, we reﬁned our algorithm so that detec-
tion of either a sinus arrhythmia, a soft murmur, a sinus rate
<100 bpm, or an in-clinic RR < 30 breaths/min excludes a diagno-
sis of CHF. Presence of a cough or crackles does not help, but a
recently worsening cough warrants increases the suspicion of
CHF. In cases where CHF is suspected, a resolution of dyspnea
with appropriate diuresis strongly supports the diagnosis of CHF.
How well the reﬁned algorithm performs with ﬁrst opinion clini-
cians remains to be determined.
Disclosures: Disclosures to report.
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paralysis (ACVIM Foundation Grant) and has provided continu-
ing education talks for general practitioners over the last 4 years,
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EFFECTS OF TREATMENT WITH THROMBOXANE A2
SYNTHASE INHIBITOR ON PULMONARY HYPERTEN-
SION: A PILOT STUDY. J. Lee1, W. Kim2, W. Yoon3, H. Kim1.
1VIP Animal medical center, Seoul, South-Korea, 2Columbia
University, New York, USA, 3Guardian Angel Veterinary Hospi-
tal, Anyang, South-Korea
Thromboxane A2 (TXA2) is an important multifactorial mediator
in the pathogenesis of pulmonary hypertension. Although endothe-
lium-derived TXA2 causes excessive pulmonary vascular resistance
by acting as a potent vasoconstrictor, mitogen of vascular smooth
muscle cells and promoter of platelet aggregation, there is no cur-
rent therapeutic strategy for pulmonary hypertension, targeting
TXA2 formation. The aim of this study is to assess possible beneﬁ-
cial eﬀects of inhibiting TXA2 synthesis in patients with pul-
monary hypertension.
Sixteen client-owned dogs with proven moderate-to-severe pul-
monary hypertension were randomly assigned to the treatment
(n = 8; ozagrel hydrochloride, 5 mg/kg bid PO) or control group
(n = 8; sildenaﬁl citrate, 1 mg/kg bid PO). All patients have
already been treated with standard protocol including sildenaﬁl
(1.8  0.6 mg/kg, bid). Pulmonary hypertension associated with
left-side heart failure (LA/Ao >1.6 and LVIDDn >1.7) was
excluded in the population. Several clinical indices, which relate to
hypoxia (lactate, SpO2, base excess), thrombosis (d-dimer), azote-
mia (BUN, creatinine), congestion (NT-proBNP) and echocardio-
graphic indices (peak velocity of tricuspid regurgitation, Ao/
MPA), were tracked down for four weeks.
The treatment led to signiﬁcant and gradual decreases in lactate
and d-dimer (P < 0.01; from 5.6  1.9 mmol/L to 1.8  1.0 and
from 7.4  6.8 to 1.2  1.1 lg/mL, respectively) but signiﬁcantly
increased SpO2 and base excess (P < 0.01; from 87  5.3 to
95  1.8 % and from 8.4  3.2 to 3.1  1.9 mmol/L, respec-
tively) in the patients. Compared to controls, the treatment group
exhibited statistically signiﬁcant changes in only lactate level
(P = 0.02) and SpO2 (P = 0.016). However, treatment of TXA2
synthase inhibitor showed the tendency to improve the other vari-
ables, such as NT-proBNP and tricuspid regurgitant ﬂow, impli-
cating the potential role of TXA2 synthase inhibitor in pulmonary
vascular impedance. Abnormal behavior such as licking footpads
and joints has been reported to be a putative side eﬀect of the
treatment in one case.
These results suggest that TXA2 synthase inhibitor may con-
tribute to the improvement of pulmonary hemodynamics in pul-
monary hypertension by alleviating pulmonary vasoconstriction
and preventing thrombosis.
Disclosures: No disclosures to report.
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ECHOCARDIOGRAPHIC EVALUATION OF RIGHT VEN-
TRICULAR DIMENSION AND SYSTOLIC FUNCTION IN
DOGS WITH PULMONARY HYPERTENSION. T. Vezzosi1, R.
Tognetti2, G. Costa2, F. Marchesotti3, L. Venco4, E. Zini5, O.
Domenech3. 1University of Pisa, San Piero A Grado, Pisa, Italy,
2Department of Veterinary Sciences, University of Pisa, San Piero
A Grado, Pisa, Italy, 3Department of Cardiology, Istituto Veteri-
nario di Novara, Granozzo Con Monticello, Novara, Italy, 4Clin-
ica Veterinaria Lago Maggiore, Dormelletto, Novara, Italy,
5Department of Internal Medicine, Istituto Veterinario di Novara,
Granozzo Con Monticello, Novara, Italy
Pulmonary hypertension (PH) may lead to right ventricular (RV)
remodeling, dysfunction and right-sided congestive heart failure
(R-CHF). RV enlargement and dysfunction are strongly associated
with prognosis in humans with PH. Reference intervals for RV
size and systolic function have been described in healthy dogs. The
aims of this study were to assess RV size and systolic function in
dogs with PH and to verify if they are associated with severity of
PH.
This was a prospective, multicenter, observational study. We
included 138 client-owned dogs: 64 with PH and 74 healthy. PH
was classiﬁed according to tricuspid regurgitation pressure gradient
(TRPG) in mild (TRPG: 36–50 mmHg; n = 18 dogs), moderate
(TRPG: 51–75 mmHg; n = 14 dogs) and severe (TRPG
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>75 mmHg; n = 32 dogs). Fourteen dogs with PH had R-CHF.
Echocardiographic evaluation of the RV was obtained from the
left apical 4-chamber view optimized for the right heart. RV
dimension was evaluated through the RV end-diastolic area
(RVEDA) index, calculated as RVEDA divided by body surface
area. Echocardiographic indices of RV systolic function were tri-
cuspid annular plane systolic excursion (TAPSE) and RV frac-
tional area change (FAC) normalized for body weight (TAPSEn
and FACn, respectively).
RVEDA index was signiﬁcantly higher in dogs with mild, moder-
ate and severe PH than in healthy dogs (P < 0.05 for each contrast).
No diﬀerences in RVEDA index were found between dogs with
moderate and severe PH. RVEDA index was signiﬁcantly higher in
dogs with R-CHF in comparison to dogs without R-CHF
(P < 0.0001). TAPSEn below the reference interval was found in 1/
14 dogs with moderate PH and in 4/32 with severe PH, but did not
signiﬁcantly diﬀer among dogs with mild, moderate and severe PH
in comparison to healthy. FACn below the reference interval was
found in 4/14 dogs with moderate PH and 6/32 with severe PH, and
did not signiﬁcantly diﬀer between dogs with and without PH, irre-
spective of the severity. No diﬀerences in TAPSEn and FACn were
found between dogs with and without R-CHF.
In conclusion, the RVEDA index was increased in dogs with PH
and in those with R-CHF, suggesting that it may represent a useful
parameter to assess PH severity. Because TAPSEn and FACn were
abnormal in only a few dogs with moderate-to-severe PH, these
parameters of RV dysfunction do not seem to be linked to R-CHF
in this species. Further studies are therefore needed to identify addi-
tional factors associated with R-CHF in dogs with PH.
Disclosures: No disclosures to report.
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CAUDAL VENA CAVA ASSESSMENT IN DOGS WITH
RIGHT-SIDED CONGESTIVE HEART FAILURE: A PILOT
STUDY. A.C. Merveille1, E. Darnis1, S. Boysen2, K. Gommeren1.
1University of Liege, Liege, Belgium, 2University of Calgary, Cal-
gary, Canada
Right-sided congestive heart failure (R-CHF) secondary to right-
sided heart or pericardial diseases is characterized by increased
right atrial, systemic venous and capillary pressures. Direct right
atrial pressure measurements are considered the gold standard for
identifying R-CHF, but are invasive. In human medicine, sono-
graphically identifying a distended, non-compliant caudal vena
cava (CVC) is a non-invasive means of detecting R-CHF and/or
estimating intravascular volume. Sonographic CVC dimensions in
healthy dogs have been reported. However, the eﬀect of R-CHF
on CVC dimensions is not well described. The objective of this
study was to determine if CVC measurements, obtained via three
diﬀerent sonographic views, from dogs with R-CHF are outside
reference intervals (RI).
Dogs presenting with right-sided heart disease and ascites were
prospectively evaluated. Via longitudinal subxiphoid views (SV),
maximal and minimal CVC diameter (SV-CVCMax, expiration,
SV-CVCMin, inspiration) and collapsibility index (CI) were mea-
sured. Transverse 11–13th right hepatic intercostal views (HV) were
used to measure maximal and minimal CVC (HV-CVCMax, HV-
CVCMin) and aortic diameter. A single CVC and aortic diameter
(PV-CVC, PV-Ao) were measured via longitudinal right paralum-
bar views (PV). CVC dimensions were adjusted for the three views
using allometric scaling as well as indexed to aortic diameter for
HV and PV. Data were compared to a RI previously established
by the authors using 126 healthy dogs of various breeds. Data
were expressed as median and range.
Six dogs weighing 19.2 kg (7.2–33.9), were included. Diagnosis
included pulmonary hypertension (n = 3), congenital heart disease
(n = 2) and pericardial eﬀusion (n = 1). 6/6 and 5/6 dogs had SV-
CVCMax and SV-CVCMin above RI, respectively. All dogs had
CI (19% (7–24)) within RI. HV-CVCMax and HV-CVCMin were
above RI in 5/6 and 4/6 dogs, respectively. 2/6 HV-CVCMax/Ao
and HV-CVCMin/Ao ratios were above RI. The PV-CVC/Ao
ratio was 1.28 (1.13–1.47), and above RI in 4 dogs. The PV-CVC
diameter, using allometric scaling, was above RI in one dog.
This pilot study suggests that an enlarged CVC is observed in
dogs with evidence of R-CHF. CVC distension may be easiest to
identify at the SV. This could be due to the proximity CVC in
relation to the right atrium and/or the inﬂuence of the respiratory
cycle on the CVC diameter between healthy dogs and dogs with
R-CHF when measured at the SV. In contrast to human medicine,
there was no diﬀerence in CI between dogs with R-CHF and
healthy dogs. A larger study is needed to conﬁrm these ﬁndings.
Disclosures: No disclosures to report.
ESVC – O – 7
HEART RATE VARIABILITY IN DOGS WITH INTRACRA-
NIAL DISEASE. R.R. Blake, K. Marioni-Henry, N.M. Rze-
chorzek, Y. Martinez-Pereira. University of Edinburgh, Roslin,
UK
In humans, alterations in heart rate variability (HRV) have been
associated with various forms of intracranial disease due to distur-
bances in the autonomic nervous system. HRV has been shown to
hold prognostic value in these patients.
The aims of this study were to evaluate alterations in HRV in
dogs with clinical signs of intracranial disease and the relationship
of HRV with the results of brain imaging and outcome.
Ambulatory electrocardiographic recordings were prospectively
obtained from 12 client-owned dogs with a history and/or neuro-
logical examination consistent with intracranial disease. Data was
collected for a minimum of 12 h the night before brain imaging
(MRI or CT), while the dogs were hospitalized. Control data was
gathered from 25 healthy dogs used in a parallel study on HRV.
The data was analyzed using Novacor Holtersoft Ultima Version
2.5.5. Time and frequency-domain measurements of HRV, Poin-
care plots and their descriptors were generated from the data.
Two dogs from the diseased group were excluded, one due to
the presence of persistent arrhythmia and another due to a record-
ing time of less than 12 h. The mean heart rate of the diseased
group was higher than that of the control group when HRV
parameters were calculated from 6 h of resting data for each
group. All of the measured parameters of HRV (SDNN,
SDNNIDX, PNN50%, RMSSD, SD1, SD2, SD1/SD2, HFmsec2,
LFmsec2), apart from SDANN, were lower in the diseased group
than the control group (P < 0.03). There was no distinct Poincare
plot pattern evident for the diseased group when compared to the
healthy controls. There was no signiﬁcant diﬀerence in any of the
HRV measurements over 12 h of recording between dogs with
intracranial lesions present on imaging (n = 7) and those with no
imaging abnormalities (n = 3). Neither was there a signiﬁcant dif-
ference between those who were alive 3 months following data col-
lection (n = 5) and those who were not (n = 5).
This pilot study suggests that the presence of intracranial dis-
ease may be associated with a reduction in HRV in dogs, regard-
less of the underlying etiology. HRV does not appear to be
predictive of brain imaging ﬁndings in a small cohort of dogs with
clinical signs of intracranial disease, and there does not appear to
be a relationship between HRV and survival.
Disclosures: No disclosures to report.
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GENETIC BACKGROUND OF FOCAL JUNCTIONAL
TACHYCARDIA WITH ISORHYTHMIC ATRIOVENTRICU-
LAR DISSOCIATION IN LABRADOR RETRIEVERS. G. Kiss1,
G. Nyır~o2, A. Patocs2, E. Javorszky3, B. Balint4, I. Nagy4,5, F.
Manczur1. 1Department and Clinic of Internal Medicine, Univer-
sity of Veterinary Medicine, Budapest, Hungary, 2Department of
Laboratory Medicine, Semmelweis University, Budapest, Hungary,
31st Department of Pediatrics, Semmelweis University, Budapest,
Hungary, 4Seqomics Biotechnology Ltd, Morahalom, Hungary,
5Institute of Biochemistry, Biological Research Centre of the
Academy of Sciences, Szeged, Hungary
Focal junctional tachycardia with isorhythmic atrioventricular dis-
sociation is a known arrhythmia in Labrador retrievers. Because
of breed predisposition of this type of arrhythmia, genetic back-
ground is strongly suspected in the dog. Recently, we diagnosed
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the disease in several Labradors including a family with three con-
secutive generations. The aim of our study was to describe the
inheritance pattern and to identify potentially causative gene
mutations in our population. Study population consisted of 12
Labradors. Eight dog was diagnosed with diﬀerent severity of the
disease, one was a 13 years old healthy littermate in an aﬀected
family, three dogs (>10 years old) from diﬀerent breed lines served
as controls. Clinical diagnosis was made by electrocardiography
and echocardiography. Inheritance pattern was studied by pedigree
analysis. Genomic DNA was isolated from EDTA-anticoagulated
blood samples using a commercial kit. Whole exome sequencing
(WES) of healthy and diseased littermates was used to identify
candidate mutations (Illumina HiSeq2500 next generation sequenc-
ing system, Agilent Sure Select Canine All Exon 54 Mb library-
kit, 50x-coverage, CanFam3.1 annotation). Selection of target
mutations in genes related to calcium transport was based on clini-
cal experience with calcium channel blocker diltiazem, that could
eﬀectively control the disease. Sanger-sequencing was used to vali-
date WES results in the study population and in controls
(ABI3500 capillary-sequencing system, BigDye3.1 chemistry). The
disease was present in all generations (aﬀecting both genders) of
the aﬀected Labrador family, although the symptoms varied
among the individuals. Sudden death at young age occurred in the
oﬀsprings of parents that were both clinically aﬀected. Develop-
ment of congestive heart failure between 5 and 8 years of age due
to tachycardiomyopathy was another observed phenotype, while
there were also some clinically asymptomatic dogs with or without
the arrhythmia. Comparison of the WES data of the healthy and
diseased littermates resulted in 1629 diﬀerences in coding regions.
After ﬁltering for calcium turnover related targets a homozygous
single nucleotide variant (c.[3019C>A]; [Gln1007Lys]) in Ryan-
odine receptor-2 (RyR2) gene and a heterozygous insertion
(c.246_247insCAG; p.Gln92_Ser93insGln) in the calcium activated
potassium channel gene (KCNN2) were identiﬁed. Both were con-
ﬁrmed to be present in all of the clinically aﬀected (related and
unrelated) dogs and absent in healthy controls by Sanger-sequen-
cing. Pedigree analysis suggests an autosomal dominant inheri-
tance pattern with strong but incomplete penetrance and variable
expression in the aﬀected Labrador family. The identiﬁed RyR2
and KCNN2 mutations may have a causative role in the disease
development in Labrador retrievers.
Disclosures: No disclosures to report.
ESVC – O – 9
IMMUNOFLUORESCENT LOCALIZATION OF PLAKOGLO-
BIN IN ENDOMYOCARDIAL BIOPSY SAMPLES TO DIAG-
NOSE ARRHYTHMOGENIC RIGHT VENTRICULAR
CARDIOMYOPATHY (ARVC) IN THE DOG. E.M. Oxford1, R.
Pariaut1, M. Tursi2, P.R. Fox3, R.A. Santilli1. 1Cornell University
Hospital for Animals, Ithaca, USA, 2Department of Veterinary
Sciences, University of Turin, Turin, Italy, 3Caspary Institute, The
Animal Medical Center, New York, USA
In early stages of ARVC, diagnosis is diﬃcult due to the absence
of echocardiographic changes and day-to-day arrhythmia variabil-
ity. A deﬁnitive diagnosis requires histopathologic identiﬁcation of
transmural ﬁbrofatty replacement of the right ventricle. Reduction
of immunoﬂuorescent signal for the desmosomal protein plakoglo-
bin has been reported in ARVC-aﬀected humans and boxers.
Reduction in plakoglobin signal within endomyocardial biopsy
samples (EMBs) may help diagnose ARVC.
EMBs were obtained with owner consent from 48 dogs: 42 with
advanced cardiac disease and six asymptomatic boxers (>5 years)
with mild to moderate ventricular arrhythmia (VA) burden. Inves-
tigators were blinded to breed and clinical signs of the dogs.
ARVC was diagnosed from EMBs by histopathology (MT) in 5
dogs. Of these, 3 had clinical signs consistent with ARVC (2 box-
ers, 1 English bulldog). Two were asymptomatic boxers with a
moderate VA burden. Confocal microscopy was performed
(EMO) to detect immunoreactive signal for plakoglobin in EMBs.
Samples were prepared with antibodies recognizing cadherin (inter-
calated disc marker) and plakoglobin.
Forty-two samples were positive for cadherin signal and 6 were
non-diagnostic. Plakoglobin signal was reduced in 4 samples: 2
boxers and 1 English bulldog with clinical signs and
histopathologic diagnoses of ARVC. The fourth sample was from
a mongrel diagnosed with myocarditis. Plakoglobin signal was pre-
sent in all 6 asymptomatic boxers, including those with a
histopathologic diagnosis of ARVC.
These results suggest that reduced plakoglobin signal in EMBs
may help to diﬀerentiate ARVC from other myocardial diseases in
dogs, speciﬁcally when clinical signs of disease are present.
Disclosures: No disclosures to report.
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RIGHT VENTRICULAR VOLUME QUANTIFICATION MEA-
SURED BY REAL-TIME 3D ECHOCARDIOGRAPHY AND
ECG-GATED 64 SLICE MDCT IN HEALTHY DOGS. N.L.
Leblanc, K.F. Scollan. Oregon State University, Corvallis, USA
Accurate assessment of right ventricular (RV) structure and func-
tion is an integral component of a complete cardiology evaluation
in veterinary patients. Assessment of RV performance is particu-
larly important in patients with pulmonary hypertension, congeni-
tal heart disease, and acquired myocardial disease aﬀecting the
RV. There is evidence in human medicine suggesting RV function
is strongly associated with outcomes in many conditions. The aim
of this study was to evaluate the accuracy of right ventricular vol-
ume (RVV) and function quantiﬁcation using three-dimensional
echocardiography (3DE) compared to electrocardiogram-gated
multidetector computed tomography (ECG-gated MDCT).
Six intact hound cross dogs weighing between 19.5–23.8 kg were
anesthetized using a standardized protocol and spontaneous venti-
lation. Each dog underwent an ECG-gated MDCT and complete
3DE examination. Right ventricular end-diastolic volumes (EDV),
end-systolic volumes (ESV), stroke volume (SV), and ejection frac-
tion (EF) were measured using software speciﬁc for RVV quantiﬁ-
cation from 3DE and MDCT data sets. Correlation and levels of
agreement between methods were determined, and intra- and inter-
observer variability was assessed for 3DE.
There were no statistically signiﬁcant diﬀerences between SV
(P = 0.16) and EF (P = 0.31) obtained by MDCT and 3DE. There
were signiﬁcant diﬀerences between EDV (P = 0.03) and ESV
(P = 0.01) RVV obtained by MDCT and 3DE. No statistically sig-
niﬁcant diﬀerence in HR was noted between methods (P = 0.84).
The correlation between MDCT and 3DE was very good for EDV
and ESV (R = 0.87), moderate for EF (R = 0.60) and poor for SV
(R = 0.31). Bland-Altman analysis showed a systematic underesti-
mation of RVV derived from 3DE compared to MDCT, with an
average bias of 15 and 10.3 mL for EDV and ESV, respectively.
The intra- (EDV 12%, ESV 18%) and interobserver (EDV 14%,
ESV 11%) variability was acceptable for 3DE.
The results of this study suggested use of 3DE to measure RVV
in healthy dogs was feasible with acceptable reproducibility. Mea-
sures of RVV by 3DE underestimate those made by MDCT, there-
fore absolute volumes of these imaging techniques are not
interchangeable. However, there were no signiﬁcant diﬀerences for
EF between methods, which suggests that 3DE may be used to
evaluate global RV function and monitor trends with disease
states. A larger prospective study in dogs with and without cardiac
disease is needed to delineate the beneﬁts and constraints of these
methods.
Disclosures: No disclosures to report.
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FEASIBILITY OF INTRACARDIAC ECHOCARDIOGRAPHY
IN DOGS: A PILOT STUDY . C. Damoiseaux1, V. Chetboul1, V.
Gouni1, M. Lavennes1, C. Poissonnier1, L.E. Carazo Arias1, M.P.
Alvarado1, L. Behr2, A. Morlet2, F. Laborde2, N. Borenstein2.
1Ecole Nationale Veterinaire d’Alfort, Unite de Cardiologie
d’Alfort, Maisons Alfort, France, 2IMMr, Paris, France
The intracardiac echocardiography (ICE) technology uses a cathe-
ter-based steerable ultrasound probe passed into the vessels to
image intracardiac structures and blood ﬂow from inside the car-
diovascular system, with a similar to superior image resolution as
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compared to transesophageal echocardiography (TEE). Its clinical
applications in human cardiology are growing, particularly for
interventional procedures. The aim of this pilot study was thus to
assess the feasibility of ICE in the dog during interventional proce-
dures, i.e., transcatheter PDA closures using Amplatz© Canine
Ductal Occluder (ACDO).
The study population consisted of 4 dogs (median age:
0.75 year [0.3–2.1]; body weight: 15.1 kg [9.2–20.8]). A type II
morphology PDA with left-to-right shunting was visualized in all
cases based on transthoracic echocardiography (TTE) using two-
dimensional (2D) and three-dimensional modes, as well as color-
ﬂow Doppler recordings. In 2 dogs, previous unsuccessful surgical
closure of a PDA by thoracotomy was reported by the referent
veterinarians, with placement of several hemostatic clips (Case #1)
and mild hemorrhage of the PDA corrected with resorbable hemo-
static compresses (Case #2). The ICE ultrasound system ViewMate
Z© and the ViewFlex Plus catheter© (St Jude Medical, 4.5–
8.5 MHz) were manipulated in all cases by a trained highly experi-
enced observer in ICE imaging modality and a second observer
for imaging settings if needed.
The ViewFlex Plus catheter was introduced by the left or the
right femoral artery using a 9 to 10 French introducer (depending
on dog’s size) in all cases except for the smallest dog (9.2 kg), and
was placed in the descending aorta dorsally to the ductus. In the
two dogs that underwent a previous unsuccessful surgical closure
of a PDA by thoracotomy, ICE provided a better evaluation of
the PDA morphology (Case #1) and associated lesions (Case #2)
than TEE. For Case #1, unlike ICE, TEE did not allow an opti-
mal acoustic window to accurately visualize the PDA area because
of the hemostatic clips. In all cases, ICE allowed conﬁrmation of
complete PDA occlusion using combined 2D and color-ﬂow Dop-
pler modes. Furthermore, in two dogs, ICE was used as the sole
guidance for deployment of the ACDO device.
In conclusion, this report illustrates the safe and eﬀective use of
ICE in dogs during transcatheter procedures.
Disclosures: No disclosures to report.
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USE OF TWO-DIMENSIONAL SPECKLE TRACKING
ECHOCARDIOGRAPHY TO ASSESS LEFT VENTRICULAR
SYSTOLIC FUNCTION IN DOGS WITH SYSTEMIC
INFLAMMATORY RESPONSE SYNDROME. A. Corda1, P.
Gomez-Ochoa2, G. Sotgiu3, R. Zobba1, M.L. Pinna Parpaglia1, J.
Prieto Ramos4, A. French4. 1Department of Veterinary Medicine,
University of Sassari, Sassari, Italy, 2Faculty of Veterinary Medi-
cine, University of Zaragoza, Zaragoza, Spain, 3Department of
Biomedical Sciences, University of Sassari, Sassari, Italy, 4School
of Veterinary Medicine, University of Glasgow, Glasgow, UK
Systemic Inﬂammatory Response Syndrome (SIRS) is a clinical
syndrome caused by systemic inﬂammation of infectious or non-
infectious origin. SIRS is characterized by an endogenous cascade
of interleukins and other inﬂammatory mediators such as TNF-a,
IL-6 and IL-1 which are responsible for myocardial depression
during systemic inﬂammation. Conventional echocardiographic
indices of left ventricular systolic function such as fractional short-
ening (FS) and ejection fraction (EF) are not sensitive enough to
detect mild or early systolic dysfunction in dogs suﬀering from
SIRS. Two-dimensional Speckle-Tracking Echocardiography (2D-
STE) is a new echocardiographic technique that allows an objec-
tive and quantitative evaluation of global and regional myocardial
function through the analysis of the motion of speckles that are
created by the interaction of ultrasonic beams and the myocar-
dium during the 2-dimensional examination. We tested the hypoth-
esis that 2D-STE may detect left ventricular systolic dysfunction,
not diagnosed by conventional echocardiography, in dogs with
SIRS. Seventeen dogs with evidence of SIRS and 17 healthy dogs
as a control group were included in this prospective study. All the
procedures were performed for diagnostic purpose; the control
group was composed of healthy dogs undergoing surgical castra-
tion or ovariohysterectomy. We excluded from the study breeds
predisposed to dilated cardiomyopathy, pregnant females, dogs
treated with opioids, sedatives or anesthetic drugs during the 12 h
before echocardiography. We also excluded dogs with previous
diagnosis of, or echocardiographic evidence of congenital or
acquired cardiac disease and dogs with an arrhythmia. At the time
of Hospital admission each dog was submitted to standard 2D,
M-mode, Doppler and 2D-STE with simultaneous ECG and blood
pressure measurement. Furthermore, blood samples were obtained
for CBC, biochemical proﬁle and the measurements of cTnI and
CRP serum levels. The results showed that the standard echocar-
diographic indices of systolic function such as EF, FS were not
signiﬁcantly diﬀerent between the two groups. On the contrary,
the Left Ventricular Global Longitudinal Peak Strain of endomy-
ocardial layer and the STE-derived Ejection Fraction (STE-EF)
were signiﬁcantly lower in the SIRS group than in the control
group. We did not ﬁnd signiﬁcant correlation between CRP serum
levels and 2D-STE variables and between cTnI and STE variables.
Furthermore we did not ﬁnd a signiﬁcant diﬀerence in cTnI serum
levels between the two groups. Our study demonstrated that 2D-
STE was more sensitive than standard echocardiography in detect-
ing early or mild to moderate myocardial dysfunction, not
detected by conventional echocardiography, in a population of
dogs with SIRS.
Disclosures: No disclosures to report.
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MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II
HAPLOTYPES ASSOCIATED WITH REMODELING IN
CAVALIER KING CHARLES SPANIELS WITH CHRONIC
VALVULAR HEART DISEASE. L. Bree1, R.E. Shiel1, A.T.
French2, L.J. Tong3, J. Prieto-Ramos2, L.J. Kennedy4. 1University
Veterinary Hospital, University College Dublin, Dublin, Ireland,
2Small Animal Hospital, University of Glasgow, Glasgow, Scot-
land, 3Murdoch University, Melville, Australia, 4Glasgow Univer-
sity, Glasgow, Scotland
Chronic valvular heart disease is common in the Cavalier King
Charles spaniel (CKCS). However, genetic factors contributing to
development or progression of the disease are unknown. Although
classically considered a non-inﬂammatory disease, upregulated
expression of genes involved in inﬂammation and immune function
has been identiﬁed in aﬀected valvular tissue. Therefore, genetic
determinants of the immune response could inﬂuence disease pro-
gression in individual dogs.
The aims of this study were to document major histocompatibil-
ity haplotype (MHC) dog leukocyte antigen (DLA) class II haplo-
types in the CKCS, and to examine potential associations between
individual haplotypes and progression of disease.
DLA three-locus haplotypes were determined in 190 CKCS
from the UK (n = 95) and Australia (n = 95) using sequence-based
typing methods. Six haplotypes were identiﬁed.
Echocardiography was performed in 187 dogs; 72 had evidence
of remodeling and 115 did not. Three dogs were not tested.
Remodeling was deﬁned as increased left-atrial-to-aortic ratio
(>1.5) or increased left ventricular internal diameter during dias-
tole or systole (normalized to bodyweight) (LVIDDi>1.85 or
LVIDSi>1.26). Associations between individual haplotypes and the
presence of remodeling were investigated using the Fisher’s exact
test. Odds ratios (OR) and 95% conﬁdence intervals (CI) were
also calculated. The age of the dogs ranged from 0.6 to 16.3 years.
When data from all 187 dogs were considered, two haplotypes
(DRB1*01101/DQA1*00201/DQB1*01303 and DRB1*02001/
DQA1*00401/DQB1*01303 were signiﬁcantly associated with the
presence of remodelling (P = 0.0239 and P = 0.0357; OR 3.562
(95% CI: 1.188–10.68) and 0.5181 (0.2831–0.9482), respectively).
Echocardiographic evidence of remodelling was present in 24
dogs <9 years old and absent in 37 dogs ≥9 years old.
DRB1*01101/DQA1*00201/DQB1*01303 was signiﬁcantly
(P = 0.035) associated with the presence of remodelling at a
younger age (odds ratio 3.562, (1.188–10.68)).
These results suggest an association between MHC DLA haplo-
type and the progression of chronic valvular heart disease in the
CKCS. Further studies are recommended to explore the potential
role of the immune system in the pathogenesis of this disease.
Disclosures: No disclosures to report.
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MIRNAS IN PROGRESSING CANINE MYXOMATOUS
MITRAL VALVE DISEASE. F. Traub, K. Weber, G. Wess.
Clinic of Small Animal Medicine, Veterinary Faculty, LMU
Munich, M €UNCHEN, Germany
Micro ribonucleic acids (miRNAs) are short RNA molecules
which regulate gene expression. They show a varying expression in
many diseases, including heart disease. miRNAs are stable and
detectable from blood. Therefore, they are potential biomarkers.
Myxomatous mitral valve disease (MMVD) is the most common
heart disease in dogs. In the long preclinical phase, progressive
degeneration of the mitral valve leads to eccentric left-ventricular
and -atrial hypertrophy, eventually succeeded by congestive heart
failure and death. We aimed to investigate the expression of miR-
NAs in blood plasma of dogs in consecutive stages of MMVD.
183 miRNAs were quantiﬁed from blood plasma using RT-qPCR
in 10 dogs passing 3 stages of MMVD (modiﬁed CHIEF stage B1,
B2, and C2/C3). One-way repeated measures ANOVA and pairwise
comparisons using Benjamini-Hochberg-correction showed signiﬁ-
cant diﬀerences (P < 0.05) in expression within 3 miRNAs: cfa-
miR-92b was downregulated in MMVD stage C2 compared to stage
B1 and B2 by the factor of 0.52 and 0.61, respectively. cfa-miR-92a
and cfa-miR-1306 were downregulated in MMVD stage C2 com-
pared to stage B1 by the factor of 0.60 and 0.53, respectively. There
was no signiﬁcant diﬀerence between any other stages.
The results show that there were miRNAs in canine blood plasma
that diﬀered in expression with progressing MMVD. However, the
total number of miRNAs varying and the diﬀerence between stages
were small. To evaluate the role of miRNAs as potential biomark-
ers, further studies are needed-with a bigger population eventually
including more stages of disease and healthy control subjects.
Disclosures: The authors have the following disclosures related
to the study described in their abstract: The American Kennel
Club Canine Health Foundation, Inc. (Raleigh, NC, US) provided
a research grant ($24,850) that covered the laboratory consum-
ables used in this study. There was no further ﬁnancial or other
form of support. The authors do not have commercial interests
and have not made investments related to the study. The authors’
institution does not beneﬁt from the results of the study. There
were no gifts, hospitality or travel support.
ESVC – O – 15
WHITE COAT EFFECT IN CLIENT-OWNED DOGS, AS
ASSESSED BY HIGH DEFINITION OSCILLOMETRY
(HDO). R.S. Tims, R.D. Baumwart, A.S. Hanzlicek, M.E. Payton.
Oklahoma State University, Stillwater, USA
White coat eﬀect is an elevation in blood pressure due to stress or
anxiety in a clinical setting. Diﬀerentiating white coat eﬀect from
true systemic hypertension can be challenging. The objective of
this study was to further characterize white coat eﬀect in client-
owned dogs and to determine if pharmacologic manipulation (bu-
torphanol) decreases this eﬀect.
Thirty client-owned dogs were enrolled. Clients were trained to
collect high deﬁnition oscillometric (HDO) blood pressure mea-
surements at home, and then HDO measurements were obtained
in the hospital before and after the administration of butorphanol.
A client questionnaire was completed to assess level of anxiety
with measurements at home and in hospital.
Diastolic blood pressure (DYS), mean arterial pressure (MAP),
and arterial pulse rate (HR) were signiﬁcantly higher in the hospi-
tal before butorphanol as compared with at home. The administra-
tion of butorphanol abrogated these diﬀerences. The HR was
signiﬁcantly lower after sedation as compared with before sedation
in the hospital, but it remained signiﬁcantly higher as compared
with that obtained at home.
The subjective anxiety scores at home and in the hospital were
signiﬁcantly positively correlated with the systolic (SYS), DYS,
and MAP. Anxiety scores at home and in hospital were signiﬁ-
cantly positively correlated.
In conclusion, higher DYS, MAP, and HR seen in the hospital
is likely related to a white-coat eﬀect. The administration of butor-
phanol decreased this eﬀect.
Disclosures: No disclosures to report.
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PREVALENCE AND MURMUR CHARACTERISTICS OF
INCIDENTALLY DETECTED HEART MURMURS AND
HEART DISEASE IN 12,958 YOUNG HEALTHY SHELTER
CATS. B.A.M. Mckeever1, G.P. Nicolson2, M. Awad3, M. Law-
ler3, B. Sette2, N.J. Beijerink2. 1Faculty of Science, Sydney School
of Veterinary Scienc, The University of Sydney, Camperdown,
Australia, 2Faculty of Science, School of Veterinary Science, The
University of Sydney, Camperdown, Australia, 3RSPCA NSW,
Yagoona, Australia
Information on the prevalence and cause of heart murmurs in
young cats is scarce. This prospective study was performed to
investigate prevalence of heart murmurs and heart disease, and to
explore the association between auscultatory and echocardio-
graphic ﬁndings in clinically healthy young cats.
Between May 2012 and March 2017, 12,958 healthy cats aged
≤12 months were screened by auscultation by shelter veterinarians
in a single animal shelter (RSPCA Yagoona, NSW, Australia).
Heart murmurs were detected in 221 (1.7%) cats, which were sub-
sequently within 1 month investigated by a veterinary cardiologist
(NB) or cardiology resident (GN). Murmurs were conﬁrmed in
163 cats. Murmur characteristics (timing, grade, point of maximal
intensity) were recorded. All but one murmur were systolic. The
point of maximum intensity of murmurs was often diﬃcult to
localize.
Subsequently transthoracic echocardiography was performed in
all 221 cats, after which the murmur was assessed to be pathologi-
cal or non-pathological. Cats with multiple congenital heart
anomalies were classiﬁed according to the most severe condition.
No eﬀorts were made to diﬀerentiate between physiological and
innocent murmurs, both were considered non-pathological.
Heart disease was detected in 51 cats (prevalence 0.4% total
population). Diagnoses included obstructive (n = 19) and non-
obstructive (n = 6) mitral valve dysplasia, ventricular septal defect
(n = 15), tricuspid valve dysplasia (n = 7), pulmonic stenosis
(n = 1), double chamber right ventricle (n = 1), subvalvular aortic
stenosis (n = 1), and hypertrophic cardiomyopathy (n = 1). The
murmur was non-pathological in 170 cats (of which 3 cats had
dynamic right ventricular outﬂow tract obstruction).
Grade 5–6 murmurs (n = 5) were all pathological. A positive
predictive value of a grade 3–4 murmur being associated with
pathological heart disease was 58.9% (CI 48.5% to 68.7%), whilst
negative predictive values of grade 0 and grade 1–2 murmurs being
associated with non-pathological heart disease were 96.6% (CI
87.0% to 99.1%) and 88.4% (CI 82.1% to 92.6%), respectively.
In conclusion, in this study the prevalence of heart murmurs
and heart disease were 1.7% and 0.4%, respectively, with mitral
valve dysplasia and ventricular septal defects most commonly diag-
nosed. Murmur grading was helpful in diﬀerentiating non-patholo-
gical from pathological heart murmurs.
Disclosures: Disclosures to report.
Study received funding from Australian Pet Welfare Foundation
(APWF) Authors: Niek Beijerink Speaking & consultancies: Boeh-
ringer Ingelheim, Elanco Animal Health, Bova Compounding,
CEVA Animal Health, Blackmores, Grants / Research: Luoda
Pharma.
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WHEN SHOULD WE TALK ABOUT TACHYPNEA IN CATS
AT THE VETERINARIAN’S CONSULTATION ROOM?. V.
Szatmari, E. Dijkstra. Utrecht University, Utrecht, Netherlands
Tachypnea is an important clinical ﬁnding in dogs with cardiac
and respiratory disorders. Many healthy cats, however, have a
high respiratory rate at the veterinarian’s consultation room, mak-
ing the interpretation of this ﬁnding diﬃcult. The purpose of the
present study was to establish a reference range of the respiratory
rate in clinically healthy cats at the veterinarian’s consultation
room.
Clinically healthy, client-owned cats in 6 private veterinary
practices were observed by a single investigator between May and
August 2016. The cats were brought for consultations for various
reasons. Medical history and clinical examination revealed no
abnormalities. The respiratory rates were recorded under 4
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circumstances: by the investigator at the veterinarian’s consultation
room prior and after manipulation, by the owner at home when
the cat was resting or sleeping, and by the investigator by watch-
ing a video that was recorded by the owner at home when the cat
was resting or sleeping. The owners were asked to perform the
video-recording immediately after that they counted the respira-
tory rate.
A total of 95 adult cats with a median age of 4.7 years (range
8 months–17.1 years) fulﬁlled the inclusion criteria. Calculated ref-
erence interval for the respiratory rate at the veterinarian’s consul-
tation room was 33–133 breaths/min.
Physical examination by a veterinarian led to either increased
(n = 13), decreased (n = 10) or unchanged (n = 3) respiratory rates
in the 26 cats, on which this second measurement was could be
performed.
Video-recordings were provided by 77 owners. The resting and
sleeping respiratory rates were 14–48 breaths/min (n = 36) and 13–
31 breaths/min (n = 41), respectively, both counted by a single
investigator on the video-recordings. A signiﬁcant decline in sleep-
ing respiratory rate with older age was noted: 0.4 breaths/min/
year. Only 32 owners was able to count the respiratory rate of
her/his cat. In 17 out of these 32 cases the reported value diﬀered
from the respiratory rate that was observed from the video-record-
ings. The owners’ results were either higher or lower than the res-
piratory rates counted by the investigator on the videos.
We conclude that the reference intervals that veterinary text-
books usually report for healthy cats is the resting respiratory rate.
These values are not applicable at the veterinarian’s consultation
room because many cats would erroneously be categorized to have
tachypnea. Since the resting and sleeping respiratory rates show
less variations, owners should be educated and encouraged to
count or record their pets respiratory rate before they visit
veterinarian.
Disclosures: No disclosures to report.
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HOW OFTEN DO PRIMARY CARE PRACTITIONERS REC-
OGNIZE INNOCENT CARDIAC MURMURS IN PUPPIES
DURING THE FIRST VETERINARY HEALTH CHECK?. V.
Szatmari, M.D.B. van Staveren. Utrecht University, Utrecht,
Netherlands
Innocent cardiac murmurs are often found in asymptomatic pup-
pies at the age of 7–10 weeks. To what extent these soft murmurs
are recognized by ﬁrst opinion veterinary practitioners is
unknown.
Between October 2015 and June 2016, 354 client-owned clini-
cally healthy puppies of 11 diﬀerent breeds with an age of 45–
76 days were auscultated by a veterinary cardiology specialist and
a ﬁnal year veterinary student. The same dogs had been auscul-
tated by various veterinary practitioner too, when they were 34–
69 days old. Several practitioners of 43 diﬀerent practices per-
formed the auscultation, in average 9 days earlier than the cardiol-
ogist and the student. The student had undergone a 3-h practical
training in cardiac auscultation before starting the study.
The ﬁndings of the cardiologist, student and practitioners were
compared for agreement. The practitioners’ judgments about the
presence or absence of a murmur were looked up in the puppies’
passport.
Of the 330 puppies that were auscultated by both the cardiolo-
gist and a practitioner, the cardiologist detected a murmur in 97
puppies. All murmurs were systolic and had a maximal intensity
of 1 or 2 out of 6. The agreement between the ﬁndings of the car-
diologist and the veterinary practitioners was poor (ϰ = 0.008)
and signiﬁcantly diﬀerent (P < 0.001). Cardiac murmur was heard
by the practitioners in only 1 of the 97 puppies with a murmur. A
total of 255 puppies were auscultated by both the cardiologist and
the student. A fair agreement (ϰ = 0.401) and a signiﬁcant diﬀer-
ence (P = 0.046) were found.
A weakness of the study is that the practitioners performed the
auscultation on a diﬀerent day and under various circumstances.
However, because physiologic anemia is known to contribute to
the genesis of innocent murmurs, the prevalence of innocent mur-
murs at the ﬁrst veterinary health check should have been the
same or higher than at the second time point.
We conclude that soft (innocent) cardiac murmurs in puppies at
the age of 6–10 weeks are seldom recognized by ﬁrst opinion vet-
erinarians. Soft murmurs that are detected by practitioners are
probably louder and therefore they are possibly not innocent, but
are caused by congenital cardiac anomalies. Based on the better
agreement between the ﬁndings of the cardiologist and the student,
compared to the ﬁndings of the cardiologist and the practitioners
we conclude that training has much higher eﬀect on the recogni-
tion of soft cardiac murmurs than experience, even if the training
is short.
Disclosures: No disclosures to report.
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TOWARDS CARDIAC STEM CELL THERAPY: CHARAC-
TERIZATION AND CRYOPRESERVATION OF CANINE
CARDIOSPHERE-DERIVED CELLS. L.C. Dutton1, S.A.V.
Church1, H. Hodgkiss-Geere2, B. Catchpole1, A. Huggins1, J.
Dudhia1, D.J. Connolly1. 1Royal Veterinary College, Potters Bar,
UK, 2University of Liverpool, Liverpool, UK
The use of stem cells to treat cardiac disease has gained increasing
interest in recent years. Cardiosphere-derived cells (CDCs), an
adult cardiac progenitor cell population, are the most promising
candidates for cellular therapy. Their application in rodent models
and phase 1 human trials of ischemic myocardial disease showed
promise measured by increased left ventricular function. However,
much remains unknown about their basic biology, especially in
dogs. To expand this treatment to treat canine dilated cardiomy-
opathy requires the creation of cryopreserved allogeneic cell banks
since this allows timely access to large cell numbers and avoids
obtaining diseased autologous myocardial tissue from potentially
unstable dogs. However, CDCs in culture conditions are subject to
plasticity similar to other adult stem cell populations. We therefore
investigated how passage number or cryopreservation may aﬀect
cellular potency of CDCs obtained from canine atrial explants.
CDCs were isolated and characterized from ﬁve cadavers with
consent. Mesenchymal stem cells (MSCs) were isolated for com-
parison. CDCs demonstrated a population doubling time that was
slower than MSCs (P < 0.05) but importantly was unchanged by
cryopreservation (P = 0.71). Cryopreserved CDCs also demon-
strated the same multi-lineage potential as fresh cells by showing
commitment to myocardial, endothelial and smooth muscle lin-
eages and maintained the ability to form clonal colonies. Flow
cytometry analysis revealed fresh CDCs had a high proportion of
cells expressing CD105 (89.0%  4.98) and CD44
(99.68%  0.13) with varying proportions of CD90+
(23.36%  9.78), CD34+ (7.18%  4.03) and c-Kit+
(13.17%  8.67) cells. CD45+ (0.015%  0.005) and CD29+
(2.92%  2.46) populations were negligible. Increasing passage
number correlated with an increase in the proportion of CD34+
cells and a decrease in CD90+ cells (P = 0.003 and 0.03 respec-
tively). Cryopreserved populations displayed increased positive
populations for CD34 (P < 0.001) and fewer CD90+ cells
(P = 0.042).
Our data revealed the impact of diﬀerent canine donors on cell
phenotype, as there was signiﬁcant inter-donor variability on cellu-
lar morphology and marker expression. Overall, this study shows
that despite these diﬀerences in the CD marker population, cryop-
reservation of canine CDCs is feasible without altering their diﬀer-
entiation potential. Importantly the CDCs we obtained from atrial
tissue conformed to the generally accepted proﬁle of CDCs
obtained from other species and canine ventricular tissue. Further
studies are required to investigate the fundamental biology and
further characterize the phenotype of this heterogeneous stem cell
population prior to clinical application.
Disclosures: Disclosures to report.
PetPlan Charitable Trust funded the research.
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ASSESSING THE FEASIBILITY OF ALLOGENEIC STEM
CELL THERAPY FOR CANINE DILATED CARDIOMYOPA-
THY. L.C. Dutton1, H. Hodgkiss-Geere2, B. Catchpole1, D. Wer-
ling1, J. Dudhia1, D.J. Connolly1. 1Royal Veterinary College,
Potters Bar, UK, 2University of Liverpool, Liverpool, UK
Dilated cardiomyopathy (DCM) causes signiﬁcant morbidity and
mortality with the prevalence in European Dobermans >8 years at
44%. Clinical manifestations include a dilated phenotype with con-
gestive heart failure or malignant arrhythmia causing sudden car-
diac death. As treatment options are limited, there is interest in
using cardiac stem cells. Cardiosphere-derived cells (CDCs) are an
adult cardiac progenitor cell population that can be derived in
large numbers from myocardial biopsies. Administration of CDCs
to murine models of DCM showed improved survival and to
Dobermans marginally increased systolic function. Allogeneic
CDC therapy avoids obtaining cells from unhealthy donors and
allows access to large cell numbers. Mesenchymal stem cells
(MSCs) have been shown to induce an immune-tolerant phenotype
in recipients from unrelated donors. However, MSCs are inferior
to CDCs in their cardiac regenerative capability and it is currently
unknown if canine CDCs possess a similar immune-privileged
status.
Our aim was to characterize the immune-regulatory status of
canine CDCs.
Cardiosphere-derived cells (CDCs), MSCs and lymph node cells
(LNCs) were obtained from ﬁve dogs immediately post-mortem
with owners’ consent and University ethical approval. These cells
were isolated as previously published. The ability of CDCs to form
clones, self-renew and commit to multiple lineages was assessed.
Dogs were genotyped for DLA-88 and DRB-1 and cells assessed
for MHC antigens by ﬂow cytometry. Mixed lymphocyte reactions
(MLR) incorporating responder LNCs and allogeneic stimulator
CDCs or MSCs were performed. LNCs were also cultured alone
or in combination with concanavalin A. Proliferation was assessed
by 3H-thymidine uptake.
Canine CDCs demonstrated the ability to self renew, form clonal
colonies and commit to multiple lineages (myocardial, endothelial
and smooth muscle). All dogs in the study were heterozygous for
both DLA-88 and DRB-1 and varied in haplotype. In MLR assays,
lymphocyte proliferation ability was conﬁrmed by response to con-
canavalin A stimulation. CDCs did not produce a signiﬁcant prolif-
eration in responder LNCs when compared to non-stimulated
LNCs (P = 0.36). This lack of response was conﬁrmed across multi-
ple donor and responder cells with mismatched MHC I and II hap-
lotypes. Interestingly, allogeneic MSCs stimulated a response in
LNCs when compared to non-stimulated cell LNCs (P = 0.011).
These results show that CDCs do not produce an immunologi-
cal response in an in vitro model of transplant immune-reactivity.
This demonstrates that CDCs possess immune-privileged status.
Our study provides evidence for the safe use of allogeneic CDCs
to treat canine DCM.
Disclosures: Disclosures to report.
PetPlan Charitable Trust funded this research.
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THE ASSOCIATION OF CLINICAL, LABORATORY AND
ECHOCARDIOGRAPHIC FINDINGS WITH SURVIVAL IN
108 DOGS UNDERGOING PERICARDIOCENTESIS; A RET-
ROSPECTIVE STUDY. D.G. Ohad1, G. Segev1, Y. Hazut2, Y.
Bruchim1, S. Klainbart1, J. Milgram1, I. Aroch1, E. Kelmer1.
1Koret School of Veterinary Medicine, Hebrew University of Jeru-
salem, Rehovot, Israel, 2Givatayim Vet Clinic, Givatayim, Israel
The median survival time (MST) for dogs with cardiac tamponade
(CT) varies from 1–3 months with hemangiosarcoma, to 5.2–
24.8 months in heart-base-tumor related or non-neoplastic eﬀu-
sions. We evaluated the prognostic usefulness of clinical, labora-
tory and echocardiographic ﬁndings in dogs with CT. Data were
collected retrospectively from 108 dogs with CT undergoing peri-
cardiocentesis (PC) from 2006 to 2011. Dogs alive at 30 days fol-
lowing the ﬁrst PC were deﬁned as short-term survivors. Longer-
term MST was determined from the medical records, and from
follow-up telephone interviews. The prevalence of CT was one of
265 presented dogs (0.004%). The overall long-term MST was
44 days (range 0.5–1455). Dogs with a sonographically demon-
strated cardiac mass had a shorter MST compared to others (19
vs. 90 days, P = 0.005). Males were signiﬁcantly over-represented.
Golden retriever dogs were over-represented and had a higher
occurrence of idiopathic CT. Mixed breed dogs were under-repre-
sented. PC at the Cardiology Service, ascites upon presentation,
an idiopathic CT, and pericardiectomy, were associated with a
higher, while pallor and an inability to ambulate upon presenta-
tion were associated with a lower 30-day survival rate. Survival
rates did not diﬀer between dogs undergoing PC from the right or
the left hemithorax. Survival rates did not diﬀer between dogs
undergoing a single and those undergoing several PCs. However,
median time-intervals from the ﬁrst-to-second and from the sec-
ond-to-third PCs were signiﬁcantly longer in survivors compared
to non-survivors (35 vs. 9, P = 0.001, and 21 vs. 5 days, P = 0.04,
respectively). Two dogs died prior to PC completion. Seven dogs
had an underlying myxomatous mitral valve disease. Four of these
were Dachshunds, of which three had a left atrial-wall rupture
leading to an acute, hemorrhagic CT. In the remaining three, the
pericardial eﬀusate was a modiﬁed transudate. In 31 dogs the
drained eﬀusate volume in the ﬁrst PC signiﬁcantly and positively
correlated (r = 0.77, P < 0.0001) with the pre-PC sonographic
apex-to-pericardial distance. There was no association between
apex-to-pericardial distance (P = 0.086) or volume of ﬂuid drained
during PC (P = 0.5) with the 30-day survival. Generally, dogs pre-
senting with CT have a poor long-term prognosis. However,
Golden retrievers, dogs selected for surgical pericardiectomy, those
that present with ascites, without pallor, and are ambulatory and
those with longer inter-pericardiocentesis intervals have higher sur-
vival rates. Survival rate is not aﬀected by the side of hemithorax
from which pericardiocentesis is performed.
Disclosures: No disclosures to report.
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USEFULNESS OF COLOR TDI AT THE LEVEL OF LAT-
ERAL ATRIAL TISSUE AS A PREDICTOR OF FUTURE
DEVELOPMENT OF ATRIAL FIBRILLATION IN DOGS. J.
Neves1, P. Pedro2, X. Navarro-Cubas1, E. Bode1, J. Dukes-Mce-
wan1. 1University of Liverpool, Neston, UK, 2Willows Vets, Soli-
hull, UK
The total atrial conduction time is an independent predictor of
atrial ﬁbrillation (AF) in humans. It can be estimated by pulsed-
wave tissue Doppler imaging (TDI) by measuring the time from
onset of the P wave until the peak of A’ velocity of the lateral
left atrial wall (P-PA’). A prolongation of P-PA’ identiﬁes people
at high risk of development of AF. This study investigated
echocardiographic variables (including P-PA’ measured with
Color TDI) which may identify dogs which developed AF within
6 months.
All dogs with AF were retrospectively reviewed. Those that
developed a new-onset AF within 6 months after previous echo
were included in the AF group. Dogs with underlying cardiac dis-
ease that did not develop AF within 6 months after echo were also
reviewed and included in the non-AF group. The non-AF group
were selected to have similar body weight (BW) and left atrial
dilatation (2D LA:Ao) to the AF group. P-PA’ durations were
measured oﬄine from archived color TDI images by placing the
region of interest over the interatrial septum (color P-PA’IAS) and
lateral left atrial wall (color P-PA’lateral). P-PA’ durations and echo
variables of 2D, M-Mode and pulsed-wave TDI (S’, E’ and A’
velocities) were compared between groups. Receiving operator
characteristic curves were used to identify the best AF predictor.
65 dogs were included (22 AF; 43 non-AF). Degenerative mitral
valve disease and dilated cardiomyopathy were the most frequent
cardiac diseases in both groups. Risk of new-onset AF was not asso-
ciated with a speciﬁc breed, gender, neutering status, or cardiac dis-
ease. BW, LA:Ao and color P-PA’IAS were not signiﬁcantly diﬀerent
between groups. The AF group had signiﬁcantly greater left-ventri-
cular (LV) end-diastolic (ED) and end-systolic (ES) volumes, M-
Mode LV ED and ES diameters, LV ES diameter indexed for body
weight, LV ES volume indexed to body surface area (ESVi), LA
maximal diameter (LAmax) and color P-PA’lateral. The variables with
highest Area Under the Curve (AUC) were P-PA’lateral (0.8), LAmax
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(0.73), and ESVi (0.70). A color P-PA’lateral cut-oﬀ of 81.3 ms had a
speciﬁcity of 81% and sensitivity of 65 %.
Color P-PA’lateral duration was superior to other echo variables
at predicting AF development within 6 months. LAmax had the
second highest AUC despite similar LA:Ao between groups.
Absolute LA size appears to play a more important role in AF than
relative atrial dilation. Clinically useful cut-oﬀs and intra/inter-obser-
ver variability need to be conﬁrmed in a prospective study.
Disclosures: No disclosures to report.
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ECG-GATED COMPUTED TOMOGRAPHY ANGIOGRAPHY
OF PATENT DUCTUS ARTERIOSUS IN 25 DOGS. N.J. Bei-
jerink, E. Newﬁeld, G.P. Nicolson, H. Laurendet, M.A. Makara.
Sydney School of Veterinary Science, University of Sydney, Cam-
perdown, Australia
Patent ductus arteriosus (PDA) is one of the most common con-
genital cardiac diseases in dogs. ECG-gated computed tomography
angiography (CTA) can be a complementary minimally-invasive
way in early planning of interventional occlusion. The aim of this
prospective observational study was to report CTA ﬁndings associ-
ated with PDA.
A total of 25 dogs diagnosed with PDA aged 2 to 54 months
and weighing 2.5 to 38.1 kg were enrolled: all dogs were planned
to undergo possible interventional occlusion under the same anes-
thetic directly after CTA. The contrast medium injection protocol
was individually tailored with total injection time equaling the sum
of diagnostic scan delay and scan duration. First, 1 ml/kg undi-
luted contrast medium (370 mgI/mL) was administered for two
thirds of the total injection time, directly followed by 2 ml/kg of
1:1 diluted contrast medium for one third of the total injection
time. The CT scan was triggered manually under a single breath
hold when the contrast bolus reached the descending aorta. Scan-
ning was commenced regardless of the heart rate.
Image reconstruction was performed during mid-diastole (70%
of the R-R interval). In 2 dogs the heart rate was too high (>140
BPM) to allow image reconstruction. In the other 23 dogs the
sagittal plane of the images was optimized for visualization of the
PDA. The minimal ductal diameter at the pulmonary ostium (me-
dian 3.4 mm, range 1.7–11.6 mm), ampulla diameter (median
7.0 mm, range 3.7–13.2 mm), ampulla length (median 10.7 mm,
range 6.8–18.9 mm), angle between PDA and aorta (median 149°,
range 134–155°) and Miller type PDA morphology (type I, n = 5;
type 2A/B, n = 16; type III, n = 2) were determined. A total of 23
dogs (all except the 2 dogs with a type III PDA morphology) sub-
sequently underwent successful interventional occlusion, and in all
dogs with available CTA images the suspected PDA morphology
could be conﬁrmed with ﬂuoroscopy.
In conclusion, despite ﬂuoroscopy remaining the gold standard
for accurate sizing of the PDA prior to interventional occlusion,
CTA is a complementary diagnostic method that may provide
additional relevant information for planning of catheter-based
intervention, potentially shorten surgery time and reduce the
amount of radiation to which the clinician is subjected.
Disclosures: No disclosures to report.
Niek Beijerink Speaking & consultancies: Boehringer Ingelheim,
Elanco Animal Health, Bova Compounding, CEVA Animal
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IS PROPHYLACTIC ANTIBIOTIC THERAPY NECESSARY
TO PREVENT INFECTIOUS ENDOCARDITIS IN DOGS
THAT UNDERGO TRANSCATHETER EMBOLIZATION OF
A PATENT DUCTUS ARTERIOSUS?. V. Szatmari. Utrecht
University, Utrecht, Netherlands
Transcatheter embolization of a patent ductus arteriosus (PDA) is
a commonly performed minimal invasive cardiovascular interven-
tion in dogs. Prophylactic antibiotics are routinely administered in
the perioperative period to prevent implant-related bacterial
endocarditis. Because of the worldwide increasing issue of antibi-
otic resistance, the question arises whether routine administration
of prophylactic antibiotics is evidence-based.
The present retrospective case series included client-owned dogs
that underwent a transcatheter embolization of their PDA at the
author’s clinic between 2004 and 2016. Further inclusion criteria
were that the author had to be either the primary or the supervis-
ing surgeon, at least 3 months of follow-up information had to be
available, at least one metal implant had to be delivered in the
PDA, and no local or systemic antibiotics were given on the day
of the intervention and the week thereafter. Follow-up information
was gained either via telephone interview with the owner or with
the referring veterinarian, or via re-check examinations at the
author’s clinic.
In total 54 dogs fulﬁlled the inclusion criteria. The occlusion
devices were detachable coils in 18 dogs, Amplatz canine ductal
occluders (ACDO) in 35 dogs and a human Amplatzer duct occlu-
der in 1 dog. All coils and ACDOs were implanted via the femoral
artery with the dogs under general anesthesia under ﬂuoroscopic
guidance. The median age of the dogs at surgery was 4 months
(range 2–95 months) and their median weight was 7.5 kg (range
1.9–35.7 kg). An immediate closure of the PDA was reached in 36
dogs. The median length of the procedure was 100 min (range 45–
192 min). The median length of the follow-up was 25 months
(range 3–157 months).
None of the dogs developed clinical signs that could be compat-
ible with bacterial endocarditis within 3 months after the PDA-
occlusion.
The most important weakness of the present study is its retro-
spective nature. Another weakness is that in the majority of cases
the follow-up information was gained via telephone interview.
However, bacterial endocarditis is a life-threatening condition,
which would not cause only mild symptoms. Though the 3 months
follow-up might look arbitrarily chosen, several veterinary and
humans studies use the same cut-oﬀ. Moreover, a longer incuba-
tion period is very unlikely, if bacteria are assumed to enter the
circulation during surgery.
The ﬁndings of the present study are in line with the most
recent human recommendations, which do not recommend the
routine use of prophylactic antibiotics at transcatheter PDA-
embolization.
Disclosures: No disclosures to report.
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BIOLOGICAL VARIABILITY OF N-TERMINAL PRO-B-TYPE
NATRIURETIC PEPTIDE IN FIFTY-THREE HEALTHY LAB-
RADOR RETRIEVERS OVER AN 8 MONTH PERIOD. K.
Borgeat1, S. Gomart1, M. Harrison2, A. Colyer2, F.J. Glen1, J.R.
Payne1, M.J. Hezzell1, D. Allaway2. 1Langford Vets, Bristol, UK,
2WALTHAM Centre for Pet Nutrition, Melton Mowbray, UK
Short-term biological variability of, and breed diﬀerences in, N-
terminal pro-B-type natriuretic peptide (NTproBNP) that might
inﬂuence interpretation of test results have been reported. This
study aimed to assess the variability of plasma NTproBNP mea-
surements over 8 months in healthy Labrador retrievers, and also
to investigate correlation between urine NTproBNP:creatinine
ratio (UBNP-C) and plasma NTproBNP concentration.
Fifty-three Labrador retrievers (median age 5.2 years, range
2.3–8.2 years) were maintained at WALTHAM in housing and
with study procedures complying with the Animals (Scientiﬁc Pro-
cedures) Act 1986 (UK), and residual samples were used for this
study. All dogs were healthy and echocardiographically normal.
Serial sampling of fasted plasma and urine were performed (weeks
0, 8, 16, 24 & 32) including assessment of NTproBNP, measured
in residual plasma and urine (latter indexed to creatinine).
The log10(plasma NTproBNP) was analyzed by a linear mixed
model (REML) to allow for repeated measures on each dog over
time, with a random eﬀect of dog and categorical ﬁxed eﬀects of
diet, week and their interaction. Changes from baseline to weeks
8, 16, 24, and 32, and the changes between each week, were ana-
lyzed. Percentage variability from baseline of plasma NTproBNP
was calculated. An average plasma NTproBNP for each dog over
the 5 study points was calculated (AV-BNP). NTproBNP standard
deviation (SD-BNP) was also assessed. Spearman’s correlation
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analysis was performed to investigate correlation between UBNP-
C and plasma NTproBNP.
Clinically important values in plasma NTproBNP were
detected, with wide intra-individual variability (70–130%). There
was no association between percentage variability of plasma
NTproBNP, SD-BNP or AV-BNP and any other measured vari-
able, other than a mild, positive correlation between age and AV-
BNP (r 0.429, P = 0.002). A weak positive correlation between
UBNP-C and plasma NTproBNP (rho 0.368, P < 0.001).
Plasma NTproBNP measurements in clinically healthy Labra-
dors are frequently outside laboratory reference intervals, creating
false positive tests, compounded by signiﬁcant measurement vari-
ability. UBNP-C has questionable clinical utility; further studies
are necessary to validate this measurement.
Disclosures: Disclosures to report.
Allaway, Harrison and Colyer are employees of WALTHAM, a
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CLINICAL USE OF A PATIENT-SIDE FELINE NT-PROBNP
ELISA TEST IN 281 CATS IN GENERAL PRACTICE. F.
Glen1, J.R. Payne2, M.J. Hezzell1, K. Borgeat1. 1Langford Vets,
University of Bristol, Bristol, UK, 2Highcroft Veterinary Referrals,
Bristol, UK
Although the utility of a patient-side NT-proBNP ELISA (BNP-
POC) has been described in cats screened for cardiomyopathies, its
usefulness in populations with potentially lower disease prevalence
is unknown. This retrospective study aimed to describe general
practice BNP-POC use and to estimate a positive predictive value
(PPV) for echocardiographic evidence of cardiomyopathy in
apparently healthy cats.
Clinical records from cats undergoing BNP-POC (March 2015–
March 2017) were reviewed. Signalment, history, examination ﬁnd-
ings and other clinical data were recorded, along with the veteri-
narian’s stated reason for test performance, test result (normal/
abnormal), and echocardiographic ﬁndings (where available). Left
ventricular wall thickness ≥6 mm classiﬁed cats as HCM, left atrial
enlargement (LAE) was present where LA:Ao>1.5, LA diameter
long-axis >16 mm).
BNP-POC was recorded in 281 cats: 155 were male and median
age was 11.5 years (0.2–20.0). A murmur was detected in 207/281,
a gallop in 24/281 and arrhythmias in 12/281. The most frequent
reasons for testing were: auscultated abnormalities (61.6%), pre-
anesthetic assessment (14.9%) and possible cardiac-related signs
(13.1%).
Results were abnormal in 93/281 cats (33%). Excluding those
with clinical signs (n = 37) or an unknown reason for testing
(n = 7) 81/237 apparently healthy cats tested abnormal: 39/81
underwent echocardiography. Of these, 23/39 (59%) had HCM,
with 17/39 (44%) having LAE. No cats were diagnosed with other
classes of heart disease.
In a general practice population of apparently healthy cats,
BNP-POC had an estimated PPV for HCM of 59%, and for LAE
of 44%. Prospective studies are needed to validate this test in a
larger population.
Disclosures: No disclosures to report.
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DIAGNOSTIC AND PROGNOSTIC UTILITY OF SURFACE
ECG IN CATS WITH LEFT VENTRICULAR HYPERTRO-
PHY. G. Romito1, C. Guglielmini2, A. Diana1, M.O. Mazzarella1,
M. Cipone1, M. Baron Toaldo1. 1University of Bologna, Ozzano
Emilia, BO, Italy, 2University of Padova, Padova, Italy
In human cardiology, surface electrocardiography (ECG) is used
for the risk stratiﬁcation of patients aﬀected by cardiomyopathies.
The aim of the present study is to assess if ECG can show similar
usefulness in cats with left ventricular hypertrophy (LVH).
Fifty-ﬁve privately owned cats (20 clinically healthy and 35 with
LVH) were retrospectively selected. Complete physical examina-
tion, indirect measurement of arterial blood pressure, echocardiog-
raphy, 2-min peripheral 6-lead ECG, and standard blood work,
including serum thyroxine concentration were available. ECG
measurements included: detection of any type of arrhythmia; heart
rate; amplitude and duration of P wave and QRS complex; ST
segment elevation or depression; mean electrical axis of P and T
wave, and QRS complex; and PQ, QRS, QT, and QT corrected
for heart rate (QTc) duration. In cats with LVH, outcome data
and cause of death were annotated, when available.
Sinus rhythm was diagnosed in all healthy and in 24/35 (68.6%)
cats with LVH. The remaining cats with LVH showed diﬀerent
types of rhythm disturbance, including third degree atrioventricu-
lar block (AVB) (2/35, 5.7%), sinus rhythm with isolated atrial (2/
35, 5.7%) or ventricular ectopic complexes (2/35, 5.7%), sinus
bradycardia (1/35, 2.9%), sinus rhythm associated with both ﬁrst
degree and second degree AVB (1/35, 2.9%), sinus rhythm associ-
ated with second degree AVB (1/35, 2.9%), accelerated idioventric-
ular rhythm (1/35, 2.9%) and ventricular tachycardia (1/35, 2.9%).
The presence of any type of arrhythmia had sensitivity of 31%,
speciﬁcity of 100%, negative predictive value of 45%, and positive
predictive value of 100%, in identifying LVH. ECG measurements
were performed in all healthy cats and in 29/35 cats with LVH.
Only QT and QTc were statistically diﬀerent between healthy cats
and cats with LVH (P < 0.007 for both variables). Among the
healthy cats, the highest values for QT and QTc were 180 ms, and
200 ms, respectively. Survival data were available for 23/29 cats
with LVH where ECG measurements were performed. Of these
10/23 died for cardiac related cause. Median survival time was
58 days and not measureable for cats with QT>180 ms and
QT≤180 ms, respectively, and 125 days and not measureable for
cats with QTc>200 ms and QTc≤200 ms, respectively. Both
QT>180 ms and QTc>200 ms were predictors of death for cardiac
related causes (P = 0.042 and P = 0.017, respectively).
Surface ECG seems to provide useful diagnostic and prognostic
information in cats with LVH.
Disclosures: No disclosures to report.
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NOTCHED QRS COMPLEXES IN DOGS WITH AND WITH-
OUT STRUCTURAL CARDIAC DISEASE: 85 CASES. R.L.
Winter, R.M. Bates, S. Jung. Auburn University, Auburn, AL,
USA
The objectives of this study were to describe the signalment and
cardiac disease diagnosis in dogs with notched QRS complexes of
normal duration, as well as to describe the speciﬁc leads and num-
ber of leads with notched QRS complexes on ECG. Medical
records and ECGs from 85 dogs with notched QRS complexes in
at least 1 ECG lead were evaluated. A retrospective review of digi-
tally stored ECGs and associated medical records of dogs with a
recorded ECG as part of routine clinical evaluation was per-
formed. Medical records were reviewed for signalment and cardiac
disease diagnosis in dogs with notched QRS complexes identiﬁed.
The age at time of ECG recording was 9.15 +/- 3.38 years for the
85 dogs with notched QRS complexes in at least 1 ECG lead.
Most dogs (78.8%) had 3 or less ECG leads with notched QRS
complexes. Most dogs (69.4%) with notched QRS complexes in at
least 1 lead had cardiac disease. The odds ratio of a dog having
cardiac disease if more than 1 lead was identiﬁed with notched
QRS complexes was 3.97. The most common cardiac disease iden-
tiﬁed was chronic atrioventricular valvular degeneration (CVD),
and the majority of these dogs (80%) had 2 or less leads with
notched QRS complexes. In conclusion dogs with and without car-
diac disease can have notched QRS complexes, and the likelihood
of a dog having cardiac disease that has more than 1 ECG lead
with notched QRS complexes is signiﬁcant which should warrant
diagnostic evaluation.
Disclosures: No disclosures to report.
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PLASMA METABOLOMICS REVEALS LOWERED CAR-
NITINE CONCENTRATIONS IN OVERWEIGHT LABRADOR
RETRIEVER DOGS. J.J. S€oder, K. H€oglund, J. Dicksved, R.
Hagman, H. Eriksson R€ohnisch, A. Moazzami, S. Wernersson.
Swedish University of Agricultural Sciences, Uppsala, Sweden
The prevalence of dog obesity is increasing and a better under-
standing of the metabolism of overweight dogs is needed to
improve obesity prevention and treatment. This study aim to
detect and quantify plasma metabolites during a feed challenge-test
in dogs and to identify alterations in the metabolism related to
overweight. Twenty-eight healthy intact male Labrador retriever
dogs were included, 12 of which were classiﬁed as lean (body con-
dition score (BCS) 4–5 on a 9-point scale) and 16 as overweight
(BCS 6–8). After overnight fasting, plasma samples were collected
and dogs were fed a high-fat meal. Postprandial plasma samples
were collected hourly for 4 h. Nuclear magnetic resonance (NMR)
was conducted and 41 plasma metabolites were statistically evalu-
ated. The results showed that all postprandial time points diﬀered
from the fasting time point in multivariate discriminant analysis
(cross-validated ANOVA: P = 0.00014). Eleven speciﬁc metabo-
lites with peak concentrations mainly at 2 or 3 h postprandially
contributed to the separations. Carnitine was identiﬁed as a
metabolite related to overweight at all time points in stepwise
logistic regression analysis (P = 0.03) and overweight dogs had
lower carnitine response in a mixed model repeated measures anal-
ysis (P = 0.005). Notably, the fasting carnitine concentration in
overweight dogs (mean  SD, 9.4  4.2 mM) was very close to a
proposed reference limit for carnitine deﬁciency. These ﬁndings
demonstrate that NMR is suitable for metabolic evaluations in
feed-challenges in dogs. The lowered carnitine concentration in
overweight dogs warrants further investigation as it could indicate
carnitine deﬁciency and an altered lipid metabolism in overweight
dogs.
Disclosures: No disclosures to report.
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SILICA UROLITHIASIS IN A DOG - A CASE REPORT. B.
Kiefer-Hecker, B. Dobenecker. Ludwig-Maximilians-Universit€at
M€unchen, Oberschleissheim, Germany
Silica-containing uroliths in dogs occur very infrequently (≤0.5%
of analyzed uroliths) in Europe,1,2 although Schenk et al. (2010)3
observed a peak of 13% in 2009 in Switzerland. The aﬀected dogs
were predominately male (88–93%)4 and between 7.2 to
8.63,4 years old.
A 10 year old neutered male terrier mongrel (BCS 3/5) with a
history of pancreatitis was examined for abdominal pain. During
an abdominal ultrasonic examination that revealed no abnormali-
ties of the pancreas but hyperechoic structures in the bladder the
dog urinated. The urine sediment was positive for bacteria, ery-
throcytes and leucocytes but not crystals. Antimicrobial treatment
was started. The pancreatic lipase was within the reference range.
Two weeks later a urine sample collected by the owner contained
numerous struvite crystals; another sample obtained one week
later by cystocentesis revealed no crystals and no signs of inﬂam-
mation and a urine pH of 7.1. The ultrasonographic examination
of the bladder a few days afterward showed multiple uroliths. 20
stones were removed surgically and the analysis revealed 100%
silica.
It is hypothesized that silica uroliths may be related to silica
intake by plants or plant by-products with diet or by consumption
of soil (>90% silica) secondary of diet-associated pica.5 In this case
the dog was fed a commercial gastro intestinal low fat dry diet for
1 year. Additionally, the dog regularly consumed feces of feral
rabbits on its daily walks since more than 2 years. The analysis of
a sample of such feces showed that it contained high amounts of
insoluble ash (7% of fresh matter or 12.3% vs. 4% dry matter in
pet rabbits). The intake of such feces together with soil sticking to
it might have caused silica uroliths in this case, since no signs of
dysuria or abnormal ultrasonographic examinations of the bladder
or urinalysis did recur after the dog was kept from consuming rab-
bit feces for more than three month.
References: 1Hesse et al. Canine cystine urolithiasis, Can Vet J
2016;57(3):277–281; 2 Roe et al. Analysis of 14,008 uroliths from
dogs in the UK over a 10-year period, J Small Anim Pract
2012;53:634–640; 3 Schenk et al. Silica-containing uroliths in dogs
from CH, ECVIM-CA Congress 2010:303; 4Hesse & Neiger Harn-
steine bei Kleintieren, Stuttgart: Enke, 2008; 5Osborne et al.
Canine silica urolithiasis, J Small Anim Pract 1999;1:213–230.
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KNOWING THE TOTAL AMOUNT OF PHOSPHORUS IN A
DIET IS NOT ENOUGH - DIFFERENT SOURCES HAVE DIF-
FERENT EFFECTS. B. Dobenecker, S. Siedler. Ludwig Maximil-
ians University, Oberschleissheim, Germany
The restriction of phosphate (P) intake is crucial in patients with
chronic renal insuﬃciency (CRI), especially in case of hyperphos-
phatemia. Major sources of P are proteins, bones and cartilages as
well as inorganic supplements for nutritional and technical pur-
poses. To date, the total amount of P in a diet is used to assess
the daily load of P for the patient. Besides, P excess is suspected
to play a role also in the pathogenesis of CRI. The aim of this
study was to test the eﬀects of diﬀerent P sources on the body
based on a diﬀerent availability of the mineral.
In 8 adult Beagles the aD of P and Calcium (Ca) was deter-
mined after feeding a control diet (0.5% P/DM) for 18d (13d
adaptation, 5d balance). This was repeated aiming at 2.2% P/DM
by adding diﬀerent phosphates (CaHPO4, NaH2PO4, poultry meal,
Na5P3O10, Ca (H2PO4)2, bone meal, KH2PO4, K4P2O7) while
adjusting the Ca/P ratio to ~1.3/1 using CaCO3 (exceptions diet
poultry meal: Ca/P 1.7/1; diet Na5P3O10: 1.5% P/DM due to low
acceptance) with wash-out periods of ≥10d. Serum P, Ca and PTH
was determined at d18 pre- and 2 h postprandially. Pre- and post-
prandial urine was analyzed for creatinine and P. Statistics:
ANOVA (Bonferroni) or Kruskal Wallis (Tukey) according to
data distribution.
Compared to control aD P was reduced in diet CaHPO4, pen-
taphosphate, poultry and bone meal. In postprandial urine P/crea-
tinine increased signiﬁcantly in all diets but control, poultry and
bone meal. The same was true for postprandial serum P concen-
trations with levels even above reference range in NaH2PO4,
Na5P3O10, Ca (H2PO4)2, KH2PO4 and K4P2O7. Postprandial PTH
levels increased up to threefold in Na and K compounds
(NaH2PO4, Na5P3O10, KH2PO4, K4P2O7) and Ca (H2PO4)2 caus-
ing mean concentrations near or above reference range.
For the ﬁrst time this study demonstrated in dogs systematic
diﬀerences in P digestibility and metabolism between diﬀerent P
sources often used in petfood. Because of the relevance of P in
renal diets but also because of the potentially harmful eﬀects of
elevated serum P and PTH levels on skeleton, cardio-vascular sys-
tem and kidneys in healthy animals, the intake of highly soluble P
compounds such as Na and K Phosphates have to be assessed dif-
ferently. The knowledge of the total amount of P in a diet does
not suﬃce to decide about adequacy or potential harm.
Disclosures: No disclosures to report.
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AGREEMENT OF TWO PREPILL CORTISOL MEASURE-
MENTS IN DOGS WITH HYPERCORTISOLISM TREATED
WITH TRILOSTANE. S. Sieber-Ruckstuhl1, C. Musella1, W.
Burkhardt1, B. Riond2, C.E. Reusch1, F.S. Boretti1. 1Clinic for
Small Animal Internal Medicine, Z€urich, Switzerland, 2Clinical
Laboratory, Vetsuisse Faculty, University of Zurich, Zurich,
Switzerland
The ideal method to monitor trilostane therapy in dogs with
hypercortisolism (HC) is still controversial. Lately, determination
of the pre-trilostane (prepill) serum cortisol concentration has been
shown to be more repeatable than either post-trilostane or
post-ACTH stimulation cortisol. Therefore, the prepill cortisol
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concentration may be superior to other cortisol measurements for
monitoring purposes.
As it is well known that cortisol concentrations can ﬂuctuate
and are inﬂuenced by certain circumstances (e.g. stress), the aim of
this study was to investigate the agreement of two prepill cortisol
measurements in dogs with HC during trilostane therapy.
Client owned dogs with HC treated with trilostane twice daily
were prospectively enrolled. Cortisol concentrations were measured
two times 1 h apart just before the next trilostane dose (prepill 1
and 2). Each value was assigned to one of three groups according
to the control of cortisol release: excessive (<41 nmol/L), adequate
(41–138 nmol/L) or inadequate (>138 nmol/L). The Wilcoxon
signed rank test was used to examine for signiﬁcant diﬀerences
between the paired measurements and the spearman rank correla-
tion was calculated. The degree of agreement between group
assignments was quantiﬁed by kappa.
A total of 47 cortisol pairs of 16 dogs with HC were included.
Prepill 1 and 2 did not diﬀer signiﬁcantly (P = 0.18). There was a
signiﬁcant correlation between the two values (P < 0.0001,
r = 0.73). Compared to prepill 1, prepill 2 was higher in 17, equal
in 5 and lower in 25 pairs. Group agreement between prepill 1 and
2 was 70% (moderate agreement - weighted kappa 0.5). In 30% of
the pairs group assignment disagreed, which would have led to a
diﬀerent therapeutic decision. In some dogs certain circumstances
(e.g. excessive barking during hospitalization, diﬃculties during
blood collection) were identiﬁed as potential factors explaining the
discrepancy between prepill 1 and 2.
In conclusion, in a substantial number of dogs there was a large
diﬀerence between the two prepill values, which was ascribable to
certain events during hospitalization in some dogs. Recording of
any incident during handling that might aﬀect cortisol release
seems important. Whether the measurement of two prepill values
is of true beneﬁt compared to the determination of only one has
to be evaluated in further studies.
Disclosures: Disclosures to report.
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STEROL-O-ACYL TRANSFERASE 1 (SOAT1) EXPRESSION
IN CANINE CORTISOL-SECRETING ADRENOCORTICAL
TUMORS: PROVIDING THE BASIS FOR A FUTURE TREAT-
MENT OPTION. G.J. van Staalduinen, K. Sanders, D.M. Peter-
son, M.C.M. Uijens, A. Slob, S. Galac. Utrecht University,
Utrecht, Netherlands
Current medical treatment options in dogs with cortisol-secreting
adrenocortical tumors (ATs) are trilostane or mitotane. However,
trilostane is a palliative treatment and has no eﬀect on the tumor
itself, while mitotane does have adrenocorticolytic activity, but can
cause serious adverse eﬀects. ATR-101, a new orally available
drug, is known to have selective adrenocorticolytic activity in gui-
nea pigs, dogs, monkeys and humans, and is currently being tested
in a phase II clinical trial for ATs in humans. ATR-101 is a selec-
tive and potent sterol-O-acyltransferase 1 (SOAT1) inhibitor,
which leads to the accumulation of free cholesterol in adrenocorti-
cal cells, resulting in endoplasmic reticulum stress and ultimately
leading to apoptosis. Inhibition of SOAT1 could be an interesting
therapy option in dogs with ATs, but can only be useful if canine
ATs express SOAT1.
The aim of this study was to determine whether the use of a
selective SOAT1 inhibitor such as ATR-101 could have potential
in the treatment of canine ATs. To this end, we evaluated the
SOAT1 mRNA expression with RT-qPCR in 59 ATs (44 carcino-
mas and 15 adenomas) and 12 normal adrenals (NAs), and protein
expression with immunohistochemistry (IHC) in 47 ATs (36 carci-
nomas and 11 adenomas) and 4 NAs. Slides were stained with
polyclonal rabbit-anti-human antibody and antibody speciﬁcity
was conﬁrmed with western blot. A semiquantitative H-score for
SOAT1 protein expression was calculated by multiplying the area
of positive staining with the staining intensity grading score.
SOAT1 mRNA was detectable with RT-qPCR in all samples
tested. No signiﬁcant diﬀerences were found between NAs (mean
fold change 1.05  0.31), adenomas (1.17  0.60) and carcinomas
(1.76  1.39), but expression was more variable in ATs and in
particular in carcinomas. No signiﬁcant diﬀerences were found in
protein expression between NAs (H-score 5.97  1.82), adenomas
(5.41  2.03) and carcinomas (5.54  3.26), but carcinomas again
showed more variable expression and three carcinomas had low to
absent SOAT1 protein expression (H-score lower than one).
In conclusion, SOAT1 mRNA was present in all and SOAT1
protein in 94% of our samples, providing a solid base that a selec-
tive SOAT1 inhibitor could have great potential as a future treat-
ment in canine ATs. To determine the eﬀect of ATR-101 in canine
ATs, further studies are warranted.
Disclosures: No disclosures to report.
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CYP17 INHIBITOR ABIRATERONE ACETATE AS A
PROMISING FUTURE TREATMENT FOR CANINE HYPER-
ADENOCORTICISM: IN VITRO INVESTIGATIONS. W.L. de
Wit, K. Sanders, J.W. Hesselink, J.A. Mol, S. Galac. Utrecht
University, Utrecht, Netherlands
Cushing’s disease or pituitary-dependent hypercortisolism (PDH)
is a common endocrine disorder in dogs. At present, medical man-
agement of canine PDH consists of either trilostane or mitotane
therapy. Both treatments have disadvantages associated with the
induction of hypoadrenocorticism. Therefore, a more speciﬁc inhi-
bition of glucocorticoid synthesis is desirable. Our recent studies
indicate that the steroidogenic enzyme cytochrome P-450c17
(CYP17) could be an interesting target for selective inhibition of
cortisol production without impeding the synthesis of aldosterone.
Abiraterone acetate (AA), a highly selective irreversible CYP17-
inhibitor, is already available on the market and successfully used
for the treatment of castration-resistant prostate cancer in humans.
In addition, the registration for human application will probably
enable a relatively straightforward implementation into veterinary
clinical practice. As side eﬀects of AA are mostly related to
hypocortisolism, this approach seems interesting as a novel medi-
cal treatment option for canine hypercortisolism.
The aim of this study was to determine the eﬀects of AA on
cortisol synthesis; on mRNA expression of steroidogenic genes
encoding for CYP17, 3b-hydroxysteroid dehydrogenase (3b-HSD)
and Ki67, a cellular marker for proliferation; and on adrenocorti-
cal cell viability.
Canine primary adrenocortical cell cultures from adrenal glands
of seven healthy dogs were incubated with various concentrations
of AA. PDH was mimicked by co-incubation with synthetic
ACTH (Synacthen). After 48 h of incubation, RNA was isolated
to evaluate gene expression using real-time quantitative PCR (RT-
qPCR). Culture medium was removed for measurement of cortisol
after 72 h of incubation. In addition, cell viability was assessed
using alamarBlue assay.
AA dose-dependently decreased cortisol concentration in
ACTH-stimulated adrenocortical cells with an IC50 value of
24.2 nM (P < 0.0001). At the highest AA concentration of 10 µM,
the average suppression of cortisol synthesis was 92.5%
(SEM  3.5). The mRNA expression of CYP17, 3b-HSD and
Ki67 was not signiﬁcantly altered after incubation with AA.
Finally, AA did not signiﬁcantly aﬀect adrenocortical cell viability.
We conclude that AA is eﬀective in reducing cortisol synthesis
in vitro without aﬀecting adrenocortical cell viability and prolifera-
tion. Therefore, AA seems to be a promising future treatment
option in the medical management of canine Cushing’s disease. To
ascertain this, further in vivo studies are warranted.
Disclosures: No disclosures to report.
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MOLECULAR PROGNOSTIC MARKERS IN CANINE COR-
TISOL-SECRETING ADRENOCORTICAL TUMORS. K. San-
ders, E. Teske, K. Cirkel, B. van Nimwegen, M.C.M. Uijens, H.S.
Kooistra, J.A. Mol, J.W. Hesselink, S. Galac. Utrecht University,
Utrecht, Netherlands
Assessment of malignancy in canine cortisol-secreting adrenocorti-
cal tumors (ATs) remains challenging. No previous studies have
linked molecular markers to survival times in dogs after adrenalec-
tomy, making it diﬃcult to give a reliable prognosis. The aim of
this study was to identify molecular prognostic markers in a large
cohort of canine ATs. This could not only enhance insight in indi-
vidual prognosis, but could also provide potential future treatment
targets.
Fifty-nine dogs with hypercortisolism due an AT that under-
went adrenalectomy between 2002 and 2015 at the authors’ institu-
tion and of which follow-up information was available, were
included in this study. Three classes of potential prognostic factors
were reviewed: ﬁrstly clinical data, including body weight, age at
time of surgery, gender, neuter status and tumor size; secondly
immunohistochemical Ki67 labeling index, and thirdly mRNA
expression of factors associated with proliferation of ATs, includ-
ing SF-1, PTTG1, PBX1, VAV2, RRM2, TOP2A, Ki67, CCND1,
MC2R and BCL2. Univariate analysis was performed with the
Cox proportional hazards model for continuous variables and the
Log Rank test for bivariate variables. Multivariate analysis was
performed using multiple linear regression with forward selection.
Median survival time was 63.6  9.4 months. In the univariate
analysis, signiﬁcant prognostic factors were tumor volume in cm3
(P = 0.015, hazard ratio (HR) = 1.004), maximal diameter of
tumor in cm (P = 0.047, HR = 1.284), Ki67 labeling index
(P < 0.001, HR = 1.220) and mRNA expressions of SF-1
(P = 0.021, HR = 60.244), PTTG1 (P = 0.024, HR = 12.321),
PBX1 (P = 0.005, HR = 8.714), and TOP2A (P = 0.035,
HR = 7.191). Forward stepwise multivariate analysis identiﬁed
Ki67 labeling index (P = 0.024, HR = 1.574) and SF-1 mRNA
expression (P = 0.044, HR = 1.936*106) as independent predictors
of poor survival.
In conclusion, most important predictors of poor survival are
Ki67 labeling index and SF-1 expression. These results show the
importance of including Ki67 staining in histopathological assess-
ment of canine ATs. Moreover, since pharmacological manipula-
tion of SF-1 is possible, the considerable impact of SF-1
expression on prognosis indicates great potential of SF-1 as a
treatment target in canine ATs in the near future.
Disclosures: No disclosures to report.
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THE USE OF CHROMOGRANIN A EPITOPES VASO-
STATIN AND CATESTATIN AS BIOMARKERS FOR CATE-
CHOLAMINE-PRODUCING TUMORS IN DOGS. O.V.
H€oglund1, O. Yoshida2, K. Asano2, K. Ishigaki2, M. Stridsberg3,
J.M. Hanson1. 1Swedish University of Agricultural Sciences, Upp-
sala, Sweden, 2Nihon University, Fujisawa, Japan, 3Uppsala
University, Uppsala, Sweden
Pheochromocytomas may be diﬃcult to diﬀerentiate from adreno-
cortical tumors in dogs until diagnosis with histopathology is
obtained. Fine-needle aspiration biopsy of adrenal masses is an
invasive technique, with risk for complications. Measurement of
urine catecholamine metabolites necessitates acidiﬁcation of the
urine with hydrochloric acid and associated handling risks. Ideally,
a blood marker that reliably can diﬀerentiate between cate-
cholamine-producing tumors and adrenocortical tumors, would be
preferable. However, direct measurement of plasma catecholami-
nes and their metabolites are less reliable than measurement of
urine catecholamine metabolites in dogs. Measurement of serum
inhibin concentrations is useful in gonadoectomized dogs only. In
human medicine, chromogranin A (CgA) is an established marker
for neuroendocrine tumors (NETs). Chromogranin A is stored in
secretory granules of neuroendocrine tissues and co-secreted with
epinephrine and norepinephrine at sympathetic stimuli. The
metabolites of CgA are more stable in plasma than are the cate-
cholamines. The aim of the present study was to measure and
compare serum concentrations of the CgA epitopes vasostatin and
catestatin in serum collected before surgery from dogs with histo-
logically conﬁrmed catecholamine-producing tumors and dogs with
adrenocortical tumors.
Serum samples were collected before surgery from 23 dogs with
adrenal tumors and in one dog with an extra-adrenal neuroen-
docrine tumor. All tumors and their tissue origin were conﬁrmed
by histopathology. There were 12 catecholamine-producing tumors
(11 pheochromocytomas, 1 extra-adrenal tumor), and 12 adreno-
cortical tumors. Serum concentrations of vasostatin and catestatin
were analyzed by a radioimmunoassay (RIA) that has previously
been validated for the use in dogs. Statistical analysis was per-
formed with a non-parametric test using the software R version
3.0.2.
In the dogs with catecholamine-producing tumors, the median
serum vasostatin concentration was 0.82 nmol/L (IQ range, 0.52–
1.60 nmol/L). In the dogs with adrenocortical tumors, the median
serum vasostatin concentration was 0.50 nmol/L (IQ range, 0.34
to 0.59 nmol/L). Serum vasostatin concentrations were signiﬁ-
cantly higher in dogs with catecholamine-producing tumors, than
in dogs with adrenocortical tumors (Wilcoxon signed rank test,
independent groups, P < 0.05). There was no statistically signiﬁ-
cant diﬀerence in serum catestatin concentrations between the two
groups.
Based on the results from this study, it can be concluded that
the serum CgA epitope vasostatin may be a valuable serum bio-
marker to diﬀerentiate catecholamine-producing tumors from
adrenocortical tumors.
Disclosures: Disclosures to report.
The research was ﬁnanced by a grant from Ture F and Karin
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PILOT STUDY ASSESSING THE USE OF CABERGOLINE
IN THE MANAGEMENT OF DIABETIC ACROMEGALIC
CATS. C.J. Scudder, K. Hazuchova, R. Gostelow, V. Woolhead,
Y. Forcada, D.B. Church, R.C. Fowkes, S.J.M. Niessen. Royal
Veterinary College, Hatﬁeld, UK
Cabergoline is a dopamine 2 receptor (D2R) agonist which is a
second line medical therapy for human acromegalic patients. Pasir-
eotide, a somatostatin analogue, is the only eﬀective medical man-
agement option for feline acromegaly but its cost is a limiting
factor for many owners. Our work has demonstrated dopamine
receptors within the feline acromegalic pituitary and we hypothe-
sized that cabergoline would improve diabetic control and IGF-1
concentrations of diabetic acromegalic cats.
This was a prospective cohort study of client-owned diabetic
acromegalic cats, Ethics approval URN 2016 1604. Enrolment cri-
teria were: a diagnosis of diabetes mellitus, an IGF-1 concentra-
tion >1000 ng/mL and owners declining alternative treatment
options for acromegaly. Patients were admitted to the hospital on
day 0, underwent pituitary imaging and started cabergoline ther-
apy (Kelactin, Kela N.V.) on day 1. Cats were monitored in hospi-
tal until day 4 and were discharged to continue treatment at
home. Serum IGF-1 and fructosamine were measured on day 0,
day 4 and month 1. Any possible medication side eﬀects were
recorded. Descriptive statistics and non-parametric tests were used
to analyze the data.
Six cats were enrolled. The ﬁrst three cats received 5 µg/kg
q24 h PO and the second three cats received 10 ug/kg q24 h PO
of cabergoline. The median IGF-1 concentration at day 0 was
1797 ng/mL (range 890–>2000) which was not statistically diﬀerent
to day 4 and month 1 (1884 ng/mL and 1754 ng/mL, respectively).
The median fructosamine concentration on day 0 was 551 lmol/L
(range 454–887) which was not statistically diﬀerent from day 4
and month 1 (551 to 569, respectively). All cats were receiving PZI
insulin (ProZinc, Boehringer) and the median dose on day 0 (1.1
units/kg q12 h) was not diﬀerent to day 4 and month 1 (1.1 and
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1.2, respectively). Three patients experienced a single gastrointesti-
nal upset event (inappetence, diarrhea) which resolved within three
days. One of the six cats experienced an improvement of diabetic
control (fructosamine day 0 was 454 lmol/L and month 1 was
288 lmol/L while insulin dose on day 0 was 1 unit/kg q12 h and
month 1 was 0.2 units/kg q12 h) although there was no decrease
of IGF-1 concentration (day 0: 890 ng/mL; month 1: 929 ng/mL).
Cabergoline therapy, using the investigated dose and duration,
was not associated with a reduction in IGF-1 concentration in the
tested diabetic acromegalic cats; glycemic control improved in one.
Additional cases, alternative dosing regimens and longer-term fol-
low-up are being assessed.
Disclosures: Disclosures to report.
The diabetic remission clinic is supported by Nestle Purina and
Boehringer Ingelheim.
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SERIAL CHANGES IN INSULIN-LIKE GROWTH FACTOR 1
AND IMPACT ON HYPERSOMATOTROPISM-SCREENING
IN FELINE DIABETES MELLITUS. V.L. Woolhead, L. Teo
Whee Wen, C. Scudder, R. Gostelow, G. Harman, Y. Forcada,
D.B. Church, S.J.M. Niessen. Royal Veterinary College, North
Mymms, UK
Hypersomatotropism [HS] is the underlying cause of diabetes mel-
litus in a substantial number of diabetic cats. Serum insulin-like
growth factor-1 [IGF-1] measurement is currently the test of
choice, with concentrations greater than 1000 ng/mL having a
95% positive predictive value. Therefore, all commercial laborato-
ries currently use this value as a cut-oﬀ to indicate likely HS pres-
ence. However, endogenous insulin availability aﬀects IGF-1
synthesis, thereby possibly reducing test sensitivity, especially in
newly insulin-treated diabetic acromegalics.
This study’s two main questions were: 1. How many newly
diagnosed and treated diabetic cats demonstrate serum IGF-1 ini-
tially not suggestive to subsequently become suggestive of HS
using this cut-oﬀ (1000 ng/mL)? 2. How strong is the correlation
between endogenous insulin and IGF-1 concentrations in
untreated diabetic cats?
Serial blood samples of diabetic cats were prospectively
recruited from ﬁrst opinion UK veterinary practices within
180 days of initiating insulin treatment. Serum IGF-1 and basal
serum endogenous insulin were evaluated using a validated and
commercially oﬀered RIA and ELISA, respectively; the latter in
untreated diabetic cats only. Mann Whitney test was used to com-
pare groups and Spearman rank correlation coeﬃcient to assess
correlation between endogenous insulin and IGF-1; P < 0.05 was
considered signiﬁcant. Serial blood samples of 219 cats were
recruited (two samples: 103 cats; three: 55; four: 44; ≥ ﬁve: 17).
Sixty-two (28.3 %) cats had at least one IGF-1 measurement
>1000 ng/mL (median 1576 ng/mL, range 1001–>2000); a median
of 0.6 units/kg/injection insulin (range 0–2.4) was administered. Of
the cats with IGF-1 >1000 ng/mL, 20 (9.1 %) initially showed
IGF-1 <1000 ng/mL; therefore, the attending clinician could have
discarded the possibility of HS in these patients. Median subse-
quent IGF-1 increase was 594 ng/mL (range 71–1495), having ini-
tially received a median of 73 days of insulin treatment (range 25–
154). Basal endogenous insulin in untreated diabetic cats with
IGF-1 <1000 ng/mL (n = 106; median 29.0 ng/L, range 9.2–791)
was signiﬁcantly lower than in those with IGF-1 >1000 ng/mL
(n = 15; median 64.2 ng/L, range 9.2–490; P = 0.024). A moderate
positive correlation (rs = 0.42, P < 0.0001) was detected between
endogenous insulin and IGF-1 in untreated cats. In this study,
approximately 1 in 10 newly diagnosed diabetic cats with an IGF-
1 suggestive of underlying HS, based on the currently advocated
cut-oﬀ, will initially show a negative value using this cut-oﬀ.
Lower endogenous insulin, which moderately correlates with IGF-
1, and/or suboptimal current cut-oﬀ value advice, could be con-
tributing factors.
Disclosures: No disclosures to report.
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ULTRASTRUCTURAL CHARACTERIZATION OF PANCRE-
ATIC BETA-CELLS IN CATS WITH DIABETES MELLITUS.
E. Zini1, S. Dalla Riva2, L. Cavicchioli2, E. Salesov1, L. Vignato2,
M. Osto1, F. Fracassi3, R. Chiocchetti3, M. Valente2, T.A. Lutz4,
C.E. Reusch1, M. Della Barbera2. 1Clinic for Small Animal Inter-
nal Medicine, Zurich, Switzerland, 2University of Padua, Padua,
Italy, 3University of Bologna, Bologna, Italy, 4Institute of Veteri-
nary Physiology, Zurich, Switzerland
Dysfunctional pancreatic beta-cells are crucial in the pathophysiology
of diabetes. Based on light microscopy, diabetic cats have reduced
number of beta-cells but whether secretory granules and mitochondria,
which are central to cellular function and viability, have abnormal
morphology is unknown. Furthermore, a recent investigation ques-
tioned the role of islet amyloid in the pathogenesis of diabetes in cats
since its amount did not diﬀer between diabetic and age-matched con-
trol cats. However, intracellular aggregation of amylin into oligomers,
rather than extracellular amyloid, may be the principle of beta-cell tox-
icity in type 2 diabetes. Therefore, the aims of the study were to charac-
terize ultrastructural lesions of beta-cells in diabetic cats with emphasis
on granules, mitochondria and intracellular amylin aggregation.
Pancreases of diabetic and control cats euthanized for any dis-
ease were prospectively collected. Samples were harvested within
1 h from death and glutaraldehyde-ﬁxed. Control cats were selected
to be matched for age, sex and body weight. Sections were prepared
for electron microscopy and immunogold labeling by using anti-
insulin and anti-amylin antibodies. Beta-cell morphology was
assessed, including beta-cell granule area, eccentricity (minimum-to-
maximum diameter ratio), granule number, as well as beta-cell
mitochondrial area, number and inter-cristae distance. Intracellular
accumulation of amylin-positive material outside the granules was
explored. Non-parametric tests were used for statistical analysis.
Five diabetic cats and 5 controls were included. Diabetic cats had
beta-cells with clearer cytoplasm than control cats. The median area
of beta-cell granules was higher in diabetic than controls [0.144 µm2
(0.047–0.252) vs. 0.035 µm2 (range: 0.027–0.046); P < 0.05] and their
median number lower [0.5/µm2 (0.3–2.8) vs. 5.6/µm2 (range: 3.9–7.8);
P < 0.05]; eccentricity did not diﬀer. The median inter-cristae dis-
tance of mitochondria was higher in diabetic than controls [0.064 µm
(0.052–0.075) vs. 0.034 µm (range: 0.032–0.043); P < 0.05]; their area
and number did not diﬀer. Mitochondria of diabetic cats appeared
swollen. Amylin-positive material outside the granules was observed
in the cytoplasm of 3 diabetic cats and in none of the controls.
In conclusion, the reduced number of granules might suggest
that the remaining pool of beta-cells in diabetic cats is less func-
tional or exhausted by the excessive workload. The reason behind
the larger granule size is uncertain. The increased inter-cristae dis-
tance of mitochondria in diabetic cats, as well as their swollen
appearance, might suggest increased permeability and loss of func-
tion. The appearance of amylin-positive material outside of gran-
ules suggests intracellular aggregation of amylin monomers to
oligomers, which may possibly contribute to beta-cell death.
Disclosures: Disclosures to report.
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THE DIABETIC CLINICAL SCORE (DCS): EVALUATION OF
A SIMPLE STANDARDIZED QUANTIFICATION TOOL TO
ALLOW RAPID DESCRIPTION OF CLINICAL SIGNS IN
DIABETIC DOGS. S.J.M. Niessen1, K. Hazuchova1, E. Bowles1,
R. Gostelow1, C. Scudder1, V. Woolhead1, H. Darcy1, Y. For-
cada1, A. Poppl2, F. Venzon Varela2, E. Furrow3, L. Fleeman4,
D.B. Church1. 1Royal Veterinary College, North Mimms, UK,
2Universidade Federal do Rio Grande do Sul, Brazil, 3College of
Veterinary Medicine, University of Minnesota, MN, USA, 4Ani-
mal Diabetes Australia, Melbourne, Australia
Glycemic parameters, such as fructosamine, glycosylated hemoglo-
bin and serial glucose measurements (SGMs), are always to be
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interpreted in light of the clinical signs being exhibited by diabetic
pets. Sample artifacts, assay-issues, inter-day variation and stress
can yield deceiving laboratory results. Likewise, the clinical history
suﬀers from inter-person variation, due to varying ways of asking
or answering questions, interpreting non-standardized language,
forgetting questions and lack of quantiﬁcation. The aim of this
study was to evaluate the newly designed simple Diabetic Clinical
Score (DCS) in diabetic dogs. The DCS was previously validated
for use in diabetic cats.
Diabetic dog owners were asked to choose the speciﬁc severity
(ranging from none/ normal, mild, moderate to severe) of speciﬁc
diabetic clinical signs (polyuria and polydipsia, polyphagia, atti-
tude/ activity). The extent of possible weight loss was established
by weighing (none; mild: <5%; moderate: 5–10%; severe: >10%).
The severity was subsequently converted into a score ranging from
0 (none/ normal) to 3 (severe), yielding a summarized total score
(DCS) for all signs combined ranging from 0 (no clinical signs) to
12 (maximum clinical signs). The DCS was correlated with one or
more of following objective parameters obtained at the same visit:
fructosamine, average blood glucose during SGMs (AvBG) or
water intake diary. Appropriate descriptive and correlation statis-
tics used.
Sixty-seven diabetic dogs were assigned a DCS (median 4; range
0–10). A signiﬁcant correlation was present between the AvBG
(n = 16, Spearman’s rho: 0.656, P < 0.001), daily water intake
(n = 32, Spearman’s rho: 0.605, P < 0.0003) and the DCS. A sig-
niﬁcant correlation between the DCS and fructosamine (n = 38,
Spearman’s rho: 0.340, P < 0.04) was also present though only
when dogs with concurrent hyperadrenocorticism, hyperlipidemia,
hypothyroidism and diabetic ketoacidosis were removed from the
analysis. Seventy-nine percent of owners reported the questions to
be clear/ completely clear.
The DCS proved easy to comprehend by dog owners. The sig-
niﬁcant correlation between DCS and objective clinical parameters
suggests it could represent a simple objective tool to describe, com-
municate and quantify the clinical signs encountered in diabetic
dogs in clinical practice and research settings. Diﬀerences between
the DCS and objective parameters should be further investigated.
Disclosures: No disclosures to report.
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THYROID AND RENAL FUNCTION IN CATS POST LOW-
DOSE RADIOIODINE THERAPY. N.C. Finch1, J. Stallwood1,
S. Tasker1, A. Hibbert2. 1University of Bristol, Bristol, UK, 2The
Feline Centre, Langford Vets, Bristol, UK
Iatrogenic hypothyroidism can develop post-radioiodine treatment
for feline hyperthyroidism; its incidence may be dose-dependent.
Cats that develop iatrogenic hypothyroidism have a greater inci-
dence of development of azotemia than cats that remain euthyroid.
Dogs with experimentally-induced hypothyroidism have both
decreased glomerular ﬁltration rate (GFR) and endogenous crea-
tinine production. This suggests that using creatinine as a marker
of kidney function in hypothyroid cats could underestimate the
incidence of development of kidney disease. This longitudinal
study evaluated thyroid and renal function in cats post low-dose
(111 MBq) radioiodine therapy.
Hyperthyroid cats presented for low-dose radioiodine therapy
to The Feline Centre, Langford Vets were prospectively enrolled
into the study. At baseline, one, six and 12-months post-radioio-
dine treatment, thyroid and renal function were evaluated via
total thyroxine (TT4) and thyroid stimulating hormone (TSH),
and via serum creatinine concentration (SCr) and GFR (corrected
slope-intercept iohexol clearance), respectively. Cats were catego-
rized as overt hypothyroid (TT4 < 15 nmol/L, TSH>0.15 ng/mL),
subclinical hypothyroid (TT4≥15–60 nmol/L, TSH>0.15 ng/mL),
euthyroid (TT4≤60 nmol/L, TSH≤0.15 ng/mL) and hyperthyroid
(TT4>60 nmol/L) at each timepoint. Decreased GFR was deﬁned
as <0.92 mL/min/kg and azotemia as SCr>175 µmol/L.
Twenty-seven cats were recruited into the study with 21 com-
pleting the 12-months follow-up; two were lost at one-month and
four at 12-months. Two cats (8%) remained persistently hyperthy-
roid, of which one underwent repeat radioiodine treatment. Five
cats (20%) remained hyperthyroid at one-month but were euthy-
roid by 6-months. Seven cats (28%) developed overt
hypothyroidism over the 12-months (2/7 at one-month, 4/7 at 6-
months and 1/7 at 12-months) of which two were preceded by sub-
clinical hypothyroidism and none of these cats regained normal
thyroid function by 12-months. One cat had subclinical hypothy-
roidism at 12-months with no further follow-up available. No cats
developed transient overt or subclinical hypothyroidism. Of the
cats that developed overt hypothyroidism, 4/7 (57%) developed
decreased renal function by 12-months. Decreased GFR preceded
azotemia development in 2/4 (50%) of these cats.
Twenty-eight percent of cats developed overt hypothyroidism
that could be documented up to 12-months post-treatment. This
highlights the importance of continued monitoring of thyroid func-
tion post-treatment even for cats receiving low-dose radioiodine
therapy. Reduced renal function was documented in 57% of
overtly hypothyroid cats, with GFR detecting decline in renal
function earlier than SCr, suggesting GFR may be more useful to
monitor renal function in cats post-radioiodine therapy. However,
the study is limited by the small number of cats developing overt
hypothyroidism and further studies evaluating the optimal method
for detecting early decline in renal function are required.
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EVALUATION OF SYMMETRIC DIMETHYLARGININE
(SDMA) IN DOGS WITH PRIMARY HYPOADRENOCORTI-
CISM UNDER LONG-TERM MINERALOCORTICOID
REPLACEMENT THERAPY. J.I. Casado Diaz1, N. Sieber-Ruck-
stuhl1, F.S. Boretti1, F. Fracassi2, C.E. Reusch1. 1Vetsuisse-
Faculty, University of Zurich, Z€urich, Switzerland, 2Department
of Veterinary Medical Sciences, University of Bologna, Bologna,
Italy
In the majority of dogs with primary hypoadrenocorticism (PH),
the disease is characterized by an absolute deﬁciency of glucocorti-
coids and mineralocorticoids. Consequently, those patients require
life-long replacement of both hormones. Since application of the
respective drugs do not restore physiological hormone levels and
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biorhythm, overdose may be possible during long-term manage-
ment. Unlikely to glucocorticoid excess, overdose of mineralocorti-
coids may go clinically unnoticed. Due to their role as key
mediators for renal damage and progression of kidney disease,
mineralocorticoid overdose represents a matter of concern.
The aim of the study was to investigate kidney function by
means of SDMA and creatinine (Cr) in dogs with PH during long-
term mineralocorticoid therapy.
Twenty-seven client-owned dogs with PH receiving either des-
oxycorticosterone pivalate (DOCP) or ﬂudrocortisone acetate (FC)
for a minimum of 12 months were included in the study. Concen-
trations of Cr had been measured during regular re-evaluations
and were retrieved from the medical records retrospectively.
SDMA was measured using the validated immunoassay at the ref-
erence laboratory (IDEXX Diavet).
Treatment time ranged from 12 to146 months (median 47).
Nine dogs had been treated with FC, 8 dogs with DOCP and in
10 dogs FC had been changed to DOCP because of poor response
or adverse eﬀects. At the time of diagnosis 3 dogs had elevated
SDMA whereas Cr was elevated in 8 dogs, both parameters nor-
malized after starting therapy. Two dogs developed persistent ele-
vated SDMA 18 and 32 months after starting therapy with FC
and DOCP respectively, followed by an elevated Cr 14 and
4 months later. Clinical signs and further work up were consistent
with chronic kidney disease (CKD) in both dogs. Although
SDMA was within the reference interval in all other dogs, 3 dogs
showed an elevated Cr, being permanent in one of them. A signiﬁ-
cant correlation between SDMA and Cr was demonstrated
(r = 0.35; P = .0013). There was no statistical evidence of any dif-
ferences in Cr or SDMA between the FC and the DOCP groups.
In conclusion, selected dogs may develop CKD during long-
term mineralocorticoid therapy. The prevalence of CKD in PH
might be higher than in the general dog population, however this
has to be veriﬁed in a larger number of dogs. The signiﬁcance of
an elevated Cr with normal SDMA is unclear, possibly reﬂecting
prerenal azotemia or early kidney dysfunction.
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A COMPARISON OF THE ACTH CONCENTRATIONS IN
DOGS WITH STABLE HYPOADRENOCORTICISM BEING
TREATED WITH EITHER FLUDROCORTISONE OR
DESOXYCORTONE PIVALATE AND PREDNISOLONE. S.
Spence, S. Fowlie, E. Roberts, I. Ramsey. University of Glasgow,
Glasgow, UK
Desoxycortone pivalate (DOCP) (Zycortal, Dechra) is a pure
mineralocorticoid and so concurrent doses of glucocorticoids need
to be individually titrated; currently this is done on the basis of
clinical signs. In contrast, most dogs treated with ﬂudrocortisone
(a mixture of mineralocorticoid and glucocorticoid) do not receive
additional glucocorticoid supplementation following stabilization.
The objective of this study was to compare the ACTH concentra-
tions in dogs treated with ﬂudrocortisone with the same dogs when
treated with DOCP and prednisolone.
A prospective, cross-over trial was performed using 33 dogs
with hypoadrenocorticism who had been previously stabilized on
ﬂudrocortisone. Each dog was randomly allocated to one of two
groups, each of which were treated with 3 months of ﬂudrocorti-
sone then 3 months of DOCP and prednisolone (or vice versa).
The prednisolone dose was adjusted according to clinical signs.
Two dogs failed to complete the trial. Three patients received
prednisolone concurrently for at least part of the ﬂudrocortisone
phase and the data from these dogs in this phase were removed
from further analysis. ACTH levels were measured at the start and
end of each treatment phase using an immunoradiometric assay
(NationWide Laboratories). Tests for normality were performed
and Mann-Whitney U tests were used to compare the various
ACTH concentrations and the prednisolone doses at the start and
end of the DOCP phase. A Pearson correlation was used to com-
pare the ﬁnal prednisolone dose and ACTH concentrations at the
end of the DOCP phase.
There was a signiﬁcant diﬀerence between the ACTH concentra-
tions after DOCP (median = 2.5 pg/mL) compared to those after
ﬂudrocortisone (median = 150 pg/mL) or before starting DOCP
(median = 128 pg/mL). There was also a signiﬁcant reduction in
prednisolone dose during the DOCP phase from a median starting
dose of 0.22 mg/kg to 0.13 mg/kg. After 3 months of treatment
with DOCP and prednisolone 21 out of 31 dogs had ACTH con-
centrations less than 10 pg/mL (suggesting suppression of the
ACTH secretion). No signiﬁcant correlation was found between
the ﬁnal prednisolone dose and the ACTH concentration at the
end of the DOCP phase. In contrast, 18 of the 31 dogs had ACTH
concentrations more than 100 pg/mL (possibly suggesting inade-
quate glucocorticoid supplementation) following 3 months of
treatment with ﬂudrocortisone.
It is concluded that in many dogs with hypoadrenocorticism
being treated with DOCP, the dose of prednisolone has the poten-
tial to be further reduced based on ACTH concentrations.
Disclosures: Disclosures to report.
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PREVALENCE OF HYPERALDOSTERONISM AND HYPER-
TENSION IN CATS WITH CHRONIC AZOTEMIA. A.C. Hag-
blom, J.M. Hanson. Swedish University of Agricultural Sciences,
Uppsala, Sweden
Primary hyperaldosteronism (PHA) is suggested to be more com-
mon in cats than previously thought. Because of its proﬁbrotic
and proinﬂammatory eﬀects, aldosterone may contribute to the
progression of hypertension and kidney damage.
The aim of the present study was to perform a pilot study on
the plasma aldosterone concentration (PAC), plasma renin activity
(PRA), and hypertension in cats with chronic azotemia in Sweden.
Twenty-one cats with chronic azotemia were included in the
study. Blood samples were collected into pre-chilled EDTA tubes
and centrifuged at +4°C. The separated plasma was stored at
80°C until transport at 70°C to the commercial laboratory for
analysis. PAC was measured with an ELISA, PRA with a radioim-
munoassay, and blood pressure (BP) with high-deﬁnition oscillom-
etry. Statistical analysis was performed with non-parametric tests
with the free software R version 3.3.2.
In the 21 cats, median PAC was 21 pmol/L (range, <20 to 127
pmol/L; reference range, 87 to 224 pmol/L). In seventeen cats the
PAC was below reference range, in 10 of these the PAC was below
detection limit (20 pmol/L). Median PRA was 0.30 ng/mL/hr
(range, 0.0 to 4.5 ng/mL/hr; reference range, 0.14 to 3.85 ng/mL/
hr). Five of the 21 cats had a PRA below the reference range.
Median aldosterone-to-renin activity ratio (ARR) was 86 (range,
14 to 4300). Eleven of the 21 cats were hypertensive (BP ≥
160 mmHg). Median PAC in hypertensive cats was 43 pmol/L
(range, <20 to 127). Median PAC in normotensive cats was <20
pmol/L (range, <20 to 77). There was no statistical diﬀerence in
PAC or PRA between hypertensive and normotensive cats (Mann-
Whitney-Wilcoxon test, P = 0.09 and P = 0.10, respectively).
Five of the 6 cats with a PAC >70 pmol/L were hypertensive.
Four of the 5 hypertensive cats had a PRA below or in the lower
reference range. The ARR in these 4 cats was 513, 673, 720, and
1200. One cat (ARR 1200) was euthanized. Histopathological
examination revealed a mixed diﬀuse and nodular hyperplasia of
the z. glomerulosa of the right adrenal gland, and bilaterally
chronic to active interstitial nephritis. The remaining two cats had
an ARR of 23 and 122.
The results of the present study indicate presence of renin-inde-
pendent aldosterone secretion in 19% of the cats with chronic azo-
temia. A surprisingly high proportion of the cats had a subnormal
PAC. This is an observation that needs further investigation,
before conclusions are drawn.
Disclosures: Disclosures to report.
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THE USE OF A TRH STIMULATION TEST, WITH MEA-
SUREMENT OF PLASMA CONCENTRATIONS OF
GROWTH HORMONE AND THYROID STIMULATING
HORMONE, TO DIFFERENTIATE BETWEEN PRIMARY
HYPOTHYROIDISM AND NON-THYROIDAL ILLNESS IN
DOGS. T. Pijnacker, C.F. Vermeulen, M. van der Vinne, H.S.
Kooistra, J.A. Mol. Utrecht University, Utrecht, Netherlands
Hypothyroidism is one of the most common endocrinopathies in
dogs. The diagnosis of hypothyroidism relies upon measurement
of basal plasma concentrations of total thyroxine (T4) and thyroid
stimulating hormone (TSH). A low plasma T4 combined with a
high plasma TSH points to primary hypothyroidism. However,
30–38% of hypothyroid dogs have TSH values within the refer-
ence range. Consequently, a low plasma total T4 concentration in
combination with a plasma TSH concentration within the refer-
ence range does not distinguish between dogs with hypothyroidism
and dogs with non-thyroidal illness (NTI). A potential interesting
observation from previous studies (Lee et al; 2001, and Diaz-
Espi~neira et al; 2008) is that hypothyroidism in dogs is associated
with increased release of growth hormone (GH).
The aim of this study was to evaluate whether a TRH stimulation
test can diﬀerentiate between dogs with NTI and dogs with hypothy-
roidism that have a plasma TSH concentration within the reference
range, by measuring plasma concentrations of GH and TSH.
21 dogs with clinical signs consistent with hypothyroidism, a
plasma TT4 concentration below the reference interval (19–
46 nmol/L), and a plasma TSH concentration within the reference
interval (<0.60 µg/L) were included in this study. Thyroid scintig-
raphy was performed to classify dogs as having hypothyroidism or
NTI. All dogs underwent a TRH stimulation test in which plasma
concentrations of TSH and GH were measured twice before intra-
venous administration of 10 µg/kg TRH (t = 15 and t = 0) and
30 and 45 min after TRH administration.
11 of the 21 dogs were classiﬁed as hypothyroid and 10 dogs as
having NTI by thyroid scintigraphy. There were no diﬀerences in
baseline characteristics between the groups except for gender. The
plasma TSH concentration did not change signiﬁcantly in the
hypothyroid dogs after administration of TRH, whereas it signiﬁ-
cantly increased in the NTI dogs (P < 0.001). In contrast, the
plasma GH concentration increased signiﬁcantly in the hypothy-
roid dogs after TRH administration (P = 0.009), whereas it did
not change in the NTI dogs.
The TRH stimulation test with measurement of circulating con-
centrations of TSH and GH could be used to diﬀerentiate between
hypothyroid dogs and NTI dogs that have clinical signs of
hypothyroidism, a low basal TT4 concentration and a basal TSH
concentration within the reference interval. This is a promising test
which might be of valuable use in primary veterinary practice.
Disclosures: Disclosures to report.
This study was partially funded by a grant from the American
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INTERRELATION BETWEEN THYROID FUNCTION AND
SEX HORMONES IN FEMALE GERMAN SHEPHERD
DOGS. P. Scarpa1, F. Iavazzo1, M. Beccaglia2, A. Monino3, P.
Dri3, G. Milite3. 1University of the Study of Milan, Milan, Italy,
2Ambulatorio Veterinario Beccaglia, Lissone, MB, Italy, 3Animal
Care srl, Martignacco, UD, Italy
In veterinary literature, data about the interaction between thyroid
gland and female reproductive status are lacking. Furthermore,
previous studies have often referred to male dogs and few data are
available about thyroid inﬂuence on diﬀerent phases of the bitch
estrous cycle.
The aim of this study was to determine the inﬂuences of the dif-
ferent phases of estrous cycle on thyroid hormones in German
Shepherd bitches.
Seventeen clinically healthy German Shepherd bitches
(9 months to 6 years old) were monitored during a complete
estrous cycle (proestrus, estrus, diestrus, anestrus); the diﬀerent
phases were determined by vaginal cytology. Two blood samples
were collected by cephalic vein in each phase, between 11 am and
2 pm, after 12–24 h fasting. Thyroid hormones (TT4, fT4, TT3,
fT3), TSH, progesterone, 17-ß-estradiol, serum triglycerides and
cholesterol were assessed in each blood samples. At the beginning
and at the end of the study a complete hematological and bio-
chemical evaluation was also performed. Seven bitches were bred
during the study, and hormone concentrations were also evaluated
during pregnancy.
Data were statistically analyzed: correlation test was performed
between thyroid and pituitary hormones with age, between the dif-
ferent hormones assessed (thyroid, pituitary and sexual hormones)
and between estradiol and cholesterol. One-way ANOVA was used
to compare the averages of each parameter (thyroid/pituitary) in
diﬀerent phases of the cycle and in diestrus gravidarum and not
gravidarum.
Eﬀect Size (Cohen’s d) or Root Mean Square Standardized
Eﬀect were calculated to measure the magnitude and strength of
the statistically signiﬁcant research ﬁndings.
A signiﬁcant negative correlation between age and TT4
(r = 0.367; P < 0.05), fT4 (r = 0.266; P < 0.05), fT3
(r = 0.335; P < 0.05) was found.
One way ANOVA showed that TT4 concentration during
estrous and diestrous phase, was signiﬁcantly higher than in proe-
strous and anestrous phase (P = 0.0332).
TSH concentration during diestrus and pregnancy was not sig-
niﬁcantly diﬀerent by two tails T-test (P = 0.0507), even though a
higher TSH concentration during pregnancy was evident.
TT4 (r = 0.40289; P < 0.001) and fT4 (r = 0.260; P = 0.0067)
were positively and signiﬁcantly associated with progesterone.
TSH was positively and signiﬁcantly correlated with 17-ß-estra-
diol (r = 0.2; P = 0.0388), while TT4 was negatively and signiﬁ-
cantly correlated with 17-ß-estradiol (r = 0.3179; P = 0.0008).
Cholesterol was negatively and signiﬁcantly correlated with 17-
ß-estradiol (r = 0.3355; P = 0.0001) and was signiﬁcantly higher
during diestrus (r = 0.3355; P = 0.0001). There was no signiﬁcant
correlation between total triglycerides and 17-ß-estradiol.
Results showed an inﬂuence of reproductive status on thyroid
function, especially during progesterone-prevalent phase (diestrus)
and especially relating to TT4 concentration.
Disclosures: No disclosures to report.
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CALIBRATED AUTOMATED THROMBOGRAPHY TO
EVALUATE THROMBIN GENERATION IN DOGS WITH
IMMUNE-MEDIATED HEMOLYTIC ANEMIA. B.Y. Cuq1,
S.L. Blois1, R.D. Wood1, A.C. Abrams-Ogg1, C. Bedard2, G.A.
Wood1. 1Ontario Veterinary College, University of Guelph,
Guelph, Canada, 2Faculty of Veterinary Medicine, University of
Montreal, ST Hyacinthe, Canada
Up to 60% of the mortality in dogs with immune-mediated hemo-
lytic anemia (IMHA) is associated with thrombosis or dissemi-
nated intravascular coagulation. No conventional hemostatic test
is accurate to evaluate the risk for hypercoagulability. Viscoelastic
testing has been proven to be inﬂuenced by anemia, and might not
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reliably assess hemostasis in IMHA patients. Calibrated automated
thrombography (CAT) is a thrombin generation (TG) assay that
has been validated in clinically healthy dogs. The objective of the
study was to assess the suitability of TG in the assessment of
hypercoagulability in IMHA patients. IMHA was determined by
the presence of anemia, spherocyte and positive slide agglutination
test or positive Coomb’s Test. CBC, coagulation proﬁle and CAT
parameters (lag time, time to peak, peak, endogenous thrombin
potential) were performed in all IMHA patients, at the time of
diagnosis and then at 48 and 96 h. Lag time was prolonged for
IMHA patients at day 0 (D0) and D2; and time to peak was
higher on D0 but not statistically diﬀerent on D2 or D4 compared
to healthy dogs. Peak was higher in dogs with IMHA at D0, D2
and D4. There was no statistical diﬀerence in the endogenous
thrombin potential between IMHA and healthy dogs. No correla-
tion between the CAT parameters and blood cell count, coagula-
tion parameters or the likelihood for the patient to be discharged.
Prolonged lag time and time to peak indicate hypocoagulation in
IMHA dogs early in the disease onset, however, based on peak
value, IMHA patients appear to generate more thrombin once
coagulation is initiated compared to normal dogs. TG was not
useful in predicting patient outcomes.
Disclosures: No disclosures to report.
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EFFECT OF IMMUNE-SUPPRESSIVE TREATMENT ON
CYTOKINE PRODUCTION IN HEALTHY DOGS. J.R.S. Dan-
drieux1, T.M. Archer2, L. Narayanan2, R. Wills2, C.S. Mansﬁeld1.
1University of Melbourne, Werribee, Australia, 2College of Veteri-
nary Medicine, Mississippi State University, USA
Immunosuppressive drugs are the cornerstone of treating immune-
mediated diseases in dogs. Currently, dosage adjustments are often
based on resolution of clinical signs and monitoring for adverse
eﬀects. Recently, a validated pharmacodynamic assay (PD) has
been used to monitor dogs treated with cyclosporine by assessing
interleukin-2 (IL-2) and interferon-gamma (INFc). There is no
study to date looking at cytokine secretion and detection in dogs
receiving other immunosuppressive drugs.
The aim of this study was to evaluate multiple immunosuppres-
sive drugs and determine individually whether they aﬀected secre-
tion of IL-2, IL-6, IL-10, INFc or tumor necrosis factor alpha
(TNFa) in healthy dogs using a multiplex assay.
Blood was obtained from healthy adult Walker hounds before
and after immunosuppressive treatment at standard doses using a
randomized crossover study design. Treatments included azathio-
prine, cyclosporine, mycophenolate mofetil, leﬂunomide, or pred-
nisone. Blood was sampled prior to and following 7 days of
treatment. Four dogs were tested for each drug with a minimum
wash out period of three weeks. Whole blood was activated with
either phorbol 12-myristate 13-1 acetate and ionomycin (PMA/I)
or lipopolysaccharide (LPS). Cytokines in the supernatant were
analyzed using a multiplex assay. The Kruskal-Wallis test was
used to test for carryover eﬀects of the drugs. The Wilcoxon
signed-rank test was used to assess each activator eﬀect on cyto-
kine production.
Pre-treatment, stimulation of blood with PMA/I signiﬁcantly
increased INFc, IL-10, and TNFa, whereas stimulation with LPS
signiﬁcantly increased IL-6, IL-10, and TNFa production (P
<0.001 for all cytokines). There was no signiﬁcant increase in IL-2
with either activator. No signiﬁcant carry over eﬀect was detected
for any of the drugs used.
Azathioprine, leﬂunomide, and mycophenolate treatments did
not reliably change cytokine production for any of the cytokines
tested. Dogs treated with cyclosporine had no detectable IL-10,
TNFa, and INFc after treatment when blood was stimulated with
PMA/I. All dogs treated with prednisone had marked reduction in
their TNFa production (<30% of pre-treatment concentration)
after PMA/I stimulation. All dogs, and 3 out of 4 dogs, had a
reduction of at least 80% in TNFa and IL-6 concentrations
respectively after LPS stimulation.
Speciﬁc patterns of cytokine suppression may be useful to moni-
tor eﬃcacy of immunosuppression in dogs treated with cyclospor-
ine and prednisone. No clear trend was seen with the other
immunosuppressive drugs tested.
Disclosures: Disclosures to report.
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IDENTIFICATION OF ANTINUCLEAR ANTIBODIES IN
DOGS USING IMMUNODIFFUSION. H. Hansson-Hamlin, S.
Hahne, H.D. Bremer. Swedish University of Agricultural Sciences,
Uppsala, Sweden
Circulating antinuclear antibodies (ANAs) are commonly present
in the systemic autoimmune disease Systemic Lupus Erythemato-
sus (SLE) and in other SLE-related diseases, in humans as well as
in dogs. Certain canine breeds, such as German shepherd dogs
and Nova Scotia duck tolling retrievers (NSDTRs), have been
shown to be overrepresented for autoimmune diseases.
The indirect immunoﬂuorescence (IIF)-ANA test is the standard
method for detecting ANAs. Further testing for ANA speciﬁcities
with diﬀerent techniques, such as ELISAs, immunoblot or immun-
odiﬀusion, is routinely performed in humans, but not in dogs, to
aid in the diagnosis of disease. Several speciﬁc ANAs identiﬁed in
humans have been identiﬁed also in suspected canine SLE or SLE-
related disorders but in many cases the main antigen targeted by
the antibodies cannot be identiﬁed. IIF-ANA positive dogs are
usually divided into two subgroups depending on their ﬂuores-
cence pattern, a speckled pattern with no chromosomal reactivity
or a homogenous pattern with chromosomal reactivity. Previous
studies have shown that only dogs with a speckled IIF-ANA pat-
tern are positive on immunodiﬀusion.
Our aim was to investigate if the immunodiﬀusion (ID) tech-
nique, using sera from IIF-ANA positive dogs, may identify speci-
ﬁc ANAs of relevance in human patients and also identify
diﬀerent subgroups of unknown antigens.
Sera from 32 IIF-ANA positive dogs with speckled ﬂuorescence
pattern were part of the study (21 German shepherd dogs, three
NSDTRs and eight dogs of seven other diﬀerent breeds). Ten
healthy dogs of diﬀerent breeds were used as controls. Thirty-one
of the 32 IIF-ANA positive dogs were positive on immunodiﬀu-
sion. Twenty-nine of the positive dogs could be further divided
into three separate groups based on their reactions on immunodif-
fusion. Group 1 (n = 4) and group 2 (n = 16) had reactivity to
unknown antigens (diﬀerent between the groups). Group 3 (n = 9)
had antibodies directed to RNP. A breed associated ANA speci-
ﬁcity was observed in both NSDTRs and German shepherd dogs.
All NSDTRs belonged to group 1, while group 2 consisted only of
German shepherd dogs.
The ID technique thus shows that IIF-ANA canine sera may be
divided into subgroups reﬂecting the same speciﬁc ANA reactivity.
In most of the dogs the speciﬁc ANA reactivity could not be iden-
tiﬁed, which might indicate dog-speciﬁc autoantigens. Further
investigations of canine sera are needed in order to identify the
speciﬁc antigen reactivity of these ANAs.
Disclosures: No disclosures to report.
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SHORT- AND LONG-TERM MORBIDITY AND MORTALITY
IN DOGS AND CATS FOLLOWING CARDIOPULMONARY
ARREST. L. Brown1, T. King2. 1Murdoch University, Murdoch,
Australia, 2Veterinary Specialist Services, Underwood, Australia
The RECOVER initiative has generated interest regarding the
poor prognosis for veterinary patients suﬀering cardiopulmonary
arrest (CPA) and produced evidence-based guidelines for their
care. There is, however, scant documentation of post-discharge
outcomes for animals that survive. This study aimed to describe
mortality associated with in-hospital CPA, determine median sur-
vival time of dogs and cats that survive CPA, and examine the
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incidence and persistence of acquired neurological deﬁcits. Medical
records of animals that underwent cardiopulmonary resuscitation
(CPR) at a referral centre were reviewed. Factors examined
included species and age, managing department, location in hospi-
tal of arrest, primary disease process, closed versus open CPR,
return of spontaneous circulation (ROSC), time to death, and
cause of death. Where survivors to discharge were identiﬁed, the
animal’s primary care veterinarian was contacted for provision of
medical records following discharge. A total of 241 animals under-
went CPR (196 dogs and 45 cats) with 116 (48%) animals achiev-
ing ROSC and 29 of 41 (12%) surviving to discharge. Complete
medical records were obtained for 79% (23/29) of survivors. Five
of 29 (17%) had neurological deﬁcits including depressed menta-
tion, ataxia, circling and blindness on leaving hospital. All had
either complete resolution or signiﬁcant improvement of neuro-
logic deﬁcits within one month. Eight animals (35%) died follow-
ing discharge prior to completion of the study period, however
two were excluded from analysis as they were discharged explicitly
for a palliative visit. The remaining six animals had a median sur-
vival time of 1284 days (502–1508 days). Fifteen animals (65%)
were alive on completion of the study, with a median of 1362 days
following discharge (162–2901). The proportion of animals surviv-
ing to discharge was similar to that reported in the veterinary liter-
ature. Whilst the immediate prognosis for animals undergoing
CPA is poor, for animals surviving to discharge life expectancy is
reasonable and the prognosis good for improvement of acquired
neurological deﬁcits.
Disclosures: No disclosures to report.
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FELINE PRIMARY ERYTHROCYTOSIS: A MULTICENTRE
RETROSPECTIVE CASE SERIES (18 CASES). H. Darcy1, K.
Simpson2, I. Gajanayake3, M. Seth4, Y.L. Mcgrotty5, B. Szlado-
vits1, B. Glanemann1. 1Royal Veterinary College, Potters Bar,
UK, 2Goddard’s Veterinary Group, London, UK, 3Willows Refer-
ral Service, Solihull, UK, 4Animal Health Trust, Newmarket, UK,
5Vet Specialist Services Ltd., Stirling, UK
Feline primary erythrocytosis (PE) is a rare myeloproliferative dis-
order causing excessive increase in packed cell volume (PCV).
Veterinary literature is sparse with isolated reports and minimal
information regarding prognosis. We evaluated a retrospective
multicentre case series of feline PE, with the aim of increasing
understanding of disease progression to guide management and
prognostication. Theories of possible underlying genetic causes
were evaluated by comparing the natural history of feline PE to
human polycythemia vera (PV).
Cases required documentation of increased PCV (>48%), suﬃ-
cient investigation to exclude relative and secondary erythrocyto-
sis, and follow-up data for at least twelve months or until death.
Eighteen cats from ﬁve UK veterinary hospitals were included.
No signiﬁcant trends in signalment were noted. Seizures and men-
tation changes were the most common presenting signs (both
n = 10). Median PCV and total protein were 70% and 76 g/L
respectively, with no other consistent blood cell changes. Sixteen
cats survived to discharge. Phlebotomy was performed initially in
15/16 cats and after discharge in 10/16. Six cases eventually
required no further phlebotomies. Hydroxyurea was the most com-
mon adjunctive therapy (n = 10). Fourteen patients were alive at
the time of writing (survival time >12 months).
This case series demonstrates that management of feline PE is
generally well-tolerated with evidence of prolonged survival times.
Disease characteristics are similar to a subset of human PV caused
by mutations in exon 12 of the janus kinase 2 gene, representing a
possible future therapeutic target.
Disclosures: No disclosures to report.
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INVESTIGATION OF A FUNGAL ETIOLOGY IN CANINE
IDIOPATHIC PULMONARY FIBROSIS. E. Roels1, C. Barrera2,
L. Millon2, M.M. Rajam€aki3, J. Talbot4, C. Clercx1, V. Barrs4.
1University of Liege, Liege, Belgium, 2Department of Mycology,
UMR6249 Chrono-Environnement, University Hospital,
Besancon, France, 3Department of Equine and Small Animal
Medicine, Faculty of Veterinary Medicine, Helsinki, Finland,
4Sydney School of Veterinary Science, Faculty of Science, Marie
Bashir Instit, Sydney, Australia
Canine idiopathic pulmonary ﬁbrosis (CIPF) is a progressive
parenchymal lung disease of unknown origin and poorly under-
stood pathophysiology that mainly occurs in old West Highland
white terriers (WHWTs). Computed tomographic and histopatho-
logical ﬁndings of CIPF share characteristics of both human usual
intestinal pneumonia (UIP) (typical pattern of IPF in humans)
and non-speciﬁc interstitial pneumonia (NSIP) patterns. In
humans, a NSIP pattern is commonly observed in hypersensitivity
pneumonitis. This inﬂammatory pulmonary syndrome results from
sensitization to inhaled antigens such as fungal particles and can
cause irreversible lung ﬁbrosis in chronic stages. Given that no eti-
ologies have been identiﬁed for CIPF, the objective of this study
was to investigate a potential fungal cause. A conventional pan-
fungal PCR assay targeting the conserved rDNA gene internal
transcribed spacer (ITS) regions of fungi, using two primer pairs
(ITS1-ITS2, ITS1-ITS4) was performed using DNA extracted from
lung tissue samples from WHWTs aﬀected with CIPF (n = 26)
and age-matched unaﬀected controls (n = 14). DNA of soil Asper-
gillus fumigatus isolates were included as positive controls. Water
samples were tested as negative controls. Additionally, serum sam-
ples from 8 WHWTs aﬀected with CIPF and 8 age-matched unaf-
fected WHWTs were tested for precipitins against 10 species of
environmental fungus using electrosyneresis on cellulose acetate.
Fungal ITS1-ITS2 and ITS1-ITS4 sequences were not ampliﬁed
from any lung sample, suggesting that invasive fungal infection or
heavy colonization is unlikely in CIPF. On the other hand, results
of the serological assay revealed the presence of ≥ 2 arcs of precip-
itins (indicative of a positive result) in 55 of the 160 reactions
tested (35 positive results in CIPF population vs. 20 in controls,
P = 0.013), supporting an increased prevalence of environmental
fungal exposure in CIPF dogs compared with controls. For
Lichtheimia corymbifera, a commonly involved antigen in human
farmer’s lung hypersensitivity pneumonitis, the number of precip-
itin arcs was signiﬁcantly higher in CIPF dogs in comparison with
controls (P = 0.04). Whether this ﬁnding reﬂects a lung sensitiza-
tion to fungal allergens and is involved in the pathogenesis of
CIPF warrants further investigation.
Disclosures: No disclosures to report.
ESVIM – O – 8
CLINICAL FEATURES OF 70 CASES OF CANINE IDIO-
PATHIC EOSINOPHILIC LUNG DISEASE. S. Keegan1, P. Sil-
vestrini2, Y. Martınez-Pereira3, P. Watson4, J. Lopez-Alvarez5, R.
Blake3, A. Kortum4, D. Casamian-Sorrosal6. 1University of Bris-
tol, Langford, UK, 2School of Veterinary Medicine, University of
Liverpool, UK, 3School of Veterinary Science, University of Edin-
burgh, UK, 4School of Veterinary Medicine, University of Cam-
bridge, UK, 5UK, 6Dick White Referrals, UK
Records of all cases diagnosed between 2004 and 2016 with eosi-
nophilic bronchitis (EB) or idiopathic eosinophilic bronchopneu-
mopathy (EBP) at four university hospitals in the UK were
reviewed. Cases were excluded if full records were not available or
if other pulmonary disease such as neoplasia or parasitic pneu-
monitis was identiﬁed. The following information was retrieved:
breed, age, sex, weight, clinical signs, presence of eosinophilia, tho-
racic imaging ﬁndings, bronchoscopy results (classiﬁed as mild;
moderate; severe), BALF cytology results (eosinophilic pleocytosis
classiﬁed as mild 10–25%; moderate 25–50%; severe >50%), infec-
tious disease screening and concurrent disease processes. The fol-
lowing subgroups were created: acute (<1 month of clinical signs)
versus chronic (>1 month of clinical signs); EB1 (no radiographic
changes or bronchial/peribronchial pattern) vs. EBP1 (interstitial /
alveolar patterns) and EB2 (no radiographic changes) vs. EBP2
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(any pulmonary pattern). Group comparisons by chi-square or
Fisher’s exact test were carried out in regards to age, weight, bron-
choscopy score, presence of eosinophilia or bronchiectasis and
degree of eosinophilia in BALF.
The inclusion criteria were met by 70 cases. Median age was
4 years (IQR 1–6). Females (63%; 44/70) and cross-breed dogs
(17%; 17/70) were most commonly aﬀected. The commonest clini-
cal sign was cough (94%; 66/70). There were 69% (48/70) classi-
ﬁed as chronic and 32% (22/70) as acute. EB1 group was 46%
(32/70) versus EBP1 group 54% (38/72) and EB2 group was 81%
(57/70) versus EBP2 group 19% (13/70). Circulating eosinophilia
occurred in 36% (25/70) and bronchiectasis in 14% (10/70) of
cases. Bronchoscopy score was mild (38%; 25/68), moderate (54%;
37/68) and severe (9%; 6/68). BALF results were mild in 10% of
patients (7/70); moderate in 29%(20/70) and severe in 61%(43/70).
EB cases (EB1 (P = 0.003) and EB2 (P = 0.002)) were less likely
to have eosinophilia. EB2 cases had higher degree of eosinophilic
pleocytosis on BALF (P = 0.006) and no EB2 case suﬀered from
bronchiectasis. There was no diﬀerence (P > 0.05) in any of the
other clinical variables between EB versus EBP groups or between
acute and chronic cases.
The conclusions of this study include: dogs with eosinophilic
lung disease (ELD) in general and EBD in particular were more
commonly young to adult and female and cross-breed dogs were
commonly aﬀected. EB dogs without radiographic changes repre-
sent a diﬀerent ELD population with less severe eosinophilic pleo-
cytosis in BALF and absence of bronchiectasis and eosinophilia.
Unlike the situation in human medicine, there are no obvious clin-
ical or diagnostic diﬀerences between acute and chronic ELD in
dogs.
Disclosures: No disclosures to report.
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THERAPY AND LONG-TERM FOLLOW-UP OF 70 CASES
OF CANINE IDIOPATHIC EOSINOPHILIC LUNG DISEASE.
S. Keegan1, P. Silvestrini2, Y. Martınez-Pereira3, P. Watson4, J.
Lopez-Alvarez5, R. Blake3, A. Kortum4, D. Casamian-Sorrosal6.
1University of Bristol, Langford, UK, 2School of Veterinary Medi-
cine, University of Liverpool, UK, 3School of Veterinary Science,
University of Edinburgh, UK, 4School of Veterinary Medicine,
University of Cambridge, UK, 5UK, 6Dick White Referrals, UK
Records of 70 cases (2004–2016) diagnosed with idiopathic eosino-
philic bronchitis (EB) or idiopathic eosinophilic bronchopneu-
mopathy (EBP) were reviewed. Total response (TR) or partial
response (PR) was resolution or improvement of clinical signs
respectively. Remission or long-term remission was absence of res-
piratory signs following discontinuation of therapy for more than
one or six months respectively. Relapse was reoccurrence of clini-
cal signs during remission. The following subgroups were estab-
lished: acute (<1 month of clinical signs) versus chronic (>1 month
of clinical signs); EB1 (no radiographic changes or bronchial/peri-
bronchial pattern) versus EBP1 (interstitial/alveolar patterns); EB2
(no radiographic changes) versus EBP2 (any pulmonary pattern);
prednisolone dose (≤ = 1 mg/kg/day; antiinﬂammatory-A- vs.
>1 mg/kg/day; immunomediated-I-). These groups were compared
for achievement of remission and long-term remission with chi-
square or Fisher’s exact test. Probability of achieving remission
and long-term remission was evaluated by Kaplan Meier curves/
long rank test.
Oral Prednisolone was administered to 96%(67/70) of cases
(4% received single-inhaled therapy) and 37%(25/67) of those also
received combined inhaled ﬂuticasone (no diﬀerence between sub-
groups; P < 0.05). Immunosuppressive or antiinﬂammatory pred-
nisolone was started in 46%(31/67) or 54%(36/67) of cases
respectively (no diﬀerence between subgroups; P < 0.05). In 5%(2/
36) of the latter an increase to an immunosuppressive dose to con-
trol the clinical signs was required. The 1, 2, and 4-year survival
to death/euthanasia due to respiratory disease was 95%, 95% and
91% respectively. TR and PR occurred in 93%(65/70) and 7% (5/
70) of cases respectively. Remission and long-term remission was
achieved in 60%(42/70) and 41%(24/58) of cases respectively.
Relapse occurred in 24%(10/42) of cases during remission and in
4%(1/24) during long-term remission. Achievement of TR, PR,
remission or long-term remission and the probability of achieving
remission or long-term remission was not diﬀerent (P > 0.05)
between subgroups although a possible trend towards increased
likelihood of achieving long-term remission for the I versus A
group was observed.
The conclusions of this study include: Idiopathic eosinophilic
lung disease rarely leads to euthanasia or death and clinical
response is achieved in all dogs. Unlike the situations in humans
we found no evidence that dogs with EB versus EBP or dogs with
acute versus chronic disease diﬀer in outcome. Many dogs
achieved a total response and remission with anti-inﬂammatory
dose of prednisolone (plus/minus inhaled therapy). However,
whether dogs in which an immunosuppressive dose is not used are
less likely to achieve long-term remission warrants further studies.
Disclosures: No disclosures to report.
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DEVELOPMENT OF RESPIRATORY DYSBIOSIS AS CATS
TRANSITION FROM HEALTHY TO ASTHMATIC AIR-
WAYS. A.I. Vientos-Plotts, A.C. Ericsson, C. Reinero, H. Rindt,
M.E. Grobman. University Of Missouri College of Veterinary
Medicine, Columbia, MO, USA
In humans, deviation from a core airway microbiota is thought
to predispose to development, exacerbation or progression of res-
piratory diseases. Our objective was to describe changes in the
airways and fecal microbiota as cats transitioned from healthy
(day 0) to asthmatic, in the early (6 weeks) and chronic
(36 weeks) stages. The gut microbiota inﬂuences microbial com-
munities at distant sites. However, as asthma is a localized dis-
ease, we hypothesized that it would result in decreased richness
and diversity of the lower airway microbiota, contributing to a
state of dysbiosis, while the fecal microbiota would remain
unaﬀected.
Fecal, oropharyngeal (OP), and bronchoalveolar lavage (BAL)
samples were collected from eight healthy research cats before
(day 0) and at 6, 12, 24 and 36 weeks after experimental asthma
induction using Bermuda grass allergen. Extracted DNA under-
went PCR of the 16S rRNA gene. Once sequenced, richness, diver-
sity, and relative abundance of representative operational
taxonomic units (OTUs) were determined via RM ANOVA on
ranks (P < 0.050). Principal component analysis (PCA) was used
to visualize relatedness of samples. Diﬀerences in community com-
position between time-points were tested using PERMANOVA of
Bray-Curtis similarity indices.
Feces had decreased richness between day 0 and 6 weeks
(P < 0.001) only. In OP samples, richness increased at 6 and
36 weeks versus day 0 (P = 0.036 and 0.02, respectively). No sig-
niﬁcant change in relative abundance of predominant taxa was
found in fecal or OP samples over time. In BAL, richness signiﬁ-
cantly decreased from day 0 to 6 and 36 weeks (mean #OTUs 96,
47 and 21, respectively; P < 0.001). Relative abundance of Pseu-
domonadaceae decreased from day 0 to 36 weeks (68% to 0.12%;
P < 0.001) with increases in Sphingobacteriaceae, and Bradyrhizo-
biaceae (from 0.08% to 52.16% and from 0.40% to 32.58%;
P < 0.001). Within BAL, PERMANOVA detected signiﬁcant dif-
ferences (P < 0.001) in diversity between samples collected at day
0 and week 36 compared to all other time-points.
Upper and lower airway communities diﬀer from each other
and from the fecal microbiota. In upper airways, increased rich-
ness without change in relative abundance of predominant taxa
was noted after asthma induction. In contrast, lower airway
microbiota undergo signiﬁcant changes in early and chronic stages
of asthma. Decreases in relative abundance of organisms associ-
ated with healthy airways supports the concept of airway dysbio-
sis. Knowledge of changes in asthmatic airway microbial
populations opens the door to investigation of modulation of air-
way microbiota to attenuate disease.
Disclosures: No disclosures to report.
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DOCUMENTING SILENT REFLUX AND MICROASPIRA-
TION EVENTS USING NUCLEAR SCINTIGRAPHY IN
HEALTHY DOGS. M.E. Grobman, C.A. Maitz, C. Reinero.
University of Missouri College of Veterinary Medicine, Columbia,
USA
Aspiration-related respiratory syndromes are well recognized in
humans. About half of healthy adults aspirate without apparent
clinical consequence. Understanding the frequency and severity of
reﬂux and microaspiration in healthy individuals is critical to
determining their role in respiratory disease pathogenesis. In dogs,
analogous information is lacking. The objective of this pilot study
is to use scintigraphic reﬂux studies to investigate frequency, loca-
tion, and duration of reﬂux and aspiration events in healthy dogs.
Healthy dogs without aero-digestive symptoms within the pre-
ceding 6 months were fed a meal containing (3 mCi) colloidal
99 m-technetium phytate (99mTcP). Time activity curves (TACs)
were quantiﬁed over the pharynx and three esophageal zones at 5
and 30 min post-ingestion. Static images of the lungs were
obtained at 2 and 18 h to evaluate for aspiration. Reﬂux was char-
acterized by counts exceeding background activity by 200%. Data
were reported descriptively as median and range.
Five healthy adult dogs (median 4 years, range 3–9 years) were
enrolled. All dogs had >1 reﬂux event (median 3, range 2–4, total
15) over the 5 min dynamic collection period. Reﬂux was limited
to distal esophageal reﬂux with rising (n = 1; reﬂux with failure of
clearance) and falling (n = 14; reﬂux with appropriate clearance)
TACs. Pharyngeal contamination was identiﬁed in one dog. Aspi-
ration was not observed in any dog.
In dogs, scintigraphic reﬂux studies can document reﬂux and
may complement videoﬂuoroscopic swallow studies and esopha-
geal pH monitoring. Reﬂux, but not aspiration, is common in
healthy dogs and must be considered during interpretation of
results in clinically aﬀected dogs.
Disclosures: Disclosures to report.
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DIAGNOSIS OF PULMONARY ANGIOSTRONGYLOSIS IN
DOGS WITH NEGATIVE NON-INVASIVE TESTS (BAER-
MANN ANALYSIS AND ANGIODETECTTM©). A.M. Canonne1,
F. Billen2, I. Peters3, C. Clercx2. 1National Veterinary School of
Alfort, Maisons Alfort, France, 2Faculty of Veterinary Medicine,
University of Liege, Liege, Belgium, 32TDDS Laboratories,
University of Exeter, Exeter, UK
Canine angiostrongylosis is now considered as an emerging condi-
tion in Belgium. The gold standard for the diagnosis is based on
the detection of ﬁrst-stage larvae by Baermann fecal analysis.
However, the imperfect sensitivity is the main disadvantage of this
test. Alternative methods including serological or molecular assays
have been developed to improve diagnosis. Detection of circulating
antigens seems to enable diagnosis before patency; however, sensi-
tivity in naturally-infected dogs with negative Baermann analysis
has not been documented. PCR on bronchoalveolar lavage ﬂuid
(BALF) has recently been reported as valuable tool and helpful in
dogs with negative Baermann analysis.
Comparative usefulness of fecal or serological tests and BALF
analysis has not been investigated in naturally-infected dogs. The
aim of this study was to report and compare results of the rapid
test detecting circulating antigens, Baermann analysis and PCR on
BALF in a small series of dogs with angiostrongylosis.
Dogs with suspected angiostrongylosis based on clinical ﬁnd-
ings, for which results of three diﬀerent diagnostic methods were
available, were retrospectively included. The three methods were
PCR, performed on BALF, the rapid blood test (AngioDetectTM©,
Idexx Laboratories) and Baermann analysis, performed on three
fecal samples.
Seven dogs were selected. Owners reported cough and dyspnea
of variable severity from 2 weeks to 2 months’ of duration. PCR
on BALF was positive in all dogs while the rapid test was negative
in 4 dogs and uninterpretable in another one. Among the 4 dogs
with negative rapid test, Baermann analysis was also negative in 3
dogs. Bronchoscopy and PCR on BALF were thus essential for
diagnosis in 3 dogs, which presented moderate-to-severe clinical
signs from 2 to 4 weeks. If PCR on BALF is considered as gold
standard, relative sensitivities of the rapid test and Baermann anal-
ysis would be of 29% and 42%, respectively.
In conclusion, even though Baermann analysis and the rapid
test should be used as ﬁrst-line tools because of their availability,
cost-eﬀectiveness and non-invasiveness, they might be of lower
sensitivity than BALF PCR analysis in early cases. Based on this
small descriptive series, bronchoscopy and PCR on BALF may be
considered in clinically-suspected dogs in which both rapid test
and Baermann analysis are negative. Further studies including
ELISA assays for antigens or antibodies are warranted to
help select the most appropriate diagnostic tests in canine
angiostrongylosis.
Disclosures: No disclosures to report.
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DISCRIMINATION BETWEEN COUGH AND NON-COUGH
BEHAVIORS USING ACOUSTIC WAVE RECORDINGS. M.E.
Grobman1, T.E. Lever2, C. Reinero1. 1University of Missouri Col-
lege of Veterinary Medicine, Columbia, USA, 2Department of
Otolaryngology, University of Missouri, Columbia, USA
Cough is a protective mechanism, promoting clearance of the res-
piratory tract, while also contributing to pathology of clinical dis-
ease; as such, it is a both a marker for and target of therapeutic
intervention. Cough assessment in dogs is subjective, generally
based on owner’s perceptions. An objective method of evaluation
is needed. In humans, acoustic cough monitoring provides objec-
tive data on cough number and intensity by examining acoustic
waveforms. We hypothesized that healthy dogs would demonstrate
cough waveforms which could be distinguished from other acous-
tic behaviors (AB); whine, bark, growl, lick, drink, chew and
throat-clear. Data were obtained from 10 healthy employee-owned
dogs with informed consent. Acoustic behaviors were recorded
using a CTA-laryngeal-microphone and analyzed using RavenPro
© bioacoustics analysis software for AB duration, peak amplitude
and frequency, time to peak amplitude and frequency, power, and
energy. Inter- and intra-group statistical analysis was performed
using a one-way ANOVA on ranks with P < 0.05 being signiﬁ-
cant. With the exception of throat-clear, cough was distinguished
from every other evaluated AB by one or more of the analyzed
waveform parameters (P < 0.001). No between-subject diﬀerences
were identiﬁed between cough and throat-clear groups for any
waveform parameter. All other behaviors showed statistically sig-
niﬁcant within-group variation (P < 0.001). Cough and throat-
clear (a clinically similar mechanism to protect the airways) have
repeatable acoustic features that are distinguishable from other
common AB and are consistent between dogs. Acoustic monitor-
ing may provide an objective means for evaluating cough in dogs
with respiratory disease and assessing response to therapeutic
intervention.
Disclosures: No disclosures to report.
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TRACHEAL STENT IN DOGS: OUTCOME PREDICTION
AND OWNER SATISFACTION ASSESSMENT. E. Robin, K.
Le Boedec, J. Hernandez. CHV Fregis, Arcueil, France
Tracheal stenting is indicated for dogs with refractory tracheal col-
lapse. Information regarding clinical improvement and owner sat-
isfaction following stenting is scarce. The objectives of this study
were to (i) screen for clinical, radiographic, and endoscopic predic-
tors of improvement and survival after tracheal stenting, and
(ii) assess long-term owner satisfaction.
Dogs treated by tracheal stenting from 2011 to 2016 were retro-
spectively identiﬁed. Only dogs that had survived for = 100 days
after stenting were included. Data extracted from medical records
and thoracic radiograph review were assessed as potential clinical
improvement and survival predictors via univariate and multivari-
ate analyses. Clinical improvement was studied via 4 parameters
(coughing, respiratory distress, noisy breathing, and fatigability)
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ranked by owners based on severity before and after stenting using
a subjective 10-point scale. Owner satisfaction was measured via a
10-point scale.
Twenty-seven dogs were included. Median survival time after
stenting was 560 days (range 104–1837). No predictors of clinical
improvement after stenting were identiﬁed. Age at stenting
(P = 0.036), fatigability score improvement (P = 0.007), noisy
breathing score improvement (P = 0.044), total clinical score
improvement (P = 0.019), and owner satisfaction (P = 0.001) were
signiﬁcantly associated with survival after stenting on univariate
analysis. Age at stenting (P = 0.01), noisy breathing score
improvement (P = 0.028), and owner satisfaction (P = 0.002)
remained signiﬁcant survival predictors on multivariate analysis.
The median satisfaction score was 7.5 (range 0–10) and 85 % of
owners would redo the procedure.
Based on these results, age at stenting, owner satisfaction, and
noisy breathing improvement are prognostic factors after tracheal
stenting. Owner satisfaction was overall good.
Disclosures: No disclosures to report.
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METICULOUS DEBRIDEMENT AS SOLE MANAGEMENT
FOR SUCCESSFUL OUTCOME IN 6 DOGS WITH SINONA-
SAL ASPERGILLOSIS (SNA). C. Stengel. Tierklinik Hofheim,
Hofheim, Germany
We have shown than topical antifungal medication with meticu-
lous debridement results in an overall success rate for SNA in 58
of 62 (94%) dogs (JAVMA 2017; 250:309). It is well known, how-
ever, that fungal hyphae do not invade the mucosa but can only
be found at the mucosal surface and within material collected
from the nasal cavity (J Comp Pathol 2005; 132:283). Conse-
quently, meticulous debridement alone might be successful to clear
SNA.
Dogs with nasal discharge were prospectively enrolled if CT
and endoscopic ﬁndings were indicative of SNA and fungal culture
and PCR was positive for A.fumigatus. Trephination of frontal
sinus was performed if involvement was seen on CT and it could
not be reached endoscopically. Fungal plaques were loosened with
a curette and removed from the aﬀected frontal sinus by suction
or with ﬂushing using copious amounts of balanced electrolyte
solution (up to 5 L). If no trephination was performed, fungal pla-
ques and necrotic material in the sinus were loosened with forceps
under endoscopic guidance and then ﬂushed out. Once there was
no evidence of fungal material left in the frontal sinus, ﬂushing
and suction were continued in the nasal cavity. This procedure of
ﬂushing and suctioning, lasting up to 2 h, was performed until all
visible fungal material and necrotic tissue were removed. No anti-
fungal drugs were used. Recheck endoscopy with sinonasal ﬂush-
ing was repeated 3–5 weeks later. Resolution of SNA was deﬁned
as absence of visible fungal plaques with no or negligible amounts
of necrotic material present during the second ﬂushing and no
clinical signs 4 months later based on telephone communication.
So far 9 dogs were enrolled, 6 (mean 6.5 years old) with
>4 months re-evaluation. 1 dog died unrelated to SNA 2 months
after enrolment. Trephination was performed in 4/6 dogs. No fun-
gal material was seen in any of the 6 dogs at the recheck endo-
scopy (after median 26 days) and all owners conﬁrmed no nasal
discharge at the telephone communication (after median
204 days).
This preliminary study suggests that antifungal drugs are not
needed for the treatment of canine SNA if debridement is per-
formed meticulously and absolutely all fungal material is removed.
Disclosures: No disclosures to report.
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FIBROBLAST GROWTH FACTOR 23 AND SYMMETRIC
DIMETHYLARGININE IN FELINE CHRONIC KIDNEY DIS-
EASE. H.J. Sargent, J. Elliott, Y.M. Chang, R.E. Jepson. Royal
Veterinary College, London, UK
The diagnosis of chronic kidney disease (CKD) in cats is currently
made using creatinine as an indirect marker of glomerular ﬁltra-
tion rate (GFR), together with historical and clinical information
and evaluation of urine concentrating ability. However, creatinine
is recognized to be insensitive for the early decline in GFR. Sym-
metric dimethylarginine (SDMA) is a novel biomarker of GFR,
with studies suggesting it may be more sensitive than creatinine in
detecting this early decline. Fibroblast growth factor 23 (FGF-23)
is a phosphaturic hormone known to increase with declining GFR
and has been shown to be predictive of the onset of azotemia in
cats >9 years, indicating disturbed phosphate homeostasis.
The introduction of SDMA, has led to the identiﬁcation of cats
where SDMA is increased but plasma creatinine remains within
reference interval (RI). There is currently little understanding of
the metabolic changes present in these cats. The aim of this study
was to examine the relationship between plasma FGF-23 and
SDMA concentrations in non-azotemic geriatric cats.
Clinicopathological information from cats (≥ 8 years) was
sourced from the records of two ﬁrst opinion practices. Cats with
a current or historical diagnosis of azotemic CKD (creatinine
>177 µmol/L), a serum thyroxine >40 nmol/L or other chronic dis-
ease were excluded. Cats were categorized into two groups: ele-
vated SDMA (>14 µg/dL) and SDMA within RI (≤14 µg/dL).
Stored samples were used to quantify FGF-23 in all cats. Data are
presented as median [25th, 75th percentile]. Comparisons were
made between groups using Mann-Whitney U tests and relation-
ships between numerical variables were evaluated using Spear-
man’s correlation.
Twenty-eight cats with elevated SDMA (17 [16, 19] µg/dL) and
61 cats with SDMA within reference interval (11 [10, 12] µg/dL)
were included. Cats with elevated SDMA had signiﬁcantly higher
FGF-23 (377.7 [202.6, 610.9] pg/mL vs. 219.6 [143.2, 295.1] pg/ml,
P = 0.003) and creatinine (156 [141.8, 171.5] µmol/L vs. 128 [109,
148] µmol/L, P < 0.001) concentrations. Phosphate concentration
did not diﬀer between groups (P = 0.593). A weak positive rela-
tionship was demonstrated between FGF-23 and SDMA
(rS = 0.34, P = 0.001) and between FGF-23 and creatinine
(rS = 0.23, P = 0.03).
Cats with elevated SDMA had higher FGF-23 concentrations
than those with SDMA within RI suggesting the presence of alter-
ation in phosphate homeostasis despite no signiﬁcant diﬀerence in
plasma phosphate concentrations. Further studies are required to
identify factors inﬂuencing this relationship and the utility of
FGF-23 concentration to inform management of cats with early
stage CKD.
Disclosures: Disclosures to report.
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IMMUNOHISTOCHEMICAL STAINING OF A-KLOTHO
PROTEIN IN FELINE KIDNEY TISSUE. D.H.N. van den
Broek, J.S. Lawson, R. Chang, J. Elliott, R.E. Jepson. Royal
Veterinary College, London, UK
Renal a-klotho functions as a co-receptor for ﬁbroblast growth
factor 23 (FGF-23) and therefore plays an important role in phos-
phate homeostasis. The transmembrane protein is primarily found
in the renal tubules and its expression is reduced in patients with
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chronic kidney disease (CKD). In human studies and animal mod-
els, a-klotho deﬁciency has been associated with hyperphos-
phatemia, renal ﬁbrosis, and increased mortality. Chronic kidney
disease is a common disorder in aging cats, with hyperphos-
phatemia and FGF-23 excess as important prognostic indicators,
but the role of a-klotho has not been assessed in cats to date.
Therefore, we aimed to localize renal a-klotho protein in feline
kidney tissue.
Formalin-ﬁxed paraﬃn-embedded sections of post-mortem kid-
ney tissue from cats with varying kidney function were immuno-
histochemically stained using a rabbit polyclonal anti-a-klotho
antibody (1:2000 dilution, anti-klotho antibody, ab203576, Abcam,
Cambridge, UK) and visualized with an immunoenzymatic antigen
detection system (rabbit speciﬁc HRP/DAB detection kit, ab64261,
Abcam, Cambridge, UK). Mouse kidney sections were used as a
positive control, and feline kidney sections incubated with isotype-
speciﬁc immunoglobulins as a substitute for the primary antibody
served as a negative control for staining speciﬁcity. Sections were
counterstained with hematoxylin. Western blot analysis was per-
formed on feline renal tubular cell lysate to assess molecular size
of the antibody-bound protein.
Western blot analysis showed the primary antibody bound a
single antigen of 120–130 kDa in size, which is the appropriate
molecular size for a-klotho. No positive staining was detected in
the negative isotype control sections, conﬁrming the speciﬁcity of
the staining for a-klotho. Alpha-klotho protein expression was
identiﬁed immunohistochemically both in the proximal and distal
tubules of murine and feline kidney tissue, with more intense stain-
ing of the distal tubules compared to the proximal tubules.
Renal a-klotho protein expression in cats shows similarities to
its expression reported in other species. Further work is necessary
to investigate if loss of a-klotho expression occurs in feline CKD
and how this relates to renal ﬁbrosis and mineral and bone disor-
der in cats with CKD.
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SYMMETRIC DIMETHYLARGININE (SDMA) COMPARED
TO CREATININE FOR DETECTION OF DECREASED GFR
IN 97 DOGS WITH STABLE KIDNEY FUNCTION. L. Pelan-
der1, J. H€aggstr€om1, R. Heiene2, H. Syme3, J. Elliott3, I. Ljung-
vall1. 1Swedish University of Agricultural Sciences, Uppsala,
Sweden, 2Evidensia Norra Halland, Kungsbacka, Sweden, 3Royal
Veterinary College, North Mymms, UK
Early detection of decreased glomerular ﬁltration rate (GFR) in
dogs is diﬃcult. Current methods are insensitive and reference
ranges are wide. More sensitive biomarkers are warranted. The
aim of this study was to investigate the usefulness of the new mar-
ker symmetric dimethylarginine (SDMA) in comparison with crea-
tinine for detection of decreased GFR in dogs with and without a
stable diagnosis of chronic kidney disease (CKD).
Ninety-seven client-owned dogs were prospectively included into
the study, 67 dogs with a diagnosis (or a strong suspicion) of
CKD, and 30 healthy dogs. All dogs underwent physical examina-
tion, blood pressure measurements, urinalysis, hematology and
blood biochemistry, cardiac and urinary ultrasound examinations,
and scintigraphy for calculation of glomerular ﬁltration rate
(mGFR). Decreased mGFR was predeﬁned as <30.8 ml/min/L
and it was normalized to estimated extra-cellular plasma volume
(ECFV) instead of body weight because of less dependency on
hydration status of the dog. Estimation of ECFV was performed
according to routine using the Rutland-Patlak plot, a
mathematical model that describes the transfer of 99mTechnetium-
DTPA from the blood compartment to the renal compartment.
Creatinine and SDMA were positively correlated (r = 0.82). The
reciprocal of creatinine and SDMA were both linearly correlated
with GFR (R2 = 0.62 and 0.55, respectively). The sensitivity of
creatinine and SDMA at their pre-speciﬁed cut-oﬀs (46–115 µmol/
L and 0–14 µg/dL, respectively) for detection of an abnormal
GFR was exactly the same (89.7%) in the dogs of this study. The
speciﬁcity was 89.7% for creatinine and 86.8% for SDMA.
In conclusion, the diagnostic performance of creatinine and
SDMA, when using their pre-speciﬁed cut-oﬀs, for detection of a
decreased GFR in the dogs of this study was similar.
Disclosures: No disclosures to report.
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SDMA IN HYPERTHYROID CATS BEFORE AND AFTER
TREATMENT WITH RADIOIODINE. E. Buresova1, E. Stock1,
E. Vandermeulen1, D. Paepe1, L. Duchateau1, H.P. Lefebvre2, S.
Daminet1. 1Faculty of Veterinary Medicine, Ghent University,
Merelbeke, Belgium, 2Ecole Nationale Veterinaire de Toulouse,
Toulouse, France
Increased glomerular ﬁltration rate (GFR) and decreased muscle
mass make identiﬁcation of chronic kidney disease (CKD) in
hyperthyroid cats challenging. Symmetric dimethylarginine
(SDMA) is a promising indirect renal biomarker that correlates
closely with GFR in healthy geriatric and CKD cats. The aim of
this study was to evaluate SDMA reliability as a renal biomarker
in hyperthyroid cats. Forty-seven client-owned hyperthyroid non-
azotemic (creatinine <168 lmol/L) cats were prospectively enrolled
and treated with radioiodine (131I). Antithyroid medication was
discontinued 10 days prior to 131I treatment. Cats had to be free
of any other medication at least for 14 days prior to 131I treatment
and free of any other clinically relevant systemic disease. Crea-
tinine and SDMA (IDEXX SDMATM Test) were determined
before (T0) and 1 month after (T1) treatment. GFR (plasma
exogenous creatinine clearance test) was measured at T0 and T1 in
10 of 47 cats. As expected, creatinine signiﬁcantly increased
(P < 0.001) and GFR signiﬁcantly decreased (P < 0.001) after 131I
treatment. SDMA did not signiﬁcantly change over time
(P = 0.37). Only 1 cat became azotemic (creatinine >168 lmol/L)
at T1 while having normal SDMA at both time points. SDMA
was elevated (>14 lg/dL) in 6 of 47 cats at T0 and normalized
after treatment in 4 cats. GFR was available in 1 of these 6 cats
and was within normal limits (SDMA normalized at T1). SDMA
at T1 was increased above 14 lg/dL in 1 cat with borderline low
GFR which was deﬁned as GFR <1.9 ml/min/kg. Pearson correla-
tion (n = 10) between GFR and SDMA was moderate to low
(r = 0.48, P = 0.16 at T0 and r = 0.36, P = 0.31 at T1) and
correlation between GFR and creatinine was moderate (r = 0.54,
P = 0.11 at T0 and r = 0.51, P = 0.13 at T1). Forty of forty-one
cats with pre-treatment SDMA within reference interval remained
non-azotemic post-treatment. However, not enough patients
became azotemic post-treatment to evaluate if SDMA can predict
post-treatment renal azotemia. Previous studies showed that
SDMA is a promising renal biomarker but further studies are nec-
essary to more fully assess its utility in feline hyperthyroidism.
Disclosures: Disclosures to report.
This study was supported by Idexx laboratories.
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INTERLEUKIN 6 AND INTERLEUKIN 18 AS MARKERS OF
KIDNEY INJURY IN DOGS. H. Chen, Y. Avital, I. Aroch, G.
Segev. Koret school of veterinary medicine, Rehovot, Israel
Available markers of acute kidney injury (AKI) lack sensitivity
and speciﬁcity; consequently, diagnosis of AKI is delayed and
Grade-I AKI is commonly unrecognized. We hypothesized that
urinary interleukin (IL) 6 (IL-6) and 18 (IL-18) are sensitive and
speciﬁc markers of AKI. Urine samples from healthy dogs, dogs
with lower urinary tract disease (LUTD), chronic kidney disease
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(CKD), acute kidney injury (AKI) and at risk for AKI, were col-
lected. Urine concentrations of IL-6 and 18 were measured using
ELISA and corrected to urinary creatinine (uIL-6.18/uCr). Sixty-
six dogs were included. There was a positive correlation between
IL-6 and IL-18 (P < 0.001, r: 0.65). Median uIL-6/uCr of
healthy, LUTD, CKD, AKI and dogs at risk were 0.026 pg/mg
(range:0.01–2.28), 0.04 pg/mg (range:0.02–2.93), 0.08 pg/mg
(range:0.04–8.28), 0.46 pg/mg (range:0.06–58.05) and 6.5 pg/mg
(range:0.04–19.74) respectively. Median uIL-18/uCr was 0.025 pg/
mg (range:0.01–0.14), 0.03 pg/mg (range:0.02–0.26), 0.08 pg/mg
(range:0.03–4.29), 0.32 pg/mg (range:0.01–5.38) and 0.12 pg/mg
(range:0.03–0.95) respectively. There was a signiﬁcant diﬀerence in
uIL-6/uCr and uIL-18/uCr among the study groups, with both
higher in the AKI group compared with other groups, except uIL-
18/uCr, which was not diﬀerent between the AKI and CKD
groups. Median uIL-6/uCr and uIL-18/uCr of dogs at risk for
AKI, were higher compared with healthy dogs (P = 0.034,
P = 0.045 respectively). ROC analysis of uIL-6/uCr and uIL-18/
uCr as AKI predictors had an area under the curve of 0.85 and
0.78 respectively. uIL-6/uCr and uIL-18/uCr cut-oﬀ points of 0.11
and 0.13 were associated with sensitivity and speciﬁcity of 96%
and 70% respectively, and 83% and 70% respectively. In conclu-
sion, IL-6 and IL-18 are sensitive and speciﬁc markers of AKI.
Disclosures: No disclosures to report.
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APPLICATION OF NOVEL KIDNEY-SPECIFIC BIOMARK-
ERS FOR CANINE KIDNEY DISEASES. G. Segev1, I. Aroch2,
F. Giosi3, J. Quinn3, M. Yerramilli3, A. Yochai2, M. Yerramilli3.
1Koret Scholl of Veterinary Medicine, Beit Hashmonai, Israel,
2Koret School of Veterinary Medicine, Israel, 3IDEXX Laborato-
ries, Inc., Westbrook, Maine, USA, Israel
AKI is associated with high mortality, partially due to its late
recognition using available markers. Current research aims to
identify new AKI biomarkers, however, their speciﬁcity is ham-
pered when these are also expressed in extra-renal tissues.
Recently, assays were developed for kidney-speciﬁc urinary clus-
terin (uClus) and serum and urine cystatin B (sCysB, uCysB,
respectively). To assess their utility, 40 dogs were recruited and
categorized to healthy controls, chronic kidney disease (CKD),
AKI and UTI.
Median uClus/uCr was 40 ng/mg (range 3–157), 43 (12–6189),
1740 (391–11,834) and 6964 (102–69,855) in control, UTI, CKD
and AKI groups, respectively. It diﬀerentiated control and AKI
(receiver operating [ROC] area under curve [AUC] 0.96, 95% CI:
0.88–1.00). ROC analysis applied to all dogs, had an AUC of
0.86, (95% CI: 0.72–0.97). A cut-oﬀ of 3380 ng/mg resulted in
80% sensitivity and 90% speciﬁcity. Median sCysB was 206 ng/
mL (range 113–291), 608 ng/mL (200–1348) and 1763 ng/mL
(604–4175), in control, CKD and AKI groups, respectively. It dif-
ferentiated control and AKI (AUC 1.0, 95% CI: 1.00–1.00). ROC
analysis applied to all dogs showed AUC of 0.91 (95% CI: 0.79–
1.00). A 700 ng/mL cut-oﬀ, gave 88% sensitivity and 86% speci-
ﬁcity. ROC analysis of uCysB comparing AKI to all other groups
gave an AUC of 0.87 (95% CI: 0.74–1.00). A 485 ng/mL cut-oﬀ
was associated with sensitivity and speciﬁcity of 79% and 83%,
respectively.
In conclusion, these novel kidney-speciﬁc biomarkers diﬀerenti-
ated AKI from healthy controls and other urinary tract condi-
tions. Their speciﬁcity is a major advantage compared to
previously reported biomarkers.
Disclosures: Disclosures to report.
Farace, J. Quinn, M. Yerramilli, M. Yerramilli are Employees
of IDEXX Laboratories, Inc., Westbrook, Maine, USA.
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PREVALENCE OF URINARY TRACT INFECTION IN DOGS
WITH CHRONIC KIDNEY DISEASE: A RETROSPECTIVE
STUDY OF 201 CASES. A. Lamoureux1, F. Da Riz2, J.L.
Cadore1, E. Kraﬀt1, C. Maurey2. 1VetAgro Sup, Campus Veteri-
naire de Lyon, Marcy L’etoile, France, 2Ecole nationale veterinaire
d’Alfort, Universite Paris Est, Maisons Alfort, France
Studies have shown an increased prevalence of urinary tract infec-
tion (UTI) in cats with chronic kidney disease (CKD) but no
information is available in dogs. The aims of our study were to
determine the prevalence of UTI in a cohort of dogs with CKD
and to investigate the impact of age, sex (including neuter status)
and IRIS stage.
Dogs were retrospectively recruited from two veterinary teach-
ing hospitals between January 2010 and June 2016 if they were
diagnosed with CKD and had a culture performed on urine col-
lected by cystocentesis. CKD was diagnosed in dogs with an
increased blood creatinine concentration (≥125 µmol/L) and con-
sistent clinical and/or ultrasonographic signs (azotemic dogs); and
in dogs with a creatinine concentration <125 µmol/L but having
renal proteinuria, minimally concentrated urine with ultrasono-
graphic signs of CKD or abnormal renal histology (IRIS stage 1).
Azotemic dogs were categorized in IRIS stages 2 to 4 if they had
creatinine values measured at least two weeks apart, others were
left unstaged. Dogs with diseases which could predispose to UTI
or receiving treatment which could impact urinary speciﬁc gravity
were excluded. Diﬀerences between groups were assessed using the
Chi-square or the Mann-Whitney tests with statistical signiﬁcance
deﬁned as P < 0.05.
Two hundred and one dogs were included and 32% of them
had a UTI. Escherichia coli was identiﬁed in 73% of them. Lower
urinary tract signs were only reported in 9% of dogs with a UTI.
Sixty-one azotemic dogs could not be staged and 41% of them
had a UTI. Twenty eight percent of dogs with stage 1, 44% of
dogs with stage 2, 30% of dogs with stage 3 and 9% of dogs with
stage 4 CKD had a UTI. Dogs with stage 4 had signiﬁcantly less
UTI than dogs in stage 2 or 3 (P = 0.005 and 0.046, respectively).
There was no signiﬁcant diﬀerence between the other groups. No
signiﬁcant diﬀerence was found in the prevalence of UTI with age
or neutering, but the prevalence of UTI was higher in females
(46%) than in males (21%) (P = 0.0003).
The prevalence of UTI in this population of dogs with CKD
was 32% but most of them were asymptomatic. As already
described, females were overrepresented. Because of this high
prevalence, a urine culture could be recommended in any dog with
CKD regardless of its age, sex and IRIS stage; even though the
true clinical impact of this ﬁnding is currently unknown.
Disclosures: No disclosures to report.
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WHOLE GENOME SEQUENCING OF ESCHERICHIA COLI
ISOLATED FROM THE URINARY TRACT OF INDIVIDUAL
DOGS OVER TIME. T. Johnstone, D. Bulach. Faculty of Veteri-
nary and Agricultural Sciences, University of Melbourne, Wer-
ribee, Australia
Phylogeny and antibiotic resistance proﬁle (resistome) of urinary
E. coli isolated from individual dogs at diﬀerent time points were
investigated to gain a better understanding of recurrent or persis-
tent E. coli UTI. The microbiology database of the U-Vet Wer-
ribee Animal Hospital was screened for urinary E. coli isolated
from dogs with at least two positive urine cultures. Comorbidities
on the date of the respective urine culture were retrieved from the
dogs’ medical records. E. coli strains were recovered from frozen
storage banks and subjected to whole genome sequencing. The
core genome of study strains was compared to reference strain
ABU83097 and multi-locus sequence types (MLST) were identi-
ﬁed. Strain resistomes were determined by searching genomes for
38 known antibiotic resistance genes. Seventy-six E. coli strains
from 19 dogs were analyzed. All dogs had conditions that predis-
posed to UTI and were treated with antibiotics after positive urine
cultures. The number of examined E. coli strains per individual
dog ranged from 2 to 8 (median 3.5); they had originally been
recovered over a median time span of 146.5 days (range 9–
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2450 days). Overall, E. coli were phylogenetically diverse; 25 diﬀer-
ent MLST were recorded. Core genomes were 73.9–95.2% similar
to the reference. None of the E. coli isolated had identical core
genomes. However, in 18/19 dogs, 2 to 6 (median 2.5) E. coli with
highly similar core genomes (with single nucleotide diﬀerences
ranging from 25 to 457) were identiﬁed. These highly similar
E. coli had originally been cultured from urine of aﬀected dogs
over a median time span of 84 days (range 7 to 602 days) and in
15/18 cases, all highly similar strains had identical resistomes over
time. In 10 dogs, at least one strain that was phylogenetically dif-
ferent was also present; in 3 dogs, these strains were cultured
between episodes with 2 highly similar strains. Thirty-ﬁve of 76
strains (46%) were phenotypically multi-drug-resistant (MDR).
Up to 13 diﬀerent antibiotic resistance genes (median 2.5) were
identiﬁed. There was no apparent correlation between time point
of strain isolation (i.e. late or early in disease) and MDR status.
Results of this study suggest that the majority of E. coli isolated
from the urine of dogs with comorbidities either belong to one
evolving lineage, or that several highly similar lineages co-exist in
any given dog. Changes in resistome were uncommon.
Disclosures: Disclosures to report.
Dr Bulach is aﬃliated with Doherty Applied Microbial Geno-
mics, The Doherty Institute, Melbourne, Australia.
The laboratory work for this abstract was performed at the
Doherty Institute, which is aﬃliated with the University of
Melbourne.
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VIRULENCE AND ANTIMICROBIAL RESISTANCE OF
ESCHERICHIA COLI SEQUENCE TYPE 131 H30 AND
OTHER HUMAN PANDEMIC CLONES SPREADING IN
COMPANION ANIMALS. A. Belas, C. Marques, A. Franco, C.
Pomba. Faculty of Veterinary Medicine - CIISA, Lisbon, Portugal
The ﬂuoroquinolone-resistant (FQR) O25b-H30 subclone of E. coli
sequence type 131 (ST131-O25b-H30), with its nested ESBL
(CTX-M-15)-associated H30Rx subset, is the most global dissemi-
nated virulent B2 group E. coli multidrug-resistant lineage causing
infection in humans. Within phylogenetic group D, the sequence
type 648 complex (STc648) is another human increasingly resis-
tance-associated E. coli lineage. This study aimed to detect and
evaluate the prevalence of human pandemic clones among E. coli
strains causing urinary tract infection in companion animals and
to characterize their virulence and antimicrobial resistance.
For this study 298 E. coli (1999–2014) isolated from companion
animals with urinary tract infection were studied regarding clonal
background, virulence and antimicrobial resistance. Susceptibility
towards sixteen antimicrobial agents was done by the disk diﬀu-
sion. PCR-based assays were used to detect the phylogroup (A,
B1, B2 and D), Pathogenicity associated-islands (PAIs) (n = 8),
urovirulence genes (n = 8), antimicrobial resistance genes (n = 13),
the human pandemic E. coli ST131–O25b, O25b-H30, O25b-
H30Rx and O16 lineages. Furthermore, all third-generation cepha-
losporin (3GC) resistant E. coli were typed for MLST in order to
detect E. coli sequence type 648 complex. Regarding phylogenetic
background the isolates were predominantly from group-B2 (55.4
%, n = 165/298), followed by group-A (16.1%, n = 48/298),
group-B1 (14.8%, n = 44/298) and group-D (13.8%, n = 41/298).
The group-B2 ST131-O25b and O16 lineages represented 10%
(n = 30/298) of all the uropathogenic strains and ST131-O25b-H30
was the most common 25.0% (n = 7/28), all were MDR and FQR.
The ST131-O25b-H30 most common pathogenicity and virulence-
associated genes proﬁles were PAI ICFT073- PAI IV536-PAI IICFT073
(28.6%, n = 2/7), ecp-papEF-iucD (27.3%, n = 3/7). About 43%
of ST131-O25b-H30 strains (n = 3/7) were the FQR H30Rx–
blaCTX-M-15 producer subclone. Among the 3GC-resistant E. coli
phylogroup D, the most represented lineage was the ST648 71.4%
(n = 10/14), followed by ST405, ST1775, ST57 and ST354 (7.1 %,
n = 1/14 each). All ST648 isolates were MDR, blaCMY-2 producers
and one had also blaCTX-M-9. ST648 PAIs and virulence genes pro-
ﬁles belonged mostly to PAI ICFT073PAI IV536 (40.0%, n = 4/10),
PAI II536-PAI ICFT073-PAI IV536 (30.0%, n = 3/10), and ecpA-
papEF (70%, n = 7/10), respectively.
In this study we report for the ﬁrst time the detection of the
worldwide-disseminated ST131-O25b-H30 virulent, MDR and
FQR human clone and its CTX-M-15-H30Rx subclone in compan-
ion animals. The detection of human high-risk pandemic E. coli
lineages causing UTI in companion animals besides the animal
health problem is a great public-health concern.
Acknowledgements: With ﬁnancial support of CIISA and FCT
through Project UID/CVT/00276/2013. AB and CM hold FCT
PhD grants SFRH/BD/113142/2015 and SFRH/BD/77886/2011.
Disclosures: Disclosures to report.
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URINARY BIOMARKER CONCENTRATIONS IN CANINE
URINARY TRACT INFECTIONS. M.D. Dunning1, O.M. Rus-
sak1, C. Dor1, O. Coldrick3, E. Moodey2, L. Barrass-Hemmens2,
K. Slater2. 1University of Nottingham, Leicestershire, UK,
2Avacta Animal Health, Wetherby, UK, 3Torrance Diamond
Diagnostic Services, Innovation Centre, University of Exeter,
Renne Drive, Exeter, UK
Diagnosis of canine urinary tract infections (UTI) is based on a pos-
itive urine culture and inﬂammatory sediment. In practice, culture
and/or sediment analysis are not always performed prior to using
antibiotics; which is at odds with rational prescribing. In-clinic mea-
surement of biomarkers to speciﬁcally test for a UTI, would there-
fore be of great value. In humans, the concentration of a number of
urinary biomarkers increases in UTI. As yet, these have not been
evaluated in dogs to determine if they behave similarly.
Aim: To determine whether measuring inﬂammatory biomarkers
in canine urine could correctly identify bacterial infection.
Hypothesis: CRP, IL-6, procalcitonin and lactoferrin concentra-
tions in canine urine with conﬁrmed infections are signiﬁcantly
increased compared with controls.
Speciﬁc canine ELISAs were developed for CRP, IL-6, procalci-
tonin and lactoferrin. These were selected given their association
with UTI in human medicine. Assays underwent comprehensive
validation prior to initiating this study.
The above biomarkers were measured in residual urine samples
following routine urinalysis, from a cohort of dogs with conﬁrmed
UTI (n = 25) and from a control cohort without UTI (n = 26).
Inclusion criteria for the UTI group was a positive urine culture
and inﬂammatory urine sediment. Control samples had an inactive
sediment and sterile culture. This study was approved by the
establishment’s ethical review committee.
For comparing non-parametric datasets, Mann-Whitney tests
were performed; for multiple comparisons between non-parametric
datasets, the Kruskal Wallis test was used.
There was a signiﬁcant increase in CRP (P < 0.009) and lactofer-
rin (P < 0.018) concentrations between UTI samples and controls.
Enterococci signiﬁcantly increased CRP concentrations compared
with Coliforms (P < 0.008) and mixed bacterial populations
(P < 0.03). Enterococci signiﬁcantly increased IL-6 concentrations
compared with Coliforms (P < 0.03). Enterococci signiﬁcantly
increased procalcitonin concentrations compared with mixed bacte-
rial populations (P < 0.0004). ROC curves were used to determine
sensitivity and speciﬁcity for CRP and lactoferrin for detecting a
UTI. A CRP cut-oﬀ of 1.87 ng/mL, gave a sensitivity of 52% and
speciﬁcity of 90%. A lactoferrin cut-oﬀ of 151.3 ng/mL, gave a sen-
sitivity of 80% and speciﬁcity of 100%. Combining CRP and lacto-
ferrin gave a sensitivity and speciﬁcity of 100% for a UTI.
Correlation between CRP and lactoferrin was excellent (r = 0.95).
This pilot study demonstrates novel urine biomarkers, either
alone or in combination, can identify UTI in dogs. Some bacteria
increase the concentration of biomarkers in the urine more than
others. These results demonstrate potential value in measuring uri-
nary biomarkers in-clinic to screen urine samples for infection,
improving antibiotic stewardship.
Disclosures: Disclosures to report.
Dr Dunning has a consultancy role for AVACTA animal
health. Dr Slater is Chief Scientiﬁc Oﬃcer for AVACTA animal
health Dr’s Moody and Barrass-Hemmens are assay development
scientists employed by AVACTA animal health.
564 ECVIM Abstracts
ESVNU – O – 11
EVOLUTION OF IONIZED CALCIUM CONCENTRATION
OVER TIME IN CATS WITH URETERAL OBSTRUCTION:
39 CASES. M. Garcia1, M. Manassero2, M. Canonne-Guibert2,
V. Fabres2, M. Menard2, G. Benchekroun2, C. Maurey2. 1Ecole
Veterinaire D’alfort, Maisons Alfort, France, 2National School of
Alfort, Maisons Alfort, France
Calcium oxalate (CaOx) ureterolithiasis has emerged as a cause of
feline ureteral obstruction (UO) in the last few years. Several risk
factors of UO were identiﬁed including hypercalcemia. One study
showed that hypocalcemia is frequent in cats with urethral
obstruction and hyperphosphatemia has been hypothesized as a
causal factor. The aim of this retrospective study was to assess
how ionized calcium concentration (iCa) varies in cats with UO
after UO management.
Cats with UO (group 1) in which iCa was measured at least three
times over a minimal period of 15 days, were enrolled and compared
to a control group including cats with CKD (stage IRIS 2 or over:
group 2). UO was treated by medical or surgical procedure.
Group 1 included 39 cats and group 2 included 37 cats. At time
of diagnosis (D0), there was no diﬀerence in median creatinine
concentration, median iCa and distribution of hypercalcemic, nor-
mocalcemic or hypocalcemic cats between both groups. Median
phosphorus concentration was signiﬁcantly higher in group 1
(73.7 mg/L [32–200] vs. 42 mg/L [25–91]) (P < 0.001) at D0.
Over time, a signiﬁcant increase in proportion of hypercalcemic
cats was observed in the group 1 at the end of the study versus at
D0: 33.3% [95% CI: 18.5–48.1] versus 12.8% [95% CI: 2.3–
23.3%] (P < 0.001). The average time of onset of hypercalcemia in
these 13 cats was 50.5 days (range: 2–1170) and among them only
2 were hypercalcemic from D0. In group 2 proportion of cats
normo- or hypercalcemic did not vary during the study period.
Our results suggest that iCa should be monitored in cats with
UO as presence of ionized hypercalcemia could be misdiagnosed
at time of diagnosis and becomes evident after UO treatment.
These results suggest that concurrent hyperphosphatemia could
explain this ﬁnding. Identiﬁcation of ionized hypercalcemia as a
potential risk factor for UO is important and should appropriately
be managed in these cats.
Disclosures: No disclosures to report.
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URINARY FINDINGS SUGGESTING EARLY RENAL
INVOLVEMENT IN CATS WITH FELINE MORBILLIVIRUS
INFECTION. P.E. Crisi1, F. Dondi2, E. de Luca3, E. Febo1, K.
Vasylyeva2, E. Ferlizza2, G. Savini3, A. Luciani1, A. Lorusso3, A.
Boari1. 1University of Teramo, Teramo, Italy, 2Alma Mater Stu-
diorum-University of Bologna, Ozzano Dell’Emilia, Bologna,
Italy, 3Istituto Zooproﬁlattico Sperimentale dell’Abruzzo e del
Molise (IZSAM), Teramo, Italy
Feline Morbillivirus (FeMV) has been associated with renal lesions
in cats, however a clear association between infection and the
development of chronic kidney disease (CKD) remains to be
elucidated.
With the aim of characterizing urinary ﬁndings, urinalysis, urine
chemistry and qualitative proteinuria results were retrospectively
evaluated in 14 cats with RT-PCR positive urine for FeMV
(FeMV+). FeMV+ were compared to 21 CKD and 22 healthy
blood donor cats. For all of the animals the following information
was available: signalment, history, physical exam, clinicopathologi-
cal evaluation including CBC, serum chemistry proﬁle, urinalysis
including urine speciﬁc gravity (USG), dipstick, sediment examina-
tion, urine protein-to-creatinine ratio (UPC), fractional excretion
of electrolytes, urine SDS-PAGE stained with Coomassie blue,
and urine culture. Kidney histopathology and immunohistochem-
istry for FeMV were evaluated at necropsy (n = 3). Data were
analyzed with descriptive statistics and compared using non-para-
metric tests (Kruskal-Wallis test). P -values <0.05 were considered
signiﬁcant.
The FeMV+ were outdoor domestic shorthaired cats, 8 neutered
males, 6 females (5/6 spayed), median age was 35 months (range
14–101). FeMV+ had signiﬁcantly decreased USG (median 1054,
range 1022–1065) and urine creatinine (median 227.23 mg/dL,
range 83.02–489.75) when compared to healthy subjects (median
1067, range 1040–1080, P < 0.00001; median 406.50 mg/dL, range
195.32–575.58; P < 0.00001; respectively). No statistical diﬀerences
were detected for serum creatinine (median 0.81 mg/dL, range
0.67–2.13 vs. median 1.46 mg/dL, range 0.78–2.13) and urea (me-
dian 45.35 mg/dL, range 30.20–63.30 vs. median 46.47 mg/dL,
range 31.47–73.01) and for electrolyte fractional excretions. All
urine cultures were negative.
A signiﬁcant increase in UPC was observed in FeMV+ (median
0.19, range 0.08–1.03) when compared to healthy subjects (median
0.10, range 0.04–0.40, P < 0.0003), while statistical diﬀerences were
not detected between infected cats and CKD cats (median 0.23,
range 0.10–0.80). In FeMV+, SDS-PAGE qualitative proteinuria
showed diﬀerences if compared to the healthy cats. In particular, a
tubular pattern was evidenced, with a decrease of uromodulin and
an increase in the number and intensity of low molecular weight
proteins, indicating a renal involvement, although less severe than
in CKD cats. Renal pathology showed tubulo-interstitial nephritis
and positive immunohistochemical stain for FeMV-N protein in
tubular cells.
Urine ﬁndings in FeMV+ suggest the presence of early tubulo-
interstitial damage characterized by tubular proteinuria and mild
reduction of urine concentrating ability. No urine electrolyte han-
dling dysfunctions were detected. Further prospective studies com-
bining long-term patient follow-up, renal pathology and urine
evaluation are warranted to obtain a better characterization of
potential FeMV-associated renal damage.
Disclosures: No disclosures to report.
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EFFECTS OF A NON-ABSORBENT LITTER ON URINALY-
SIS RESULTS IN CATS. J.G. Pebre, H.P. Lefebvre, B.S. Rey-
nolds. National Veterinary School, Toulouse, France
Commercially available non-absorbent litters are becoming
increasingly popular for urine collection in cats. The objective of
this study was to assess the eﬀects of such device on routine feline
urinalysis results, a potential issue that has not been addressed to
date.
Thirty-one cats subjected to cystocentesis for urinalysis as part
of their diagnostic work-up were included. A fraction of the urine
sample collected by cystocentesis was immediately processed to
obtain a reference urinalysis (USG, dipstick and UPC). The
remaining urine was poured on the non-absorbent litter in a tray,
urine specimens were then retrieved from the tray immediately and
after 3, 6 and 12 h at room temperature and urinalysis was
repeated at each term The eﬀects of urine timely contact with litter
on urinary analytes were assessed using a General Linear Model
and Dunnett’s test.
The range of results obtained from the reference specimens was
wide but the vast majority of samples were negative for ketones,
glucose and bilirubin. Testing urine retrieved from the tray with
ketones reagent pads was found to be unreliable. Results for 5/8
analytes tested were statistically diﬀerent from those of the refer-
ence specimen at 9 occasions. The observed diﬀerences were clini-
cally relevant for USG after 3, 6 and 12 h and for the protein
reagent pad result of the dipstick after 12 h.
In conclusion, urine collected within 12 h of contact with the
non-absorbent litter tested is suitable for UPC measurement and
most dipstick reagent-pads but not for USG assessment.
Disclosures: No disclosures to report.
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DETERMINING THE PH IN CANINE URINE: COMPARING
VISUAL AND AUTOMATED READING VARIABILITY OF
URINE DIPSTICK ANALYSIS WITHIN A SMALL ANIMAL
TEACHING HOSPITAL. M. Garcia, M. Ferreira, A. Gow.
Royal (Dick) School of Veterinary Studies, Roslin, UK
Urine pH measurement is performed during routine urine analysis
evaluation. Although using a pH meter has been shown to give
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more accurate results, urine dipsticks are most commonly used in
veterinary medicine. Accurate pH measurement is important, as it
may indicate urinary infection, risk of urolith formation and
reﬂect the acid-base systemic status of a patient. This study evalu-
ated the inter-operator reproducibility of canine urine pH readings
when performing urine dipstick chemical analysis by direct stan-
dard visualization and automated analysis in a small animal teach-
ing hospital.
Urine from in-patients was collected between 28 and 40 h prior
to the study and was kept refrigerated. The pooled sample was
divided in three and each sample was titrated with NaOH and HCl
to achieve a consistent visual urine dipstick pH reading of 6 (Sam-
ple 1), 7 (Sample 2) and 7.5 (Sample 3). Respective readings of
5.44, 6.55 and 7.66, were obtained with a calibrated reference bench
top pH meter. Samples were kept chilled during the study period.
Study participants were given one aliquot each sample and six
urine dipsticks. Each operator was asked to measure and record
the urine pH from each aliquot using ﬁrst standard visual and
then automated analyzer reading methods.
Nineteen ﬁnal year students, 7 veterinarian surgeons and 4 vet-
erinary nurses participated in the study. Standard visual reading
pH values, with number of participants recording the results in
brackets, were: Sample 1: 6 (14), 6.5 (14), 7 (2); Sample 2: 6 (2),
6.5 (2), 7 (1), 7.5 (22), 8 (3); and Sample 3: 6 (1), 7 (1), 7.5 (3), 8
(25). Using the automated analyzer, the results obtained were:
Sample 1: 5.5 (1), 6 (29); Sample 2: 7 (26), 7.5 (4); Sample 3 7 (1),
7.5 (25), 8 (3), 8.5 (1). Concordance of results between study par-
ticipants and the authors occurred in 39/90 (43%) of visually read,
and 79/90 (88%) of automated analyzer results. Sample 2 was
visually reported as alkaline (pH of 8) by 4 participants and acid
(pH of 6) by 2 participants.
In conclusion, standard visual reading of urinary dipstick
demonstrated poorer inter-operator reproducibility when measur-
ing canine urinary pH in comparison with an automated method.
This has potential clinical implications in that the same sample
was classiﬁed as acidic and alkaline in some instances, potentially
aﬀecting clinical decision making.
Disclosures: No disclosures to report.
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ASSESSMENT OF KIDNEY INJURY IN CANINE PARVOVI-
RAL INFECTION BY COMPARING NOVEL URINARY KID-
NEY INJURY BIOMARKERS WITH ROUTINE RENAL
FUNCTIONAL PARAMETERS. M.F. van den Berg1, J.P. Schoe-
man2, P. Defauw1, Z. Whitehead2, A. Breemersch1, K. Goethals1,
S. Daminet1, E. Meyer1. 1Ghent University, Merelbeke, Belgium,
2University of Pretoria, Pretoria, South Africa
Dogs with naturally occurring parvovirus infection may be at risk
of developing acute kidney injury due to several risk factors,
including severe dehydration, systemic inﬂammatory response syn-
drome, and sepsis. Early detection of kidney injury is important,
yet challenging, because conventional renal parameters, such as
serum creatinine (sCr) and blood urea nitrogen (BUN), are insen-
sitive markers for early stages of kidney injury and dysfunction.
Therefore, the aim of this study was to investigate potential kidney
injury in dogs with naturally occurring parvoviral infection by
comparing standard to novel urinary biomarkers.
Twenty-two dogs with parvoviral infection were prospectively
enrolled and compared with eight clinically healthy control dogs.
Blood and urine samples were collected at presentation (T0) in
both groups and 24 h later (T1) in the patient group. Urinary
immunoglobulin G (uIgG) and C-reactive protein (uCRP) were
measured to document glomerular injury, whereas urinary retinol-
binding protein (uRBP) and neutrophil gelatinase-associated lipo-
calin (uNGAL) served as biomarkers for tubular injury. These
biomarkers were compared to routine renal functional parameters,
including sCr, BUN, urinary protein:creatinine ratio (UPC), and
urine speciﬁc gravity (USG). Commercial ELISAs validated for
the measurement of canine uIgG, uCRP, uRBP, and uNGAL were
used. Statistical analysis was performed using non-parametric
Mann-Whitney and Wilcoxon signed rank tests.
At T0, dogs with parvovirus infection had signiﬁcantly higher
concentrations of uIgG (P < 0.01), uCRP (P < 0.0001), uRBP
(P < 0.001), and uNGAL (P < 0.05) compared to healthy dogs.
At T1, only uCRP and uRBP remained signiﬁcantly higher com-
pared to controls (P < 0.0001 and P < 0.01, respectively), while
concentrations of uIgG decreased signiﬁcantly from T0 (P < 0.001)
in parvovirus infected dogs. In marked contrast, both at T0 and
T1, sCr was signiﬁcantly lower in dogs with parvoviral infection
(P < 0.01 and P < 0.001, respectively) compared to healthy dogs,
while BUN was not signiﬁcantly diﬀerent (P = 0.21). Although
both USG and UPC were signiﬁcantly higher in dogs with par-
vovirus at T0 (P < 0.01 and P < 0.001, respectively), only UPC
remained signiﬁcantly higher at T1 (P < 0.05) compared to healthy
dogs.
In conclusion, this study shows that dogs with parvoviral infec-
tion had acute kidney injury, which manifested both at the
glomerular and tubular level, and remained undetected by the rou-
tine renal functional markers sCr and BUN. Our results emphasize
the added value of novel kidney injury urinary biomarkers to
detect and monitor these patients at risk.
Disclosures: No disclosures to report.
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ARE PROTEIN KINASE INHIBITORS OF USE IN THE
TREATMENT OF CANINE LYMPHOMA? A SCREENING IN
VITRO STUDY WITH MULTIPLE PROTEIN KINASE INHI-
BITORS IN CANINE LYMPHOID CELL LINES|. M. Zand-
vliet1, P. Dubreuil2. 1Utrecht University, Utrecht, Netherlands,
2CRCM, Signaling, Hematopoiesis and Mechanism of Oncogene-
sis, Equipe Labellisee, Marseille, France
Introduction: Canine lymphoma, the most common hematopoi-
etic neoplasia in the dog, is routinely treated with a multi-drug
chemotherapy protocol. Despite a high initial response rate, tumor
relapse is common and often resistant to chemotherapy, resulting
in treatment failure. Alternative treatment options are mandatory
and since masitinib showed a mild anti-proliferative eﬀect on lym-
phoid cells other protein kinase inhibitors (PKIs) might provide
this alternative.
Materials and Methods: GL-1 is a canine B-cell lymphoid cell
line and GL-40 its doxorubicin/vincristine resistant subline demon-
strating P-gp overexpression. Cell lines were cultured as previously
described. Cell viability was assessed using a colorimetric assay
(alamarBlue). Cells were seeded in 96-well plates at a density of
2 x104 cells per well in cell culture medium containing a concen-
tration range (0, 0.1, 1 and 10 µM) of the PKI tested and incu-
bated for 48 h at 37°C, 5% CO2. AlamarBlue (resazurin) was
added 3 h prior to analysis and the reduced ﬂuorescent molecule
(resoruﬁn) was measured by light absorbance in a ﬂuorescence
spectrophotometer (560EX nm/590EM nm). Experiments were
performed in triplicate.
Cell survival was calculated by dividing light absorbance in
treated cells by that in control cells after correction for back-
ground absorbance. Concentration dependent eﬀects were ana-
lyzed by non-linear regression after log transformation of PKI
concentration. Median inhibitory concentration (IC50) was calcu-
lated as a measure of the PKI’s antiproliferative eﬀect. Graphs
were ﬁtted according to a sigmo€ıd dose–response curve.
Results: IC50 for the various PKIs in the GL-1 cells ranged
from <0.1 µM (BI-2536, Sorafenib, Quizartinib, Sunitinib, Tocera-
nib), 0.1–1 µM (TAE684, SGI-1776, TAE226, Tozasertib), 1–
10 µM (Dasatinib, Pazopanib, Nilotinib, Erlotinib, Axitinib) and
>10 µM (Geﬁtinib, Imatinib, Masitinib, Lapatinib, Vandetanib).
No relevant diﬀerences were found in IC50 between GL-1 and
GL-40 for any of the PKIs tested.
Conclusion/Discussion: Several PKIs inhibited lymphoid cell
proliferation with good direct activity shown for inhibitors of
PLK1, Raf, FLT3, ALK, Pim-kinase, FAK, and Aurora Kinases
and these require further (clinical) evaluation. PKIs targeting c-
KIT, PDGFR, VEGFR showed variable antiproliferative eﬀects,
while PKIs targeting EGFR had little to no inhibitory eﬀect. The
PKIs tested showed similar IC50 in both the GL-1 and GL-40
cells suggesting that P-gp overexpression has no role in tumor
resistance to PKIs guaranteeing their value in case of tumor resis-
tance to cystostatic drugs.
Disclosures: Disclosures to report.
P. Dubreuil has been involved in research on Masitinib and
ABScience.
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MASITINIB TREATMENT FOR ADVANCED STAGE III AND
IV CANINE MELANOMA. A. Giuliano, J. Dobson. University
of cambridge, Cambridge, UK
Masitinib is a tyrosine kinase inhibitor (TKI) licensed for treat-
ment of non-resectable canine mast cell tumors, its major targets
include c-kit, PDGFR and FAK kinases. Aberrant expression of
c-Kit and FAK have been found in human patients aﬀected by
cutaneous and mucosal melanoma. Masitinib and other TKIs with
similar targets have been used in human patients with advanced
stage melanoma bearing c-kit mutations with some encouraging
results. The role of c-kit, FAK and PDGFR in canine melanoma
has not be extensively investigated. Although c-kit mutation seems
uncommon, strong c-kit expression has been found in around 50%
of canine oral melanoma, however, correlation of c-kit mutation/
expression with prognosis is still uncertain PDGFR expression has
been found in around 50% of oral canine melanoma and was
shown to correlate with a worse prognosis in one study. The
expression and importance of FAK in canine melanoma has not
been reported yet.
The aim of this small study was to assess response rates and to
a lesser extent survival, in advanced stage III and IV canine mela-
noma treated with masitinib, as a proof of concept that masitinib
may potentially play a role in treatment of this disease.
Eleven dogs were prospectively enrolled, two with digital, one
anal and eight oral melanoma. Only dogs with progressive gross
disease despite conventional treatment were included in the study.
All the dogs were staged with thoracic radiography and ﬁne needle
aspirate of the regional lymph node when palpable. One dog had
thoracic CT and abdominal ultrasound. All dogs had previously
received various combinations of surgery, radiotherapy and mela-
noma vaccine treatment.
Two dogs achieved partial response, ﬁve dogs stable disease and
four progressive disease. For all 11 dogs median TTP (time to
tumor progression) and MST (median survival time) were 66 and
124 days respectively. Masitinib was generally well tolerated with
side eﬀects only observed in three patients. One experienced Grade
1 anemia and neutropenia, one Grade 2 anorexia and one Grade 1
diarrhea.
Mucosal melanoma is an aggressive disease that carries a poor
prognosis, no eﬀective systemic treatments are currently available
to control the progression of metastatic disease. This small study
showing some eﬃcacy in end stage disease, indicates that masitinib
oﬀers potential for treatment of canine melanoma. Further studies
in earlier stage disease and possibly in combination with other
modalities are needed to support our ﬁndings.
Disclosures: Disclosures to report.
Masitinib tablets were donate by AB Science.
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TOCERANIB PHOSPHATE IN FIFTEEN DOGS WITH
STAGE 4 ANAL SAC APOCRINE GLAND ADENOCARCI-
NOMA. J. Elliott. Willows Referral Service, Solihull, UK
A variety of therapies are employed in the management of anal
sac apocrine gland adenocarcinoma (ASAGA); including surgery,
radiotherapy and chemotherapy. Toceranib phosphate (Palladia)
has shown anti-cancer activity in dogs with advanced ASAGA,
which may be related to receptor tyrosine kinase expression such
as KIT, RET and PDGFR.
Whilst some patients present with advanced regional nodal
metastases (typically to the ilio-sacral lymphatic centre; stage 3b)
unfortunately some present with distant metastases which can tem-
per owners’ desire to choose aggressive loco-regional therapies
including lymph node extirpation or radiotherapy. Indeed such
therapies would also not treat the distant metastatic deposits and
so systemic therapy would still be a requirement for successful
management.
Fifteen dogs presented between 2012 and 2016 with stage 4
ASAGA (presence of distant metastases) with no prior therapy;
other than in two patients where the primary tumor in the anal
sac had been surgically excised as a diagnostic procedure.
Presenting clinical signs were related to abnormal defecation in
only eight patients with other dogs diagnosed due to incidental
discovery for another problem (n = 4), PUPD (n = 1) and spinal
pain (n = 2).
A variety of breeds were represented though 40% were English
Cocker Spaniels. All dogs had lymph node metastasis. Other sites
of metastasis included lung (n = 11), liver (conﬁrmed in n = 4 and
highly suspicious in n = 3), lumbar spine (n = 2) and kidney, skin
and peritoneum (all n = 1).
The median toceranib dose was 2.4 mg/kg (range 2.1–2.6) and
was administered on a Monday-Wednesday-Friday basis. Concur-
rent medications were ﬁrocoxib (n = 5), carprofen (n = 1) and
prednisolone (n = 1); the latter being for management of concur-
rent hypercalcemia of malignancy. No serious toxicities were seen
during toceranib therapy. Three episodes of hematological toxicity
(grade I anemia; n = 2 and transient mild thrombocytosis; n = 1)
were seen. One dog experienced an episode of grade 2 diarrhea;
necessitating a short treatment break and re-institution at a lower
dose.
Routine repeat staging was advised, and when performed a
reduction in tumor burden (but classiﬁed as stable disease) was
seen in all but one patient; where progressive disease was
observed.
Median survival time of toceranib-treated patients was 359 days
(range 66–1024 days) which is substantially higher than 71 days
(median; 95% CI: 6–136 days) or 82 days (95% CI: 0–247 days)
previously reported with a variety of non-TKI therapies.
Toceranib phosphate can be a successful and well-tolerated
monotherapy for dogs with stage 4 ASAGA.
Disclosures: No disclosures to report.
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EFFECT OF TOCERANIB PHOSPHATE (PALLADIA) ON
OUTCOME IN DOGS WITH ANAL SAC CARCINOMA. K.D.
Lyons1, C. Siedlecki2, H. Wilson-Robles1, P. Bergman3. 1Texas
A&M University, College Station, USA, 2VCA Bay Area Veteri-
nary Specialists, San Leandro, USA, 3VCA Clinical Studies, Los
Angeles, USA
Canine apocrine gland anal sac adenocarcinoma (AGASACA)
comprises 17% of perianal malignancies in the dog. Despite local
and systemic therapy, relapse is common. Evidence suggests vary-
ing expression of tyrosine kinase inhibitor targets in canine AGA-
SACA. Objective responses to toceranib phosphate (Palladia)
have been reported. The purpose of this study was to evaluate
progression and survival outcomes in dogs with AGASACA trea-
ted with toceranib. Medical records were retrospectively reviewed
for response, outcome, and toxicity. Data was available for 83
dogs with a median age of 11 years and a median weight of 23 kg.
Sixty percent of patients had presumed metastasis at the time of
diagnosis. Twenty four percent were hypercalcemic at the time of
diagnosis. Seventy-seven percent received previous therapy includ-
ing surgery, radiation, and chemotherapy. Toceranib was a ﬁrst-
line systemic agent in 48% of dogs, either adjunct to previous
local therapy or as the sole treatment modality. Median toceranib
dosage was 2.7 mg/kg with a median treatment duration of
126 days. Most adverse events were mild, but resulted in dose
alteration and/or treatment holiday in 53% and drug discontinua-
tion in 38%. Objective response rate was 62% with an additional
23% of patients experiencing stable disease. Twenty two percent
of patients were alive at time of statistical analysis, 23% died of
disease, and 23% were lost to follow up. Median overall survival
time (OST) was 1395 days. Median progression-free survival (PFS)
was 1247 days, including patients who received additional therapy
after toceranib. Median progression-free interval (PFI) was
328 days. Response to toceranib was associated with previous
treatment (P: 0.026) and lack of previous steroid therapy (P:
0.012). On multivariate analysis, only tumor size at diagnosis was
prognostic for OST (P: 0.018), although presence of metastasis at
diagnosis showed a trend towards signiﬁcance (P: 0.055). Tumor
size at diagnosis, lack of previous steroid therapy, and metastasis
at diagnosis were all prognostic for PFI on multivariate analysis
(P: 0.01, 0.035, and 0.020, respectively). Neither response to tocer-
anib therapy nor previous treatment (other than toceranib) were
signiﬁcantly associated with outcome.
This is the ﬁrst study evaluating outcome and survival data in
dogs with AGASACA treated with toceranib. Results suggest that
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toceranib may extend overall survival in dogs with AGASACA.
Reported response rates and toxicity are similar to previous studies.
Disclosures: No disclosures to report.
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THE OCCURRENCE OF FELINE NEOPLASIA; A COMPAR-
ISON BETWEEN DANISH AND NORTH AMERICAN CATS.
B. Børresen1, M.A. Heden2, M.S. Kent3, A.T. Kristensen1.
1Copenhagen University, Frederiksberg, Denmark, 2Evidensia
Djursjukhuset G€oteborg, G€oteborg, Sweden, 3University of Cali-
fornia Davis, Davis, USA
Feline cancer epidemiologic studies from North America all date
prior to 1980 and suggest hemolymphatic cancers are the most
common types of cancer. More recent publications are mainly
European and suggest the integument is the most commonly
aﬀected system. This may be due to geographical or temporal dif-
ferences. This study aimed to describe and compare the occurrence
of cancer using a North American and Danish population of cats
from the same time period.
Cases from the Danish Veterinary Cancer Registry (DVCR)
and UC Davis (UCD) between 2005 and 2013 were included; ﬁnd-
ing 511 neoplasms from 479 cats (DVCR) and 1544 neoplasms
from 1352 cats (UCD). There were signiﬁcantly more neutered
males and females (P = 0.041 and P < 0.001) and a signiﬁcantly
higher percentage of malignant tumors from UCD (P < 0.001)
compared to the DVCR. Epithelial neoplasms were the most com-
mon tissue in both data sets. Skin and adnexa was the most com-
monly aﬀected site in both groups, followed by the gastrointestinal
system. Intact females had a similar relative risk of having mam-
mary neoplasia compared to neutered females in both data sets
(UCD 5.35 [1.53–18.65], DVCR 5.42 [4.02–7.31]), but there was a
signiﬁcant higher proportion of mammary gland tumors in the
Danish data (P < 0.001).
Comparison between Danish and American cats showed that
epithelial tissue and the integument were most commonly aﬀected
at both sites. The higher proportion of mammary gland tumors in
DVCR data is likely related to the higher percentage of intact
females.
Disclosures: No disclosures to report.
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EXPRESSION OF FELIS CATUS GAMMAHERPESVIRUS-1
ORF73, F7 AND ORF50 IN FIV-ASSOCIATED LYMPHOMA
BIOPSIES. M. Aghazadeh1, M. Shi1, R. Troyer2, A. Mcluckie1,
S. Lindsay1, V. Barrs1, J. Beatty1. 1University of Sydney, Sydney,
Australia, 2College of Veterinary Medicine, Oregon State Univer-
sity, Corvallis, USA
Felis catus gammaherpesvirus-1 (FcaGHV-1), a candidate lym-
phomagenic virus discovered in 2013, infects an estimated 200 mil-
lion cats worldwide. In humans, the gammaherpesviruses (GHV)
Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated her-
pesvirus (KSHV) are causal in up to 95% of HIV-associated lym-
phomas. In cats, feline immunodeﬁciency virus (FIV) infection is
associated with the development of high-grade B-cell lymphomas.
Whether FcaGHV1 plays a role in FIV-associated lymphomas is
under investigation.
The gold standard for determining causality in EBV-associated
lymphomas is the detection of viral transcripts expressed during
latency that promote uncontrolled growth. The aim of this study
was to investigate FcaGHV1 gene expression in FIV-associated
lymphoma. We targeted 3 FcaGHV1 open reading frames (ORFs).
Two were identiﬁed by comparative sequence analyses; ORF73, a
homologue of EBNA1 which is expressed in all EBV-associated
malignancies and F7, a homologue of KSHV vFLIP, which
encodes an anti-apoptotic protein. The third, ORF50, was identi-
ﬁed during our RNA-Seq analyses of feline lymphoma transcrip-
tome. Its homologue is a KSHV lytic cycle activator.
Frozen biopsies from cases of high-grade B cell lymphoma aris-
ing in cats seropositive for FIV and seronegative for FeLV were
identiﬁed in our tissue bank. Cases were included if tumor DNA
was positive for FcaGHV1 on PCR. Nine samples met the inclu-
sion criteria.
Total RNA was puriﬁed from frozen tissue and treated with
DNase. One-step RT-PCR assays amplifying FcaGHV1 ORF73,
F7, and ORF50 (mRNA splice product) were designed and opti-
mized. The identity of RT-PCR products migrating at the expected
size was conﬁrmed by sequencing. In 5 cases, expression of 1, 2 or
3 FcaGHV1 genes was detected. Four cats tested negative for all
three transcripts.
This study demonstrates, for the ﬁrst time, expression of
FcaGHV1 in feline lymphoma tissues. Investigations to localize
FcaGHV1 gene expression to cell type and to determine tissue
speciﬁcity are warranted.
This study was funded by the Morris Animal Foundation grant
number D15FE-001.
Disclosures: No disclosures to report.
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HIGH PRETREATMENT D-DIMER CONCENTRATION IS
ASSOCIATED WITH POOR PROGNOSIS IN 48 DOGS WITH
HIGH-GRADE LYMPHOMA. P. Boye1, F. Serres1, F. Floch1, L.
Marescaux1, D. Tierny2. 1ONCOVET, Villeneuve D’ascq, France,
2OCR, Siric ONCOLille, Parc Eurasante, Loos, France
In humans, pretreatment plasma D-dimer levels have been
reported to predict survival in several types of malignancies. The
objective of this study was to evaluate the prognostic value of pre-
treatment D-dimer levels in dogs with high-grade lymphoma.
Forty-eight owned-dogs with multicentric high-grade lymphoma
were enrolled in a prospective and observational clinical study.
Signalments, clinical ﬁndings, histology and cytology reports,
immunophenotype, complete clinical staging and response to treat-
ment were recorded for all dogs according to the WHO classiﬁca-
tion. Pretreatment D-dimer levels were measured with a
quantitative D-dimer turbidometric immunoassay (Nyco Card
Reader II, NYCOMED).
Dogs were randomly assigned into two diﬀerent treatment
groups in a blinded fashion, for receiving anti-neoplastic drug
(etoposide phosphate or F-14512). All dogs involved in the
study followed the same protocol over a period of 8 weeks. The
protocol consisted of four cycles of F14512 (0.075 mg/kg)
or etoposide phosphate (100 mg/m2) IV injections every 2 weeks
with a 3-h injection once daily on 3 consecutive days. Short-
term response was assessed by repeating complete staging at
day 62, according to the RECIST criteria published for periph-
eral nodal lymphoma in dogs. Dogs were then followed every
month until relapse. In case of relapse, a complementary
CHOP-based chemotherapy protocol was proposed to the dog’s
owner.
The median value of pretreatment plasma D-dimer was 0.4 lg/
mL (range: 0.1–14.3 lg/mL). The optimal cut-oﬀ value of D-dimer
based on Progressive Free Interval (PFI) was 0.5 lg/mL (HR:
2.22, P = 0.014). A D-dimer level >0.5 lg/mL was signiﬁcantly
associated with inferior PFI (54 vs. 104 days, P = 0.01). Dogs with
a D-dimer level >0.5 lg/mL had a signiﬁcantly worse survival than
those with a D-dimer level ≤ 0.5 lg/mL (OS: 93 vs. 177 days,
P = 0.01). High D-dimer levels were not correlated with na€ıve ver-
sus relapsed lymphoma, B versus T lymphoma, clinical stage, sub-
stage and morphotype. High D-dimer levels remained an
independent predictor for treatment received (etoposide phosphate
vs. F14512, P = 0.97). There was no diﬀerence in response rate
and PFI between dogs treated with F-14512 versus etoposide phos-
phate (ORR: 44% vs. 45%, P = 0.92; PFI: 86 vs. 87.5 days,
P = 0.34 respectively).
In conclusion, pretreatment plasma D-dimer level may serve as
a simple but eﬀective predictor of prognosis in dogs with high-
grade lymphoma. High pretreatment D-dimer levels were associ-
ated with short PFI and poor overall survival in 48 dogs enrolled
in a prospective double-blind randomized clinical trial.
Disclosures: Disclosures to report.
This study was conducted by Oncovet Clinical Research (OCR)
as part of a collaborative research project between OCR and
Pierre Fabre Medicament.
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EFFICACY OF CHEMOTHERAPY AND CLINICAL OUT-
COME IN PRIMARY, METASTATIC FELINE PULMONARY
CARCINOMAS: AN OBSERVATIONAL STUDY. E. Treggiari1,
A. Taylor2, M.A. Pellin3, G. Romanelli4, P. Valenti5, G.A. Pol-
ton6, K. Curran7, P. Brown8, S.L. Mason9. 1Willows Veterinary
Centre and Referral Service, Solihull, UK, 2Royal Veterinary Col-
lege, Hatﬁeld, UK, 3School of Veterinary Medicine, University of
Wisconsin, Madison, USA, 4Clinica Veterinaria Nerviano, Ner-
viano, Milano, Italy, 5Clinica Veterinaria Malpensa, Samarate,
Varese, Italy, 6North Downs Specialist Referrals, Bletchingley,
UK, 7Oregon State University, College of Veterinary Medicine,
Corvallis, USA, 8Small Animal Specialist Hospital, North Ryde,
Australia, 9Queens Veterinary School Hospital, University of
Cambridge, Cambridge, UK
Pulmonary carcinomas are infrequently documented in cats and
intra/extrathoracic metastatic disease appears common. While sur-
gery is the gold standard for operable tumors, there are no studies
assessing the eﬃcacy of medical treatment in cases of metastasis.
The aim of this study was to determine the clinical response to
chemotherapy in primary feline pulmonary carcinomas with evi-
dence of metastatic disease.
Medical records from multiple institutions were searched for
cats with cytologically or histopathologically conﬁrmed primary
pulmonary carcinomas, with concurrent computed tomography-
suspected metastases, that subsequently underwent treatment with
cytotoxic chemotherapeutics or tyrosine kinase inhibitor drugs.
Cats that underwent surgical resection of the primary tumor and/
or associated metastases were not included.
Thirteen cats were selected for inclusion. Median age was
12 years (range 6–16 years) and median body weight 3.9 kg (range
3.1–8.2). Presenting clinical signs included coughing (9), tachypnea
(5), gastrointestinal signs (4), abdominal pain (1) and lethargy (1).
A diﬀuse nodular pattern, consistent with metastasis to the lung
parenchyma, was present in all cases: additional locations were
identiﬁed in 6 cases (intrathoracic nodes [5], kidneys [1]). Medical
treatments included vinorelbine (3), carboplatin (4), toceranib
phosphate (4) and metronomic cyclophosphamide (2). All cats had
variable improvement in clinical signs after initiation of treatment
and experienced moderate to mild toxicity, with no cats requiring
hospitalization due to adverse events.
Overall median time to progression (TTP) with ﬁrst line medical
treatment was 99 days (range 32–317 days). Four cats had evi-
dence of disease progression while on chemotherapy and received
rescue treatment, with a TTP ranging from 8 to 85 days. In 2
cases, only a clinical response could be assessed; of these, one had
renal metastases at diagnosis and the other developed renal metas-
tases while receiving treatment. These two patients initially demon-
strated stable disease but later developed intraocular and
retrobulbar metastases, respectively. Of patients with repeat imag-
ing, 1 cat had a partial response, 6 had stable disease and 4 pro-
gressive disease. The overall median survival time was 139 days
(range 50–497 days). Four cats were still alive at the time of data
analysis with a median follow-up of 428 days (range 81–625 days).
This study suggests that chemotherapy may achieve stable dis-
ease in cats with primary, metastatic lung tumors. Extended sur-
vival times are possible, with some cats surviving over a year.
Based on these results, medical treatment appears to be well toler-
ated and should be considered in advanced disease stage.
Disclosures: No disclosures to report.
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OVARIAN TUMORS IN THE BITCH - PATHOLOGICAL
FINDINGS AND AMH VALUES. H. Aupperle-Lellbach1, K.
Klose2, A. Coelfen3, C. Beitzinger3, B. Walter4, K. J€ager3, F. Kas-
sous5, C. Weber3. 1Laboklin GmbH&Co.KG, Bad Kissingen, Ger-
many, 2Institut of Veterinary -Pathology, Leipzig, Germany,
3Laboklin, Bad Kissingen, Germany, 4Clinic of Small Animal Sur-
gery and Reproduction, M€unchen, Germany, 5National veterinary
school, Alfort, France
Although various neoplasms may occur in the canine ovary, only
few studies with mainly small case numbers are available (Review:
Arlt & Haimar 2016). Elevated Anti Muellerian-Hormone (AMH)
concentrations have been described in granulosa cell tumors
(GCT) in women and mares but not in dogs until now.
Aims of the study: (i) Pathological characterization of a higher
number of canine ovarian neoplasms with a correlation to breed
and age; (ii) Evaluation of AMH values in canine GCTs and other
ovarian tumors.
Ovarian neoplasms of 280 bitches (age 9  3 years) were sub-
mitted (2013–2016) for histopathological routine diagnosis, includ-
ing macroscopic and immunohistochemical (cytokeratin, CD3,
CD79a, CD31, actin) investigations.
In 21 cases, pre-operative serum samples were available for ret-
rospective AMH value measurements with an automated Chemilu-
minescence-Immunoassay.
Ovarian tumors (unilateral/bilateral) were diagnosed as GCT (86/
11), ovarian carcinoma (41/23) and adenoma (32/8), teratoma (17/3),
dysgerminoma (14/2), leiomyoma (6/0), leiomyosarcoma (5/0), heman-
giosarcoma (3/0), stromal tumor (2/0), lymphoma (4/3), luteoma (5/0),
multiple diﬀerent neoplasms (4/11). Certain signs of malignancy were
obvious in 23 GCTs, six dysgerminomas, one teratoma and all carci-
nomas, lymphomas, sarcomas and cases with multiple tumors.
Bitches with teratomas were younger (median 6 years) than
dogs with other ovarian neoplasms (median 9 years).
Median diameters were 1.5 cm of normal ovaries, 3.0 cm of
ovarian adenomas and carcinomas, 4.5 cm of GCTs and dysgermi-
nomas, 5.3 cm of teratomas.
Within the ovarian tumor population, the breed groups, Sheep-
dogs & Cattledogs (FCI-1) and Spitz & primitive types (FCI-5)
were represented with 14.7% and 5.3% respectively. However,
looking at all samples (AS) and percentage of all tumor samples
(TS) submitted to LABOKLIN during the years, these breed
groups were less represented: Sheepdogs & Cattledogs: AS 7.33%
and TS 6.7%; and Spitz & primitive types: AS 7.8% and TS
1.74%.
AMH Values (ng/mL) were signiﬁcantly higher in GCTs (me-
dian: 5.13, 1.12 to >23.00, n = 9) than in dysgerminomas (median:
0.25; 0.03–0.26, n = 3), ovarian carcinomas and adenomas (me-
dian: 0.61; 0.01–0.89, n = 9).
In conclusion, Sheepdogs & Cattledogs (FCI-1) and Spitz &
primitive types (FCI-5) seem to have a predisposition for ovarian
tumors. Although varying in median size and age of the bitch, ovar-
ian neoplasms are not distinguishable by clinical or macroscopical
ﬁndings. Histological investigation is needed for ﬁnal diagnosis and
prognosis. However, measurement of AMH serum concentration
may help to identify GCT pre-surgically. Further studies will be per-
formed to investigate AMH values in cases with ovarian cysts.
Disclosures: Disclosures to report.
Several authors of this study belong to Laboklin GmbH &
Co.KG - a diagnostic laboratory, which is oﬀering the AMH mea-
surement for clients.
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INITIAL EVALUATION OF GUM ARABIC COATED
RADIOACTIVE GOLD NANOPARTICLES IN CANINE PRO-
STATIC CANCER. S.M. Bechtel1, A. Upendran1, J.C. Lattimer,
J. Kelsey2, C.S. Cutler2, K.A. Selting1, J.N. Bryan1, C.J. Henry1,
B.K. Flesner1, E. Boote3, D.J. Tate1, M.E. Bryan1, K.V. Katti1,
R. Kannan1. 1University of Missouri, Columbia, USA, 2Missouri
University Research Reactor, Columbia, USA, 3Spectrum Health,
Grand Rapids, USA
Gum arabic coated radioactive gold nanoparticles (GA-198AuNP)
are eﬀectively retained and result in 80% tumor reduction in a
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mouse model of human prostatic carcinoma. Our objectives were
to determine the toxicity and preliminary eﬃcacy of GA-198AuNP
administered intralesionally to dogs with spontaneously occurring
carcinoma of the prostate. The hypothesis was that intralesional
GA-198AuNP would cause short term swelling but cause no sys-
temic toxicity and result in tumor stabilization or shrinkage. Fol-
lowing Institutional Animal Care and Use Committee approval,
dogs with a diagnosis of prostate carcinoma without bladder
involvement were eligible for enrollment with informed owner con-
sent. Staging was performed and injection of GA-198AuNP was
achieved with CT guidance (100–200 lL per site in multiple sites,
total amount varied based on tumor size). A complete blood
count, chemistry panel, and urinalysis were performed weekly for
4 weeks following treatment; a CT scan was performed 4 weeks
after treatment. Nuclear scintigraphy was performed regularly
(15 min, 1 h, 4 h, 1, 2, 4, and 5 days post-injection) to determine
the degree of retention of GA-198AuNP in the prostate. Following
the 4 week trial period, chemotherapy could be started at the dis-
cretion of the pet owner. Twenty-two dogs were enrolled; 3 dogs
had metastasis to the lymph nodes in the sublumbar region and 19
dogs had no evidence of metastasis. Two dogs were treated to a
biologically equivalent dose of 50 Gy and 20 dogs were treated to
105 Gy. One dog died 12 days post injection due to urethral
obstruction from either tumor swelling or disease progression. Fol-
lowing this event, dogs with evidence of urethral obstruction had
urethral stents placed (n = 15) prior to treatment. Fifteen dogs
received chemotherapy. The median survival time of dogs receiving
chemotherapy was 132 days (range 55–420 days) compared to
56 days (range 12–255 days) in dogs that did not. The average
tumor retention of GA-198AuNP was 70% at 5 days post-injec-
tion; loss occurred into the urine through the bladder. No accumu-
lation of dose was found in heart, lung, liver, spleen, and kidney
as determined by whole body planar imaging up to 5 days post-
treatment. The median reduction in tumor volume was 10% one
month after GA-198AuNP therapy in 14 dogs. In conclusion, intra-
tumoral administration of GA-198AuNP caused no acute systemic
toxicities in any dog and may be eﬀective in decreasing tumor size,
however, local tumor swelling is possible and dogs must be closely
monitored for evidence of urethral obstruction.
Disclosures: Disclosures to report.
Grant and ﬁnancial support: This work was supported by a grant
from the University of Missouri Institute of Clinical and Transla-
tional Sciences, NIH-SBIR Phase II contract (HHSN26120100010
0C), and Shasun NBI, LLC. AU, KVK and RK are co-founders of
Nanoparticle Biochem, Inc.
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RE-EMERGENCE OF FELINE PANLEUKOPENIA IN AUS-
TRALIA. V. Barrs1, J. Brailey1, A. Allison2, M. Kelman1, J.
Meers3, J.A. Beatty1, E.C. Holmes1. 1University of Sydney, Cam-
perdown, Australia, 2Cornell University, Ithaca, USA, 3Australia
Feline panleukopenia, a highly contagious and often fatal disease
of cats, is caused by feline panleukopenia virus (FPV) or canine
parvovirus (CPV), both strains of Carnivore protoparvovirus 1.
Clinical disease has rarely been seen in Australia since the mid-
1970s until 2014, when an outbreak was reported to a national
online disease surveillance reporting tool.
The aim of this study was to determine the strains of Canine
protoparvovirus 1 and epidemiological factors involved in out-
breaks of feline panleukopenia reported since 2014. Veterinarians
and shelter owners were contacted to arrange site-visits, collect
samples and obtain information about animal movements, biose-
curity and vaccination protocols for qualitative analysis. DNA
was extracted from feces or tissues of representative cats from each
outbreak with clinical signs of panleukopenia and/or positive fecal
antigen CPV tests, for PCR and sequencing of the VP2 gene. Phy-
logenetic analysis of outbreak and CPV-like and FPV-like VP2
sequences available on GenBank was performed using the maxi-
mum likelihood method.
Three outbreaks causing over 350 fatalities were identiﬁed in;
(A) 2014, Melbourne; (B) 2015, Melbourne and Mildura, a city
540 km from Melbourne; (C) 2016, Melbourne and Sydney. Out-
breaks in Mildura and Melbourne were caused by identical or clo-
sely related FPV genotype(s), while the Sydney outbreak was
caused by a diﬀerent FPV genotype. Most cases were from munici-
pal, charitable or private shelters. Shelters with the highest number
of fatalities did not perform routine vaccination. In shelters that
did administer vaccines, disease occurred in incompletely vacci-
nated cats or cats not vaccinated due to respiratory disease. Move-
ment of unvaccinated cats from municipal shelters to networks of
private foster carers was identiﬁed in all outbreaks, including
between Melbourne and Mildura in outbreak B. The median age
of cats at diagnosis was 8 weeks. All outbreaks occurred from
summer to autumn, coinciding with peak shelter intakes of kittens.
Feline panleukopenia, caused by FPV, has re-emerged as a
major cause of mortality in Australian feline shelters in association
with inadequate vaccination and biosecurity practices.
Disclosures: Disclosures to report.
This study was funded by grants from the NSW Cat Protection
Society and the Australian Companion Animal Health Founda-
tion, IRMA Project ID 1822469.
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INVESTIGATION OF FECAL PARVOVIRUS SHEDDING IN
ASYMPTOMATIC SHELTER HOUSED CATS IN AUS-
TRALIA. P.J. Byrne, J.A. Beatty, V.R. Barrs. University of Syd-
ney, Camperdown, Australia
Canine parvoviruses (CPVs) and feline panleukopenia virus (FPV)
are strains of Carnivore protoparvovirus 1. CPV2a-c can infect and
replicate in both canids and felids. Using conventional PCR, a
recent study reported a high prevalence of fecal shedding of CPVs
among asymptomatic shelter cats in the UK, identifying cats as a
potential reservoir of infection.
The aim of this study was to determine the prevalence of fecal
shedding of CPVs in asymptomatic shelter-housed cats in Aus-
tralia. One hundred stool samples from unvaccinated cats housed
in a dual canine/feline shelter were collected and stored at 80°C
until testing. Viral DNA was extracted from feces by homogeniza-
tion of a 10% w/v solution of feces in phosphate buﬀered saline
(PBS), boiling of the supernatant after centrifugation, chilling on
ice and repeat centrifugation. To identify PCR inhibition in fecal
DNA extracts, dilutions (1:10 and 1:20) of supernatant were
spiked with feline genomic DNA (138 ng) and tested using a PCR
amplifying the feline GAPDH gene. Feline GAPDH was ampliﬁed
in all spiked fecal samples at a 1:20 dilution, and in 99 samples at
a 1:10 dilution. PCR inhibition of GAPDH in one sample at 1:20
dilution was abolished at a 1:50 dilution.
Fecal DNA extracts (1:10 and 1:20 dilutions (n = 99), 1:50 dilu-
tion (n = 1)) from shelter cats were screened for the presence of
CPV and FPV using a PCR assay amplifying a 529 bp region of
the VP2 gene using primers 555-F and 555-R. PBS processed in
parallel with samples from extraction to PCR served as a negative
control and DNA from a previously sequenced canine CPV isolate
as a positive control. In samples testing positive, the complete VP2
gene was sequenced to diﬀerentiate FPVs from CPVs. CPV DNA
was not detected in the stool of any cat. FPV DNA was detected
in the stool of 4 cats.
In contrast to results of a UK shelter, fecal shedding of CPV by
asymptomatic shelter-housed cats was not detected in this study
and the prevalence of FPV shedding was low. Future studies to
screen for Carnivore Protoparvoviruses using quantitative PCR
assays are warranted to rule out low-level shedding undetectable
by conventional PCR.
Disclosures: Disclosures to report.
Conﬂict of Interest The authors declare no potential conﬂict of
interest regarding research, authorship and/or publication of this
article. Funding The authors received research grants from Boeh-
ringer Ingelheim PTY LTD, 78 Waterloo Rd, Macquarie Park
NSW 2113 Australia, and the University of Sydney, Camperdown
NSW 2006 Australia.
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CLASS A CPG OLIGONUCLEOTIDES IN CATS WITH NAT-
URALLY OCCURRING FELINE PANLEUKOPENIA INFEC-
TION: A PROSPECTIVE CASE-CONTROL STUDY. F.F.
Ferri1, F. Porporato1, H. Lutz2, M. Meli2, G. Gerardi3, L.M. Cop-
pola3, D. Bernardini3, B. Contiero3, N. Kohan Ranjbar2, C. Calle-
gari1, R. Hofmann-Lehmann2, E. Zini4. 1Istituto Veterinario di
Novara, Granozzo Con Monticello - Novara, Italy, 2Clinical Lab-
oratory, Vetsuisse Faculty, University of Zurich, Zurich, Switzer-
land, 3University of Padua, Padova, Italy, 4Clinic for Small
Animal Internal Medicine, University of Zurich, Zurich, Switzer-
land
Feline panleukopenia virus (FPV) infection leads to severe
leukopenia and gastrointestinal signs in cats, with mortality rate of
up to 70%. Besides supportive therapy, information regarding
speciﬁc treatments is yet very limited in aﬀected cats. Class A
CpG oligodeoxynucleotides (CpG-A) are short single-stranded
DNA molecules containing unmethylated cytosine-phosphate-gua-
nosine motifs that stimulate production of type I interferons. Stud-
ies in cats showed the ability of CpG-A to induce an antiviral
state in vivo and to inhibit replication of FPV in vitro. Therefore,
aims of this study were to investigate the eﬀects of CpG-A on sur-
vival and clinical score, white blood cell (WBC), red blood cell
(RBC) and platelet counts, as well as viremia and fecal viral shed-
ding in cats naturally infected with FPV. Cats with positive fecal
parvovirus antigen test were prospectively enrolled if presenting
clinical or laboratory sings of FPV, had body weight >500 g, were
unvaccinated and not previously treated. Cats were randomly allo-
cated to receive 100 µg/kg of CpG-A or placebo subcutaneously,
at admission and after 48 h; all cases were treated with supportive
therapy. A clinical score derived from attitude, appetite, vomiting,
diarrhea and temperature was assigned daily until death or during
7 days. Blood and fecal samples were collected at admission and
at 1, 2, 7 days; complete blood counts were obtained and real-time
PCR was performed to quantify FPV DNA in blood and fecal
samples. Chi-square test and mixed ANOVA were used to com-
pare treatment groups. Forty-two cats were included: 22 received
CpG-A and 20 placebo. Survival rate did not diﬀer between cats
treated with CpG-A and placebo [11 of 22 (50%) vs. 8 of 20
(40%), respectively; P = 0.516]. Diﬀerences between groups were
not observed for clinical score, RBC, platelets, viremia and fecal
viral shedding at any time point. Mean WBC count was higher in
cats treated with CpG-A than with placebo at 7 days
(25,800  13,800/µL vs. 14,900  8400/µL, respectively;
P = 0.017) but not at the other time points. All cats showed dis-
comfort during CpG-A injections. In conclusion, treatment with
CpG-A did not improve survival or clinical score and did not
reduce viral shedding, suggesting that the drug or the treatment
regimen used in this study is not beneﬁcial in cats aﬀected with
FPV. The lack of favorable response to CpG-A might be due to
the delayed improvement of WBC counts. Of note, the administra-
tion of CpG-A may be painful in cats.
Disclosures: No disclosures to report.
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FERAL CARNIVORES ARE RESERVOIRS OF CARNIVORE
PROTOPARVOVIRUS 1 IN AUSTRALIA. J. Brailey1, D. Jenk-
ins2, M. Aghazadeh1, J. Slapeta1, J. Gorrell3, J.A. Beatty1, V.R.
Barrs1. 1University of Sydney, Camperdown, Australia, 2Charles
Sturt University, Wagga Wagga, Australia, 3University of New
England, Armidale, Australia
Disease in dogs caused by canine parvovirus (CPV) is common in
Australia. A related strain of Canine Protoparvovirus 1 (CPPV1),
feline panleukopenia virus (FPV), re-emerged in 2014 in Australia
as a major pathogen in shelter cats. In North America and Eur-
ope, wild carnivore hosts are implicated in the emergence of novel
strains of CPPV1. Australia has large populations of introduced
feral carnivores including cats (Felis catus) and foxes (Vulpes
vulpes) as well as endemic carnivores such as the endangered Tas-
manian devil (Sarcophilus harissii).
The aim of this study was to i) determine whether there is evi-
dence of CPPV1 infection in feral carnivores and viral traﬃc
between these and companion animals (ii) model in silico the
susceptibility of the Tasmanian devil to CPPV1. Reticuloendothe-
lial tissue samples were sourced from deceased feral carnivores for
PCR ampliﬁcation and sequencing of a 529 bp region of the
CPPV1 VP2 gene. Phylogenetic analysis of partial VP2 gene
sequences was performed using the maximum likelihood method.
Tasmanian devil susceptibility to infection was investigated by
comparison of their transferrin receptor type 2 (TfR) sequence at
binding sites for CPPV1 to susceptible carnivores, and phyloge-
netic analysis of TfR protein.
Tissue samples from 62 feral cats and 53 foxes collected
between 2010 and 2016 were analyzed. CPPV1 DNA was detected
in 14/62 feral cats and 0/53 foxes. CPPV1-positive cat samples, all
from animals culled in 2010, comprised 5 related FPV genotypes,
including one genotype identical to that detected in FPV outbreaks
in cat shelters in Melbourne (2014–2016), and another that was
closely related to an FPV strain identiﬁed in a Burmese kitten in
Melbourne in 1970. TfR amino-acid residues 224 and 389, critical
to parvovirus binding, are glutamate and arginine, respectively in
Tasmanian devil TfR, in contrast to leucine and lysine or aspara-
gine in canid and felid hosts. Tasmanian devil TfR protein was
only distantly related to these hosts.
This study provides evidence of feral cat reservoirs of CCPV 1
infection and viral traﬃc between feral carnivores and companion
animals in Australia. TfR gene analysis indicates that Tasmanian
devils are unlikely to be susceptible to CCPV1, which has impor-
tant biosecurity implications for captive breeding programs.
Disclosures: Disclosures to report.
This study was funded by the Australian Companion Animal
Health Foundation, A University of Sydney Charles Perkins Cen-
tre Fellowship grant and Boehringer Ingelheim.
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FELINE MORBILLIVIRUS INFECTION IN DOMESTIC
CATS IN ITALY: EPIDEMIOLOGICAL AND PATHOLOGI-
CAL ASPECTS. E. de Luca1, P.E. Crisi2, E. Febo2, M. di Tom-
maso2, D. Malatesta1, G. Zaccaria1, M. Marcacci1, G. di
Francesco1, M. di Domenico1, A. Giovannini1, G. di Guardo2, G.
Savini1, A. Boari2, A. Lorusso1. 1Istituto Zooproﬁlattico Speri-
mentale of Abruzzo and Molise, Teramo, Italy, 2University of Ter-
amo, Teramo, Italy
A novel paramyxovirus, Feline morbillivirus (FeMV), has recently
been detected in a stray cat in Italy (Piuma/2015). According to
previous studies conducted in other Countries, FeMV has been
suspected to be associated with feline chronic kidney diseases
(CKD). We aimed at: i) investigating FeMV occurrence in the pro-
vince of Teramo, central Italy, ii) associating FeMV with CKD
lesions; iii) analyzing the genome of circulating FeMVs.
Urine samples collected from cats presented to the Veterinary
Teaching Hospital (VTH, UniTE) or to local veterinary practition-
ers were screened (Group A, n 60). In addition, urine from cats
(Group C, n 72) belonging to 4 colonies were also tested, as well
as internal organs of carcasses (Group B, n 35). Formalin-ﬁxed
and paraﬃn embedded sections of kidney of cats were either
stained with H&E or incubated with Ab against FeMV-N protein.
qPCR-positive RNAs were employed for SISPA/NGS. Finally, a
portion of the polymerase (L) gene was ampliﬁed by RT-PCR
from all positive samples. Carcasses were divided into subgroups,
including B1 (+virus +lesions), B2 (+virus -lesions) and B3 (-virus
+lesions).
In Group A, 7/60 urine samples were positive by qPCR,
whereas in Group C, 20/72 samples were positive. Eight/35 car-
casses resulted positive by qPCR, with kidneys and urinary blad-
ders being constantly positive. Viral RNA was also detected in the
brain and spleen of one cat. A bilateral, subacute-to-chronic, lym-
pho-plasmacytic interstitial nephritis was observed in all the qPCR
positive cats, which also showed scattered immunolabeling for
viral antigen within their renal parenchyma, mostly involving the
cortical kidney tubules and the surrounding inﬂammatory cells.
Sequences of the L gene have been also obtained from all positive
samples. Genetic diversity has been observed between diﬀerent
groups. In C1, two putative diﬀerent viral variants (97.8 % of nt
id) have been observed, with one of these variants being present in
C2. The highest nt diﬀerence was shown by most of the obtained
sequences from all groups with Piuma/2015 (88.4–88.9% of nt id).
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While the occurrence of FeMV in Group A mirrors that seen in
cats from other Countries, FeMV occurrence in Group C is
higher. As in previous studies, genome diversity has been also
demonstrated in FeMVs circulating in our province. We believe
that the scattered viral antigen immunolabeling detected in renal
tubular epithelia, as well as in the surrounding inﬂammatory cells,
gets along very well with an intermittent viral excretion through
urine. Statistical analyses are currently underway.
Disclosures: No disclosures to report.
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EVALUATION OF A DISCRIMINATIVE REAL-TIME RT-
PCR IN CEREBROSPINAL FLUID FOR THE DIAGNOSIS
OF FELINE INFECTIOUS PERITONITIS. S. Felten1, C.M.
Leutenegger2, H.J. Balzer3, N. Pantchev3, K. Matiasek4, L. Sangl1,
S. Doenges1, S. Gruendl1, A. Fischer1, K. Hartmann1. 1Clinic of
Small Animal Medicine, Ludwig-Maximilians-Universitaet
Munich, MUNICH, Germany, 2IDEXX Laboratories Inc., West
Sacramento, USA, 3IDEXX Vet Med Labor GmbH, Ludwigs-
burg, Germany, 4Section of Clinical and Comparative Neu-
ropathology, LMU Munich, MUNICH, Germany
Ante-mortem diagnosis of feline infectious peritonitis (FIP) is par-
ticularly diﬃcult in cats without eﬀusions, of which about 40%
have neurological signs indicative of central nervous system (CNS)
manifestation.
Aim of this study was to evaluate sensitivity and speciﬁcity of a
real-time reverse transcription polymerase chain reaction (RT-
qPCR) able to distinguish the two feline coronavirus (FCoV)
pathotypes (feline infectious peritonitis virus (FIPV) and feline
enteric coronavirus (FECV)) in cerebrospinal ﬂuid (CSF) of cats
suspected of having FIP.
The study population consisted of 31 cats with conﬁrmed FIP
(six with neurological signs) and a control group of 29 cats (ten
with neurological signs) for which FIP was considered a diﬀeren-
tial diagnosis, but which were deﬁnitively diagnosed with other
diseases. CSF of these cats was tested for presence of feline coron-
avirus (FCoV) RNA by RT-qPCR and in positive cases, the
pathotype was determined according to the S gene sequence. Sensi-
tivity and speciﬁcity including 95% conﬁdence intervals (95% CI)
were calculated.
FIPV was detected in the CSF of three cats with FIP. In six
cats with FIP, FCoV RNA was detected, but virus load was too
low to allow pathotyping. FCoV was not detected in any of the
control cats.
Speciﬁcity of the RT-qPCR was 100% (95% CI: 88.1–100.0);
sensitivity for detection of any FCoV was 29.0%; sensitivity of
detection of the FIPV pathotypes in all cats was 9.7% (95% CI:
2.0–25.8), 16.7% in cats with neurological signs.
Speciﬁcity of the RT-qPCR was excellent, but a negative test
result cannot rule out FIP.
Disclosures: Disclosures to report.
Dr. Christian Leutenegger is the Head of Molecular Diagnostics
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SCREENING FOR SELECTED PATHOGENS IN TICKS
INFECTING CATS IN THE UNITED KINGDOM: A LARGE-
SCALE SURVEILLANCE PROGRAMME. F. Duplan1, S.
Davies2, S. Filler3, S. Abdullah2, S. Keyte1, H. Newbury4, C.R.
Helps3, S. Tasker1, R. Wall2. 1Langford Vets University of Bristol,
Langford, UK, 2Veterinary Parasitology and Ecology Group,
School of Biological Sciences, Life S, Bristol, UK, 3Molecular
Diagnostic Unit, Diagnostic Services, Langford Vets, School of
Veterin, Langford, UK, 4MSD Animal Health, Milton Keynes,
UK
Ticks are important vectors; cats acquire tick-borne pathogens
when bitten by ticks. Ticks derived from cats have rarely been
evaluated for the presence of pathogens; small studies have been
described in Spain, Italy and Poland but no studies have yet been
performed in ticks found on cats in the UK.
The aim of this study was to determine the prevalence of
selected tick-borne pathogens in ticks collected from cats in the
UK: pathogens evaluated were Anaplasma phagocytophilum, Bar-
tonella spp. including Bartonella henselae, Hepatozoon spp., Babe-
sia spp., Borrelia spp. including Borrelia burgdorferi sensu lato,
and hemoplasma species including Mycoplasma haemofelis (Mhf),
‘Candidatus Mycoplasma haemominutum’ (CMhm) and ‘Candida-
tus Mycoplasma turicensis’ (CMt).
Ticks were collected from cats presenting to veterinarians in
UK practices. Tick species were identiﬁed morphologically and
underwent DNA extraction using commercially available kits fol-
lowed by PCR assays (either conventional or quantitative real-time
[qPCR]) for the tick-borne pathogens speciﬁed above. All assays
had been previously validated for detection of the target species.
Feline 28S rDNA served as an endogenous internal PCR control
(assessed within the hemoplasma qPCRs). Additionally, the sam-
ples were spiked with an internal ampliﬁcation control (IAC) to
monitor for inhibition. Positive samples from the generic PCRs
(Bartonella spp., Hepatozoon spp., Borrelia spp.) were submitted
for DNA sequencing for species identiﬁcation.
A total of 541 ticks were collected. Of these 309 (57.1%) were
Ixodes ricinus, 224 (41.4%) were Ixodes hexagonus and 8 (1.5%)
were Ixodes trianguliceps. 28S rDNA was ampliﬁed from 476
(88.0%) of the ticks (undetected results likely being due to some
ticks being unfed). The IAC PCR results revealed no evidence of
inhibition. Of 541 ticks, 33 (6.1%) contained pathogens, and 1 tick
contained two. Agents detected were: 6 (1.1%) Babesia spp. (Babe-
sia microti-like & Babesia venatorum), 10 (1.8%), Borrelia spp.
(Borrelia afzelii & Borrelia garinii), 5 (0.9%) A. phagocytophilum, 7
(1.3%) Bartonella spp. (including B. henselae & Bartonella clar-
ridgeiae), 6 (1.1%) hemoplasma species [4 (0.7%) CMhm, 1
(0.2%) Mhf and 1 (0.2%) CMt]. Additionally, Hepatozoon sil-
vestris was detected.
The resulting data provide valuable information on the preva-
lence of tick-borne pathogens in ticks found on cats in the UK.
The prevalences found were similar to those reported in ticks col-
lected from dogs in the UK but lower than those reported in ticks
from cats in other European countries. This is the ﬁrst report of
the detection of H. silvestris in ticks collected from domestic cats
in the world.
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THE ROLE OF HYPOVITAMINOSIS D IN COMPLICATED
CANINE BABESIOSIS. E. Dvir1, C.T. Rosa2, R.J. Meiianby3,
J.P. Schoeman2. 1Tel Hai Academic College, Upper Galilee, Israel,
2University of Pretoria, Pretoria, South Africa, 3University of
Edinburgh, Edinburgh, Scotland
Canine babesiosis is caused by Babesia rossi and the infection is
very virulent. Some cases suﬀer from major complications includ-
ing hemolytic anemia, hepatopathy, acute renal failure, acute res-
piratory distress syndrome, hypoglycemia, cerebral hemorrhages
and pancreatitis. The disease has a mortality rate between 7 and
10%. Consequently, there is a need to improve understanding of
the risk factors associated with poor clinical outcome. The current
study examines the association between B. rossi infection and
serum concentrations of 25 hydroxyvitamin D (25(OH)D), the
major circulating vitamin D metabolite. Hypovitaminosis D has
been reported in a wide range of infectious diseases in humans
and dogs and low vitamin D status has been associated with poor
clinical outcomes. This is the ﬁrst study to investigate vitamin D
status in canine babesiosis.
The hypothesis of this study was that dogs with babesiosis
would have a lower vitamin D status than healthy dogs and that
hypovitaminosis D would be associated with disease severity. The
serum 25(OH)D metabolites were measured by high-performance
liquid chromatography. Dogs were excluded from all groups if
they were less than 1 year old, had concurrent diseases or were
receiving corticosteroids. Blood was collected upon admission. The
babesiosis cases were scored for severity. Each of the previously
described babesiosis complications, inter alia, high serum lactate,
hypoglycemia, hypercortisolemia, hypothyroxinemia, presence of
SIRS received a score of 1. Finally, the total individual severity
score was calculated.
Dogs with babesiosis (n = 35) had signiﬁcantly lower 25(OH)D
concentrations than the control group (n = 24) (24.05  17.71 vs.
88.75  38.25, P < 0.001). ANCOVA analysis demonstrated that
the eﬀect of babesiosis on 25(OH)D concentrations compared to
control dogs was still signiﬁcant after considering the eﬀect of age
and weight. In addition, hypovitaminosis D was not signiﬁcantly
aﬀected by serum creatinine and ALT concentrations, thereby
eliminating the eﬀect of renal insuﬃciency or liver damage, respec-
tively. Moreover, correlation analysis revealed that hypovita-
minosis D was not signiﬁcantly correlated with the time from last
meal (anorexia). Yet, hypovitaminosis D, was signiﬁcantly inﬂu-
enced by hypoproteinemia, hypoalbuminemia and hypoglobuline-
mia. Finally, among the babesiosis cases, the severity score had a
signiﬁcant inverse correlation (r = 0.39, P = 0.04) with serum 25
(OH)D concentrations.
These results indicate that hypovitaminosis D is associated with
canine Babesia rossi infection. The inverse correlation between 25
(OH)D concentrations and the severity score and the association
between hypovitaminosis D and hypoproteinemia, hypoalbumine-
mia and hypoglobulinemia indicate that hypovitaminosis D might
be a helpful indicator of severity and prognosis.
Disclosures: No disclosures to report.
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IS URINE CULTURE THE POOR MAN’S BLOOD CUL-
TURE? CONCORDANCE BETWEEN PARALLEL CANINE
BLOOD AND URINE CULTURES. N.R. Barash, A.J. Birken-
heuer, J. Megan. North Carolina State University, Raleigh, USA
Bloodstream infections are a substantial cause of morbidity and
mortality in critically ill veterinary patients. Blood cultures are the
gold standard for diagnosis of bacteremia, but are infrequently
obtained due to technical and practical diﬃculties in sample
acquisition. In ill patients, urine cultures are sometimes recom-
mended as surrogates for blood cultures as part of a “better than
nothing” approach. This study evaluated the ability of urine cul-
ture to predict blood-stream infection. We retrospectively evalu-
ated all blood, aerobic, and anaerobic cultures submitted at NC
State Veterinary Hospital between 2011 and 2016. We calculated
growth rates of 18% (blood), 24% (urine), and 61% (non-urine)
from 511 blood, 6797 urine, and 6552 non-urine cultures submit-
ted. Blood isolates were most commonly coagulase-positive Sta-
phylococcus spp (27%) and Escherichia coli (14%); Escherichia coli
was the most common urinary isolate (43%), along with Entero-
coccus (14%) and coagulase-positive Staphylococcus (11%). 324
urine and blood samples were submitted in parallel, of which 21
yielded simultaneous growth. Of these, only 14 samples were con-
cordant, while 7 yielded discordant urinary and bloodstream infec-
tions. Overall, urinary isolates were poorly reﬂective of
bloodstream isolates, with a sensitivity of 24% but a speciﬁcity of
87%. General concordance, including true positive (n = 14) and
true negatives (n = 232), between urinary and bloodstream isolates
was 76%. Urine culture isolates had a poor positive predictive
value (29%) but a negative predictive value of 84% for blood-
stream infection. An apparent exception is patients with suspected
urogenital infection sources (renal, prostatic, etc), in which 100%
(n = 7) had concordant urinary and bloodstream infections. Coag-
ulase-positive Staphylococcus infections were most likely to be con-
cordant. 133 non-urine samples submitted in parallel with blood
cultures were also evaluated; only biliary and intravenous catheter
samples carried a PPV >40%. In short, we recommend that if
bloodstream infection is suspected, blood cultures be acquired.
Coagulase-positive Staphylococci, if isolated from urinary tract of
ill patient, should raise clinical suspicion of a potential concordant
bloodstream infection. Due to a high discordance rate, in particu-
lar, blood cultures should be performed in any potentially septic
animal who is immunosuppressed. Bacteriuria is neither a substi-
tute nor a screen for bacteremia, and in fact, based oﬀ of our cal-
culated false negative rate, treatment of urinary tract pathogens in
likely bacteremic animals would lead to treatment for the incorrect
bloodstream pathogen 76% of the time. Though urine cultures are
encouraged as part of a complete diagnostic workup, they do not
substitute for blood cultures.
Disclosures: Disclosures to report.
Jacob ME: Director of NCSU Clinical Microbiology Laborato-
ries. No other disclosures to report.
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COMPANION ANIMALS AND HUMANS WITH UTI SHARE
COMMON UROPATHOGENIC KLEBSIELLA PNEUMO-
NIAE. C. Marques1, G. Trigueiro2, P. Cavaco3, J. Menezes1, A.
Belas1, C. Pomba1. 1Faculty of Veterinary Medicine, CIISA,
University of Lisbon, Lisbon, Portugal, 2Laboratorio de Analises
Clınicas Dr. Joaquim Chaves, Lisbon, Portugal, 3Centro de Inves-
tigac~A£o Interdisciplinar Egas Moniz CiiEM, Instituto Superior d,
Lisbon, Portugal
Klebsiella pneumoniae are important nosocomial pathogens that
are increasingly reported as multidrug-resistant (MDR). Compan-
ion animals (CA) with urinary tract infections (UTI) may become
infected with MDR and virulent K. pneumoniae and thus act as
reservoir to humans. This study aimed to characterize and com-
pare the clonal relatedness of K. pneumoniae isolated from com-
panion animals and humans with UTI. K. pneumoniae isolated
from CA (n = 26) and from community and hospital-acquired
human UTIs (n = 76) were tested by disk diﬀusion for susceptibil-
ity (AST) against 28 antimicrobials according to CLSI. Resistant
isolates were screened for sixteen resistance genes and seven viru-
lence genes by PCR. All CA isolates and third-generation cepha-
losporin resistant (3GCr) human isolates were typed by MLST.
Population structure of CA and human isolates were further char-
acterized by PFGE-XbaI macro-restriction using Dice/UPGMA
clustering analysis with a 1.5% tolerance.
The high-risk clonal K. pneumoniae lineage ST15 predominated
in CA isolates (61.5%, n = 16/26) and clustered together with a
similarity index (SI) = 69%. Most CA ST15 isolates belonged to
two clusters (ST15a, ST15b) with SI>80%. Interestingly, all CA
ST15 showed resistance to ﬂuoroquinolones and 75% (n = 12/16)
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were 3GCr mainly due to CTX-M-15. Two human ST15-CTX-M-
15 K. pneumoniae were detected, one of which belonging to ST15b
cluster. CA and human ST15-CTX-M-15 K. pneumoniae shared
ﬁmH-mrkD-kfu-ycfM virulence proﬁle with few (n = 4) also har-
boring yersiniabactin. Additionally, 3GC-susceptible human K.
pneumoniae (unknown ST) also clustered with ST15a (n = 2) and
ST15b (n = 1). All CA/human ST15a and ST15b strains were ﬂuo-
roquinolone-resistant.
The hospital adapted ST11 K. pneumoniae clonal lineage was
detected in CA (n = 1) and humans (n = 1) showing the same
MDR AST proﬁle. On PFGE analysis, both ST11 were closely
related (SI = 81.1%) and shared several virulence (ﬁmH-mrkD-
kpn-ycfM-yersiniabactin) and resistance (DHA/aphAI-IA/aac(60)-
Ib/tet(A)/sul1) genes. CA ST11 strain also harbored CTX-M-15
and qnrB.
3GCr ST348 from CA (n = 1) and humans (n = 1) showed a
cluster SI = 86.7%. Although similar in PFGE analysis, the AST
varied between the strains with CA and human ST348 harboring
CMY-2 and CTX-M-15, respectively.
This study shows that CA and humans can become infected
with clonal related K. pneumoniae some of which belonging to
high-risk clonal lineages. These results reveal the potential zoono-
tic nature of K. pneumoniae UTIs in CA and therefore infection
control measures should be advised to owners to avoid the spread
of resistant and virulent K. pneumoniae.
Acknowledgements: With ﬁnancial support of CIISA and FCT
through Project UID/CVT/00276/2013. AB and CM hold FCT
PhD grants SFRH/BD/113142/2015 and SFRH/BD/77886/2011,
respectively.
Disclosures: Disclosures to report.
With ﬁnancial support of CIISA and FCT through Project
UID/CVT/00276/2013. AB and CM hold FCT PhD grants SFRH/
BD/113142/2015 and SFRH/BD/77886/2011, respectively.
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VALIDATION OF A QPCR PANEL TO AID IN THE DIAG-
NOSIS OF DERMATOPHYTOSIS. C. Leutenegger. Idexx Labo-
ratories, Inc., West Sacramento, USA
Dermatophytosis (ringworm) is a common cutaneous fungal infec-
tion in both cats and dogs. As many as 90% of cats with dermato-
phytosis are infected by Microsporum canis. This strain is highly
contagious and has zoonotic potential, but it is not life-threatening
and it is treatable and curable. Due to the highly contagious nat-
ure of this disease, an accurate and timely diagnosis of dermato-
phytosis is very important.
The laboratory diagnosis of dermatophytes routinely includes
direct microscopic evaluation of clinical specimens followed by cul-
ture on special media considered to be the gold standard. It is con-
sidered sensitive, is able to speciate, but requires 21 days of plate
observation to yield a negative result.
Real-time polymerase chain reaction (PCR), also called quanti-
tative PCR (qPCR) is an advanced molecular technology ideally
suited for the detection of infectious pathogens. qPCR tests were
developed targeting the ITS-1 gene sequences for genus speciﬁc
Trichophyton spp. and Microsporum spp. and a beta-actin speciﬁc
Microsporum canis assay. A clinical validation included 273 sam-
ples collected from 214 cats. 201 samples were collected from 195
exposed cats without lesions; 72 samples were collected from 19
cats with conﬁrmed dermatophytosis lesions. Culture was positive
in 17 lesion samples from 7 dermatophytosis conﬁrmed cats. PCR
was positive in 15 of those samples, as well as in an additional 7
positive lesion samples from a total of 8 cats. Culture was 87%
sensitive and 88% speciﬁc when compared to PCR on lesioned
samples. Cats without lesions but exposed to diseased cats were
also tested to determine if PCR is too sensitive by detecting fomite
carriers. PCR detected 7 positive samples from 4 exposed cats;
compared to 10 culture positives from 10 exposed cats. Of the 19
cats with lesions, 6 were monitored at regular intervals during sys-
temic and topical therapy. The average time to resolution was
47 days. The shortest duration to resolution was 23 days. It is
therefore recommended that PCR monitoring should start at
around 3 weeks of treatment. In summary, qPCR compared to
conventional culture showed excellent sensitivity in clinical cases
with lesions, did not pick up signiﬁcant false positive signals in
cats exposed to but not infected with Dermatophytes and can be
used to monitor therapy success. Paired with its speed to result,
the qPCR panel has excellent utility in the diagnosis of
Dermatophytosis.
Disclosures: Disclosures to report.
Author and coauthors are employees of Idexx Laboratories, Inc.
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PREDNISOLONE THERAPY FOR CHRONIC HEPATITIS IN
THE ENGLISH SPRINGER SPANIEL: A PROSPECTIVE
STUDY OF 14 CASES. W.A. Bayton1, A. Wilson2, H. Fieten3,
N.H. Bexﬁeld4, P.J. Watson1. 1University of Cambridge, Cam-
bridge, UK, 2Craig Robinson Vets, Carlisle, UK, 3University of
Utrecht, Utrecht, Netherlands, 4University of Nottingham, Lough-
borough, UK
English Springer Spaniels (ESS) in the UK show an increased
prevalence of chronic hepatitis (CH). As a viral etiology was ini-
tially suspected, historically these dogs were rarely treated with
corticosteroids. In a previous study of 68 ESS with CH, in which
only 3 dogs were treated with corticosteroids, a median survival
time of 189 days was noted [range: 1–1211 days]. CH in the ESS
shares similarities with human autoimmune hepatitis; it occurs
more commonly in young females and has a similar histological
appearance. Anecdotally some ESS with CH responded well to
prednisolone. This study aimed to investigate the clinical and bio-
chemical response following corticosteroid treatment.
ESS being treated in ﬁrst opinion and referral practice with a his-
tological diagnosis of idiopathic chronic hepatitis were enrolled
prospectively between 2009 and 2017. Attending veterinary sur-
geons were asked to give prednisolone 1–2 mg/kg/day and submit
regular blood results and progress reports to the authors. Ten
female and four male ESS were enrolled with a median age at diag-
nosis of 5 years 7 months [range: 11 months–10 years]. No cases
had been treated with corticosteroids within 6 months of the study.
The mean prednisolone starting dose was 1.1 mg/kg/day [range: 1–
2 mg/kg/day]. All cases received additional therapies including
combinations of S-adenosylmethionine, Silybin, Ursodeoxycholic
acid, and hepatic diet. The prednisolone dose was tapered appropri-
ately over several months according to the patient’s clinical and bio-
chemical response, focusing on alkaline phosphatase (ALKP),
alanine aminotransferase (ALT) and bilirubin.
All cases showed an improvement clinically, including resolution
of jaundice (4/4), vomiting (5/5) and polyuria/polydipsia (4/4).
Two out of the 14 cases were euthanized due to CH while receiv-
ing prednisolone, with survival times of 122 and 741 days from
diagnosis. The remaining 12 patients are alive and clinically well,
with 9 patients still receiving a mean dose of 0.4 mg/kg pred-
nisolone every other day (EOD) [range: 0.25 mg/kg/EOD-1 mg/
kg/day]. The median time since diagnosis is 630 days [range: 60–
1350 days]. Two-sided Wilcoxon test demonstrated signiﬁcant (P
< 0.05) reductions in serum ALKP, ALT and bilirubin following
prednisolone therapy. Median values before and immediately after
starting immunosuppressive doses of prednisolone were 810 to
403 iu/L, 1000 to 299 iu/L and 24.0 to 4.0 lmol/L for ALKP,
ALT and bilirubin respectively.
The results of this study demonstrate a markedly improved sur-
vival over a historical cohort when ESS with CH are managed
with immunosuppressive doses of prednisolone. Serial measure-
ments of ALKP, ALT and bilirubin are useful for monitoring the
patient’s progress.
Disclosures: No disclosures to report.
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CYCLOSPORINE IN THE TREATMENT OF CANINE
CHRONIC HEPATITIS. T. Ullal1, Y. Ambrosini2, C.R.L.
Leveille-Webster2, D.C. Twedt1. 1Colorado State University, Sara-
toga, USA, 2Tufts University, Grafton, USA
Chronic hepatitis (CH) is a common hepatic disorder in dogs.
Diagnostic criteria of canine CH include persistent ALT elevations
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>2 times normal and histopathologic features based on WSAVA
guidelines, characterized by moderate to severe chronic inﬂamma-
tion, hepatocellular apoptosis or necrosis, and ﬁbrosis. Most cases
are classiﬁed as idiopathic and therefore, optimal management for
CH has not been established. Corticosteroids are reported to pro-
long survival in some dogs, suggesting an immune-mediated mech-
anism to the disease. However, corticosteroids cause signiﬁcant
side eﬀects and induce a steroid hepatopathy that confounds inter-
pretation of liver enzymes during therapy. To date, there are no
studies investigating the use of alternative immunosuppressive
therapy, such as cyclosporine (Cys), in the management of canine
idiopathic CH.
The primary aim of this retrospective study was to evaluate the
safety and eﬃcacy of Cys in the treatment of idiopathic CH. A
secondary aim was to identify any factors inﬂuencing Cys treat-
ment response or time to remission. Remission was deﬁned as nor-
malization of serum ALT. Our hypotheses were that: (i) Cys
therapy would achieve remission and (ii) Lower pretreatment clini-
cal scores and higher serum ALT would predict prolonged times
to remission.
Forty-six dogs diagnosed with idiopathic CH and treated with
Cys met the inclusion criteria. Cases were excluded if there was a
lack of biochemical data, concurrent immunosuppressive therapy,
failure to complete at least 2 weeks of Cys therapy, or evidence of
biochemical improvement with penicillamine or antibiotic adminis-
tration. Twenty-ﬁve diﬀerent breeds were represented. Ages ranged
from 0.7–14 years with a median of 8 years. Fifty-two percent
were female spayed and 43% were male castrated. Treatment side-
eﬀects included gastrointestinal signs ranging from mild inappe-
tence to vomiting and diarrhea in 39% and gingival hyperplasia in
26%. Thirty-ﬁve dogs (76%) achieved remission based on ALT
normalization. The median time to remission was 3 months. Three
dogs (6.5%) reached partial remission (ALT values declined but
remained between 1.1 and 2x the upper limit of normal). Eight
cases (17%) did not achieve remission. Initial serum ALT activity,
hepatic copper concentration (>1000 µg/g dry weight), and clinical
score did not inﬂuence remission.
Cys proved to be eﬀective in achieving remission based on nor-
malization of serum ALT in canine idiopathic CH. Limitations
include the retrospective nature of the study, concurrent therapies
given, variability of long-term follow-up, and the lack of post
treatment biopsies.
Disclosures: No disclosures to report.
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INVESTIGATION INTO HEPATOCYTE EXPRESSION AND
PROGNOSTIC SIGNIFICANCE OF SENESCENCE MARKER
P21 IN CANINE CHRONIC HEPATITIS. A.J. Kortum, E.A.
Cloup, F. Constantino-Casas, P.J. Watson. University of Cam-
bridge, Cambridge, UK
Canine chronic hepatitis (CCH) is characterized histologically by
hepatocellular apoptosis or necrosis, a variable mononuclear or
mixed inﬂammatory inﬁltrate, regeneration and ﬁbrosis. Life-
expectancy following diagnosis is unpredictable, ranging from days
to years. Reported prognostic indicators (hyperbilirubinemia,
hypoalbuminemia and presence of ascites or cirrhosis) are unreli-
able, particularly in end-stage disease. Hepatocyte expression of
p21, a universal cell-cycle inhibitor and marker of cellular senes-
cence, is strongly negatively correlated with outcome in humans
with alcoholic and non-alcoholic related liver disease and is a bet-
ter prognostic marker than histological or clinical scoring systems.
P21 expression has not been investigated in CCH.
This study investigated whether hepatocyte p21 expression is
increased in CCH and if expression is associated with survival.
Cases of CCH were retrieved from the pathology database (2004–
2016) and liver biopsy samples were reviewed using routine stains
(hematoxylin & eosin, rhodanine, and Sirius red). Immunohisto-
chemistry was performed using monoclonal mouse anti-human
p21 on all selected cases and four control liver samples with nor-
mal histology and no history of liver disease. P21 expression was
manually quantiﬁed by scoring p21-positive and p21-negative hep-
atocytes in eight high-power ﬁelds for each case by two blinded
observers and expressed as a percentage of total hepatocyte num-
ber. Kendall’s Tau correlation coeﬃcients were used to assess
relationships between p21 expression and survival time or age; sig-
niﬁcance was set at P < 0.05 (2 tailed).
Twenty two dogs with CCH were selected. There was a signiﬁ-
cant negative correlation between hepatocellular p21 expression
(median 83.17%; range 15.30–99.40) and survival (460 days; range
12–1559), but no correlation between p21 expression and age (me-
dian 7.3 years; range 2.0–12.0). Inclusion or exclusion of cases
with copper-associated disease gave similar results. Three of four
control samples from young dogs ( < 6.5 years) displayed negligi-
ble p21 expression as expected (<10%). The fourth control sample
from a 16.5-year-old dog had a high percentage of p21-positive
hepatocytes (85%).
This study demonstrates that p21 expression in normal dogs
increases with age as expected but is upregulated in CCH, indicat-
ing a state of cellular senescence irrespective of age. The median
percentage of senescent hepatocytes in CCH was higher than in
human hepatitis. These cells are indistinguishable from normal
hepatocytes using routine stains but are unable to perform normal
hepatic functions. p21 quantiﬁcation in CCH may therefore pro-
vide additional information regarding hepatic function. Further-
more, a negative correlation between p21 expression and survival
was identiﬁed, suggesting a role for p21 quantiﬁcation in determin-
ing prognosis in CCH.
Disclosures: No disclosures to report.
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CHRONIC PORTAL VEIN THROMBOSIS IN ELEVEN
DOGS. K. Sato, M. Sakai, Y. Sakamoto, C. Ishikawa, T. Watari.
Nihon University, Fujisawa Kanagawa, Japan
Portal vein thrombosis (PVT) causes partial or total obstruction of
portal blood ﬂow, leading to pre-hepatic portal hypertension.
Canine PVT is considered a rare entity and is classiﬁed into two
categories, acute and chronic, based on the presenting clinical con-
ditions. Diagnosis of canine PVT is generally performed using
abdominal ultrasound. However, ultrasound is operator depen-
dent. In humans, computed tomography (CT) angiography is pre-
ferred for the diagnosis and extensive evaluation of PVT.
We retrospectively reviewed veterinary clinical data from 2008
through 2017, and included cases that were diagnosed as PVT
using CT angiography. Chronic PVT was classiﬁed as PVT with
the absence of abdominal pain or shock. Variables including sig-
nalment, clinical signs, clinicopathological data, diagnostic imaging
ﬁndings, treatment, and outcome were collected.
Eleven dogs were included in this study (seven male, four
female). The median age and body weight were 11 years and
9.7 kg, respectively. Ten dogs had concurrent conditions, with
pancreatitis (n = 6) as the most frequent one. Glucocorticoids were
administered prior to the diagnosis of PVT in six dogs, and ascites
was conﬁrmed in four dogs. Clinicopathological analysis revealed
elevation of liver enzyme levels in eight dogs, hypoalbuminemia in
nine, and thrombocytopenia in four. Serum D-dimer concentration
was measured in ten dogs, with elevated values observed in all ten.
Abdominal ultrasonography revealed PVT in eight dogs, but the
diagnosis was missed in three. CT scan revealed PVT of the main
portal vein in ten dogs. For those dogs for which we obtained fol-
low-up data, two were re-examined using CT angiography. A
reduction in size or organizing thrombi were conﬁrmed in both.
In our study population, pancreatitis and the administration of
glucocorticoids were found to be closely associated with chronic
PVT. Although we succeeded in diagnosing PVT by ultrasonogra-
phy in the majority of the dogs, this technique failed to provide a
correct diagnosis in three. Thus, in cases where PVT is suspected
based on laboratory test results and is undetected on an abdomi-
nal ultrasound scan, CT angiography would provide an alternative
option for detailed diagnosis and follow-up.
Disclosures: No disclosures to report.
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BREED PREDISPOSITION TO GALL BLADDER MUCO-
COELES IN BORDER TERRIERS. F. Allerton1, F. Swin-
bourne1, M. Dunning2, A. Kent1. 1Willows Veterinary Referrals,
Shirley, UK, 2School of Veterinary Medicine and Science, Univer-
sity of Nottingham, UK
Gall bladder mucocoeles (GBM) are a leading cause of biliary dis-
ease in the dog. Predisposed breeds include Shetland Sheepdogs,
Cocker Spaniels, Chihuahuas and Miniature Schnauzers. Border
Terriers (BT) have not previously been described as being predis-
posed, which may reﬂect geographic diﬀerences in popularity.
A high incidence of GBM was noted in BTs in our hospital sug-
gesting a breed predisposition. Retrospective evaluation of the
medical records between January 2010 and April 2017 was per-
formed to identify all dogs with an ultrasonographic diagnosis of
GBM; 27965 dogs >2 years of age were seen over the study period.
Of these 382 (1.4%) were BTs. Thirty-seven dogs (18 BTs and 19
non-BTs including 2 Labrador retrievers, 2 Aﬀenpinschers, 2 Shet-
land sheepdogs, 2 Miniature Schnauzers and 11 other individual
breeds) were diagnosed with a GBM based on ultrasound alone
(9) or ultrasound with histopathologic conﬁrmation (28).
Odds ratio (OR) calculation was performed to evaluate predis-
position. BTs with GBM were compared to non-BTs with GBM
with respect to signalment (age, sex, neuter status), hematologic
and biochemical measures and outcome data.
The OR for BTs to present with a GBM was 72 (95% conﬁ-
dence interval 37–138). There was no signiﬁcant diﬀerence in gen-
der or neuter status between BTs with GBM and the wider
hospital population. Of the dogs with GBM, BTs were signiﬁ-
cantly older than non-BTs (median 10y10 m (range 5y11 m to
13y11 m) vs. 8y9 m (range 4y3 m to 13y) (P = 0.032)). There was
no signiﬁcant diﬀerence in hematologic or biochemical parameters
between BTs and non-BTs.
6/19 of the non-BTs and 3/18 of the BTs were managed without
surgery. 2 BTs and 5 non-BTs had one or two (2 non-BTs) con-
comitant endocrinopathies (diabetes mellitus, hypothyroidism,
hyperadrenocorticism) at presentation; post-cholecystectomy 2 BTs
were diagnosed with one endocrinopathy and 1 BT with diabetes
mellitus and hyperadrenocorticism. Median survival times could
not be calculated for either of the groups (<50% mortality). There
was no signiﬁcant diﬀerence in survival rate between groups with
11/19 non-BTs and 11/18 BTs still alive at time of writing.
On the basis of this single-centre study, BTs may have a breed
predisposition to GBM. It would be interesting to see if this data
is replicated in other European hospitals. Further study of BTs is
warranted to identify factors inﬂuencing this predisposition and
possible preventative measures.
Disclosures: No disclosures to report.
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OUTCOME OF CATS UNDERGOING SURGICAL ATTENUA-
TION OF CONGENITAL EXTRAHEPATIC PORTOSYS-
TEMIC SHUNTS THROUGH CELLOPHANE BANDING: 23
CASES. P. Valiente, B. de la Puerta, M. Trehy. North Downs
Specialist Referrals, Redhill, UK
Aim: To retrospectively evaluate attenuation of congenital
extrahepatic portosystemic shunts (CEHPSS) in cats by means of
cellophane banding (CB). To report post-operative complications
and long term outcome. (clinical response and results of serial bile
acid stimulation tests (BAST)).
Methods: Retrospective study. Medical records (from July 2008
through February 2017) of cats with CEHPSs were reviewed.
Diagnosis of CEHPSs was made by diagnostic imaging and con-
ﬁrmed during coeliotomy. Cats treated with CB that had BAST
performed pre- and post-operatively were included.
Results: Twenty- three cats were included. The study population
comprised 8 diﬀerent breeds with a median age of 8 months (4 to
33) and median body weight of 2.5 kg (1.45 to 4.7). Eleven cats
were female (5 entire, 6 spayed) and 12 cats were male (6 entire, 6
neutered).
Common clinical ﬁndings included: abnormal behavior (20/23),
ptyalism (16/23), ataxia (12/23), stunted growth (12/23) copper col-
ored irides (10/23), inappetence (10/23), depression (9/23) and
seizures (4/23). Post-meal BAST before surgery was abnormal in
all cats. Only two cats had normal fasting bile acids.
All cats received medical treatment before and after surgery.
Treatment included: lactulose (23/23); clavulanate/amoxicillin (19/
23), ampicillin (4/23) or metronidazole (2/23); levetiracetam (6/23)
phenobarbitone (2/23). Protein restricted diet was prescribed in 18/
23 cats. Median duration of medical treatment was 21 days (8 to
209) prior to surgery and 62 days (range from 14 to 2046) after
surgery.
In most cases CEHPSs were detected by ultrasound. One cat
had computed-tomography angiography. Portovenography was
performed in 9/23 cats.
BAST was performed following CB after a median of 84 days
(14 to 280 days). BAST normalized in 20/23 cats and 3/23 cats
had persistently increased results. Two of them developed multiple
acquired portosystemic shunts (one remained free of clinical signs
until 6 years later, and the other was euthanized due to seizures).
Complete closure of a patent shunt was achieved with a second
surgery in the remaining cat with abnormal BAST.
Nineteen cats were alive and free of signs at last follow-up at
least 8 months after surgery (3 to 66 months) Three cats developed
post-operative seizures. Treatment with anticonvulsants resulted in
complete or partial resolution of seizures in two cats. One cat was
euthanized due to uncontrollable seizures.
Conclusion: CEHPSs occlusion by CB in cats carries a very
good short and long-term prognosis.
Disclosures: No disclosures to report.
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TRANSCUTANEOUS FLUOROMETRIC MEASUREMENT
OF INDOCYANINE GREEN CLEARANCE AS DYNAMIC
LIVER FUNCTION TEST IN DOGS WITH CONGENITAL
PORTOSYSTEMIC SHUNT. L. Hausmann1, N. Gretz2, M. Sch-
neider1, R. Neiger3. 1Small Animal Clinic, University of Giessen,
Giessen, Germany, 2Medical Research Center, University of Hei-
delberg, Mannheim, Germany, 3Tierklinik Hofheim, Hofheim,
Germany
Indocyanine green (ICG), a ﬂuorescent dye, is solely excreted by
the liver without enterohepatic re-circulation. We have recently
shown the feasibility of a noninvasive transcutaneous ICG clear-
ance to assess hepatic function instantaneously.
In this follow-up study 10 dogs with congenital extrahepatic
single portosystemic shunt (PSS) were included. Before and
3 months after surgical closure with cellophane banding or silk
ligature a ICG clearance study was both done transcutaneously
and ﬂuorometrically by taking serial blood samples 0, 1, 3, 6, 9,
18, 42 and 64 min after iv injection of 0.2 mg/kg ICG. Transcu-
taneous ICG clearance was measured using two miniaturized
devices to detect ICG ﬂuorescence with an excitation wave length
of 760 nm and an emission wave length of 820 nm. For both
methods, half life time (HLTSe, HLTtc), plasma disappearance
rate (PDRSe, PDRtc) and 15 min retention rate (R15Se, R15tc)
were calculated based on the curve within minutes 1 to 15 after
ICG injection. PSS closure was deﬁned based on Doppler sonog-
raphy and angiography.
In 6/10 dogs, the shunt vessel was closed after 3 months. In 3/
10 dogs, the PSS was still partially open. One dog died after the
operation. Transcutaneous ICG clearance was easily performed
without complications and was well tolerated by all dogs. There
was a signiﬁcant diﬀerence between open and closed PSS for PDR
(PDRSe: P = 0.0095; PDRtc: P < 0.0001) and R15 (R15Se:
P = 0.0323; R15tc P < 0.0001) but not for HLT. Linear correlation
coeﬃcient between PDRSe / PDRtc, R15Se / R15tk and HWZSe /
HWZtk were R
2 = 0.6169, R2 = 0.4629 and R2 = 0.08629 respec-
tively. In contrast to the invasive method there was no overlap
except one dog of PDRtc and R15tc of open and closed PSS.
In this ﬁrst transcutaneous ICG clearance study of dogs with
liver disease, transcutaneous assessment was superior to the inva-
sive method and results are available immediately. The very lim-
ited invasiveness of this method and its dynamic character make
the transcutaneous liver function test with ICG clearance a worthy
test for veterinary medicine.
Disclosures: One author (N. Gretz) is owner or a patent using
transcutaneous measuring devices.
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EFFICACY OF TELMISARTAN IN HYPERTENSIVE CATS:
RESULTS OF A LARGE EUROPEAN CLINICAL TRIAL.
A.M. Glaus1, J. Elliott2, B. Albrecht3. 1University of Zurich, Zur-
ich, Switzerland, 2Department of Comparative Biomedical
Sciences, Royal Veterinary College, Univers, London, UK, 3Boeh-
ringer Ingelheim Vetmedica GmbH, Ingelheim, Germany
Hypertension (HT) and the associated risk of target organ damage
(TOD) is a well-recognized cardiovascular problem of elderly cats.
Consequently, early recognition and treatment of HT are crucial.
This prospective, multicentre, placebo controlled, blinded study
evaluated telmisartan in hypertensive cats diagnosed with systolic
blood pressure (SBP) ≥160 mmHg on two days. HT causes were
classiﬁed as chronic kidney disease (CKD), controlled hyperthy-
roidism, both combined and idiopathic. Cats with SBP>200 mmHg,
evidence of TOD or pre-treated with vasoactive substances were
excluded. Cats were randomized (2:1 ratio) to either receive 2 mg/
kg telmisartan oral solution, or placebo q24 h. The study consisted
of a 28 day eﬃcacy phase and a 120 day extended use phase. Eﬃ-
cacy of telmisartan was deﬁned a priori as signiﬁcant mean SBP-
reduction on day 14 compared to placebo and >20 mmHg SBP pop-
ulation mean reduction on day 28 compared to baseline. Pre-deﬁned
post inclusion removal criteria were adverse events, withdrawal of
owner consent, owner non-compliance, TOD and SBP>200 mmHg.
Missing SBP data were imputed in the database using the last obser-
vation carried forward method, if removal reasons had been TOD
or SBP>200 mmHg. Data are presented as mean  1SD.
The eﬃcacy population included 174 telmisartan and 88 placebo
cats. Age, body weight, breed distribution, HT causes, and base-
line SBP were similar in both groups (baseline SBP: telmisartan-
group: 179 (  9.9) mmHg; placebo-group: 177 (  10.1) mmHg).
Telmisartan treatment gave rise to a signiﬁcantly larger reduction
in mean SBP (relative to baseline) when compared to placebo on
day 14 (19  22.0 mmHg, n = 174 vs 9  17.7 mmHg, n = 88;
P < 0.0001). At day 28, the data from 9 and 1 cats were excluded
and that of two and two cats were imputed giving reduction in
SBP relative to baseline of 25  22.8 mmHg, (n = 165) and
11  16.4 mmHg, (n = 87) for the telmisartan and placebo
groups respectively. The proportion of cats with SBP reduction
>20 mmHg between baseline and day 28 was 27.6% in the placebo
group and 54.6% in the telmisartan group. The mean SBP
decrease in the telmisartan group on day 120 was
28  26.9 mmHg relative to baseline (n = 144). Adverse events
were evenly distributed in both groups during the eﬃcacy phase
and were as would be expected for elderly cats suﬀering from
CKD and other diseases of aging in the extended use phase.
In conclusion, telmisartan oral solution was safe and signiﬁ-
cantly reduced SBP by a clinically relevant magnitude in hyperten-
sive cats for the four-month study period.
Disclosures: Disclosures to report.
Study planned, organized and ﬁnanced by Boehringer Ingel-
heim.
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FACTORS AFFECTING GASTRIC MUCOSAL BARRIER
FUNCTION IN DOGS. T.L. Hill1, D. Lascelles2, M. Law2, I.
Handel3, A.T. Blikslager2. 1University of Georgia, Athens, USA,
2North Carolina State University, Raleigh, USA, 3University of
Edinburgh, Edinburgh, UK
Gastroduodenal ulceration is a recognized complication of NSAID
or corticosteroid therapy, liver disease, sepsis, and neoplasia. Ret-
rospective studies indicate that male, middle-aged and large breed
dogs are most commonly aﬀected. Rottweilers were aﬀected at
younger ages. Helicobacter has been associated with chronic gas-
tritis; its eﬀect on gastric mucosal barrier function (GMBF) is
unknown. Previous Using chamber ex vivo injury models have
examined changes in GMBF that relate to ulcer injury in vivo.
Identiﬁcation of factors associated with GMBF, as measured by
transepithelial electrical resistance (TER), could identify risk fac-
tors for gastroduodenal ulceration in vivo. In this prospective
study, TER was measured in control and acid-injured canine tissue
to determine factors associated with changes in GMBF. These
included: age, sex, neuter status, breed (large/small), and presence/
degree of Helicobacter infection.
Canine gastric mucosa was collected immediately post-mortem
from random-source dogs scheduled for euthanasia by an animal
control facility. Acidic Ringer’s solution (pH 1.2) was applied to
the mucosa for 45-min. Tissue from each dog was also maintained
at neutral pH Ringer’s solution as control. GMBF was assessed
using TER. Age, gender, neuter status, breed (large vs. small
breed) and presence/degree of Helicobacter infection were corre-
lated with baseline TER, change in control TER over time, change
in TER with acid injury, and recovery of TER after acid injury.
T-tests or Mann-Whitney Rank Sum tests were used to compare
gender, neuter status, breed (large vs. small) and presence of Heli-
cobacter with TER based on normality. Helicobacter infection was
correlated with TER using Spearman rank correlation. Age was
compared to TER using linear regression. Multiple linear regres-
sion identiﬁed predictive factors. Signiﬁcance was set at P < 0.05.
Female dogs and neutered dogs had a higher baseline TER
(P = 0.025, 0.028). Higher age was associated with decreased
recovery from acid injury (P = 0.011). Helicobacter and breed size
were not associated with changes in TER. Sex and neuter status
were predictive of baseline TER; age was predictive of recovery
from acid injury.
This study demonstrated factors associated with decreased
GMBF either at baseline or with injury. Elevated baseline TER in
female dogs may support previously reported male sex predilec-
tion. Because most of the dogs in the current study were young to
middle-aged, decreased recovery of injured mucosa may support
previous ﬁndings of predilection for middle-aged dogs to develop
ulcers. Further work is needed to determine if these factors are rel-
evant in vivo and to determine overall prevalence of disease.
Disclosures: No disclosures to report.
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EVALUATION OF THE HEMOCCULT FECAL OCCULT
BLOOD TEST KIT IN CATS. J.E. Slovak, K. Spies, N. Villarino.
Washington State University College of Veterinary Medicine, Pull-
man, USA
Fecal occult blood (FOB) testing provides a quick and easy way to
screen patients for gastrointestinal bleeding. The sensitivity of the
Hemoccult FOB test kit has been recently evaluated for use in cats
fed canine packed red blood cells. However, the development time
for test interpretation and the limit of detection of fresh whole blood
in a given stool sample has not yet been reported. Our goal was to
determine the limit of detection of whole blood in a feline stool sam-
ple, as well as determine the most accurate time to assess the FOB
sample utilizing the Hemoccult testing kit in a population of cats.
Stool from recently dewormed, healthy, indoor cats were
enrolled in the study. Two grams of stool from 3 separate cats that
tested negative on the Hemoccult FOB test were utilized as sam-
ple controls. Incremental quantities of EDTA whole blood (1–
200 µL) were added to the 6 gram pooled stool controls. The stool
samples were set up in triplicate and interpreted for each of the
following time points; fresh, 24, 48, and 72 h. The lowest repeat-
able and reliable quantity of blood detected in the stool at all time
points was 50 µl of blood. However, as little as 2 µl of blood was
detected in all control samples at fresh, and 24 h.
A minimum of 6 grams or 0.2 ozs of stool should be collected
to detect 50 µl of blood in a stool sample. Additionally, results are
repeatable when FOB tests are interpreted as fresh, 24, 48, and
72 h post set-up. FOB testing is a fast non-invasive diagnostic tool
to screen for low levels of blood in the stool of cats.
Disclosures: No disclosures to report.
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FECAL OCCULT BLOOD TESTING IN A PRESUMED
HEALTHY POPULATION OF CATS. J.E. Slovak, K. Spies, N.
Villarino. Washington State University College of Veterinary Med-
icine, Pullman, USA
Fecal Occult Blood (FOB) testing, can be a useful screening test
for cats. Unfortunately, there is limited information on using
human point of care tests in our feline patients. There are no
recent published reports of clinical FOB tests used as surveillance
for disease in a population of cats.
Our goal was to perform FOB testing using the human point of
care test Hemoccult, on healthy cats to screen for potential sub-
clinical disease. Fresh stool samples were collected from the litter-
box within 12 h of defecation for sample testing at three separate
time points. All cats were presumably healthy, recently dewormed,
and individually housed, ranging in age from 6 weeks to 5 years.
A total of 30 stool samples from 18 cats were analyzed.
The stool from each cat at each time point was tested in triplicate
using the Hemoccult FOB test kit. Test interpretation was per-
formed as fresh, 24, 48, and 72 h after the FOB test was set-up. Nine
stool samples were positive (30%) when tests were interpreted as
fresh. Only 4 or (13%) of samples remained positive at subsequent
test interpretation at 24, 48, and 72 h. The fresh positive stools were
from 6 diﬀerent cats. The subsequent positive stools were from 2 dif-
ferent cats, one of which was later diagnosed with ulcerative stom-
atitis and the other, a kitten, with signiﬁcant parasitism.
When used as a screening test, the Hemoccult FOB test
detected a positive result in 30% of the studied patient population
when interpreted as a fresh sample. However, when the test was
interpreted at 24, 48, and 72 h post set up, the positive results
were only 13% of the patient population. The FOB test is a useful
screening test in cats. Repeated testing is recommended to diﬀeren-
tiate transient from active bleeding.
Disclosures: No disclosures to report.
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SPECIFICITY OF SNAP FPLTM FOR THE DIAGNOSIS OF
PANCREATITIS IN HEALTHY CATS AND SICK CATS
WITHOUT CLINICAL SUSPICION OF PANCREATITIS. P.G.
Xenoulis, M.K. Chatzis, K. Kokkinaki, E.M. Stavroulaki, M.N.
Saridomichelakis. University of Thessaly, Karditsa, Greece
Clinical diagnosis of pancreatitis in cats is challenging. Clinical
signs are non-speciﬁc, and most available serum tests, including
serum amylase and lipase activities and feline trypsin-like
immunoreactivity (fTLI) lack speciﬁcity and/or sensitivity in this
species. Serum speciﬁc feline pancreatic lipase (Spec fPL) is cur-
rently the most useful serum test for pancreatitis in cats. Based on
this test, a rapid, in-clinic, semi-quantitative test for the estimation
of fPL (SNAP fPLTM) in serum has been developed. Currently, no
studies have evaluated the sensitivity and speciﬁcity of this tool for
pancreatitis in cats. The aim of this study was to evaluate the
speciﬁcity of SNAP fPL in two groups of cats: a) healthy cats and
b) sick cats without clinical suspicion of pancreatitis.
A total of 196 cats were included in the study. Of them, 105 were
clinically healthy (based on history and physical examination) and 91
cats were sick. The group of sick cats consisted of cats with a wide
variety of diseases, for which pancreatitis was not considered a major
diﬀerential or for which a ﬁnal diagnosis other than pancreatitis that
would explain the clinical signs was available. Whole blood was col-
lected from all cats, and serum was separated and stored until analy-
sis. The SNAP fPL test was performed and interpreted according to
the manufacturer’s instructions. Speciﬁcity was calculated for each
group of cats separately and for both groups combined.
A total of 8 of the 196 cats (4.1%) were found to have an abnor-
mal SNAP fPL result. All 8 cats belonged to the group of sick cats.
The speciﬁcity of SNAP fPL was 100% and 91.2% among healthy
and sick cats, respectively, with an overall speciﬁcity of 95.9%.
The SNAP fPL test has a high speciﬁcity for pancreatitis in
both healthy cats and sick cats without clinical suspicion of pan-
creatitis. An abnormal SNAP fPL result is not always indicative
of pancreatitis and should be followed by quantitative analysis. In
addition, due to the lack of histopathologic examination of the
pancreas, subclinical pancreatic inﬂammation cannot be excluded
in any of the 8 cats with abnormal SNAP fPL results. Further
studies are needed to evaluate the speciﬁcity of this diagnostic tool
in cats with clinical signs compatible with pancreatitis but no
histopathologic evidence of pancreatitis.
Disclosures: Disclosures to report.
(i) Dr. Xenoulis has presented lectures sponsored by Idexx Lab-
oratories in the past (ii) The SNAP fPL tests were provided by
Idexx but had no involvement in the designing of the study or the
interpretation of the results.
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METABOLIC AND CLINICAL FOLLOW-UP OF SEVEN
INAPPETENT CATS DURING ENTERAL REFEEDING. C.
Fuchs, B. Rannou, M. Hugonnard. VETAGRO SUP - Campus
Veterinaire de Lyon, Marcy L’etoile, France
Refeeding after starvation can lead to a range of ﬂuid, electrolyte
and hematologic shifts associated with metabolic abnormalities
that is called “refeeding syndrome” in humans. Refeeding syn-
drome is not well documented in cats.
A prospective study was conducted on ill cats hospitalized in an
internal medicine service who had inadequate food intake for more
than three days and were refed with enteral feeding. The objective
was to follow clinical and biological parameters known to be mod-
iﬁed in refeeding syndrome during the ﬁrst ﬁve days of enteral
refeeding. An initial nutritional assessment was done for each cat.
Sodium, phosphorus, potassium, ionized calcium, magnesium, glu-
cose, insulin, albumin, hematocrit, creatine kinase, cardiac tro-
ponin I and serum amyloid A were evaluated at the time of
feeding tube placement, and then after three and ﬁve days of
refeeding. Physiological parameters were recorded twice a day. A
daily weight was done. A nutritional plan based on the nutritional
assessment was implemented for each cat.
From February 2015 to December 2015, 16 cats were recruited.
Seven cats completed the study (stress precluded adequate blood
sampling in six cats, one cat removed the feeding tube before day 5,
two cats died). The seven cats were 9.3  3.8 years old. Six cats
were anorectic from three to seven days, one cat was dysorexic for
three months. Two cats with an hepatic lipidosis were considered at
risk to develop a refeeding syndrome. One of them with a three-
month history of dysorexia, icterus and marked emaciation at
admission developed at day 3 of refeeding severe electrolyte shifts
(marked hypokalemia and hypomagnesemia, moderate hypophos-
phatemia), aggravation of anemia, acute elevation of creatine kinase
activity and bilirubinemia concomitantly with respiratory distress,
vomiting, muscle weakness and hypotension. He was strongly sus-
pected of refeeding syndrome. None of the six other cats developed
clinical signs or remarkable biological abnormalities potentially
linked with refeeding. Glycemia and insulinemia were consistently
higher on day 3 and 5 than on day 0 on all cats. Mild to moderate
hypophosphatemia was documented in 4/6 cats, mild hypokalemia
in 2/6 cats and mild hypomagnesemia in 1/6 cats.
In this pilot study, signiﬁcant combined biological abnormalities
suspected to be linked with refeeding were observed in 1/7 cats. A
careful nutritional plan and an adequate electrolyte supplementa-
tion are critical to avoid refeeding complications. Strongly debili-
tated cats could be at risk to develop complications despite
adequate precautions.
Disclosures: No disclosures to report.
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S100A12 AND MYELOPEROXIDASE AS POSSIBLE
BIOMARKERS FOR INTESTINAL INFLAMMATION IN
DOGS. M. Hanifeh1,2, S. Sankari1, M.M. Rajam€aki1, P. Syrj€a1, S.
Kilpinen1, J.S. Suchodolski3, P. Guadiano3, J. Lidbury3, J.M. Stei-
ner3, T. Spillmann1. 1University of Helsinki, Helsinki, Finland,
2University of Tabriz, Tabriz, Iran, 3Gastrointestinal Laboratory,
Texas A&M University, College Station, USA
S100A12 and myeloperoxidase (MPO) are considered inﬂamma-
tory markers of chronic enteropathy (CE) and mainly originate
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from granulocytes. Increased concentrations of canine S100A12
(cA12) in feces and serum were found in dogs with CE. Intestinal
mucosal MPO activities have been reported to be increased in
humans with inﬂammatory bowel disease (IBD) and also in animal
models of human IBD. However, intestinal mucosal cA12 and
MPO have not been investigated in dogs with CE.
We evaluated the levels of mucosal cA12 and MPO in dogs with
CE in comparison with healthy dogs using an enzyme-linked
immunoassay and a spectrophotometric method, respectively. Addi-
tionally, we assessed the association of mucosal cA12 and MPO
levels with the canine clinical IBD activity index (CIBDAI),
histopathologic ﬁndings, clinical outcome, and serum albumin con-
centration. Intestinal mucosal biopsies were collected from 40 dogs
with CE (duodenum [n = 35], ileum [n = 12], colon [n = 15], and
cecum [n = 6]). Historical intestinal tissue samples from 18 healthy
beagle dogs served as controls (duodenum, ileum, and colon [n = 18,
each] and cecum [n = 6]). Data are presented as medians (interquar-
tile range).
In comparison to healthy controls, mucosal cA12 concentra-
tions in CE-dogs were higher in duodenum (43.93 [23.62–78.03] vs.
11.86 [7.66–29.1] µg/L; P < 0.0001) and colon (63.04 [33.53–211.53
vs. 15.94 [6.95–59.3] µg/L; P < 0.001] µg/L). Mucosal MPO activi-
ties of CE-dogs were higher than in control dogs in duodenum
(1.3 [0.77–2.16] vs. 0.41 [0.11–0.64] DA/min; P < 0.0001), ileum
(1.91 [0.72–2.83] vs. 0.75 [0.21–1.27] DA/min; P < 0.01), colon
(1.46 [0.57–3.01 vs. 0.09 [0.03–0.17] DA/min; P < 0.0001] DA/min),
and cecum (0.68 [0.3–1.55] vs. 0.19 [0.08–0.4] DA/min; P < 0.05).
Mucosal cA12 concentrations showed a signiﬁcant association
(P < 0.05) with severity of macrophage inﬁltration in the duode-
num and total histopathologic injury and epithelial injury in the
colon. Mucosal MPO activities showed a signiﬁcant association
(P < 0.05) with severity of total histopathologic injury, epithelial
injury, and eosinophil inﬁltration in the duodenum. Duodenal
cA12 concentrations showed a strong negative correlation with
serum albumin concentration (rs = €E-0.449; P = 0.007). There was
no signiﬁcant association between mucosal cA12 and MPO levels
with CIBDAI or clinical outcome.
This study showed that both mucosal cA12 concentrations and
MPO activities are increased in the duodenum and colon of dogs
with CE, with mucosal MPO being also increased in the ileum and
cecum. The results provide supporting evidence for the possible
diagnostic value of cA12 and MPO for dogs with CE.
Disclosures: No disclosures to report.
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FASTING AND POSTPRANDIAL VARIATIONS OF PLASMA
TLI, COBALAMIN AND FOLATE CONCENTRATION IN
HEALTHY BEAGLE DOGS. F. Jolivet1, B. Rannou2, J. Dahan1,
D. Concordet3, O. Dossin1. 1Ecole Veterinaire, Toulouse, France,
2Laboratoire de Biologie Medicale, VetAgro Sup, University of
Lyon, Lyon, France, 3INRA, ENVT, UPS, TOXALIM, Universite
de Toulouse, Toulouse, France
Trypsin-like immunoreactivity (TLI), cobalamin and folate are fre-
quently measured in canine gastrointestinal disorders. However the
eﬀects of preanalytical conditions on canine TLI, cobalamin and
folate have not been clearly documented. This study evaluated the
circadian variations of canine TLI, cobalamin, and folate concen-
trations in fasted and postprandial conditions.
Plasma TLI, cobalamin, and folate concentrations were mea-
sured after 12 h of fast (Time 0), every 2 h for 12 h and at 24 h in
8 healthy dogs. The same protocol was repeated after feeding after
T0 samples. TLI, cobalamin and folate were measured by
immunoassays validated in dogs (Siemens). Changes of TLI,
cobalamin and folate were evaluated with a generalized linear
model and Dunnett post-hoc test.
Mean  SD circadian TLI concentrations in fasted dogs varied
between 13.6  4.3 and 21.3  7.7 ng/mL and were signiﬁcantly
lower than T0 (P < 0.01) at 2, 4, 6, 10, and 12 h. In contrast TLI
concentrations were not aﬀected by feeding. Folate concentrations
had no circadian variation in fasted dogs but were above the
upper limit of quantiﬁcation (24 ng/mL) in most time points after
feeding. Mean fasted circadian cobalamin concentrations varied
between 466  134 and 559  170 pmol/mL and were signiﬁcantly
diﬀerent from T0 at 6, 8, 10, 12, and 24 h (P < 0.01). At 4, 6, 8,
10, and 12 h post-feeding, cobalamin concentrations were signiﬁ-
cantly lower than at T0 (P < 0.01).
Plasma TLI and cobalamin concentrations have signiﬁcant cir-
cadian variations in fasted dogs. Plasma cobalamin is signiﬁcantly
decreased for 12 h after feeding but plasma TLI remains
unchanged.
Disclosures: Disclosures to report.
Benoit Rannou is an employee of the Laboratoire de Biologie
Medicale, VetAgro Sup, University of Lyon, France where the
sample TLI, cobalamin and folates measurements were performed.
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TOTAL SERUM MAGNESIUM AND COBALAMIN CONCEN-
TRATION IN 20 CATS WITH INFLAMMATORY SMALL
BOWEL DISEASE OR SMALL INTESTINAL NEOPLASIA.
O.M. Ioannidi, F.C. Fragkou, A.O. Konstantinidis, D. Pardali,
T.S. Rallis. Aristotle University of Thessaloniki, Thessaloniki,
Greece
Magnesium is the second most abundant intracellular cation. Mag-
nesium concentration is predominantly regulated by ileum absorp-
tion and renal excretion. In human medicine hypomagnesemia
may accompany inﬂammatory small bowel disease (IBD), aﬀecting
treatment and prognosis. The aim of this study was to evaluate
total serum magnesium (tMg) and cobalamin (CBL) concentra-
tions in cats with IBD and small intestinal neoplasia (IN) and to
reveal possible correlations.
Thirty-two client owned cats were included in this study. Twelve
clinically healthy cats had comprised the control group, 13 cats
histopathologically diagnosed with lymphocytic- plasmacytic IBD
and 7 cats with IN (5 small intestinal lymphoma, 2 small intestinal
adenocarcinoma). Blood serum tMg concentration was measured
by atomic absorption using the Perkin-Elmer, A Analyst 100,
while serum CBL was measured by direct chemiluminescence tech-
nology using the ADVIA Centaur, Siemens.
Mean (SD) tMg serum concentration was 2.2 (0.3) mg/dL (me-
dian: 2.2 mg/dL, range: 2–3.1 mg/dL) in the control group, 2.34
(0.33) mg/dL (median: 2.3 mg/dL, range: 2.1–3 mg/dL) in the IN
group and 2.05 (0.35) mg/dL (median: 2 mg/dL, range: 1.3–2.9 mg/
dL) in the IBD group. Mean (SD) CBL serum concentration was
838 (306) pg/mL (median: 795 pg/mL, range: 494–1429 pg/mL) in
the control group, 358 (204) pg/mL (median: 402 pg/mL, range:
130–572 pg/mL) in the IN group and 445 (314) pg/mL (median:
420 pg/mL, range: 114–1176 pg/mL) in the IBD group.
Kruskal-Wallis test indicated that there was a statistically signif-
icant eﬀect of group on the median tMg values, v2(2) = 7.089,
P = 0.029, but the Mann-Whitney test after conducted the Bonfer-
roni-Dunn correction did not ﬁnd signiﬁcant diﬀerences among
the three groups. Also, correlation between tMg and CBL groups
was non-signiﬁcant, r(24) = 0.3, P = 0.155.
Although there was a signiﬁcant diﬀerence in the concentration
of serum tMg among the three groups, statistical analysis failed to
verify a correlation between tMg and CBL concentrations. This
could be attributed to the limited number of animals.
Disclosures: No disclosures to report
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MEGAESOPHAGUS ASSOCIATED WITH GASTRO-ESO-
PHAGEAL JUNCTION NEOPLASIA IN DOGS: 7 CASES
(2004–2016). V. Fabres1, F. Jolivet2, M. Massal2, O. Dossin2, V.
Freiche1. 1National School of Alfort, Maisons-Alfort, France,
2ENVT, University of Toulouse, Toulouse, France
Esophageal neoplasia has been reported in dogs with regurgita-
tions but only anecdotal case-reports describe megaesophagus
associated with gastroesophageal junction (GEJ) neoplasia. This
retrospective case series reports 7 cases of megaesophagus associ-
ated with GEJ neoplasia in dogs. Median (range) age and weight
at presentation were 12 (10–14) years and 26 (19–29.3) kg, respec-
tively. All cases were medium to large breed dogs. Duration of
clinical signs ranged from 3 days to 3 months with clinical signs
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including regurgitations (7), weight loss (6), cough (4), polydipsia
(3), ptyalism (2), lethargy (2), cachexia (2), and increased lung
sounds (2). Plain thoracic radiographs showed a megaesophagus
(7), a soft-tissue opacity within the caudal esophagus (3), and signs
of aspiration pneumonia (2). GEJ mass was conﬁrmed by contrast
esophagogram in two dogs. Transabdominal ultrasonography of
the GEJ was performed in 6 dogs and was abnormal in 5 dogs.
Endoscopy performed in 4 cases revealed a protruding mass in all
cases. CT imaging performed in 3 cases showed a mass at the
GEJ. One dog was treated by GEJ stenting, resulting in resolution
of clinical signs; this dog is still alive. Six dogs were euthanized
before diagnosis or lost to follow-up. Biopsies of the esophageal
masses were obtained endoscopically (2), surgically (1) or after
necropsy (3) and revealed esophageal leiomyoma (3) and
leiomyosarcoma (1) but the endoscopic samples were non-diagnos-
tic. Considering that long term survival is possible, this case series
emphasizes the importance of using additional imaging diagnostic
procedures before diagnosing idiopathic megaesophagus.
Disclosures: Disclosures to report.
The residency program of Dr V. Fabres is partly ﬁnanced by
Royal Canin. Unrelated to the subject matter of the abstract.
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FEASIBILITY OF MEASURING FECAL CALPROTECTIN
CONCENTRATIONS IN DOGS AND CATS BY THE FCAL
TURBO IMMUNOASSAY. R.M. Heilmann1, K. Truar1, J. Nes-
tler1, J. Schwarz1, N. Gr€utzner2, C. Gabris3, K. Kock3, C. Nieder-
berger3, R.M. Heilmann1. 1University of Leipzig, College of
Veterinary Medicine, Leipzig, Germany, 2Farm Animal Clinic,
Vetsuisse Faculty Bern, University of Bern, Bern, Switzerland,
3B€uhlmann Laboratories AG, Sch€onenbuch, Switzerland
Calprotectin, also referred to as the S100A8/A9 protein complex,
is involved in acute and chronic inﬂammatory responses. Fecal cal-
protectin concentrations have been demonstrated to be increased
in dogs diagnosed with inﬂammatory bowel disease (IBD) and to
decrease with successful treatment. Fecal calprotectin concentra-
tions in dogs with IBD were also correlated with the severity of
clinical signs, microscopic inﬂammatory lesions in the small intes-
tine, and the need for more aggressive (i.e., anti-inﬂammatory/
immunosuppressive) treatment (cut-oﬀ concentration: 15 lg/g). In-
house canine calprotectin assays were found to also reliably mea-
sure calprotectin in feline samples. Given the lack of wide avail-
ability of the in-house canine calprotectin assay, the aim of the
study was to assess the feasibility of measuring fecal calprotectin
concentrations in dogs and cats by the commercial fCAL turbo
immunoassay used routinely for the diagnosis and monitoring of
IBD in human medicine.
Fecal samples were obtained from 58 animals (45 dogs and 13
cats) with acute or chronic gastrointestinal disease (n = 29), other
diseases (n = 11), and clinically healthy individuals (n = 18). Fecal
samples were collected into the CALEX Cap stool extraction
device, extracted at a 1:500 dilution, and stored frozen until
analysis using the commercial fCAL turbo particle-enhanced
turbidimetric immunoassay. Statistical analysis was performed by
a non-parametric (unpaired) group comparison, with statistical
signiﬁcance set at P < 0.05.
Fecal calprotectin concentrations ranged from 0–3468.5 lg/g
(median: 18.9 lg/g) in this study, with a fecal calprotectin concen-
tration of <10 lg/g in 28 (48.3%) animals, 10–50 lg/g in 8
(13.8%), 50–200 lg/g in 13 (22.4%), and >200 lg/g in 9 (15.5%).
Signiﬁcantly higher concentrations of fecal calprotectin were
detected in dogs with acute or chronic gastrointestinal diseases
(median: 89.7 lg/g; n = 21) compared to healthy controls and
patients with diseases not localized to the gastrointestinal tract
(median: 0 lg/g; n = 24; P = 0.0017). Fecal calprotectin levels were
also higher in cats with acute or chronic gastrointestinal diseases
(median: 49.7 lg/g; n = 8) compared to healthy controls and cats
with conditions not localized to the gastrointestinal tract (median:
2.9 lg/g; n = 5), but the diﬀerence did not reach signiﬁcance (P
>0.05).
These results suggest that the fCAL turbo immunoassay can
detect fecal calprotectin in dogs and cats and can separate those
animals with gastrointestinal diseases from healthy controls. An
assay validation is currently underway and will allow further
studies on the clinical utility of the assay for fecal calprotectin in
dogs and cats with gastrointestinal diseases.
Disclosures: Disclosures to report.
Dres. Gabris, Kock, and Niederberger are employed by
B€uhlmann Laboratories AG where the fCAL turbo immunoas-
say is oﬀered on a fee-for-service basis.
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CLINICAL FEATURES OF ENGLISH COCKER SPANIELS
WITH CHRONIC PANCREATITIS MIMIC HUMAN IGG4RD.
P.J. Watson1, M.F. Coddou1, F. Capaldo1, J. Bazelle2, F. Con-
stantino-Casas1, B. Blacklaws1, J. Archer1. 1University of Cam-
bridge, Cambridge, UK, 2Davies Veterinary Specialists, Higham
Gobion, UK
English cocker spaniels (ECS) suﬀer from a distinctive form of
chronic pancreatitis (CP) associated with large numbers of duct
and vein-centered T-lymphocytes on histology. Recent studies
show a predominance of IgG4 positive plasma cells on immuno-
histochemistry in aﬀected dogs, suggesting a disease similar to
human IgG4-related disease (IgG4-RD). IgG4-RD typically aﬀects
older men and multiple organs, particularly causing inﬂammatory
mass lesions in the pancreas and dry eye, dry mouth and glomeru-
lonephritis. We recognized a similar spectrum of diseases in ECSs
presenting to our center with CP and observed an over-representa-
tion of roan dogs. The aim of this study was to describe the clini-
cal features of these ECS.
ECSs with CP presenting to the QVSH between December 2011
and March 2017 were recruited. CP was diagnosed either with
pancreatic histology (n = 2) or with both elevated cPLI and abnor-
mal pancreatic ultrasound (n = 9, of which one had positive ﬁne
needle aspirate cytology). Case records were searched for details of
signalment, clinical and clinicopathological ﬁndings, particularly
evidence of keratoconjunctivitis sicca (KCS); xerostomia; protein-
uria or other immune-mediated diseases.
20 ECS presented with suspected CP but only 12 dogs fulﬁlled
the strict inclusion criteria. There were 8 females and 4 males.
Median age was 9 years (range 4. 3–14 years). 6/10 dogs were blue
roan and 1/10 was orange roan. All dogs had gastrointestinal signs
and pain. 7/10 dogs where tears were checked had KCS. 6/7 cases
had dry oral mucous membranes suggesting xerostomia; 8/11 dogs
had proteinuria (Urine protein:creatinine ratio range 0.7–8.3). 4
cases had UPC <2 but in 2/4 cases it increased >2 on subsequent
visits. Glomerulonephritis was conﬁrmed post mortem in one dog.
Two dogs had atopy; one had inﬂammatory bowel disease and
one had pemphigus foliaceus. Three dogs had biliary tract disease.
One dog had epilepsy and two dogs developed intervertebral disc
disease. Three dogs had large mass lesions in the pancreas which
resolved on symptomatic treatment.
CP in ECSs shows remarkable clinical similarities to human
IgG4-RD with a high prevalence of KCS, xerostomia, proteinuria
and other immune-mediated diseases. Aﬀected dogs can present
with benign mass-like pancreatic lesions. The disease appears to be
more common in blue roan dogs.
Disclosures: No disclosures to report.
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CONTRAST-ENHANCED ULTRASONOGRAPHY OF THE
DUODENUM IN DOGS WITH INFLAMMATORY BOWEL
DISEASE: PRELIMINARY FINDINGS. D. Caivano1, M.C.
Marchesi1, M. Rishniw2, C. Timpano1, M.E. Giorgi1, M.T. Antog-
noni1, M.B. Conti1, A. Miglio1, E. Lepri1, F. Birettoni1. 1Univer-
sity of Perugia, Perugia, Italy, 2Cornell University, Ithaca, USA
Inﬂammatory bowel disease (IBD) commonly causes chronic diar-
rhea in dogs. Diagnosis is often challenging and relies on results
of subjective clinical indices, gastrointestinal endoscopy and
histopathological assessment of intestinal mucosal biopsies. In
humans, contrast-enhanced ultrasonography (CEUS) can quantify
intramural intestinal perfusion and correlates with disease severity
in Crohn’s disease.
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We sought to evaluate the feasibility of, and describe perfusion
patterns of CEUS in the duodenum of dogs aﬀected by IBD. We
hypothesized that CEUS would demonstrate changes in the perfu-
sion of inﬂamed duodenum and provide additional information in
the diagnosis of canine IBD.
We prospectively enrolled seventeen dogs with IBD (based on
Canine Inﬂammatory Bowel Disease Activity Index-CIBDAI,
endoscopic evaluation and histopathological assessment of duode-
nal mucosa samples). Each dog was placed in left lateral recum-
bency and the cranial portion of the duodenum was imaged in a
transversal plane. Before the endoscopy, each dog received two
boluses (0.03–0.06 ml/kg IV) of contrast agent (SonoVue,
Bracco, Italy): ﬁrst, while conscious and then after being anes-
thetized (using the same anesthetic protocol). Duodenal enhance-
ment patterns were ﬁrst evaluated qualitatively, then quantiﬁed
using dedicated software (Qontrast, Bracco, Italy).
In all dogs, the duodenal vascularization pattern was character-
ized by an initial rapid enhancement of the submucosal layer, fol-
lowed by a gradual enhancement of the mucosa. Serosa and
muscularis propria showed poor enhancement. We identiﬁed 2 pat-
terns at peak enhancement: (i) complete enhancement of the sub-
mucosal and mucosal layers without subjective demarcation
between the wall layers; (ii) incomplete enhancement of the muco-
sal layer that had a non-homogeneous, pointed, or streaked
appearance. Dogs had similar perfusion patterns whether con-
scious or anesthetized. We quantitatively analyzed enhancement
only in anesthetized dogs because of improved image quality.
Analysis revealed a 50% reduced peak enhancement intensity,
reduced regional blood ﬂow and reduced regional blood volume in
dogs with CIBDAI scores >6 (n = 4). These dogs all showed the
non-homogeneous, pointed or streaked pattern. However, we
found no relationship between perfusion patterns/parameters and
endoscopic or histopathological ﬁndings.
Our study demonstrates that CEUS of the duodenum in dogs is
feasible, and highlights the presence of diﬀerent vascular patterns
and contrast-enhancement features in dogs with IBD. Our ﬁndings
showed some association with dogs that had higher clinical grades
of IBD, but did not correlate with histopathological ﬁndings. Our
study oﬀers a novel, non-invasive imaging modality for the diag-
nosis and monitoring of canine IBD.
Disclosures: No disclosures to report.
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UTILITY OF CAPSULE ENDOSCOPY AS A COMPLEMENT
TO TRADITIONAL ENDOSCOPY. T.L. Hill1, J. Pomrantz2, J.
Solomon2. 1University of Georgia, Athens, USA, 2Inﬁniti Medical
LLC, Menlo Park, USA
Capsule endoscopy (CE) has a number of advantages over tradi-
tional endoscopy (TE): it allows for assessment of mucosal abnor-
malities of the entire gastrointestinal tract and can be performed
in conscious dogs. CE has been described in dogs as a method to
evaluate for gastrointestinal mucosal lesions. CE may be a valu-
able tool in reassessment of dogs that previously were evaluated
by TE. This study describes the use of capsule endoscopy (CE) in
dogs following traditional endoscopy (TE). Ten dogs were retro-
spectively identiﬁed that received CE within 6 months of TE
(range 0–151 days). Seven dogs received CE for assessment of sus-
pected gastrointestinal hemorrhage; CE detected gastrointestinal
mucosal lesions in the stomach and jejunum (n = 2), diﬀusely
throughout SI and colon (n = 2), jejunum (n = 1), ileum (n = 1),
and colon (n = 1) that were not detected with TE. Three dogs
received CE to assess lack of response to therapy in dogs with
chronic enteropathy. In these dogs, CE detected persistent gastric
erosions and duodenal mucosal changes seen previously with TE;
in 2/3 dogs, CE also identiﬁed lesions in additional locations not
seen with TE. CE detected gastrointestinal mucosal lesions not
detected by TE in 9/10 dogs. Though further investigation is
needed, CE appears to be a complementary and informative tech-
nique in the management of dogs with chronic GI signs that have
undergone TE.
Disclosures: Disclosures to report
Jill Pomrantz is an employee of Inﬁniti Medical LLC. Jeﬀ Solo-
mon is an equity holder of Inﬁniti Medical LLC.
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SERUM PROTEIN PROFILING OF 100 CATS WITH
INFLAMMATORY BOWEL DISEASE AND LYMPHOMA . E.
Benvenuti1, E. Bottero2, P. Ruggiero2, A. Pierini1, E. Magnanini1,
G. Lubas1, V. Marchetti1. 1University of Pisa, San Piero A Grado,
Pisa, Italy, 2Associazione Professionale Endovet, Rome, Italy
Inﬂammatory bowel disease (IBD) and lymphoma are common in
middle-aged to older cats, associated with chronic vomiting,
weight loss, and diarrhea, included in the chronic enteropathy
(CE) disorder. In cats, hypoalbuminemia in CE is considered infre-
quent, but speciﬁc investigations about protein proﬁle in these
patients have been not published . The aim of this study was to
evaluate serum protein proﬁling in cats with IBD and lymphoma,
and to compare it with clinical symptoms, endoscopic assessments
and histopathological diagnoses. FCEAI clinical index score,
CBC, serum biochemical proﬁle and urinalysis were evaluated in
100 cats aﬀected by IBD and lymphoma. Endoscopy of upper and
lower gastrointestinal tract was performed and a severity score
from 0 to 3 was assigned based on WSAVA guidelines.
Histopathological diagnosis was based on WSAVA guidelines.
Total serum protein, serum protein agarose gel electrophoresis,
and albumin-globulin ratio (A/G) were evaluated at time of diag-
nosis. Cats ranged from 1 to 17 years old (10 median), 46% were
females and 93% were European shorthair. The histologic diagno-
sis was IBD (66%) and lymphoma (34%). The most common
symptoms were vomiting (70%), weight loss (67%) and diarrhea
(37%). Mean FCEAI score was 9.4  2.59. Mean serum total pro-
tein was 6.01  0.99 g/dL. Low total protein (5.04  0.63 g/dL)
occurred in 41% of cats and only 10% had hypoalbuminemia.
Beta globulins were decreased in 70% of cats, and gamma globu-
lins were increased in 75%. A/G ratio was signiﬁcantly higher in
cats with hypoproteinemia (1.1  0.3) compared to non-hypopro-
teinemic cats (0.9  0.1). No statistical diﬀerences between protein
proﬁle and symptoms, FCEAI, gastrointestinal tract concerned,
endoscopic score, type and severity of histologic pattern were
found. Despite the hypoproteinemia was a relatively frequent ﬁnd-
ing in this work, a correlation with the clinical variables was not
established. In addition, the clinical severity, the endoscopic and
histological grading was not related to protein proﬁle. Dyspro-
teinemia with low beta globulin and high gamma globulin were
the most common alterations. In hypoproteinemic cats A/G was
higher than in non-hypoproteinemic cats. The decrease of beta
globulin could be due to malnutrition but also to iron metabolism
modiﬁcations occurring in chronic inﬂammatory disease, with
reduction of transferrin and ferritin. Hypergammaglobulinemia is
reported in human medicine as a common feature of IBD associ-
ated to extraintestinal manifestation. No data so far are available
for the prevalence and clinical signiﬁcance in cats.
Disclosures: No disclosures to report.
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RELIABILITY OF VENA CONTRACTA FOR STAGING
DEGENERATIVE CHRONIC MITRAL VALVE DISEASE IN
DOGS. A. Caro-Vadillo1, E. Pintado-Carretero2, A. Casasusolea3.
1Complutense Veterinary School, MADRID, Spain, 2Centro
Veterinario Asıs, Alcazar De San Juan CR, Spain, 3Servicio Veteri-
nario de Ecografıa de Alejandro Casasus, Madrid, Spain
It is important to obtain an accurate quantiﬁcation of mitral
regurgitation severity. This fact is especially important in order to
identify B2 patients -ACVIM classiﬁcation- that can beneﬁt from
starting medication or to prevent congestive heart failure. The
vena contracta is the narrowest portion of a jet downstream from
the regurgitant oriﬁce. The objective of the present study is to
prove if the vena contracta could be used as criteria for classiﬁca-
tion in dogs with DCMVD. One hundred and thirteen dogs suﬀer-
ing from DCMVD in diﬀerent phases according to ACVIM
classiﬁcation, have been included: B1, n = 54; B2, n = 51 and C,
n = 8. The vena contracta was measured from the parasternal left
apical four-chamber long axis view. Three measurements were
obtained for each dog and the average was obtained. The results
showed a statistically signiﬁcant diﬀerence between stages for end-
diastolic left ventricular index (EDVI), end-systolic left ventricular
index (ESVI) and vena contracta (Kruskal-Wallis for independent
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samples test). The diﬀerences were signiﬁcant between B1 dogs
and B2 dogs (P = 0.022) and between B1 and C dogs (P = 0.035)
for vena contracta. The diﬀerences were signiﬁcant between B1
dogs and B2 dogs (P < 0.0001) and between B1 and C dogs
(P < 0.001) for EDVI. The diﬀerences were signiﬁcant between B1
dogs and B2 dogs (P = 0.044) and between B1 and C dogs
(P = 0.032) for ESVI. There were no diﬀerences for these values
between B2 and C dogs. The vena contracta appears to be useful
to diﬀerentiate between early phases of DCMVD and congestive
phase of DCMVD but it seems less useful to diﬀerentiate between
B2 dogs and C dogs. It is important to remember that this mea-
surement is not useful if multiple jets are present, which is com-
mon in dogs with DCMVD. The vena contracta has an ellipsoidal
shape so the measurements could vary depending on the plane of
acquisition. Due to the fact that the vena contracta usually is
small (typically less than 0.5 cm), slight measurement errors could
lead to large mistakes and misclassiﬁcations. In human, it is rec-
ommended to measure the vena contracta from the right paraster-
nal long axis. All of these factors must be taken into consideration
from a critical point of view in the face of the present results.
Disclosures: No disclosures to report.
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RETROSPECTIVE ANALYSIS OF PULMONARY HYPER-
TENSION IN CATS WITH LEFT-SIDED CONGESTIVE
HEART FAILURE. T. Vezzosi1, K.E. Schober2. 1University of
Pisa, San Piero A Grado, Pisa, Italy, 2The Ohio State University,
Department of veterinary Clinical Sciences, Columbus, OH, USA
Pulmonary hypertension (PH) is present in approximately 70–80%
of dogs with left-sided congestive heart failure (L-CHF) and con-
tributes to clinical signs and outcome. Anecdotal evidence suggests
that PH in cats with L-CHF is much less frequent. However, data
on the prevalence of PH in cats with L-CHF is not available. This
study addresses the general hypothesis that PH secondary to L-
CHF is uncommon in cats and that echocardiographic ﬁndings in
cats with PH are diﬀerent compared to dogs.
This retrospective observational study included 56 healthy cats
and 131 cats with L-CHF imaged between 2004 and 2016 at the
Ohio State University, Veterinary Medical Center. Key diagnostic
variables included tricuspid regurgitation (TR) peak velocity, right
atrial (RA) size, right ventricular (RV) size and function, RV wall
thickness, pulmonary artery (PA) size, Doppler-derived systolic
time intervals of PA ﬂow (STIs), presence of septal ﬂattening, and
variables characterizing left atrial size and left ventricular size and
function. PH was identiﬁed if TR peak velocity was >2.7 m/sec
(estimated systolic PA pressure >35 mmHg). Parametric and non-
parametric statistical test procedures were used to compare normal
cats to cats with L-CHF, and cats with and without PH.
Tricuspid regurgitation was present in 57/131 (44%) of cats
with L-CHF. Pulmonary hypertension was present in 22/131 of
cats with L-CHF (17%). In 15/22 cases PH was associated with
cardiomyopathy, in 5/22 cases with congenital heart disease, and
in 2/22 cases to other causes. All cats with PH (22/22, 100%) had
subjectively-assessed right-sided enlargement, with larger RA and
RV diameters (P < 0.0001), thicker RV wall thickness (P < 0.05)
and higher prevalence of septal ﬂattening (6/22, 27%, P < 0.0001)
in comparison to cats without PH. Pulmonary artery size and
Doppler-derived STIs were not statistically diﬀerent between cats
with and without PH. Maximum right atrial diameter (>21.5 mm;
Sensitivity [Sn] 0.82, Speciﬁcity [Sp] 0.42) and RV ventricular
diameter (>7.8 mm; Sn 0.91, Sp 0.64) had the most accurate cutoﬀ
to predict PH compared to other variables. Method reproducibility
(measurement variability) was good, with most coeﬃcients of vari-
ation <15%.
Compared to dogs, PH is not a common ﬁnding in cats with L-
CHF. Right-sided enlargement is the main ﬁnding in cats with
PH, and right-heart dimensions should be used to suspect PH if
TR is absent or diﬃcult to measure. Further studies are needed to
identify reasons and mechanisms for the obvious diﬀerences
between dogs and cats.
Disclosures: No disclosures to report.
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FREQUENCY OF MITRAL VALVE PROLAPSE IN ADULT
HEALTHY DACHSHUND DOGS. P.H. Itikawa, G.T. Goldfe-
der, A.M. Gimenes, P.S. Backschat, S.L. Oliveira, D.P.S. Oliveira,
C.A.B. Lorigados, M.H.M.A. Larsson. School of Veterinary Med-
icine and Animal Science, University of S~ao Paulo, Sao Paulo,
Brazil
Dachshunds are aﬀected by chronic mitral valve disease (CMVD)
which is the most often heart disease in dogs. CMVD develops
mainly in small animals, but in chondrodystrophic breeds is more
common. Dachshunds are predisposed to develop mitral valve pro-
lapse (MVP) which is a systolic displacement of one or both mitral
leaﬂets beyond the mitral valve annulus. The MVP is associated
with marked sinus arrhythmia in Dachshund. The hypothesis is
that adult healthy Dachshund dogs are predisposed to exhibit
MVP before mitral regurgitation. We performed a prospective
study with client-owned animals that were screened by physical
examination, thoracic radiography, electrocardiography, systolic
blood pressure measurement, echocardiography and laboratory
tests (CBC, biochemical blood urea and creatinine). A complete
echocardiographic examination with electrocardiogram monitoring
was performed. We enrolled 69 Dachshund healthy dogs (28
[40.6%] males and 41 [59.4%] females); from 18 months to
10 years-old, weighting 8.4  2.3 kg. No heart diseases were
observed, including mitral regurgitation. Mild MVP was present in
28 (40.58%). Of these, 24 (85.71%) with sinus arrhythmia, 3
(10.71%) with normal sinus rhythm and 1 (3.57%) with sinus
tachycardia. In addition, those with sinus arrhythmia, 17 (70.83%
with mild) and 7 (29.16% with marked) sinus arrhythmia. There-
fore, healthy adults Dachshunds dogs may present MVP associ-
ated with marked sinus arrhythmia that can be a predisposing
factor to develop mitral regurgitation in the future.
Disclosures: No disclosures to report.
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PREVALENCE OF PULMONARY HYPERTENSION IN
DOGS NATURALLY INFECTED WITH ANGIOSTRONGY-
LUS VASORUM. E. Darnis, K. Gommeren, C. Clercx, K. Mc
Entee, A.C. Merveille. Liege University, Liege, Belgium
Pulmonary hypertension (PH) has been reported in dogs infected
with Angiostrongylus vasorum. Moderate to severe PH was identi-
ﬁed in a small portion of dogs, associated with shorter survival
time in a retrospective study. Only mild PH was identiﬁed in
experimentally infected dogs. The objective of this study was to
determine the prevalence and severity of PH in dogs presented to
a university clinic with A. vasorum infection and to describe associ-
ated echocardiographic changes in these dogs.
Dogs presented between November 2013 and February 2017
with conﬁrmed A. vasorum infection based on positive Baerman
coproscopy, Ag detection in blood or PCR in BALF were retro-
spectively included. Diagnosis of PH was based solely on radiogra-
phy (group 1) or plus echocardiography (group 2). In group 2, PH
severity was determined by tricuspid regurgitation velocity
(TRmax), pulmonic insuﬃciency velocity (PRmax). When no
regurgitation was measurable, indirect signs of PH such as, right
heart remodeling, main pulmonary artery dilation (PA/Ao),
acceleration time to ejection time (AT/ET), tricuspid annular plane
systolic excursion (TAPSE) and pulmonary vein diameter-to-pul-
monary artery diameter ratio (PV/PA) were taken into account.
Thirty-six dogs were included (group 1: 16; group 2: 20). Med-
ian age at the time of diagnosis was 4.5 years (3 months to
10 years). Chronic cough, dyspnea and exercise intolerance were
the main clinical complaints.
In group 2, 40% of dogs (8/20) had severe PH, 7/8 displaying a
right apical systolic heart murmur, and 3/8 being in right-sided
congestive heart failure. Prevalence of moderate and severe PH in
group 2 was 65% (13/20), two dogs displaying only indirect signs
of PH. In these dogs, median TRmax and PRmax were respec-
tively 4.65 m/sec (3.93–6.28) and 2.75 m/sec (2.03–3.73). Median
AT/ET, PA/Ao, PV/PA were 0.295 (0.178–0.49), 1.05 (0.64–1.28)
and 0.7 (0.4–1.3), respectively. Right ventricular dilation was
observed in 11/13 dogs and was considered as severe in all dogs
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with severe PH. However, TAPSE was within conﬁdence interval
for all dogs.
In group 1, only 25% of dogs had evidence of PH with mild
enlargement of pulmonary arteries. However, in group 2, two dogs
with severe PH had normal pulmonary vasculature on X-ray,
questioning the sensitivity of thoracic radiography for PH.
In conclusion, based on Doppler-echocardiography, the preva-
lence of moderate and severe PH in dogs naturally infected with
A. vasorum seems more important than previously described. Sys-
tematic ultrasound scanning of dogs infected with A. vasorum is
advised to evaluate presence and severity of PH.
Disclosures: No disclosures to report.
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SYMMETRIC DIMETHYL-ARGININE IN DOGS WITH MYX-
OMATOUS MITRAL VALVE DISEASE WITH AND WITH-
OUT PULMONARY HYPERTENSION. H. Poser, M. Berlanda,
S. Graziotto, T. Badon, B. Contiero, C. Guglielmini. University of
Padua, Legnaro, Italy
The symmetric Dimethyl-Arginine (SDMA) is produced by protein
metabolism and eliminated by renal clearance. In the recent years,
it has been used as a marker of kidney disease as it correlates with
the glomerular ﬁltration rate. In humans, SDMA is increased in
patients with cardiovascular disease and has a negative prognostic
value. The aim of the study is to assess the SDMA in dogs with
myxomatous mitral valve disease (MMVD) at various disease
stages, to evaluate the eﬀect of pulmonary hypertension (PH) and
the possible inﬂuence of cardiovascular therapies.
Dogs visited between May-2014 and September-2016 were retro-
spectively recruited if they had a diagnosis of MMVD after com-
plete cardiovascular assessment (physical examination, thoracic
radiogram, ECG, trans-thoracic echocardiography), CBC, bio-
chemistry proﬁle and a sample of serum stored at 20°C (n = 45).
A control group of healthy dogs was also included (n = 8). Dogs
with MMVD were divided according to the ACVIM guidelines in
stage B1 (n = 9), B2 (N = 11), C+D (N = 17). Dogs in the
ACVIM-groups were further subdivided into treated (N = 0, 3,
and 14,) and non-treated (N = 9, 8, 3) for groups B1, B2 and
C+D, respectively. Dogs were considered aﬀected by PH if they
had tricuspid regurgitation with peak velocity >3 m/sec and no
right ventricle outﬂow tract obstruction (N = 11). SDMA was
determined by a referring laboratory using a routinely available
immunoassay. Selected echocardiographic, CBC, biochemical
parameters, and SDMA were compared among ACVIM-groups
using Kruskal-Wallis test; the same test was used to assess the
combined eﬀect of therapies and ACVIM-group on serum urea
nitrogen (BUN), creatinine and SDMA. Correlations between
SDMA and echocardiographic, CBC, and biochemical variables
were assessed using Pearson’s test. Man-Whitney test was used to
assess diﬀerences of SDMA between PH-groups.
SDMA was increased in ACVIM-group C+D compared to
group B1 (P = 0.035) and B2 (P = 0.021); BUN was increased in
group C+D compared to healthy (P = 0.01), B1 (P = 0.007) and
B2 (P = 0.009), while creatinine was not signiﬁcantly diﬀerent
among groups. SDMA was positively and signiﬁcantly correlated
with BUN (r = 0.55; P < 0.001), Creatinine (r = 0.529; P < 0.001),
Sodium (r = 0.448; P = 0.003), Left-atrium to Aorta ratio
(r = 0.335; P < 0.025) and Mitral Valve E-wave velocity
(r = 0.334, P = 0.27). Treatment did not signiﬁcantly aﬀect
SDMA, BUN, or creatinine in any ACVIM-group. No signiﬁcant
diﬀerence of SDMA was observed between PH-groups.
Increased SDMA is observed in the advanced stages of canine
MMVD and likely reﬂects reduced renal function better than
BUN and creatinine. Therapies and PH do not seem to aﬀect
SDMA in dogs with MMVD.
Disclosures: Disclosures to report.
SDMA was determined by IDEXX Laboratories and the cost
of the analysis was partially reduced.
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LEFT VENTRICULAR HYPERTROPHY IN DOG: AN
ECHOCARDIOGRAPHIC STUDY. C. Locatelli1, A. Savarese1,
P.G. Brambilla1, I. Spalla2. 1University of Milan, Milan, Italy,
2Royal Veterinary College, Hawkshead Lane, Hatﬁeld, Hertford-
shire, UK
The assessment of the severity of left ventricular (LV) hypertrophy
in human medicine consists of three main cardiac parameters: LV
wall thickness, LV mass (LVM) and LV geometry. The latter is
assessed either by LVM/body surface area (BSA) and relative wall
thickness, RWT. Based on LV geometry, the LV is classiﬁed as
normal if LVM/BSA and RWT are within reference ranges, con-
centric remodeling as normal LVM and increased RWT, concen-
tric hypertrophy as increased LVM and RWT and eccentric
hypertrophy as normal/decreased RWT and increased LVM. Data
about normal values for LVM and RWT are scant in dogs.
The aims of this retrospective study were: (i) to determine nor-
mal values for LVM/BSA e RWT (M-mode derived) in healthy
dogs, (ii) to evaluate the eﬀect of sex, age and breed on these
echocardiographic parameters and (iii) to compare LVM/BSA e
RWT in healthy (>7 years) and hypertensive dogs.
The clinical archive (2015–2016) of the cardiology unit of
DIMEVET (University of Milan, Italy) was searched for all dogs
with a complete echocardiographic examination and systemic
blood pressure determination. Dogs were grouped into healthy
(based on no cardiac, metabolic or renal disease) or hypertensive
(according to ACVIM guidelines). From the digitally stored
echocardiographic M-mode data, LVM/BSA and RWT were cal-
culated. LVM was derived from geometric formula and indexed to
BSA. RWT was calculated as the ratio between 2 9 posterior wall
thickness and LV internal diameter at end diastole.
Eighty-three healthy dogs (48 female/35 male) and 26 hyperten-
sive dogs were included in the study. The mean (SD) LVM/BSA
and RWT were respectively 151 g/m2 (57) and 0.53 (0.10) in
healthy dogs. No diﬀerence in sex and age (dogs >7 years vs.
<7 years) was found. Sighthound dogs (n = 20) showed a statisti-
cally larger LVM/BSA (221 g/m2 vs. 129 g/m2, P = 0.00) with sim-
ilar RWT than non-sighthound dogs (n = 63) (0.54 vs. 0.53,
P = 0.74). Hypertensive dogs showed otherwise a statistically dif-
ferent RWT (0.69 vs. 0.55; P = 0.011) from healthy dogs >7years
with similar LVM (153 vs. 132 g/m2, P = 0.098).
The results of our study suggest that these echocardiographic
parameters may be of help in routinely classifying the hypertrophy
pattern/LV geometry in dogs. In contrast with human ﬁndings, no
sex diﬀerence was found in LVM/BSA. Sighthound dogs tended to
show greater LVM/BSA values, likely to represent physiologic
hypertrophy (normal RWT with increased LVM/BSA). Dogs with
systemic hypertension had increased RWT with normal LVM and
this could represent the ﬁrst response of the LV to pressure over-
load.
Disclosures: No disclosures to report.
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PULMONARY VEIN TO PULMONARY ARTERY RATIO IN
HEALTHY AND CARDIOMYOPATHIC CATS. V. Patata1, D.
Caivano2, F. Porciello2, M. Rishniw3, O. Domenech4, F. March-
esotti4, M.E. Giorgi2, H. Poser5, C. Guglielmini5, F. Spina2, F.
Birettoni2. 1Istituto Veterinario di Novara, Novara, Italy, 2Depart-
ment of Veterinary Medicine, University of Perugia, Perugia, Italy,
3Veterinary Information Network, Davis., USA, 4Department of
Cardiology, Istituto Veterinario di Novara, Novara, Italy,
5Department of Animal Medicine, Production & Health, Univer-
sity of Padua., Padua, Italy
Recognition of congestive heart failure (CHF) in dyspneic cats
is crucial for correct intervention. The pulmonary vein (PV) to
pulmonary artery (PA) ratio (PV/PA) has been proposed as an
index that might help discriminate dogs in CHF but has never
been studied in cats. We sought to determine reference intervals
for various, previously published, PV and PA variables in healthy
cats. We then examined these variables in cats with subclinical and
clinical (CHF) cardiomyopathies to determine the diagnostic utility
in identifying CHF.
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We prospectively enrolled 99 cats: 51 healthy cats, 24 subclinical
cardiomyopathic cats and 24 cardiomyopathic cats with CHF. PV
and PA were measured at the minimal and maximal diameters
from M-mode images obtained from a modiﬁed right parasternal
long axis view. Aorta and left atrium were measured from the
right parasternal short axis just after the end of systole.
Median PVmin/PAmin in healthy cats was approximately 0.51
and PVmax/PAmax was 0.67. The median distensibility of the ves-
sels was 23% for DPA and 41% for DPV. Several variables
(PVmax/PAmax, PVmax/Ao and PVmin/Ao) increased incrementally
between all 3 groups (P < 0.0001). Cats with CHF had a larger
PVmin/PAmin than subclinical and healthy cats (P < 0.0001). When
evaluating diagnostic performance of these variables (using only
cardiomyopathic cats with or without CHF), PVmin/PAmin and
PVmin/Ao had 100% speciﬁcity and 84% and 80% sensitivities,
respectively. By comparison, LA/Ao had 71% speciﬁcity and 88%
sensitivity.
Our study provides reference values for PV and PA variables in
cats. Moreover, PV/PA variables performed better than LA/AO in
discriminating cardiomyopathic cats with and without CHF.
Disclosures: No disclosures to report.
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COMPARATIVE ANALYSIS OF A PORTABLE SMART-
PHONE-BASED ELECTROCARDIOGRAPH (D-HEART)
VERSUS STANDARD 6-LEADS ELECTROCARDIOGRAPH
IN THE CANINE PATIENT. A.S. Savarese1, C.L. Locatelli1,
N.M. Maurizi2, N.B. Briante3, P.G.B. Brambilla1. 1University of
Milan, Milan, Italy, 2Department of Clinical and Experimental
Medicine, University of Florence, Florence, Italy, 3D-Heart srl,
Genova, Italy
Electrocardiogram (ECG) is an essential tool for diagnoses and
monitoring cardiac arrhythmias in veterinary medicine. However,
a low-cost, user friendly, 6-leads, smartphone-based electrocardio-
graph is still lacking.
D-Heart is a portable, smartphone-based device, which
streams the tracing via Bluetooth to any smartphone, enabling the
acquisition of an ECG on multiple leads, currently used in human
cardiology.
Aim of the study was to determine the accuracy of D-Heart
tracings, compared with the gold standard non-portable 6-lead
electrocardiograph in dog.
Standard 6-lead ECGs and D-Heart ECGs were subsequently
acquired in conscious dogs in right lateral recumbency. Each trac-
ing was saved with an anonymous ID. Two experienced observers,
independent and impartial, performed data analysis. In case of dis-
agreement, a third impartial observer adjudicated the tracing.
The sample was described, for continuous variables, by mean
and standard deviation or median and interquartile range (IQR),
when appropriate, and for categorical variable by proportion. The
concordance between the ECG methods was assessed by weighted
kw-Cohen index, with its relative signiﬁcance, taking as the end
point variable the standard 6-lead ECG group. The Bland-Altman
method with a 95% conﬁdence level was applied for P, PR, QRS,
T and QT interval measurements. Since diﬀerences between the
two measurements did not follow a normal distribution, a non-
parametric approach (median value and IQR) was used to deter-
mine the limits of agreement. P values were considered signiﬁcant
at the 0.05 level. Amplitude of the waves was not considered in
this preliminary analysis because currently the software doesn’t
allow voltage variation.
115 dogs of diﬀerent weights and breeds admitted to the Cardi-
ology Service of DIMEVET were enrolled. Mean age of dogs was
7.5  4 years. Most were intact males (45%, n = 51). The most
represented breed were mongrels (27%, n = 32).
Weighted Cohen’s kappa (kw) test between ECGs demonstrated
an excellent concordance of 0.989 (P < 0.001) in the evaluation of
the heart rhythm, of 0.991 (P < 0.001) for ST segment morphol-
ogy and of 0.838 (P = 0.040) for T wave morphology. There was a
100% concordance among P morphology assignment. P, PR,
QRS, T and QT intervals comparison with Bland-Altman method
showed an extremely good concordance for D-Heart measure-
ments (95% limit of agreement  0.9 ms for P,  10 ms for
PR,  35 ms for QRS,  5 ms for T wave). Less concordance
resulted for QT (  80 ms).
D-Heart proved eﬀective accurate recording of ECG compara-
ble to standard 6-lead ECG, opening new perspectives to improve
diagnostic tools in veterinary cardiology.
Disclosures: Disclosures to report.
This project was funded by D-Heart. Niccolo Maurizi and
Nicolo Briante are the co-founders of the social innovative
start-up D-Heart.
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USE OF GRAPHIC ORGANIZERS IN AN ELECTIVE
VETERINARY CARDIOLOGY COURSE. J.L. Ward1, S.B. Mar-
cketti2. 1Iowa State University College of Veterinary Medicine,
Ames, USA, 2Iowa State University Center for Excellence in
Learning and Teaching, Ames, IA, USA
Eﬀective teaching methods are critical for veterinary student learn-
ing of complex subjects such as cardiology. Graphic organizers
(GO) are visual and spatial displays, such as tables or charts, that
facilitate learning by making conceptual relationships between con-
tent more apparent. We hypothesized that, in an elective veteri-
nary cardiology course, study aids in the form of GOs would lead
to improved learning outcomes (higher post-test scores), improved
study eﬃciency (less time spent studying), and higher student satis-
faction compared to traditional outline (OUT) format.
This study was a mixed-method prospective randomized cross-
over design. Study participants (n = 31) were 3rd year veterinary
students at the Iowa State University College of Veterinary Medi-
cine enrolled in an elective veterinary cardiology course. Partici-
pants completed a comprehensive pre-test and were randomized
into two groups (A and B). All students received identical cardiol-
ogy content presented by the instructor via live weekly in-class lec-
tures. Following 8 pre-designated “experimental” lectures, students
were given instructor-prepared study aids summarizing the lesson
material, presented in either GO or OUT format. The following
week, students completed a post-test of content knowledge for that
lesson only, and indicated the amount of time they spent studying
for that lesson. Crossover occurred such that Group A and Group
B alternated between receiving GO and OUT for each experimen-
tal lesson. Qualitative data were collected in the form of in-depth
pre-course and post-course surveys.
Groups were comparable at baseline in terms of demographic
data, academic achievement, pre-course survey results, and pre-test
scores. Post-test scores did not diﬀer (P > 0.05) based on type of
study aid provided to students for that lesson (GO vs. OUT). Stu-
dents spent an average of 10 min (17%) less time studying per les-
son when using GO compared to OUT (P = 0.05). Student
satisfaction with both study aid formats was high, but students
preferred GO over OUT in terms of study eﬃciency (P = 0.002),
visual appeal (P < 0.001), ease of use (P < 0.004), and likelihood
of referencing the study aid in the future (P < 0.001). In conclu-
sion, in an elective veterinary cardiology course, use of GO com-
pared to OUT format study aids resulted in equivalent higher
study eﬃciency and student satisfaction, while resulting in equiva-
lent short-term learning outcomes.
Disclosures: No disclosures to report.
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FREQUENCY OF HEART MURMUR IN 69 HEALTHY
ADULT DACHSHUNDS. P.H. Itikawa, G.T. Goldfeder, A.M.
Gimenes, C.T. Amaral, P.S. Backschat, S.L. Oliveira, D.P.S. Oli-
veira, C.A.B. Lorigados, M.H.M.A. Larsson. School of Veterinary
Medicine and Animal Science, University of S~ao Paulo, Sao Paulo,
Brazil
A physiological heart murmur (PHM) can be identiﬁed in animals
with no structural abnormalities of the heart and great vessels. It
is a sound produced by blood ﬂow, usually detected in puppies,
but can be commonly observed in healthy young adult dogs. PHM
may be a result of an increased sympathetic tone, and is possible
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to be secondary to anxiety. It has been described in some breeds
and in athletic dogs during adulthood. A cross-sectional study was
performed with 69 healthy Dachshunds, including 28 males
(40.6%) and 41 females (59.4%), aging between 18 months to
10 years-old and weighting 8.4  2.3 kg. The dogs underwent
through physical examination, blood testing, echocardiogram, elec-
trocardiogram, blood pressure measurement and thoracic radiog-
raphy. No abnormalities were found. Systolic heart murmurs were
detected in 36 dogs (52.2%): 32 (46.4%) with grade II/VI and 4
(5.8%) with grade III/VI (Levine/Freeman Scale). Murmurs were
mostly located in mitral valve area (72.2%). Heart murmurs in
adult dogs are frequently indicative of pathological conditions.
However, none of the 36 dogs had structural heart abnormalities
or systemic disturbances. Therefore, this study shows a high preva-
lence of PHM in healthy adult Dachshunds.
Disclosures: No disclosures to report.
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CHOLINE CONCENTRATION AS A NEW POTENTIAL BIO-
MARKER TO DISTINGUISH PLEURAL EFFUSIONS FROM
HEART BASE TUMORS AND CARDIOMYOPATHY IN
DOGS. P.L. Levent1, Z. Yilmaz1, M.C. Cansev2. 1Faculty of
Veterinary Medicine, Uludag University, Bursa, Turkey, 2Faculty
of Medicine, Department of Pharmacology, Uludag University,
Bursa, Turkey
Research of new biomarkers in body ﬂuids to detect the primary
problem is crucial in human and veterinary medicine. Although
serum choline is suggested as emerging biomarkers in human and
dogs with myocardial ischemia, there is no available data on use-
fulness of choline levels for predicting cardiac events. Therefore,
this study was aimed to evaluate the use of choline concentration
as a potential biomarker for distinguishing pleural eﬀusions due to
heart base tumors (HBT) and dilated cardiomyopathy (DCM),
and determine whether there was a correlation between pleural
and serum choline levels in dogs.
Dogs with pleural eﬀusion due to DCM (n = 11) and HBT
(n = 8) were used as materials. Pleural eﬀusions were diagnosed by
clinical, radiological and ultrasonographic (US) examinations
along with US-guided thoracentesis. DCM was diagnosed based
on the sum of the scores (≥6 points) recommended by European
Society of Veterinary Cardiology taskforce. Pre-operative diagno-
sis of HBTs was conﬁrmed by histopathological evaluations show-
ing mesothelioma, chemodectoma, hemangiosarcoma, and aortic
body tumors. Healthy age- and breed-matched dogs (n = 10) were
used as controls. Serum free-choline concentration of each sample
was analyzed by high performance liquid chromatography in tripli-
cate and results were expressed as micromolar (lM).
Serum choline concentrations in dogs were (median [range])
14.8 [6.5–19.2] lM for healthy dogs, 14.7 [7.9–28.4] lM for DCM
and 8.7 [5.0–13.9] lM for HBTs (but not signiﬁcant between
groups). There was a statistically signiﬁcant diﬀerence (P < 0.05)
on choline concentration (Mean  SEM) in pleural ﬂuids between
dogs with DCM and HBTs; 13.5  3.9 lM and 23.1  8.5 lM,
respectively. Choline level was higher (P < 0.05) in pleural ﬂuid,
compared to that of serum in dogs with HBTs, whereas there was
not statistically signiﬁcant diﬀerence between them in dogs with
DCM. In all dogs (n = 19), choline level in pleural eﬀusions
(24.9  6.3 lM) was higher (P < 0.001) than its serum level
(10.6  1.2 lM). There were no signiﬁcant relationships (Pearson
correlation) between choline levels in serum and pleural ﬂuids in
dogs with DCM and HBT.
These data suggest that pleural ﬂuid choline concentration,
rather than its serum concentration, might be used as a new poten-
tial biomarker for distinguishing from DCM and HBTs in dogs.
Disclosures: No disclosures to report.
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EPIDEMIOLOGICAL, CLINICAL, AND ECHOCARDIO-
GRAPHIC FEATURES, AND SURVIVAL TIMES OF DOGS
WITH EBSTEIN ANOMALY: 40 CASES (2002–2017). C. Pois-
sonnier1, E. Bomassi2, V. Gouni3, C. Jamin1, C. Damoiseaux1, M.
Lavennes1, J.L. Pouchelon1, L. Desquilbet1, V. Chetboul1.
1National Veterinary School of Alfort, Maisons-Alfort, France,
2Centre Hospitalier Veterinaire des Cordeliers, Meaux, France,
3INSERM U 955, Creteil, France
Ebstein anomaly (EA) is a rare type congenital heart disease char-
acterized by an apical displacement of the tricuspid valve leaﬂets
in the right ventricle (RV), causing dilation of the right atrium
(RA) and decrease in the functional RV size. Few studies have
been dedicated to canine EA. The objective of this retrospective
study was to characterize the epidemiological, clinical, and
echocardiographic ﬁndings associated with canine EA, as well as
survival.
The case records of dogs diagnosed with EA by use of echocar-
diography (2002–2017) were reviewed. The study population con-
sisted of 40 dogs with EA (median age at diagnosis = 15 months
[IQR 7–36], male-to-female ratio = 1.5). Only medium to large
breeds were represented, the most common breed being Labrador
retriever (24/40, 60%). Eight dogs (20%) had a hemodynamically
compromise concurrent heart disease (n = 7) or respiratory disease
(n = 1), and were therefore excluded from subsequent analysis.
A right apical systolic heart murmur (median grade = 5 [IQR
4–5]) was detected in all dogs, and 13/32 dogs (41%) presented
clinical signs related to EA. Dilation of the RA was moderate to
severe in most dogs (median RA to left atrium (LA) ratio = 1.45
[IQR 1.29–1.72]). Several echocardiographic indices used in human
pediatrics to evaluate EA were calculated, including the displace-
ment index (distance from the hinge point of the anterior mitral
leaﬂet to that of the delaminated septal leaﬂet divided by body
surface area: median = 17.4 mm/m2 [IQR 12.0–21.9]) and the Cel-
ermajer index (ratio between the RA area and the sum of the areas
of the RV, LA and left ventricle, median = 1.0 [IQR 0.5–1.3]).
Follow-up was available for 25/32 dogs. Death of cardiac origin
was reported in 4/25 dogs (16%) and all-cause death in 8/25 dogs
(32%); median age at all-cause death was 73 months. Median time
to all-cause death was 74 months after the diagnosis of EA. Med-
ian time to cardiac death (CD) could not be calculated, due to the
high proportion of dogs still alive at the end of study. It is esti-
mated that 72% dogs [95% CI: 50–86%] did not present CD
160 months after the diagnosis of EA. Univariate analyses showed
that time from diagnosis to CD was associated with the presence
of ascites, clinical signs, a RA:LA ratio≥2, the presence of a right
thrill, and a Celermajer index≥1.
In conclusion, RA enlargement is signiﬁcantly associated with
decreased survival time of dogs with EA although most may live
years and may not die from CD.
Disclosures: Disclosures to report.
C. Poissonnier : Fondation Un Coeur / Vetoquinol sponsoring
for clinical projects unrelated to this study.
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UTILITY OF THE SNAP FELINE N-TERMINAL PRO-B-
TYPE NATRIURETIC PEPTIDE TEST IN DETECTING
ASYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY:
A PROSPECTIVE STUDY IN 61 CATS. C. Damoiseaux1, C.
Poissonnier1, M. Rospabe2, V. Gouni1, M. Lavennes1, E. Trehiou-
Sechi1, R. Tissier3, O. Sarret2, V. Chetboul1. 1Unite de Cardiologie
d’Alfort, Ecole Nationale Veterinaire d’Alfort, Maisons Alfort,
France, 2IDEXX Laboratories, Saint Denis, France, 3Unite de
Pharmacie-Toxicologie, Maisons Alfort, France
Hypertrophic cardiomyopathy (HCM) is the most common feline
heart disease. Currently, echocardiography is the gold standard to
diagnose feline HCM, including occult forms of the disease. How-
ever, this imaging technique requires expertise to interpret the data
and represents a ﬁnancial cost for the owner, thus limiting its
widespread use for screening “apparently healthy” cats. Therefore,
a rapidly assessed biomarker, such as a pet-side test able to iden-
tify asymptomatic HCM cats would be of interest.
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Previous studies showed that the circulating cardiac biomarker
N-terminal pro-B-type natriuretic peptide (NT-proBNP) is signiﬁ-
cantly increased in cats with moderate to severe occult HCM, as
compared to healthy cats. The aim of this prospective study was
to determine the sensibility (Se) and speciﬁcity (Sp) of the Idexx
SNAP Feline proBNP Test to diagnose HCM in asymptomatic
adults cats.
Material and Methods: The study population consisted of
prospectively recruited “apparently healthy” adult cats (2015–
2017), with or without heart murmurs. Cats with congenital heart
diseases, with other cardiomyopathy than HCM, with current or
past diagnosis of congestive heart failure, and with gallop rhythm,
were not included in the study. All cats underwent a complete
physical examination, blood pressure measurement, serum urea
and creatinine measurements, and conventional echocardiography.
Total T4 was also assessed in cats >6 years old. Plasma NT-
proBNP concentration was measured using EDTA-potassium sam-
ples and a commercially available feline speciﬁc assay. A Snap
Feline NT-proBNP was also performed (positive detection limit:
200 pmol/L), according to the manufacturer’s instructions.
Results: The study population consisted of 61 “apparently
healthy” cats (29 males and 32 females; median age: 4.9 years
[1.1–16.6]; body weight: 4.6 kg [2.5–10.5]): 31 normal cats with
both normal cardiac auscultation and echocardiography and 30
asymptomatic cats with a left apical systolic heart murmur either
related to HCM (n = 9; 6 diﬀuse HCM forms and 3 segmental
HCM forms with hypertrophy of the sub-aortic interventricular
septum) or to a minor to mild mitral valve regurgitation without
any other echocardiographic abnormality (MVR; n = 21). The
SNAP test distinguished asymptomatic HCM cats from other “ap-
parently healthy” cats (i.e., normal cats or cats with minor to mild
MVR) with 64% sensibility (Se) and 100% speciﬁcity (Sp), the
negative and positive predictive values were 93% and 100%
respectively and when only considering diﬀuse HCM forms with
100% Se and 100% Sp.
In conclusion, the SNAP Feline NT-proBNP Test may help
identifying diﬀuse HCM forms in asymptomatic cats.
Disclosures: Disclosures to report.
Study ﬁnanced by IDEXX’s laboratories.
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A RANDOMIZED DOUBLE-BLIND, PLACEBO CON-
TROLLED STUDY EVALUATING THE EFFECTS OF
SHORT-CHAIN FRUCTO-OLIGOSACCHARIDES (SCFOS)
ON CAT STOOLS ODORS. F. Herpin, F.A. Allaert. CEN
Nutrition Animal, Dijon, France
Objectives: The main objective was to evaluate the eﬀects of the
addition of short-chain fructo-oligosaccharides (scFOS) to the
daily cat feed ration on the intensity of unpleasant odors of cat
feces. The secondary objectives were to evaluate the digestive toler-
ance of the product and the cat owner’s satisfaction.
Methods: The study was a randomized, double blind, placebo
controlled study conducted on 2 parallel arms. The experimental
products were dry cat food with 1 % scFOS (Profeed, TEREOS)
or without scFOS. The inclusion criteria were: healthy cats living
in naturalistic conditions at the owner’s home, 1–15 years old,
using cat litter and whose owners were complaining of their
intense bad smells. Cats recently or currently under treatment were
excluded. The main criterion was the intensity of the odor of the
feces evaluated by owners on a 7-point Likert scale (0: no odor, 6:
unbearable). The digestive tolerance was evaluated by the consis-
tency of stools on a fecal score scale and the satisfaction criterion
was evaluated on a Likert scale. These criteria were daily collected
during 2 weeks at the beginning of the study and after about
30 days of feeding.
Results: The study covers 57 cats aged of 4.3  3.4 among
which 54.4% were female: 27 cats were included in the verum
group and 30 in the placebo group. Their characteristics and past
history were similar. The intensity of the odor of the feces were
similar in both groups at inclusion (verum 3.5  0.7 vs. placebo
3.3  0.6; P: 0.2767). The comparison between the two groups
showed that the reduction of the feces odor was greater in the
verum group than in the placebo group, 2.25 more (P:0.06) for a
reduction described in absolute values (0.9  0.9 vs 0.4  1.1)
and 2.5 more (P:0.05) when described as a percentage
(26.9  29.8 vs. 10.4  31.7). The percentage of owners who
were very satisﬁed or extremely satisﬁed with the improvement of
the odor was signiﬁcantly greater in the verum group than in the
placebo group (53.8% vs. 43.3%) and in particular the percentage
of very satisﬁed owners (19.2% vs. 0.0%). Stool consistency
remained stable in both groups, conﬁrming that scFOS are well
tolerated by cats.
Conclusions: Adding scFOS into the daily cat feed ration is ben-
eﬁcial in order to reduce unpleasant odors of cats’ stools without
altering digestive tolerance.
Disclosures: Disclosures to report.
CEN Nutrition Animal has received research grants from
Tereos.
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INCREASED DIETARY LONG-CHAIN POLYUNSATU-
RATED FATTY ACIDS ALTER PLASMA FATTY ACID CON-
CENTRATIONS AND LOWER RISK OF URINE STONE
FORMATION IN CATS. D.E. Jewell1, J.A. Brockman1, S.
Davidson1, J.L. MacLeay1, J.A. Hall2. 1Hill’s Pet Nutrition,
Topeka, USA, 2Oregon State University, Corvallis, USA
Increasing concentrations of dietary (n-3) polyunsaturated fatty
acids (PUFA), e.g., eicosapentaenoic acid (EPA) and docosahex-
aenoic acid (DHA), relative to (n-6) FA, e.g., arachidonic acid
(AA), have been shown to increase plasma concentrations of EPA
and DHA and reduce AA concentrations. The purpose of this study
was to investigate the eﬀects of increasing dietary PUFA concentra-
tions on urine characteristics. We have recently shown that lifespans
of cats with non-obstructive kidney stones is shortened compared
with control cats indicating a need to prevent stone formation and
decrease the rate of chronic kidney disease progression.
Domestic short hair cats (n = 12; mean age 5.6 years, range 2
to 9 years) were randomized into two groups and fed one of two
diets for 56 days and then crossed over to the other diet for
another 56 days. The protocol was reviewed and approved by the
Institutional Animal Care and Use Committee, Hill’s Pet Nutri-
tion, Inc. For 30 days before study initiation, cats consumed a
pretrial (control) food that contained 0.07% AA and no measur-
able EPA or DHA. After 30 days, cats were split into two groups.
Group 1 continued eating control food for 56 days. Group 2 was
fed test food for 56 days, which contained 0.16 % AA, and 0.27%
EPA and DHA combined. After 56 days, Group 1 cats were fed
test food and Group 2 cats were fed control food for another
56 days. Serum was analyzed for FA concentrations at baseline
and after each feeding period. Concurrently, urine was analyzed
for urine speciﬁc gravity (USG), calcium concentration, and rela-
tive super saturation for struvite crystals. In addition, a urine cal-
cium oxalate titrimetric test (COTT) was performed.
After consuming test food, cats had increased (all P < 0.01)
plasma concentrations of AA (36%), EPA (352%) and DHA
(200%) compared with cats consuming control food. In addition,
urine from cats fed test food had decreased USG (P = 0.04),
decreased calcium concentration (P = 0.03; 9%), decreased stru-
vite super saturation (P = 0.03; 51%) and enhanced titratability
to added oxalate before forming calcium oxalate crystals
(P = 0.06; 26%). Resistance to oxalate crystal formation was
negatively correlated with blood calcium concentration (r = ?0.41;
P < 0.01) and this relationship was unaﬀected by test food. How-
ever, feeding test food decreased USG, decreased urine calcium
concentration, and increased resistance to oxalate crystal forma-
tion. These data show that there could be signiﬁcant urinary tract
beneﬁt for cats, i.e., reduced urine stone formation, by increasing
dietary AA, EPA and DHA.
Disclosures: Disclosures to report.
D.E. Jewell, J.A. Brockman, S. Davidson, J.L. MacLeay are all
employees of Hill’s Pet Nutrition, Inc. J.A. Hall has received grant
money from Hill’s Pet Nutrition, Inc.
586 ECVIM Abstracts
ESVCN – P – 3
FOODS ENRICHED WITH BIOACTIVE INGREDIENTS
INCLUDING FISH OIL INCREASE CIRCULATING (N-3)
FATTY ACID CONCENTRATIONS, DECREASE PGE2, AND
INCREASE LEAN BODY MASS IN CATS. D.E. Jewell1, M.I.
Jackson1, J.A. Hall2. 1Hill’s Pet Nutrition, Topeka, USA, 2Oregon
State University, Corvallis, USA
Increasing concentrations of dietary (n-3) polyunsaturated fatty
acids (PUFA), e.g., eicosapentaenoic acid (EPA) and docosahex-
aenoic acid (DHA), relative to (n-6) FA, e.g., arachidonic acid
(AA), have been shown to increase plasma concentrations of EPA
and DHA and reduce AA concentrations. The purpose of this
study was to investigate the eﬀects of enriching food with bioactive
ingredients, including EPA and DHA, on body composition, and
concentrations of circulating fatty acids and the inﬂammatory bio-
marker prostaglandin E2 (PGE2). Domestic short hair cats
(n = 81; mean age 11.1 years, range 6 to 14 years) were fed a pre-
trial food for 30 days, randomized into three groups, and then fed
one of three diets for 180 days. The protocol was reviewed and
approved by the Institutional Animal Care and Use Committee,
Hill’s Pet Nutrition, Inc. The pretrial food contained 33.4% pro-
tein, 0.12% arachidonic acid (AA) and negligible EPA and DHA.
The control food contained 32.6% protein, 0.10% AA, 0.03%
EPA, and 0.02% DHA. Test food 1 (TF1) and Test food 2 (TF2)
contained 31.8% and 30.2% protein, respectively, as well as
0.04% AA, 0.095% EPA, and 0.06% DHA. Both TF1 and TF2
contained additional bioactive food factors (from broccoli, toma-
toes, oats, and peas), with TF2 having increased bioactive ingredi-
ent concentrations compared with TF1. Serum was analyzed for
FA and PGE2 concentrations initially, and at 45, 90 and 180 days.
Concurrently, body composition was determined by dual energy x-
ray absorptiometry. After consuming food for 180 days, lean body
mass (LBM) was unchanged in cats fed control food (42  30 g),
whereas cats fed TF1 (73  30 g; P = 0.02) and TF2 (197  31 g;
P < 0.01) had increased LBM. Body fat was unchanged in cats fed
control food (11  43 g), but decreased in cats fed TF1
(124  42 g; P < 0.01) and TF2 (185  43 g; P < 0.01). PGE2
concentrations were decreased in cats fed control and TFs, and
were positively correlated to the ratio of (n-6) to (n-3) FA in
serum (r = 0.31; P < 0.01) and negatively correlated to the sum of
(n-3) FA (r = ?0.30; P < 0.001). Cats consuming foods containing
plant bioactives and ﬁsh oil had reduced concentrations of the
inﬂammatory biomarker PGE2 and enhanced lean body composi-
tion, which together may aid in oﬀsetting inﬂammation and adi-
posity associated with aging in cats.
Disclosures: Disclosures to report.
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STUDIES IN A NEW BODY CONDITION SCORING BY
MORPHOMETRIC METHOD IN DOGS. A.K. Koizumi, R.
Aihara, M. Sakurada, H. Asakawa, K. Otsuji. Teikyo University
of Science, Tokyo, Japan
Body condition scoring (BCS) is the method that many clinical
veterinarians adopt as a nutritional assessment method. However,
the BCS assessment can be inconsistent because of its subjective
method. Therefore we developed a BCS palpation model to
improve the precision of the BCS assessment. Furthermore, we
studied a new BCS assessment by the morphometric method to
further improve the precision of BCS assessment. BCS is assessed
by measuring body length and the current body weight in this
method.
Thirty-nine dogs which varied in their BCS levels were used.
Breed, gender and age were neglected for the selection of the dogs.
Measurement of body fat percentage: the deuterium water dilution
method was used. After the blood collection, deuterium water of
0.2 g/kg was subcutaneously injected and the blood samples were
collected 3 h after the administration. The concentration of deu-
terium water in the blood was analyzed by radio isotope mass-
spectrometry. Body length: the length between the scapula and
ilium (BLs-i) and between the scapula and base of tail (BLs-b) was
measured. Calculation of the body weight corresponding to each
BCS: ideal body weight (IBW) was calculated as the body weight
at the body fat percentage of 20%. The body weight correspond-
ing to each BCS was calculated as follows: BCS of 5: more than
IBW 91.21, BCS of 4: IBW 91.11~1.20, BCS of 3: IBW 9
0.91~1.1, BCS of 2: IBW 9 0.81~0.9., and BCS of 1: IBW 9
0.80 or less.
The results suggest that the correlation coeﬃcient between BLs-
b and IBW was r = 0.8355, P < 0.01 and higher than the correla-
tion coeﬃcient between BLs-i and IBW. This means that measur-
ing the length of BLs-b is more accurate than measuring the
length of BLs-i. The results suggest that the IBW of each dog
could be estimated by measuring the BLs-b. The correlation coeﬃ-
cient between the BLs-b and IBW in 5 long bodied dogs (Minia-
ture Dachshund, Welsh Corgi, etc.) was higher than it in the all
subject dogs. This suggests that it is better to divide dogs into fol-
lowing three types: standard shape, long and square bodied dogs
for the morphometric BCS assessment. In addition, individual
BCS can be calculated from an estrangement percentage between
IBW and current weight by using above formula. This morphome-
tric method is simpler and more objective than the conventional
method.
Disclosures: No disclosures to report.
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VALIDATION OF A MODIFIED 9-INTEGER-UNIT BODY
CONDITION SCORE SYSTEM AND A COMPUTER-BASED
MODELING TOOL TO ESTIMATE BODY CONDITION IN
PET DOGS. W. Saengsoi1, E. Morel2, M.A. Hours2, E.J. Comer-
ford1, S. Tew1, V. Biourge2, A.J. German1. 1University of Liver-
pool, Neston, UK, 2Royal Canin Research Center, Aimargues,
France
Body condition scoring (BCS) is the most widely accepted clinical
method for estimating body fat mass in dogs. The 9-point system
is preferred but, since visual characteristics are depicted with only
5 silhouette images from a single breed, assessment of visual char-
acteristics of dogs of diﬀerent size and body shape is challenging.
Two modiﬁcations to the original 9-point BCS system were
developed with reference to an image archive of almost 3799 pho-
tographs from 155 dogs attending the Royal Canin Weight Man-
agement Clinic, University of Liverpool (Gant. BMC Veterinary
Research 2016, 12:18). Body fat mass (measured by dual-energy
X-ray absorptiometry [DEXA]) and BCS was known for all dogs,
and owners gave written permission for use of these photographs
(VREC50). The ﬁrst modiﬁcation was a paper-based system that
used a set of 5 size-speciﬁc BCS charts, for small, medium, large,
and giant breeds, respectively. The written descriptions for each
category were identical, but diﬀerent images were included for the
diﬀerent size categories. The second was a computer-based system
whereby visual characteristics were modeled on-screen by altering
body shape in 5 diﬀerent zones (chest, abdomen, back, thigh, and
pelvis), with the computer software then calculating the body con-
dition score automatically using an algorithm.
Thirty dogs of a range of breeds were used to validate both sys-
tems, all of which had been referred for surgical treatment of cra-
nial cruciate ligament disease at Small Animal Teaching Hospital,
University of Liverpool. Owners had consented to their participa-
tion in a separate research study (VREC192), involving body fat
measurement by DEXA (under the same anesthetic used for diag-
nostic and therapeutic procedures). One author (WS) assessed the
BCS for all dogs, under the supervision of a second author experi-
enced in body condition scoring (AJG). The computer system was
used ﬁrst, followed by the paper-based system.
Median BCS was 6/9 (3/9–8/9) and median body fat was 35%
(range 8–52%). There was a strong positive correlation between
body fat measured by DEXA and BCS for both the paper-
(Rs = 0.74, P < 0.001) and computer-based (Rs = 0.80, P < 0.001)
systems. Both systems also correlated strongly with each other
(Rs = 0.97, P < 0.001), and agreement was almost perfect (Cohen’s
kappa 0.89, P < 0.001).
These ﬁndings demonstrate that both the modiﬁed paper-based
and computer-based BCS systems correlate with body fat mass
measured by DEXA and can be considered for use with clinical
cases.
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SAFETY AND EFFICACY OF DAPAGLIFLOZIN, A NOVEL
ANTIDIABETIC DRUG, IN HEALTHY CATS. R.K. Burchell,
A. Gal, S.E. Burton, N.J. Cave. Massey University, Palmerston
North, New Zealand
Renal sodium glucose transporter type 2 (SGLT2) inhibitors are a
novel class of drug developed for the management of type-2 dia-
betes (T2DM) in humans. Inhibition of SGLT2 induces profound
renal glucosuria reducing blood glucose and lowering insulin
requirements in man. Adverse eﬀects are uncommon. These drugs
have not been evaluated in cats to the authors’ knowledge. In this
study 3 healthy cats were sequentially dosed with 5, 10, 15 and
20 mg of dapagliﬂozin for 5 days per treatment with a 2 week
washout between each regimen. Cats were housed in individual
cages. Hematology, serum biochemistry and urinalysis were per-
formed before and after each trial. Daily food, water intake, urine
production and 24 h urinary glucose excretion were measured for
the duration of each trial. Data was analyzed using a mixed linear
model with a ﬁxed eﬀect of ‘dose’ and ‘day’, and the random eﬀect
of ‘cat’. Dapagliﬂozin induced signiﬁcant glucosuria at all doses
used, which persisted for 5 days after the last dose for each regi-
men. The 10 mg dose induced the most signiﬁcant increase in daily
urine glucose output with a concomitant decrease in daily urine
output. One cat developed a mild hyperglobulinemia and leukocy-
tosis, but no other adverse eﬀects were noted. The cats lost weight
during each of the trials, which is one of the touted beneﬁts of the
drug in human diabetics. Polydipsia/polyuria were not observed,
nor were urinary tract infections detected during the trial. In con-
clusion, dapagliﬂozin appeared safe and is eﬀective in inducing
glucosuria.
Disclosures: No disclosures to report.
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EVIDENCE FOR REGIONAL VARIATION OF PATIENT
CHARACTERISTICS IN DOGS WITH HYPERADRENOCOR-
TICISM. K.F.A. Langner1, B.C. Duﬀ2, S. Foster2. 1Murdoch
University Australia, PERTH, Australia, 2Vetnostics, NORTH
RYDE, Australia
Patient signalment and pathological causes of canine hyperadreno-
corticism have been largely derived from studies on North Ameri-
can dog populations. It is has been suggested that these ﬁndings
are not necessarily applicable to other countries.
This retrospective study assessed 200 consecutive records of
Australian dogs between 2006 and 2009 that had samples submit-
ted to an accredited laboratory for measurement of endogenous
adrenocorticotropic hormone (ACTH) by radioimmunoassay.
Adrenal ultrasonography was not easily available for most general
veterinary practices at this time and the endogenous ACTH assay
was routinely used for diﬀerentiation of pituitary from adrenal
dependent disease. Clinical and clinicopathologic data were
obtained from the laboratory submissions and/or submitting prac-
titioner patient records. A total of 175 dogs met the inclusion cri-
teria for a conﬁrmed diagnosis of hyperadrenocorticism. This
subset was evaluated for age, body weight, sex, breed and lesion
location (pituitary vs. adrenal).
Median age of the assessed dogs was 11 years and median body
weight was 8.17 kg. Sixty-one percent of the dogs were female and
39% male. The most commonly aﬀected breeds were crossbred
dogs (32.6%) and Maltese (20.6%). Maltese crossbreds and Mal-
tese purebreds together comprised 31.4% of the study population.
Other commonly identiﬁed breeds included Australian Cattle Dog,
Jack Russell Terrier (3.4% each), Poodle, Miniature Fox Terrier,
Shi Tzu and Bichon Frise (2.9% each). Pituitary dependent hyper-
adrenocorticism was identiﬁed in 171 dogs (97.7%). A functional
adrenal tumor was found in 3 dogs (1.7%) and suspected in a
fourth dog.
The results demonstrated that Australian dogs with hypera-
drenocorticism have a lower median body weight and a higher
prevalence of pituitary dependent disease when compared to the
North American data. In addition a striking percentage of the
study population were Maltese dogs and their crosses. These ﬁnd-
ings have implications for investigation and therapy of canine
hyperadrenocorticism in Australia. They also highlight that regio-
nal diﬀerences in hyperadrenocorticism should be recognized by
veterinarians worldwide.
Disclosures: Disclosures to report.
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SYMMETRIC DIMETHYLARGININE (SDMA) IN HYPER-
THYROID CATS. A. Corsini1, S. Crosara1, G. Carotenuto2, F.
Fracassi2. 1Parma University, Parma, Italy, 2Department of Veteri-
nary Sciences, Bologna, Italy
Hyperthyroidism leads to a decrease in serum creatinine (Crea) by
increasing glomerular ﬁltration rate (GFR) and decreasing body
muscle mass. This can mask a concurrent chronic kidney disease
that might become evident after the onset of treatment. Symmetric
dimethylarginine (SDMA) is a novel, early, renal biomarker inde-
pendent of body muscle mass, therefore it might be a useful mar-
ker of renal disease in hyperthyroid cats. In humans is not clear if
hyperthyroid state could inﬂuence SDMA.
Aim of this study was to evaluate SDMA in hyperthyroid cats
at the time of diagnosis and after treatment.
This was a retrospective observational study. Nineteen hyper-
thyroid cats (TT4 > 40 mmol/L) with normal Crea (<1.8 mg/dL)
were included. Eighteen healthy cats, older than 7 years, with nor-
mal TT4 and Crea <1.8 mg/dL were enrolled as control group.
Data about physical exam, emogram, serum biochemistry and
serum TT4 concentration were evaluated. SDMA was measured
on serum left over from previous analyzes and stored at 80°C.
SDMA measurement was performed in serum samples collected at
the time of diagnosis of hyperthyroidism and after methimazole
treatment when TT4 normalized, between 10 to 90 days after initi-
ation of the treatment. Follow-up was available for 8/19 hyperthy-
roid cats; SDMA was measured using a validated immunoassay
(IDEXX SDMA test).
Hyperthyroid cats were older (P = 0.0005) and had a lower
weight (P < 0.0001) than control cats. In hyperthyroid cats Crea
at diagnosis was positively correlated with SDMA (r = 0.47,
P = 0.04) and negatively correlated with TT4 (r = 0.46,
P = 0.04). No correlation was found between SDMA and TT4 at
diagnosis (P = 0.10). In hyperthyroid cats weight was positively
correlated with creatinine (r = 0.51, P = 0.004) but not with
SDMA (P = 0.39). There was no diﬀerence for Crea between
hyperthyroid cats and controls at diagnosis (P = 0.3). Creatinine
signiﬁcantly increased (P = 0.03) after treatment despite body
weight did not (P = 0.13). No diﬀerence was found when compar-
ing SDMA in hyperthyroid and control cats at diagnosis
(P = 0.11) nor after treatment (P = 0.86). Five hyperthyroid cats
had SDMA value higher than reference range at diagnosis. Fol-
low-up after treatment was available for 2/5 only; in these 2 cats
when TT4 was normal Crea was still normal and SDMA was
increased in one. 2/5 cats showed increased creatinine when TT4
normalized, but none of them had high SDMA at diagnosis.
Based on this preliminary study hyperthyroidism seems not to
inﬂuence SDMA concentration.
Disclosures: No disclosures to report.
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LOW THYROXINE CONCENTRATIONS AFTER CON-
TROLLED FEEDING OF BOVINE THYROID GLAND TO
DOGS. L. Steinhoﬀ1, B. Ruhmann1, A. M€osseler2, M. Schmicke1.
1Clinic for Cattle, Endocrinology, University of Veterinary Medi-
cine Hannover, Hannover, Germany, 2Institute for Animal Nutri-
tion, University of Veterinary Medicine Hannover, Hannover,
Germany
Feeding of biologically appropriate raw food (BARF) including
gullet is popular: Due to the close anatomical position of the thy-
roid gland and the respective muscle tissue such diets are likely to
be contaminated with thyroid gland tissue and may cause alimen-
tary thyrotoxicosis. However, as controlled studies are missing, it
is unclear which eﬀect the absorbed total thyroxine (T4) and tri-
iodothyronine (T3) may have on the thyroid hormone status.
Because T4 levels are still routinely checked in the elderly dog and
commonly in dogs suspicious of behavioral issues it would be of
high diagnostic interest, if potential thyroid gland feeding may
interfere with the diagnostic approach. Therefore, the present
study aimed in investigating the short term eﬀect of thyroid gland
feeding on the thyroid hormone concentration in dogs. Bovine thy-
roid gland from the slaughterhouse (0.5 g/kg body weight) was fed
after 12 h fasting together with a complete dry diet. Blood samples
were taken 19 days before the experiment in order to verify euthy-
roidism in the healthy beagle dogs (n = 5). On the day of the feed-
ing experiment blood was taken before (0 and 4, 8, 24, 52 h as
well as 6 days after feeding. In the samples T4-, free T4-, T3 and
thyroid stimulating hormone (TSH) as well as thyroglobulin
autoantibodies (TgAA) were measured either using an automated
chemiluminescence immunoassay (Immulite 1000 System, Sie-
mens Diagnostics, USA) or a commercially available TgAA assay
(Oxford Laboratories, MI, USA).. No dog had TgAA. After feed-
ing thyroid gland there was an increase up to 7.8 fold basal levels
of T4, free T4 and T3 serum concentrations. Serum levels returned
to basal levels after 52 h, however, three of ﬁve dogs showed T4
and fT4 concentrations below the reference range 52 h and 6 days
after single controlled thyroid gland feeding. TSH levels were sup-
pressed after feeding for 52 h. None of the dogs showed any clini-
cal symptoms of hyperthyroidism. Feeding of thyroid tissue to
healthy dogs resulted in distinct eﬀects on the thyroid hormone
blood concentration. Initially single feeding of thyroid gland lead
to considerably higher T4 levels but afterwards also to lower T4
and fT4 concentrations. Therefore, if euthyroidism should be diag-
nosed, administration of dog food containing thyroid gland should
be carefully ruled out for the last seven days.
Disclosures: No disclosures to report.
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C-REACTIVE PROTEIN IN DOGS DIAGNOSED WITH
HYPOADRENOCORTICISM. J.G. Lyngby, J.F.H. Lundsgaard,
L.R. Jessen, L.N. Nielsen. University of Copenhagen, Frederiks-
berg, Denmark
C-reactive protein (CRP) is a major acute phase protein and a
marker of systemic inﬂammation in dogs. C-reactive protein, and
indirectly the innate immune system, has not previously been eval-
uated in dogs with Hypoadrenocorticism (HA). Accordingly, the
aim of this study was to investigate if dogs with HA were able to
mount an acute phase response assessed by an elevated CRP.
Medical records were reviewed for patients newly diagnosed
with hypoadrenocorticism between May 2010 to March 2017.
Dogs were considered having HA if both a pre- and post ACTH
stimulation cortisol were ≤55 nmol/L. Dogs were excluded if they
were not newly diagnosed with HA, or had received treatment for
either hypoadrenocorticism or hyperadrenocorticism, or if they did
not have a CRP measured around the time of diagnosis.
Three hundred and twenty-two medical records from dogs with
an ACTH stimulation performed were screened. Seventeen dogs
with HA were identiﬁed. Of these, nine dogs with hypoadrenocor-
ticism were included in this retrospective case series. The median
age at time of presentation was 5.5 years and included three intact
males, two neutered males, two intact females and two spayed
females. The most prevalent clinical signs included vomiting (6/9),
weight loss (6/9), and diarrhea (3/9), and all of the dogs had at
least one of these clinical signs. Six of nine dogs had azotemia.
The mean CRP was 62.2 mg/L, with an inter quartile range:
20.45–89.66 mg/L (reference 0–25 mg/L). Seven out of nine dogs
had an elevated CRP. Interestingly, the two dogs with
normal CRP were non-azotemic and clinically stable at the time of
presentation.
In conclusion, dogs with hypoadrenocorticism are able to
induce CRP production. This could indicate that at least part of
the innate immune response is functional. Dogs with HA often
have a normal neutrophil count, making neutrophils unreliable as
marker of inﬂammation in HA. C-reactive protein could therefore
be a useful biomarker for acute inﬂammation in patients with HA
when other markers of inﬂammation are not reliable.
Disclosures: No disclosures to report.
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SYSTEMIC HYPERTENSION IN DIABETIC CATS: DOES IT
REALLY MATTERS?. P. Garcıa San Jose1, I. Clares Moral1, S.
Gonzalez Sanz1, P. Casals Canal1, R. Garcıa del Real Torralva1,
M.D. Perez Alenza2. 1Hospital Veterinario Complutense, Madrid,
Spain, 2Departamento de Medicina y Cirugıa Animal, Universidad
Complutense, Madrid, Spain
Hypertension in diabetic humans is common (prevalence 40–80%)
and related with hyperglycemia, duration of the disease and sev-
eral complications. In diabetic cats, previous studies shown that
hypertension is not present or it is uncommon. The aims of this
study were to determine prevalence of hypertension in feline dia-
betes mellitus (DM) and its potential relation with diﬀerent
parameters (age, body condition score (BCS), BCS previous to
diagnosis, sex, glycemic control, time since diagnosis, concurrent
diseases, chronic corticoid treatments, diabetic neuropathy and
remission).
Thirty diabetic cats were assessed for the ﬁrst time at the Veteri-
nary Teaching Hospital Complutense between January 2013 and
April 2016. Systolic blood pressure (SBP) was measured using
Doppler methodology. Hypertension was deﬁned as ≥160 mm Hg,
and subclassiﬁed following the ACVIM consensus and the ISFM
guidelines. BCS was categorized from 1 to 9, being 5 the ideal
weight. No cat was receiving anti-hypertensive treatment.
Age ranged from 3 to 16 years, 23/30 males and 7/30 females;
all neutered excepting one male. At diagnosis 12/30 (40%) of the
cats were underweight. Previous to diagnosis no cat was under-
weight, in fact 83% (25/30) were overweight.
Prevalence of hypertension was 30% (9/30) and 4/30 had severe
hypertension (≥180 mm Hg). Concurrent diseases known to be
associated with hypertension were present in 9/30 cats (30%).
Hypertension and SBP values were not correlated with age, time
since diagnosis, sex, glycemic control, corticoid excess, remission
or diabetic neuropathy.
BCS previous to diagnosis was negatively correlated with SBP
(P = 0.039). None of the overweight cats previous to diagnosis
were hypertensive (P = 0.008). Also, underweight cats at diagnosis
shown a higher prevalence of hypertension than those with a
BCS≥5 (50% and 25% respectively; P = 0.038).
Prevalence of hypertension was diﬀerent in diabetic cats without
concurrent diseases (0%), diabetic cats with a disease not associ-
ated with hypertension (29%) and those with a disease known to
increase SBP (56%)( P = 0.023).
Remission was present in 11/27 cats (41%) with a median time
of 4.2  3.5 months. Remission was positively correlated with the
presence of diabetic neuropathy at ﬁrst visit (P = 0.052).
Hypertension seems to be infrequent in diabetic cats as previ-
ously reported, and it is positively correlated with concurrent dis-
eases associated with hypertension and negatively correlated with
BCS before diagnosis. The relation between hypertension, obesity
and diabetes in cats is not similar to observed in humans. In
hypertensive diabetic cats, it is recommended to search for other
diseases causing the elevated blood pressure.
Disclosures: No disclosures to report.
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SYSTEMIC HYPERTENSION IN DOGS WITH DIABETES
MELLITUS. P. Casals Canal1, P. Garcıa San Jose1, I. Clares
Moral1, S. Gonzalez Sanz1, R. Garcıa del Real Torralva1, M.D.
Perez Alenza2. 1Hospital Veterinario Complutense, Madrid, Spain,
2Departamento de Medicina y Cirugıa Animal, Universidad Com-
plutense, Spain
The relationship between diabetes mellitus (DM) and hypertension
is complex. In humans, DM is associated with hypertension, but
information on blood pressure in diabetic dogs is scarce. It has
been reported in diabetic dogs, that males and dogs with longer
duration of diabetes have higher blood pressure (BP) values. Fur-
thermore, obesity is associated with increases in BP in a variety of
species but its role in dogs is unclear. Aims of this study were to
identify the frequency of hypertension in dogs with DM, and char-
acterize the relationship between hypertension and age, sex, repro-
ductive status, duration of DM, body condition score, concurrent
diseases and treatment with corticoids.
Medical records of all diabetic dogs presented to the Internal
Medicine Service of the Veterinary Teaching Hospital Com-
plutense Madrid from July 2013 to March 2017 were reviewed. BP
using a Doppler device was assessed at the ﬁrst visit. Hypertension
was deﬁned as a systolic blood pressure (SBP) ≥160 mm. Dogs
receiving antihypertensive medication at this moment were
excluded. Following the ACVIM guidelines, hypertensive animals
were sub-classiﬁed according to the risk of target organ damage
and antihypertensive treatment was administered if deemed appro-
priate. Good control of DM was considered with fructosamine
values <350 micromol/L, glucose curve values ranging from 90 to
250 mg/dL and absence of DM clinical signs.
Fifty-three dogs were included, 25 females (12/25 intact and 13/
25 neutered), and 28 males (15/28 intact and 13/28 neutered). Ages
ranged from 0.2 to 13.7 years. At ﬁrst visit in our hospital, 44/53
dogs did not have a good control of DM.
Twenty-ﬁve dogs were considered hypertensive (25/53; 47%).
Hypertension was signiﬁcantly positively correlated to age
(P = 0.009). No signiﬁcant correlation between hypertension and
sex, reproductive status, concurrent diseases, time since DM diag-
nosis or obesity was observed. Hypertension was not signiﬁcantly
correlated with the control of DM; however, none of the dogs
considered as in good control of the diabetes had severe hyperten-
sion (P = 0.067).
Hypertension was signiﬁcantly associated with chronic corticoid
excess, due to hyperadrenocorticism or exogenous administration
(12/19)( P = 0.05).
Hypertension was present in 47% of diabetic dogs (similar to
the prevalence reported in previous studies), and age and corticoid
excess were signiﬁcantly related to it. Obesity in diabetic dogs was
not related to hypertension as it has been observed in non diabetic
dogs.
Disclosures: No disclosures to report.
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CANINE ELECTROLYTE ANALYSIS IN DOGS WITH
HYPOADRENOCORTICISM: A COMPARISON OF TWO IN-
HOUSE ANALYZERS WITH A REFERENCE LABORATORY.
S.J. Fowlie, S. Spence, E. Roberts, I. Ramsey. University of Glas-
gow, Glasgow, UK
Dogs receiving treatment for hypoadrenocorticism are typically
monitored by analysis of their serum sodium (Na+) and potassium
(K+) concentrations and the Na+: K+ ratio alongside their clini-
cal signs. There is a desire for veterinarians to be able to measure
these concentrations in-house, allowing same day dose changes as
opposed to waiting for the results from a reference laboratory.
The aim of this study was to compare these electrolyte concen-
trations and Na+: K+ ratios obtained from two in-house elec-
trolyte analyzers (IDEXX Catalyst Dx and IDEXX Vetstat)
with a reference laboratory (Olympus AU600) in a cohort of dogs
with hypoadrenocorticism.
Cases (n = 33) were prospectively enrolled into a clinical trial
comparing ﬂudrocortisone to DOCP in the treatment of hypoad-
renocorticism. All dogs had multiple electrolyte measurements
taken at various time points during treatment. A total of 343
samples were tested by the reference laboratory using the Olympus
AU600 analyzer. Of these, 280 samples were also tested using the
Catalyst Dx analyzer and 61 by the Vetstat analyzer. Some
samples were tested using all three analyzers.
The Catalyst Dx and Vetstat showed good correlation to
the Olympus AU600 for Na+ and K+ concentrations and Na+:
K+ ratio. For the Catalyst Dx these were r = 0.714, 0.830 and
0.858 respectively, all with a P < 0.0001. For the Vetstat these
were r = 0.816, 0.955 and 0.959, all with a P < 0.0001. The mean
diﬀerence (Bland-Altman plot) for Na+ was 5.84 mmol/L with a
standard deviation of 3.69 for the Catalyst Dx and
11.67 mmol/L and 2.46 for the Vetstat. The mean diﬀerence
and standard deviation for K+ was 0.15 mmol/L and 0.36
respectively for the Catalyst Dx and 0.01 mmol/L and 0.17 for
the Vetstat. Finally, the mean diﬀerence and standard deviation
for the Na+:K+ ratio was 0.20 and 2.90 respectively for the Cat-
alyst Dx and 3.07 and 1.83 for the Vetstat.
Both in-house analyzers displayed good correlation with the ref-
erence laboratory for the electrolytes measured. However, both
analyzers persistently recorded higher Na+ concentrations. Analy-
sis of K+ concentrations was closer to the reference laboratory
but the eﬀect of the increased Na+ resulted in the Na+: K+ ratio
also being higher. This could have clinically signiﬁcant eﬀects
in the management of dogs with hypoadrenocorticism and
care should be taken when using target ranges based on a
reference analyzer when using results from in-house electrolyte
measurements.
Disclosures: Disclosures to report.
The lead author’s position and this study are jointly funded by
Dechra Ltd and the University of Glasgow.
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CONCURRENT PITUITARY AND ADRENOCORTICAL
TUMORS IN DOGS WITH SPONTANEOUS HYPERCORTI-
SOLISM. K.L. van Bokhorst, S.A.E.B. Boroﬀka, H.S. Kooistra,
S. Galac. Faculty of Veterinary Medicine, Utrecht University,
Utrecht, the Netherlands
Spontaneous hypercortisolism or Cushing’s syndrome in dogs is
due to a pituitary tumor (PT) or an adrenocortical tumor (AT),
but concurrent PT and AT have also been reported. The objective
of this retrospective study was to analyze the clinical and com-
puted tomographic (CT) imaging data of a large group of dogs
diagnosed with spontaneous hypercortisolism to report for concur-
rent PT and AT.
The clinical records of 202 dogs with spontaneous hypercorti-
solism, referred to the authors’ institution, were reviewed. Diagno-
sis was based on physical and biochemical changes suggestive of
hypercortisolism and conﬁrmed by endocrine function tests. Endo-
crine tests revealing dexamethasone resistance in combination with
an endogenous plasma ACTH concentration <40 ng/mL was inter-
preted as functional AT. In all dogs, pre- and postcontrast CT of
both the pituitary gland and the adrenal glands was performed. A
pituitary/brain (P/B) ratio >0.31 was interpreted as enlarged, con-
sistent with a PT. Heterogeneous adrenal structure, asymmetric
shape, and adrenal width >15 mm were consistent with an AT.
Adrenal expansion into blood vessels greatly supported the
diagnosis of an AT.
In dogs with suppressible hypercortisolism (122/202), 78 dogs
(64%) showed an enlarged pituitary gland (median P/B ratio 0.43,
range 0.32–1.21) on CT. Two of these 78 dogs were diagnosed
with a concurrent AT. In the remaining dogs with suppressible
hypercortisolism (44/122; 36%) a pituitary microadenoma (median
P/B ratio 0.27, range 0.07–0.31) was diagnosed.
In the non-suppressible group (80/202), 47 of the 80 dogs
(59%) had an enlarged pituitary gland (median P/B ratio 0.57,
range 0.35–1.50) and in 8 of the 80 dogs (10%) a concurrent AT
was present. In the remaining 33 dogs (41%) from this group, the
pituitary gland was not enlarged (median P/B ratio 0.23, range
0.09–0.30). Among them, a pituitary microadenoma was diag-
nosed in 6 dogs. In the other 27 dogs, ATs (2 bilateral, 25 unilat-
eral) were diagnosed and conﬁrmed by a plasma ACTH
concentration < 40 ng/mL in all cases and by histopathology in
21/27 cases.
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We conclude that concurrent adrenal and pituitary lesions are
present mainly in dogs with non-suppressible hypercortisolism.
Results of this study show that CT evaluation of both the pitu-
itary and the adrenal glands should always be included in the diag-
nostic work-up of dogs with hypercortisolism to provide optimal
treatment and prognosis.
Disclosures: No disclosures to report.
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PREVALENCE OF NEUROLOGICAL SIGNS IN HYPOTHY-
ROID DOGS AT DIAGNOSIS. S. Gonzalez Sanz1, R. Garcıa del
Real Torralva1, P. Garcıa San Jose1, I. Clares Moral1, P. Casals
Canal1, M.D. Perez Alenza2. 1Hospital Veterinario Complutense,
Madrid, Spain, 2Departamento de Medicina y Cirugıa Animal,
Universidad Complutense, Spain
Neurological signs (NS) can occur in canine hypothyroidism and
sometimes, they are the unique manifestation of this disease. The
objective of the present retrospective study was to evaluate the fre-
quency of NS, including seizures, among hypothyroid dogs at
diagnosis. Fifty-nine dogs newly diagnosed with hypothyroidism at
The Veterinary Teaching Hospital Complutense Madrid between
October 2011 and March 2017 were reviewed.
Age ranged between 2.3 and 6.5 years, 24/59 females, 37/59
males, 29/59 intact and 30/59 neutered. Duration of clinical signs
before diagnosis ranged from 1 to 24 months (mean
9  6.7 months). Clinical signs, body condition score (BCS), con-
current diseases, body weight, total-thyroxine (tT4) ,free-thyroxine
(fT4), thyroid stimulating hormone (TSH) and cholesterol levels
were recorded.
Neurological signs were present in 17/59 dogs (29%), being sei-
zures the most common (13/17), while 4/17 dogs presented other
NS (vestibular deﬁcits, megaesophagus, head bobbing syndrome
and peripheral neuropathies).
No association was observed between seizures and age, sex,
BCS, duration of signs before diagnoses, tT4 and fT4 levels, repro-
ductive status or other NS.
Mean plasma TSH in dogs without seizures (2.0  1.7 ng/mL)
was signiﬁcantly higher than in dogs without this NS
(1.3  2.2 ng/mL) (P = 0.04). Among the 13 dogs that presented
seizures, 7/13 (54%) had normocholesterolemia and 6/13 (46%)
hypercholesterolemia; including one dog (8%) with plasma choles-
terol levels above 620 mg/dL. However, in the group of dogs with-
out seizures, only 4/29 (14%) presented normal cholesterol levels
and 25/29 (85%) hypercholesterolemia, including 12/29 (41%) with
plasma cholesterol levels above 620 mg/dL of (P = 0.01).
Prevalence of seizures at diagnosis was higher in dogs with clini-
cal evidence of myxedema (4/9; 44%) compared with dogs without
this clinical sign (9/50; 18%) (P = 0.078).
Neurological signs have been described to occur in 7.5% of
hypothyroid dogs. However, in the present study, 29% of hypothy-
roid dogs had NS, and among them, 76.5% presented seizures.
Probably, our diagnostic protocol used for convulsive patients, were
thyroid hormones testing is always included before anticonvulsive
treatment is administered, is related with this ﬁnding. Diﬀerent
mechanisms have been proposed to explain the development of NS
in hypothyroid dogs, including alterations in axonal transport and
ischemia. Hypercholesterolemia and atherosclerosis and consequent
hypoxia of Central Nervous System has been observed and pro-
posed as a cause of NS; however, in the present study hypercholes-
terolemia is deﬁnitely not related to seizures. Clinical evidence of
myxedema though seems to be related with seizures.
Disclosures: No disclosures to report.
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EVALUATION OF ONE PORTABLE BLOOD GLUCOSE
METER AND ONE PORTABLE GLUCOSE-KETONES
METER IN DOGS. F. del Baldo, E. Malerba, S. Corradini, I.
Rovatti, A. Zeppi, F. Dondi, F. Fracassi. University of Bologna,
Ozzano Dell’Emilia, Italy
Nowadays only few Portable Blood Glucose Meters (PBGMs)
have been developed speciﬁcally for use in dogs and cats. Recently
one glucometer (Gluco Calea, WellionVet; GC) and one glucose-
ketones meter (Belua, WellionVet; BE) have been developed for
use in veterinary medicine. The aims of this study were to assess
the accuracy and precision of these devices in canine venous and
capillary blood samples based on ISO 15197:2013 and to evaluate
packed cell volume (PCV) interferences.
Samples were obtained from 45 non anemic dogs (PCV 37–
54%) and 10 anemic dogs (PCV<37%) divided into three glycemic
ranges: high (>140 mg/dL), medium (90–139 mg/dL), and low
(<90 mg/dL). Paired measurements of glucose and 3-az-hydroxy-
butyrate (3-HB) from capillary and venous blood samples were
determined using the two devices and compared with the results of
reference methods (enzymatic hexokinase and 3-HB-dehydrogen-
ase, respectively) obtained by an automated chemistry analyzer
(Beckman-Coulter AU480). Linear regression, Bland Altman plots
and the Parkes error grid analysis (EG) were used to assess the
accuracy. PCV interferences for glucose measurement were
assessed comparing the diﬀerences between PBGMs readings and
reference method values in anemic and non-anemic dogs. To assess
within-run precision, glucose concentrations obtained from 12
samples, belonging to the three glycemic ranges, were measured 10
times within 10 min. Between-day precision was assessed by testing
each manufacturer’s glucose control solution over 10 consecutive
days. P < 0.05 was considered signiﬁcant.
Mean diﬀerences (mg/dL) between measurements of each
PBGM on capillary and venous blood and values measured by the
reference method were: GC 37.8  24.2, 44.1  27.2, BE
20.4  28.6 and 10.2  25.1 respectively. A positive signiﬁcant
correlation between all paired samples was found for both devices
(r > 0.89). However neither PBGMs fulﬁlled ISO requirements:
82.21% and 84.08% of glucose values measured respectively on
capillary and venous blood using GC fell in zone A+B of EG;
86.7% and 97.8% of glucose values measured respectively on cap-
illary and venous blood by BE fell in zone A+B of EG. Within-
run and between-day precision were adequate. The eﬀect of PCV
was signiﬁcant and higher results with lower PCV were observed.
The correlations between capillary and venous 3-HB and refer-
ence 3-HB were r = 0.48 and r = 0.59, respectively. Mean diﬀer-
ences between capillary and venous 3-HB and reference method
were 0.05 (0.57) and 0.07 (0.79) respectively; within-run preci-
sion was adequate.
Our results show that both GC and BE are not suﬃciently
accurate and safe for clinical use in dogs.
Disclosures: Disclosures to report.
Devices and test strips were provided by manufacturers (Wel-
lionVet).
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SERUM SYMMETRIC DIMETHYLARGININE (SDMA) IN
DOGS WITH HYPOTHYROIDISM. G. Carotenuto, S. Corra-
dini, A. di Paola, F. Dondi, F. Fracassi. University of Bologna,
Ozzano Dell’Emilia, Italy
Canine hypothyroidism is associated with decreased glomerular ﬁl-
tration rate (GFR), while serum creatinine (SCr) concentrations
are rarely increased above the reference interval (RI) in hypothy-
roid dogs. Symmetric dimethylarginine (SDMA) is considered a
biomarker for early detection of renal dysfunction and resulted
strongly correlated with GFR in dogs. In humans, SDMA is sig-
niﬁcantly higher in hypothyroid compared to healthy people. The
aim of this study was to evaluate the SDMA concentrations in a
population of hypothyroid dogs (HD) at the time of diagnosis
(T0) and after treatment (T1). Fourteen dogs aﬀected by sponta-
neous hypothyroidism and 20 healthy dogs (control group) were
included. The diagnosis of hypothyroidism was based on consis-
tent clinical signs, laboratory ﬁndings, including serum total T4
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and cTSH concentrations below and above the RI, respectively. In
dogs with normal cTSH, rhTSH stimulation test was performed to
conﬁrm the diagnosis. SCr was measured for diagnostic or check-
up purposes and SDMA was measured afterwards from surplus of
serum stored at 20°C. In HD such measurements where per-
formed at T0 after 15 to 112 days (median 64.5) of treatment (T1)
with levothyroxine (10–15 µg/kg q12 h PO). SDMA was measured
using a validated immunoassay (IDEXX SDMA test).HD had a
median age of 4 years (4–15), median body weight (BW) of 37.5 kg
(7.9–53), 7/14 were male (1 castrated) and 7/14 female (3 spayed).
There were no signiﬁcant diﬀerences regarding signalment and BW
between HD and control group. Median SDMA concentrations (RI
<14 µg/dL) were 10 µg/dL (6–17), 13.5 µg/dL (7–20) and 10.5 µg/
dL (5–17) in healthy dogs, HD at T0 and T1, respectively. SDMA
concentrations were signiﬁcantly higher in HD at T0 in comparison
with healthy dogs (P < 0.029) and HD at T1 (P < 0.031). Among
HD, 7/14 had SDMA above the RI at T0 and only 1/14 (7%) at T1.
At T0, 4/14 HD had SCr above the RI (>1.35 mg/dL). SCr concen-
tration was signiﬁcantly higher in HD at T0 compared to HD at T1
(P < 0.0082), and in one dog SCr was above the RI at T1. No signif-
icant correlation was observed between SDMA and T4, and SDMA
and SCr in the HD at T0 and T1.
This study shows that in HD SDMA concentrations are fre-
quently above the RI at diagnosis and normalize after treatment.
The GFR modiﬁcations that are present in canine hypothyroidism
may be better detected with SDMA compared to SCr.
Disclosures: No disclosures to report.
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EVALUATION OF ONE PORTABLE BLOOD GLUCOSE
METER AND ONE PORTABLE GLUCOSE-KETONES
METER IN CATS. E. Malerba, F. del Baldo, S. Corradini, A.
Zeppi, I. Rovatti, F. Dondi, F. Fracassi. University of Bologna,
Ozzano Dell’Emilia, Italy
Numerous portable blood glucose meters (PBGMs) have been devel-
oped during the last decade, the majority of which is designed for
use in humans. Recently one glucometer (Gluco Calea, WellionVet;
GC) and one glucose-ketones meter (Belua, WellionVet; BE) have
been developed for use in veterinary medicine. The aims of this
study were to assess the accuracy and precision of these devices in
feline venous and capillary blood samples based on ISO 15197:2013
and to evaluate packed cell volume (PCV) interferences.
Samples were obtained from 29 non anemic cats (PCV 30–47%)
and 18 anemic cats (PCV<30%) divided into three glycemic
ranges: high (>140 mg/dL), medium (90–139 mg/dL), and low
(<90 mg/dL). Paired measurements of glucose and 3-az-hydroxy-
butyrate (3-HB) from capillary and venous blood samples were
determined using the two devices and compared with the results of
reference methods (enzymatic hexokinase and 3-HB-dehydrogen-
ase, respectively) obtained by an automated chemistry analyzer
(Beckman-Coulter AU480). Linear regression, Bland Altman plots
and the Parkes error grid analysis (EG) were used to assess the
accuracy. PCV interferences for glucose measurement were
assessed comparing the diﬀerences between PBGMs readings and
reference method values in anemic and non-anemic cats. To assess
within-run precision, glucose concentrations obtained from 14
samples, belonging to the three glycemic ranges, were measured 10
times within 10 minutes. Between-day precision was assessed by
testing each manufacturer’s glucose control solution over 10 con-
secutive days. P < 0.05 was considered signiﬁcant.
Mean diﬀerences (mg/dL) between measurements of each
PBGM on capillary and venous blood and values measured by the
reference method were: GC 30.7  35.4, 35.6.2  40.5, BE
15.5  35.5 and 15.0  24.1 respectively. A positive signiﬁcant
correlation between all paired samples was found for both devices
(r > 0.89). However neither PBGMs totally fulﬁlled ISO require-
ments, but 100% of glucose values measured on venous blood
using BE fell in zone A+B of EG. Within-run and between-day
precision were adequate. The eﬀect of PCV was signiﬁcant (higher
results with lower PCV) only for BE.
The correlations between capillary and venous 3-HB and refer-
ence 3-HB were r = 0.66 and r = 0.82 respectively. Mean diﬀer-
ences between capillary and venous 3-HB and reference method
were 0.07 (1.15) and 0.30 (1.48) respectively; within-run
precision was adequate.
Our results show that GC is not suﬃciently accurate while the
superior performances of BE supports its clinical use in cats.
Disclosures: Disclosures to report.
Devices and test strips were provided by manufacturers (Wel-
lionVet).
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BRONCHOALVEOLAR LAVAGE ANALYSIS USING UREA
DILUTION STANDARDIZATION IN DIAGNOSIS OF RESPI-
RATORY DISEASES IN DOGS. A.E.H. Paul1, P. Irwin2, J.
Stayt3, C.S. Mansﬁeld4. 1Anderson Moores Veterinary Specialists
Ltd, Hursley, Winchester, UK, 2Murdoch University, Murdoch,
Perth, Australia, 3Vetpath Laboratory Services, Perth, Australia,
4University of Melbourne, Parkville, Melbourne, Australia
Considerable variation has been reported in total cell counts and
concentration of biochemical markers due to variable recovery of
pulmonary epithelial lining ﬂuid (PELF) in bronchoalveolar lavage
(BAL) ﬂuid. A number of chronic respiratory conditions can be
diﬃcult to diagnose deﬁnitively and accounting for dilution of
PELF may allow us to better diﬀerentiate respiratory disease. Dif-
ferentiation of various chronic respiratory diseases may be made
via analysis of BAL ﬂuid using urea concentration of BAL relative
to blood urea concentration as a marker of dilution of PELF.
Assessment of cell counts after adjusting for dilution may allow
diﬀerentiation of the primary disease process in dogs presenting
with respiratory signs.
Client-owned dogs presenting for investigation of respiratory
disease were included. All dogs had a BAL performed and BAL
cell counts were corrected after using urea as a marker for dilution
and comparison of urea in blood to that of urea in BAL ﬂuid. A
ﬁnal diagnosis of respiratory disease was made after retrospective
analysis of all diagnostic investigations and response to treatment.
Seventy two BAL samples from a total of 48 dogs were ana-
lyzed and thirteen primary causes of respiratory disease identiﬁed
based on diagnostic investigation including BAL cell cytology and
treatment response. Respiratory diseases were also assigned to
inﬂammatory, non-infectious, infectious, upper respiratory tract or
respiratory neoplasia categories based on the disease diagnosed.
There was no statistical diﬀerence in the adjusted total cell counts
of BAL ﬂuid (BALF) from dogs with diﬀerent respiratory diseases
or disease groups. Mycoplasma spp had no eﬀect on the total cell
count in dogs with chronic bronchitis.
This study suggests total cell counts of BAL ﬂuid corrected for
dilution by urea concentration cannot be used to distinguish
between diﬀerent respiratory diseases. A larger number of cases
and cross section of respiratory disease may further identify signiﬁ-
cant diﬀerences in total and diﬀerential cell counts of various dif-
ferent diseases.
Disclosures: This study was funded by the Australian Compan-
ion Animal Health Foundation and supported by the Australian
and New Zealand College of Veterinary Scientists Research Grant
Amanda Paul and Jason Stayt also indicate that they have no aﬃl-
iations or ﬁnancial involvement with any organization or entity
with a ﬁnancial interest in, or in ﬁnancial competition with, the
subject matter or materials discussed in this article. Caroline
Mansﬁeld has funding for research provided by Australian
Research Council, Canine Research Foundation (Australian Ken-
nel Club), Comparative Gastroenterology Society, NexVet Biolog-
ics, PlasVac, Blackmores, Hills Pet Nutrition. She is also provided
an Honoraria for travel/speaking in 2017 provided by Nestle Pur-
ina, FSAVA. Peter Irwin has funding from the Australian
Research Council, Canine Research Fund and Australian Com-
panion Health Foundation for ongoing research projects.
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PREVALENCE OF DEGENERATIVE JOINT DISEASE IN
MATURE INDOOR CATS. H.P. Huang1, T.C. Tai2, S.H. Chiu1,
Y.C. Wu2, Y.H. Lien2. 1National Taiwan University, Taipei, Tai-
wan, 2Azu Clinic for Animals, Taipei, Taiwan
The aims of this investigation were to report the radiographic
prevalence of DJD and physical changes in the appendicular skele-
ton and its clinical relevance in mature indoor cats.
One hundred and sixteen apparently healthy mature client-
owned cats were included (age > 6 years). All cats were kept
exclusively indoors. These owners reported no lameness was
observed of these cats over the last six months. All cats underwent
a full physical examination and orthopedic evaluation of the
appendicular and axial skeleton (signs of pain, instability, eﬀusion
and crepitus, performed by the same assessor). Body condition
score (BCS, 5-point system) was also assessed. Each cat was gently
restrained for radiographic examination without sedation. Radio-
graphs of both shoulders, elbows, carpi, coxofemoral joints, stiﬂes,
and tarsi were evaluated. Among 116 cats, 111 (95.7%) cats had
at least one appendicular joint aﬀected with radiographic
osteoarthritis. The prevalence of DJD in shoulders, elbows, carpi,
coxofemoral joints, stiﬂes, and tarsi were 15/116 (12.9%), 86/116
(74.1%), 82/116 (70.7%), 17/116 (14.7%), 71/116 (61.2%), and 11/
116 (9.5%), respectively. Results of multivariate general linear
model analyses indicated that DJD in elbows and coxofemoral
joints was associated with BCS (P = 0.008 and P = 0.014, respec-
tively). DJD in hocks was associated with BCS, gender and neuter-
ing (P = 0.039). Sixty six (56.9%) cats had decreased mobility, and
further discriminant analysis indicated that decreased mobility was
associated with presence of DJD in hocks (P = 0.014); whereas 21
(18.1%) cats hesitated to jump down, and further discriminant
analysis indicated that hesitation of jump down was associated
with presence of DJD in elbows (P = 0.009). Presence of DJD and
decreased mobility was not associated with age or body weight.
Based on this investigation, DJD was highly prevalent in indoor
cats. The front limb joints were commonly aﬀected with DJD. The
living environment (exclusive indoors, ﬂooring materials and lim-
ited access to exercise) might contribute to the high prevalence of
DJD in this cohort.
Disclosures: The study was self-funded. The authors declare
that they have no competing interests. The study was carried out
in accordance with the code of the Research Ethics Oﬃce of
National Taiwan University: No ethical approval was needed if no
trial therapy (tested medicine) was involved in the study. All own-
ers of cats whose cases were included in this study signed up their
written consent for agreement of participating in a research study.
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ORAL CARICA PAPAYA IN THE SUPPORTIVE CARE OF
INFECTIOUS THROMBOCYTOPENIA IN BLEEDING DOGS.
B. Rengaswamy, A.P. Nambi. Madras Veterinary College, Chen-
nai, India
Carica papaya leaf extracts have been used orally to recover plate-
let counts and to control bleeding in human patients with Dengue
fever. The active components of papaya carica extract have been
proved earlier to inhibit immune mediated platelet destruction and
possible bone marrow suppression to fasten the natural course of
recovery by increasing the platelet counts. In this report we stud-
ied the eﬀect of Caprica papaya in the treatment of infectious
thrombocytopenia in dogs. During a one-year period 60 thrombo-
cytopenic dogs with ehrlichiosis, babesiosis, and/or leptospirosis
referred to Madras Veterinary College Teaching Hospital were
studied. They had mild (platelets 50,000–100,000/µl) to severe (pla-
telets 25,000–50,000/µl) thrombocytopenia and evidence of bleed-
ing. In addition coagulation proﬁles, buccal mucosal bleeding
times, saline agglutination tests, spherocyte reviews, direct
Coombs’ (Direct Antiglobulin) tests, von Willebrand Factor
assays, platelet-associated antibody (PSAb) assays, bone marrow
aspiration cytology, and DEA 1 typings were determined. Platelet-
rich plasma or fresh whole blood were transfused in case of severe
(platelets <20,000 cells/µL) thrombocytopenia and/or anemia and
all dogs received doxycycline and prednisone for ehrlichiosis and
leptospirosis, Imidocarb for babesiosis,. Carica papaya leaf extract
was administered at 5 mL per 10 kg body weight twice a day for
3 weeks. Platelet counts increased signiﬁcantly faster in dogs
receiving Carica papaya from day 2–7 compared to those receiving
only other treatments. Also the bleeding signs appear to improve
more rapidly with Carica papaya, and no side eﬀects were
observed. In conclusion Carica papaya may be an inexpensive,
easily available thrombopoietic supplement to more rapidly con-
trol thrombocytopenia and bleeding in dogs with hemoprotozoan
diseases along with transfusions, speciﬁc infectious disease and
immunosuppression.
Disclosures: No disclosures to report.
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METHEMOGLOBINEMIA CAUSED BY CYTOCHROME B5
REDUCTASE DEFICIENCY: GENETIC STUDIES AND
LONG-TERM TREATMENT WITH ORAL METHYLENE
BLUE. J. Jaﬀey1, M. Harmon1, N. Villani1, E. Creighton1, G.
Johnson1, U. Giger2, J. Dodam1. 1University of Missouri Veteri-
nary Health Center, Columbia, USA, 2University of Pennsylvania
School of Veterinary Medicine, Philadelphia, USA
Methemoglobin, which cannot carry oxygen due to oxidized iron,
may accumulate when the cytochrome b5 reductase system is over-
whelmed by toxins or genetically dysfunctional. We report here on
the diagnostic study of hereditary methemoglobinemia of a dog
and a novel long-term treatment.
A juvenile male mixed breed was presented for lethargy, exercise
intolerance, and aggression. Cyanosis, tachycardia, and tachypnea
were observed which persisted during oxygen supplementation.
Arterial blood gas analysis by co-oximetry indicated increased
methemoglobin concentration (27%; normal < 2%) with normal
arterial oxygen tension. After initial intravenous methylene blue
(MB; 1 mg/kg) administration, the dog was treated long-term with
oral MB (1.5 mg/kg, q48 h). Both reduced the methemoglobine-
mia and resolved the clinical signs during the 63-day observation
period.
The erythrocytic cytochrome b5 reductase activity, measured by
NADH-ferricyanide reductase assay, was low (6% compared to
control), while the cytochrome c reductase activity was normal. A
whole genome sequence (369) of this dog contained two heterozy-
gous CYB5R3 missense mutations with a serine for glycine substi-
tution predicted at codon 72 and a leucine for isoleucine
substitution predicted at codon 190. Both missense mutations are
very likely to be deleterious, suggesting that each was inherited
from a diﬀerent parent and that each contributed to the recessive
methemoglobinemia in a compound heterozygous state.
This is the ﬁrst molecular genetic report of CYB5R3 variants
and long-term management with oral MB of hereditary methe-
moglobinemia of a dog with cytochrome b5 reductase deﬁciency.
Further studies on other aﬀected dogs are in progress.
Disclosures: No disclosures to report.
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PREVALENCE OF GAIT ABNORMALITIES IN PUGS: A
QUESTIONNAIRE BASED SURVEY. C. Rohdin1, K. Hultin
J€aderlund2, I. Ljungvall1, K. Lindblad-Toh3, J. H€aggstr€om1.
1Swedish University of Agricultural Sciences, Uppsala, Sweden,
2Norwegian University of Life Sciences, Faculty of Veterinary
Medicine, Oslo, Norway, 3Department of Medical Biochemistry
and Microbiology, Science for Life Laboratory, Uppsala, Sweden
Abnormal gait can be the result of musculoskeletal and/or neuro-
muscular conditions. The Pug breed is predisposed for speciﬁc
orthopedic conditions and neuromuscular problems in the Pug
breed has become increasingly recognized in the last few years.
Lameness, as the result of musculoskeletal problems, and spinal
cord disorders, characterized by paresis and ataxia, were reported
in a British study in 2.4% versus 1.4% of the Pugs attending pri-
mary veterinary care. The prevalence of spinal cord disorders pre-
sented from the United Kingdom poorly corresponds to a Swedish
insurance data report suggesting a seven-fold increase in mortality
rate for ataxia, paresis and collapse in Pugs compared to other
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breeds. Adding the attention ‘wobbly Pugs’ are given on the inter-
net suggests a need to investigate the prevalence of gait abnormali-
ties in the Pug in a systematic way. The aim of this prospective
study was to investigate the prevalence of gait abnormalities in a
cohort of Swedish Pugs by using an owner-based questionnaire
targeting signs of gait abnormality and video footage showing the
dog´s gait. The study also aimed at evaluating associated condi-
tions of abnormal gait; including other health disorders prevalent
in the breed. The owners reported gait aberrations in 20.2 % of
the Pugs with a prevalence increase with increasing age. Adding
the Pugs that were reported to show indirect signs of gait abnor-
malities (wearing their nails and dorsal aspect of the skin on their
paws) increased the prevalence of gait abnormalities in the breed
from 20.2% to 30.7%. These results suggest gait abnormalities to
be a more signiﬁcant health problem than previously reported.
Indeed, the single, listed, most common cause for death/euthana-
sia, reported by the owners, was a gait abnormality. In conclusion,
gait abnormalities were a common ﬁnding in the Pug breed. Wear-
ing of the nails and/or skin on the dorsum of the paws, predomi-
nately in the thoracic limbs, were frequently found and from a
comparably young age. The result of the questionnaire and the
video analysis suggest neurological disorders are predominately
responsible for the high prevalence of gait abnormalities in the
Pug breed. The prevalence of abnormal gait was signiﬁcantly asso-
ciated with age and with dyspnea. The gait abnormalities were not
associated with overt signs of pain but were associated with reluc-
tance to go for walks.
Disclosures: No disclosures to report.
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COMPARING THE SUBMAXIMAL EXERCISE TEST
RESULTS AND SEVERITY OF BRACHYCEPHALIC
OBSTRUCTIVE AIRWAY SYNDROME IN PUGS AND
FRENCH BULLDOGS. M. Aromaa, M.M. Rajam€aki, L. Lilja-
Maula. University of Helsinki/Faculty of Veterinary Medicine,
Helsinki, Finland
In addition to respiratory diﬃculties, exercise intolerance and
impaired recovery are major signs of brachycephalic obstructive
airway syndrome (BOAS). Therefore, we investigated the correla-
tions of the 6 min walk test (6MWT) or the 1000 m walk test
results with a veterinary assessment of BOAS severity in a group
of prospectively recruited 1–5 years old Pugs (N = 35) and French
Bulldogs (FBs) (N = 42). For severity of BOAS, dogs graded as
having no or mild signs of BOAS were referred to as the BOAS-
group and those having moderate or severe signs as the BOAS+
group based on veterinary physical examination ﬁndings. The
BOAS- Pugs walked longer distance (P = 0.002) in 6MWT (mean
584  33 m, range 505–630) and shorter time (P = 0.006) in
1000 m walk test (mean 10.17  0.67 min, range 9.39–11.94) than
BOAS+ Pugs (6MWT 517  64 m, range 400–585; 1000 m test
12.26  2.23 min, range 10.25–17.55). Similarly, the BOAS- FBs
walked longer distance (P = 0.063) in 6MWT (639  51 m, range
575–745) and shorter time (P = 0.012) in 1000 m test
(9.47  0.66 min, range 8.15–10.77), than BOAS+ FBs (6MWT
593  73 m, range 435–695; 1000 m test 10.72  1.25 min, range
8.42–12.15). BOAS- Pugs and FBs recovered also more quickly
than BOAS+ Pugs and FBs (P = 0.002; P = 0.007). In conclusion,
submaximal exercise test could be used as non-invasive tool for
evaluation of severity of BOAS.
Disclosures: No disclosures to report.
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BRONCHIECTASIS IN IRISH WOLFHOUNDS WITH
RECURRENT BACTERIAL PNEUMONIA. S.J. Viitanen, A.K.
Lappalainen, M.M. Rajam€aki. University of Helsinki, Helsinki,
Finland
The development of bronchiectasis (BE), an irreversible dilation of
the bronchi, is a well-established complication after bacterial or
viral pneumonia in humans. BE leads to defects in the mucociliary
clearance and predisposes to the development of new bacterial res-
piratory infections. BE has been described in dogs with variety of
respiratory diseases, but the connection to recurrent bacterial
infections has not been fully established. A breed predisposition to
acute bacterial pneumonia (BP) has been described in the Irish
wolfhound (IWH), but the etiology is largely undiscovered.
High resolution computed tomography (HRCT) was performed
to 10 IWHs with recurrent BP (median age 6.0 years, range 0.8–
7.7 years; median number of previous BPs 4, range 2–6). All dogs
were examined when they were clinically healthy and not receiving
antibiotics. HRCT ﬁndings comprised mild to severe bronchiecta-
sis (9/10 dogs), mild to moderate local bronchointerstitial pattern
(2/10), mild local interstitial pattern (1/10), parenchymal band (1/
10), locally thickened pleura 1/10 and subpleural band (1/10).
Bronchiectasis was detected in a single lung lobe in 3/9, in 2 lung
lobes in 3/9 and in 3 lung lobes in 3/9 dogs. Left and right cranial
lobes and the right middle lobe were most often involved.
In our study, BE was commonly detected in IWHs with recur-
rent BP. The development of BE is likely a post-infectious conse-
quence of previous BPs. The presence of BE may further facilitate
the development of new respiratory infections and may therefore
act as a predisposing cause to recurrent BP.
Disclosures: No disclosures to report.
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INVESTIGATION OF THE NASAL MICROBIOTA IN
HEALTHY DOLICHOCEPHALIC DOGS AND DOGS WITH
SINONASAL ASPERGILLOSIS (SNA). E. Vangrinsven, B.
Taminiau, E. Roels, A. Fastres, C. Auquier, F. Billen, G. Daube,
C. Clercx. University of Liege, Angleur, Belgium
Sinonasal aspergillosis (SNA) most commonly aﬀects middle-aged
dolichocephalic dogs and is characterized by a destructive rhinitis
and sinusitis, in the absence of fungal deeper tissue invasion.
Pathogenesis of the disease is, to date, not fully understood. An
uncontrolled and detrimental inﬂammatory response to commensal
fungal colonization of the nasal cavities and sinuses has been sug-
gested. In humans, a role of the bacterial microbiota in the regula-
tion of host immune responsiveness to fungi has been
hypothesized. Therefore, the objective of the present study was to
identify and characterize the microbiota present in nasal cavities
of client-owned dogs diagnosed with SNA compared with healthy
age and breed-matched non-aﬀected dogs.
Nine large breed dolichocephalic dogs diagnosed with SNA (6
males, 3 females, mean age 5.5 years) and 10 healthy age-and
breed-matched dogs (7 males, 3 females, mean age 5 years) were
included. DNA was extracted from a sterile swab introduced in
the distal third of the right nasal cavity under general anesthesia.
Metagenetic analysis was performed on V1-V3 hypervariable
region of 16S rDNA after total bacterial DNA extraction from
nasal specimens and sequencing on a MiSeq Illumina sequencer.
Taxonomical assignation and microbiota community analysis were
done with MOTHUR V1.35 with an OTU clustering distance of
0.03. Diﬀerences of population abundance between groups were
assessed using multiple t tests with Holm-Sidak multi-test correc-
tion (signiﬁcance < 0.05).
Sequencing revealed that Proteobacteria and Firmicutes were the
two most predominant phyla in both groups; representing together
almost 80% of the total bacterial abundance. The remaining 20%
were composed of Bacteroidetes and Fusobacteria in diseased dogs,
and of Actinobacteria almost exclusively in healthy dogs. At family
level, a signiﬁcantly higher abundance of Lactobacillaceae were
found in SNA dogs, while Moraxellaceae signiﬁcantly predomi-
nated in controls. Analysis of diversity metrics revealed that bacte-
rial species richness and diversity were signiﬁcantly higher in SNA
dogs compared with controls.
In conclusion, results of the present study demonstrated the
presence of nasal microbiota alteration in dogs aﬀected with SNA
in association with an increased bacterial diversity. However,
whether such changes are a cause or a consequence of the disease
is unknown and warrants further investigation.
Disclosures: No disclosures to report.
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RETROSPECTIVE STUDY OF CLINICAL FINDINGS,
TREATMENT AND OUTCOME IN DOGS AND CATS DIAG-
NOSED WITH DYSAUTONOMIA. K.E. Clarke1, S.M. Lalor1,
C. Breheny2, S. Adamantos3, R.E. Jepson4, E. Milne2, D.A.
Gunn-Moore2. 1Willows Veterinary Centre and Referral Service,
Shirley, UK, 2Royal Dick School of Veterinary Studies and the
Roslin Institute, Roslin, UK, 3Langford Vets, University of Bris-
tol, Bristol, UK, 4Royal Veterinary College, London, UK
Dysautonomia is a disease characterized by degeneration of auto-
nomic neurons. Previous retrospective case series have been small,
single center and indicate a grave prognosis. The aim of this study
was to perform a retrospective, multicenter review of clinical data
relating to dogs and cats diagnosed with dysautonomia and to
evaluate the outcome in those patients. Cats and dogs with clinical
signs consistent with dysautonomia were included in this retrospec-
tive study. A total of 34 cats and 19 dogs were included. Reported
clinical signs included esophageal, gastric and intestinal dysmotility
and distension, urinary retention and dysuria, reduced or absent
tear production, third eyelid protrusion and inappropriate mydria-
sis. Vomiting and regurgitation were commonly reported in both
species (cats n = 29/34, dogs n = 17/19), while signs consistent with
urinary retention were primarily reported in dogs (n = 14/19) and
third eyelid protrusion was more frequently reported in cats
(n = 20/34). Diagnostic imaging ﬁndings included aspiration pneu-
monia, megaesophagus, gastrointestinal dilation with either ﬂuid
or gas and bladder distension. Esophageal dilation was the most
often identiﬁed diagnostic imaging ﬁnding in cats (n = 20/34),
while in dogs gastrointestinal distension was most commonly iden-
tiﬁed (n = 5/19). Regularly instituted treatments included gastroin-
testinal prokinetics such as cisapride and metoclopramide, feeding
tube placement (esophageal and percutaneous endoscopic gastros-
tomy tubes) and medications to treat urinary retention such as
bethanechol. The overall survival to discharge was 36%. The mor-
tality rate prior to discharge was 71% in cats and 53% in dogs.
Longer term survival (greater than two years) was seen in three
dogs and six cats. In this retrospective study clinical signs, diag-
nostic imaging ﬁndings, treatment and prognosis were all similar
to previous retrospective publications. This paper has illustrated
that some individuals are able to survive this disease and can have
a good long-term prognosis. Prospective studies are required to
identify risk factors that indicate whether a patient is likely to sur-
vive and thus if it is worth embarking upon treatment.
Disclosures: No disclosures to report.
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RETROSPECTIVE STUDY ON 33 CASES OF CANINE PRI-
MARY IMHA: CLINICO-PATHOLOGICAL FEATURES, FOL-
LOW-UP AND PROGNOSTIC FACTORS. A. Gavazza, G. de
Feo, S.M. Levi, A.A. Medina Valentin, V. Marchetti, G. Lubas.
University of Pisa, San Piero A Grado, Pisa, Italy
Primary immune-mediated hemolytic anemia (pIMHA) is the most
common immune-hematological disease in dogs, yet it still repre-
sents a prognostic and therapeutic challenge for many veterinari-
ans. So far, only a limited number of prognostic indicators and
outcome scores are accepted consistently.
Inﬂuence of treatments initiated by referring veterinarians on
clinico-pathological features, disease severity, follow-up, and sur-
vival time were investigated from time of presentation (T0) to our
referral center up to 4 months post presentation. CHAOS and
Tokyo severity scores were applied to all cases and compared with
the disease outcome. Furthermore, several clinico-pathological
signs were studied as prognostic factors at time of discharge from
the Veterinary Hospital (TD), at 30 days and 120 days after
discharge.
Thirty-three cases of pIMHA (according to standard clinical
and clinico-pathological criteria) collected between February 2010–
2016 were included. Data regarding history, blood and urine labo-
ratory tests, and immunosuppressive treatments was collected.
Patients were divided into two groups (16 patients previously trea-
ted by the referring vets, group A, and 17 untreated, group B) and
statistically compared.
In group A platelet count (P = 0.002) and serum concentrations
of alkaline phosphatase (P = 0.010) were signiﬁcantly higher than
group B at T0. In group B serum concentrations of total protein
(P = 0.025), globulins (P = 0.002), C-reactive protein (P = 0.003),
and lactate dehydrogenase (P = 0.028), and urinary parameters as
pigmenturia (P = 0.0003) and bilirubinuria (P = 0.041) were signif-
icantly higher than group A at T0 (Mann-Whitney test). CHAOS
severity score was more predictive of outcome than Tokyo severity
score at 30 and 120 days (Odd Ratio, OR, respectively 15.1 and
10.7). In addition, a few clinico-pathological signs were statistically
related with a worse prognosis (OR): urea concentration (>55 mg/
dL) at TD, hyperbilirubinemia (>1.5 mg/dL) and number of nucle-
ated RBCs (≥30/100 WBC) at T30 and T120, thrombocytopenia
(<150 9 109/L) at TD, T30 and T120. Group B dogs had higher
mortality rate (47%) than group A dogs (13%) after 2 weeks from
T0 (P > 0.05, Kaplan–Meier curve).
In conclusion, previous immunosuppressive treatments by refer-
ring veterinarians may weaken the clinician’s ability to properly
assess patient’s prognosis. This study conﬁrmed some literature
information regarding diagnosis, prognosis and survival times of
dogs suﬀering of IMHA and it adds additional prognostic factors
such as urea concentration, hyperbilirubinemia, circulating nucle-
ated RBCs and thrombocytopenia.
Disclosures: No disclosures to report.
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DIAGNOSTIC ACCURACY OF THE MACRO-ENDOSCOPIC
BRONCHIAL ASPECT FOR THE DIAGNOSIS OF EOSINO-
PHILIC BRONCHITIS. E. Bottero1, E. Benvenuti1, P. Ruggiero1,
D. Falcioni1, E. Mavilio1, N. di Girolamo2. 1Associazione Profes-
sionale Endovet, Rome, Italy, 2Centro Veterinario Specialistico,
Rome, Italy
Bronchoscopy is commonly used for to evaluate dogs with acute
and chronic coughs. Our aim was to evaluate the diagnostic accu-
racy of the macroscopic endoscopic exam of the bronchial mucosa
for the diagnosis of eosinophilic bronchitis. A retrospective multi-
institutional diagnostic accuracy study was performed including all
the dogs presenting with acute or chronic coughs and that under-
went bronchial endoscopy by the Endovet Italian Group between
January 2014 and December 2016. The reference standard was the
cytological evaluation of the bronchoalveolar lavage. The primary
outcome was sensitivity, speciﬁcity, positive predictive value, and
negative predictive value of endoscopic visualization of nodules
for the diagnosis of eosinophilic bronchitis. Of the 845 cases stud-
ied, a total of 781 dogs fulﬁlled the inclusion criteria with cytologi-
cal evaluation of the bronchoalveolar lavage. The dogs ranged in
age from 0.4 to 16 years (8.0 median, 4.0 SD), in body weight
from 1.5 to 45 kg (13.0 median, 9.5 SD), and 325 (41.6%) were
females. A ﬁnal diagnosis of eosinophilic bronchitis was given for
113 (15.6%) cases, and 99 (13.6%) presented nodules during
macroscopic endoscopy. In the ﬁnal logistic regression model,
detection of nodules during endoscopy, higher age, and lower
body weight were associated with a diagnosis of eosinophilic bron-
chitis. Odds of having eosinophilic bronchitis were 34.4% (18.9–
62.6; P < 0.001) greater in dogs presenting nodules during endo-
scopy. The risk of eosinophilic bronchitis increased by 23% (14–
32%; P < 0.001) for a one-year increase in age, and by 3% (0–
5%; P = 0.048) for each kilogram decrease in body weight. Visual-
ization of nodules during endoscopy had a sensitivity of 56.6%
(47.0–65.9%), speciﬁcity of 94.3% (92.3–95.9%), positive predic-
tive value of 62.7% (54.3–70.5%), and negative predictive value of
92.8% (91.2–94.1%). Based on the high speciﬁcity and high nega-
tive predictive value, visualization of nodules during endoscopy is
highly indicative of eosinophilic bronchitis. However, the lack of
visualization of nodules during endoscopy does not exclude the
presence of eosinophilic bronchitis.
Disclosures: No disclosures to report.
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REFLUX ASPIRATION CAN BE DETECTED IN LUNGS OF
DOGS WITH RESPIRATORY DISEASE. M. M€a€att€a1, H.P.
Laurila1, S. Holopainen1, L.I. Lilja-Maula1, M. Melamies1, S.J.
Viitanen1, L.R. Johnson2, N. Koho1, M. Neuvonen1, M. Niemi1,
M.M. Rajam€aki1. 1University of Helsinki, Helsinki, Finland,
2University of California, Davis, USA
Gastroesophageal reﬂux and microaspiration (MA) of small
amounts of gastric juice have been associated with various human
respiratory diseases, including idiopathic pulmonary ﬁbrosis and
asthma. MA can be documented by measuring proteins originating
from the gastrointestinal tract in bronchoalveolar lavage ﬂuid
(BALF). In this study, bile acids were measured by mass spec-
trometry in BALF from West-Highland White Terriers (WHWTs)
with canine idiopathic pulmonary ﬁbrosis (CIPF, n = 33), healthy
WHWTs (n = 13), dogs with bacterial pneumonia (BP, n = 11),
healthy Irish Wolfhounds (IWHs) with previous BPs (n = 8), dogs
with chronic bronchitis (CB, n = 13), dogs with eosinophilic bron-
chopneumopathy (EBP, n = 9), dogs with laryngeal dysfunction
(LD, n = 19), healthy English Bulldogs (EBs, n = 26) and healthy
Beagles (n = 6).
Concentrations of 17 diﬀerent bile acids were determined and
total bile acid (TBA) concentration was calculated as a sum of
these. TBA was above minimum detection limit in 79 % of CIPF
(26/33), 45 % of BP (5/11), 54 % of CB (7/13), 44 % of EBP (4/9)
and 63 % of LD (12/19) dogs. In healthy dogs, bile acids in BALF
were detected less commonly in IWHs (0%, 0/8), EBs (8%, 2/26)
and Beagles (0%, 0/6) than in healthy WHWTs (54 %, 7/13).
Results suggest that MA occurs in various canine respiratory dis-
eases. In healthy dogs bile acids were detected only in WHWTs
which could be associated to the breed predisposition of CIPF.
Disclosures: Disclosures to report.
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CLINICAL AND LABORATORY ALTERATIONS IN 37 DOGS
DIAGNOSED WITH LUNGWORM INFECTION: A RETRO-
SPECTIVE STUDY (JULY 2010–APRIL 2017). V.G. Greci.
Ospedale Veterinario Gregorio VII, Roma, Italy
Lungworm infection is a potentially life-threatening parasitic infec-
tion in the canine species. Most common clinical presentation is
respiratory distress and coughing; neurological manifestations and
DIC have also been reported.
The aim of this study is to report the clinical and laboratory
alterations in 37 dogs diagnosed with lungworm infection.
The mean age was 46.7 months (2–156 months); 24 dogs were
male (21 intact; 3 neutered) and 13 dogs were female (6 intact; 7
spayed). Seven dogs were mixed-breed; the others belonged to dif-
ferent breeds. Fifteen dogs had a history of risk exposure.
Main duration of clinical signs was 11.4 days (1–60 days) with
coughing (23 dogs) and dyspnea (16) the main symptoms. Five
dogs had acute occurrence of neurological sign and one dog devel-
oped neurological signs few days after diagnosis. Thoracic radio-
graphs were characterized by a mild (4) to diﬀuse moderate (8) or
severe (25) mixed alveolar-bronchial-interstitial pattern.
CBC-count was performed in 33 dogs and showed anemia (15/
33), leukocytosis (16/33), neutrophilia (15/33), eosinophilia (16/33),
monocytosis (12/33), basophilia (5/33), lymphocytosis (3/33) and
low PLT count (14/33). Biochemistry was performed in 29 dogs
and showed increase in total protein count (13/29), globulin count
(16/29), CPK (17/29), amylase (14/29), C-reactive protein (22/29),
phosphorus (11/29) and urea (9/29). Protein serum electrophoresis
was available in 14 dogs and showed increased in the b1 fraction
and in the b2 fraction in 11 and 13 dogs respectively. Urinalysis
was available in four dogs and PU/CU was increased in two dogs.
Coagulative proﬁle was performed in 17 dogs and was suggestive
of DIC in 13 dogs, eleven of these dogs had a mean hematocrit of
24% (17.1–30.1%)
Twenty dogs were positive on fecal examination and two were
negative; one of these dogs was positive for Angiostrongylus vaso-
rum (IDEXX Angio-detect-test). Twenty-two dogs were positive
on the IDEXX Angio-detect-text and one was negative but
positive on fecal examination but lungworm typing was not sub-
mitted. One dog was diagnosed on BAL. Three dogs were diag-
nosed post mortem, two had A. vasorum infection and the other
dog had a mixed infestation with A. vasorum and Filaroides Osleri.
Overall seven dogs died; the others recovered.
Lungworm infection should be included in the diﬀerential diag-
nosis of dog presenting with respiratory disease and acute onset of
neurological signs. Though hematological alteration are non-speci-
ﬁc, presence of DIC, increase globulin count with increase in the b
fraction should aware the clinician of a possible undergoing lung-
worm infection.
Disclosures: No disclosures to report.
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COMPARISON OF THREE DIFFERENT GUIDELINES FOR
BLOOD TRANSFUSION APPLIED IN A POPULATION OF
ITALIAN FELINE DONORS TO REDUCE THE RISK OF
TRANSFUSION TRANSMISSIBLE INFECTIONS. A. Miglio1,
M.L. Marenzoni1, S. Lauzi2, M. Coletti1, S. Paltrinieri2, M.T.
Antognoni1. 1Department of Veterinary Medicine, Perugia, Italy,
2Department of Health, Animal Science and Food Safety
(VESPA), University of Mil, Milan, Italy
The increased demand for blood transfusion in animals causes the
need to have an adequate number of donors. At the same time, a
high level of blood safety must be guaranteed and diﬀerent guideli-
nes (GLs) deal with this topic.
Aim of the present study was to evaluate the appropriateness of
diﬀerent GLs in preventing transfusion-transmissible infections
(TTI) in Italian feline blood donors.
Blood samples were collected from 31 cats enrolled as blood
donors by owner’s voluntary choice at an Italian blood bank dur-
ing approximately 1 year. Possible risk factors for TTI were
recorded. Based on Italian, European and American GLs, speciﬁc
TTI, including hemoplasmas, Feline Leukemia Virus (FeLV),
Feline Immunodeﬁciency virus (FIV), Anaplasma phagocytophilum,
Ehrlichia spp., Bartonella spp., Babesia spp., Theileria spp.,
Cytauxzoon spp., Leishmania donovani sensu lato and Feline
Coronavirus (FCoV), were screened. Rapid antigen and serological
and biomolecular investigations (PCR) were used. Several PCR
protocols were compared to detect hemoplasma and FeLV DNA.
The presence of at least a recognized risk factor for TTI was
reported in all cats. They resulted negative for FIV and FeLV,
whereas 5 (16.1%) positive for FCoV antibodies using rapid tests.
PCR were negative for all tested microorganisms, except 4 cats
(12.9%) positive for hemoplasma DNA and one (3.2%) for FeLV
provirus. However, this latter resulted positive only with the most
sensitive PCR protocol applied, but not with the others.
Since the diﬀerent GLs recommend diﬀerent protocols and that
they can diﬀerently classify a candidate donor as suitable or not, a
harmonization of recommendations, especially on the main TTI to
screen and on the choice of the best sensitive serological or molec-
ular tests, with possible variations according to the local epidemio-
logical situation, would be advisable to improve the general level
of the veterinary blood safety. Moreover, considering the proﬁle at
high risk of TTI of blood donors and consequent costs and time
of the procedures to guarantee blood safety, tools to select donors
at low risk should be developed. Appropriate recruitment strate-
gies, currently not considered in GLs, questionnaire-based risk
proﬁle, educational courses for owners and the possibility to estab-
lish a permanent group of safe blood donors could improve the
identiﬁcation of suitable donors, reducing the necessity to perform
a wide screening.
Disclosures: No disclosures to report.
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EFFICACY AND SAFETY OF TWO NEW HIGH PROTEIN-
LOW CARBOHYDRATE DRY DIETS IN STERILE, FELINE
STRUVITE UROLITHIASIS. C. Maurey Guenec1, G. Chaix2, I.
Leriche2, S. Fournel2. 1ENVA, Maisons Alfort, France, 2VIRBAC,
Carros, France
Urolithiasis is a common cause of Feline Lower Urinary Tract
Disease (FLUTD). The most common feline uroliths are calcium
oxalate and struvite. Dietary dissolution is safe and eﬀective for
eradication of sterile struvite uroliths in cats. Richness in moisture
and/or sodium and/or protein in order to increase water intake
and thus to increase diuresis, urinary ﬂow and the frequency of
micturition may vary between commercially diets. This prospec-
tive, multicenter, randomized, double blinded clinical trial evalu-
ated the eﬃcacy and safety of two new high protein-low
carbohydrate dry diets in sterile, struvite urolithiasis in cats with
signs of non-obstructive FLUTD.
Cats enrolled in the study were randomly assigned either to diet
A,1 formulated to achieve dissolution and prevention of struvite
uroliths, or to diet B,2 formulated to dissolve struvite uroliths.
Cats were followed up to 14 days after the uroliths had been dis-
solved, latest to D56  2. Physical examination, urinalysis, and
abdominal ultrasound were performed weekly. Analyses were per-
formed using the software SAS version 9.4. The signiﬁcance
threshold was set to a=0.05 two-sided.
Thirty-three cases were recruited and supplied with Diet A
(n = 17) or Diet B (N = 16) according to the randomization proce-
dure. The mean time of struvite dissolution was 13.1 days and
14 days respectively for diet A and Diet B (n.s). The mean time to
disappearance of at least one urinary sign was 7 days for diet A
and 11.4 days for diet B (P = 0.03). On D7, all cats from group A
and 75% of cat from group B had no more urinary signs
(P = 0.04). Mean urinary pH was decreased in groups A and B at
the end of the study (6.1  0.5 and 6  0.6, respectively) com-
pared to D0 (7.2  0.8 and 7.2  0.7, respectively). In group B,
urine speciﬁc gravity signiﬁcantly decreased (P = 0.01) from D0
(1.046  9.8) to the end of the study (1.036  12.5). In group A,
urine speciﬁc gravity decrease was not signiﬁcant. Two and 4 cats
of groups A and B respectively exhibited transitory adverse events,
possibly related to the diet (mild diarrhea or mild vomiting). These
events resolved spontaneously and did not lead to the exclusion of
any cat.
The new high protein – low carbohydrate tested diets were
eﬀective for dissolution of feline struvite urolithiasis.
Disclosures: Disclosures to report.
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THE EFFECT OF STORAGE TEMPERATURE AND BORIC
ACID PRESERVATION ON QUANTITATIVE BACTERIAL
CULTURE FOR DIAGNOSING CANINE URINARY TRACT
INFECTION. T.M. Soerensen, L.R. Jessen, M. Moeller, H. Pat-
sekhina. University of Copenhagen, Frederiksberg C, Denmark
Quantitative bacterial culture (QBC) is the gold standard for diag-
nosing urinary tract infection (UTI). Current guidelines recom-
mend that QBC is performed within 24 h of collection and that
urine, if unpreserved, is stored and transported at refrigeration
temperatures. However, temperature-controlled transport is expen-
sive and may not always be feasible in veterinary practice, indicat-
ing a need for alternative storage methods.
The aim of this study was to investigate the eﬀect of storage
temperature and boric acid preservation on QBC of canine urine.
The hypothesis was that i) urine stored non-preserved by refrig-
eration (COOL) or preserved in commercially available urine
preservation swabs containing boric acid (Copan UriSwabTM) at
room-temperature (BA-ROOM) for 24 and 48 h, respectively,
would be non-inferior to the reference QBC and that ii) there
would be no signiﬁcant diﬀerence in sensitivity and speciﬁcity of
the two storage methods.
Canine urine samples received at the veterinary microbiology
laboratory at UCPH between February 2015 and March 2016
were prospectively included in the study. After initial reference
QBC, urine samples were split into three aliquots. Two aliquots
were stored at room temperature in Copan UriSwabTM, and one
aliquot was stored refrigerated in an unpreserved microfuge tube,
for 24 h and 48 h, respectively. Signiﬁcant bacteriuria was deter-
mined with regard to urine collection method according to current
recommendations.
Non-inferiority was concluded if the lower limit of the one-sided
95% conﬁdence interval was above 85% (D = 0.15). McNemar’s
v2 test was performed to compare sensitivity and speciﬁcity for the
two storage methods.
A total of 179 samples from 141 dogs were included. Signiﬁcant
bacteriuria was found in 42% of the samples according to refer-
ence QBC. With an overall accuracy of 94–97%, all storage condi-
tions were non-inferior to reference QBC, except for BA-ROOM
at 48 h which had an inferior sensitivity. However, there was no
signiﬁcant diﬀerence between the sensitivity of the two methods at
the two time points (P = 0.06–1.00).
The results show that boric acid preservation at room tempera-
ture is a valid alternative to refrigeration and that reliable QBC
can be obtained after storage of canine urine for 24 h by both
methods.
Disclosures: Disclosures to report.
Copan UriSwab(TM) kit kindly donated by Copan Italia.
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MICROALBUMINURIA IN DOGS INFECTED WITH DIROFI-
LARIA REPENS. F. Manczur1, F.A. Falus1, N. Kubik1, L.
M€uller1, Z.S. Vizi1, A. Sterczer1, G.Y. Rabnecz2, N. Balogh2.
1University of Veterinary Medicine, Budapest, Hungary, 2Praxislab
Kft, Budapest, Hungary
Microalbuminuria (MAU) is associated with underlying renal and
systemic diseases in dogs. Glomerular disease and proteinuria is
common in dogs naturally or experimentally infected with Diroﬁ-
laria immitis. The prevalence of MAU in dogs with experimentally
infected heartworm disease is higher than in healthy animals.
Diroﬁlaria repens is the causative agent of subcutaneous canine
diroﬁlariasis and is considered an emerging zoonosis in many parts
of Europe. D. repens infection is usually associated with no or
only minor clinical signs in dogs. It is not known whether D.
repens is capable of producing similar glomerular lesions and pro-
teinuria to those caused by heartworm infection.
The purpose of this study was to determine the prevalence of
MAU (urinary albumin to creatinine ratio, UAC >0.03) and pro-
teinuria (urinary protein to creatinine ratio, UPC >0.5) in dogs
naturally infected with D. repens.
Blood and urine samples were taken from 70 clinically healthy
beagles kept in two closed colonies with similar housing and feed-
ing conditions. Extensive laboratory work up was used to reveal
any underlying disease and to distinguish D. repens infection from
occult heartworm disease (incl. modiﬁed Knott-test, two diﬀerent
Ag-ELISA tests and Diroﬁlaria species speciﬁc real time PCR).
Urine was obtained by cystocentesis and albumin was measured
with a formerly validated commercial human immunoturbidimetric
method. Exclusion criteria were severe laboratory alterations, a
positive D. immitis test or positive urine culture. Some older,
otherwise eligible, D. repens infected dogs also had to be excluded
as there were no older animals without infection to age match the
two groups.
After all the exclusions, there remained 29 D. repens infected
and 27 non-infected beagles. There were no statistically signiﬁcant
diﬀerences between the two groups in respect of their age, weight
and sex ratio. There were signiﬁcantly more dogs with MAU in
the D. repens infected group compared to the non-infected beagles
(28% vs. 4 %, P = 0.0150). There were also more proteinuric dogs
in the infected group (24% vs. 7%), but it did not yield a signiﬁ-
cant diﬀerence (P = 0.0885).
Our study showed that the prevalence of MAU in dogs infected
with D repens is higher than that observed in other non-infected
dogs kept in the same conditions. Further studies are needed to
determine whether dogs infected with D. repens and MAU will
progress to develop overt proteinuria and renal failure.
Disclosures: Disclosures to report.
The research was partly supported by Bayer Hungary.
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SYMMETRIC DIMETHYLARGININE (SDMA) AND
NEPHROPATHY IN DOG: DIAGNOSTIC UTILITY IN CLINI-
CAL PRACTICE. J. Zambarbieri, M. Giraldi, B. Ruggerone, S.
Faverzani, P. Scarpa. University of Milan, Milan, Italy
Symmetric dimethylarginine (SDMA) has been proposed as a sen-
sitive and speciﬁc renal biomarker whose concentration increases
earlier than serum creatinine (SCr) as glomerular ﬁltration rate
decreases. SDMA is a promising parameter in the diagnosis and
management of chronic kidney disease (CKD) and it is included
into the International Renal Interest Society (IRIS) guidelines.
The aim of the study is to assess the usefulness of a single deter-
mination of SDMA in the evaluation of renal status in dogs at
risk or aﬀected with CKD, and to evaluate its correlation with
SCr and other parameters of renal function.
Ninety-ﬁve dogs were consecutively selected within the patients
referred to the University Veterinary Hospital of Milan. On the
ﬁrst clinical examination, all these dogs underwent to physical
examination, hematology and blood chemistry (included serum
SDMA and SCr). Urinalysis and urinary protein:creatinine ratio
(UPC) were performed in 89 cases while ultrasound examination
was done in 60 dogs. All the dogs were staged according to the
IRIS guidelines. Statistical analysis was performed by JMP 7 soft-
ware (SAS Institute Inc., Cary, USA).
SDMA showed, as expected, a signiﬁcant correlation with SCr,
urine speciﬁc gravity (USG) and UPC ratio (P < 0.05). IRIS stag-
ing, according to SCr, resulted as follows: 26 (27.4%) dogs were
included in stage 0, 39 (41%) in stage 1, 12 (12.6%) in stage 2, 17
(17.9%) in stage 3 and 1 (1.1%) in stage 4. SDMA evaluation
modiﬁed IRIS staging in 12 (12.6%) dogs. SDMA was increased
in 51 (53.7%) dogs; in 8 (15.7%) of these, SDMA was equal to
the cut-oﬀ value (14 lg/dL). In 29 (56.9%) of the “high SDMA”
cases, SCr was >1.4 mg/dL while in the others 22 (43.1%) there
were already one or more alterations: decrease of USG in 14
(63.6% of 22) cases, increase of UPC ratio in 15 (68.2%) cases,
ultrasound features suggestive of CKD in 9 (40.1%) cases. SDMA
was the only altered parameter in 4 (4.2%) dogs. SDMA was nor-
mal and creatinine slightly increased in 1 (1.1%) dog.
SDMA is a useful and reliable parameter for the diagnosis and
management of CKD but the evaluation of other markers of renal
function and diagnostic imaging are essential in order to correctly
approach the patient from the diagnostic and therapeutic point of
view, especially at the ﬁrst clinical presentation. Furthermore,
patients with normal SCr and altered SDMA require a further
evaluations to conﬁrm the development of CKD.
Disclosures: No disclosures to report.
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ULTRASOUND-GUIDED RENAL BIOPSY SIGNIFICANTLY
INCREASES URINARY N-ACETYL-BETA-D-GLUCOSAMI-
NASE INDEX ACTIVITY IN DOGS WITH DIFFUSE
PARENCHYMAL NEPHROPATHIES. A.R. Codea1, V.M. Mir-
cean1, O. Sarpataki1, B. Sevastre1, A. Bizo2, C.P. Popovici1, S.A.
Bogdan1, L.I. Oana1. 1Faculty of Veterinary Medicine Cluj-
Napoca, Cluj-Napoca, Romania, 2University o Medicine and
Pharmacy ‘‘Iuliu Hatieganu’’, Cluj-Napoca, Romania
Ultrasound guided renal biopsy is an essential diagnostics method
which, by facilitating histopathological examination can increase
the accuracy of the diﬀerential diagnosis between acute and
chronic nephropathies and will help the clinician perform an etio-
logic diagnosis, issue a prognosis and orient the therapy of the
majority of parenchymal nephropathies. Due to the relative inva-
siveness and potential adverse eﬀects, the use of renal biopsy is
limited among practitioners. In this study we evaluate the intensity
of renal damage induced by renal cortex sampling and the clinical
consequences of such a procedure. We examined 28 dogs, mixed
breed and variable ages, 11 (39, 29 %) males and 17 (60, 71 %)
females that were referred to our clinic and underwent ultrasound
guided renal biopsy in order to establish a deﬁnite diagnosis.
Patients were presented with a variety of diﬀuse nephropathies:
kidney lymphoma: 1 (3.57%), glomerulonephritis: 13 (46.43%),
tubulointerstitial nephritis: 11 (39.29 %) and nephrocalcinosis: 3
(10.71%) of which 18 (64.29 %) were in acute kidney failure and
10 (35.71 %) were chronic renal patients. The type and the sever-
ity of renal lesions were correlated with changes in urinary NAG
index (iNAG), and speciﬁc serum renal damage markers such as
urea, creatinine, phosphorus and ionized calcium. To quantify the
side eﬀects of percutaneous renal biopsy the magnitude of post
biopsy hematuria and changes in urinary iNAG activity were eval-
uated. The results indicate a signiﬁcant post biopsy increase in uri-
nary iNAG activity in all patients that underwent this procedure
(100.08  34.45 (U/g) pre-biopsy iNAG vs. 147.65  33.26 (U/g)
post-biopsy iNAG, P < 0.001) suggesting an intensiﬁcation in
renal tubular damage consecutive to kidney puncture and
sampling.
Transitory macro- or microhematuria were constant ﬁndings in
all dogs that underwent ultrasound guided renal biopsy but the
magnitude and extent could not be associated with PLT(109/L),
aPTT (s) and PT (s) levels in our patients, and resolved after 12–
24 h without therapeutical interventions.
Percutaneous ultrasound guided renal biopsy is a relatively safe
minimal invasive diagnostic procedure which will induce a series
deleterious eﬀects on kidney structure and function, but we con-
sider that a correctly obtained tissue sample with a high diagnostic
value is of greater importance than the complications associated
the sampling procedure.
Disclosures: No disclosures to report.
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EVALUATION OF INFECTIVE AND REPLICATIVE PROP-
ERTIES OF A REPLICATION-SELECTIVE ONCOLYTIC
VACCINIA VIRUS (VVTG17990) ON CANINE, FELINE, POR-
CINE AND HUMAN CELL LINES. J.S. Beguin1, C. Maurey1,
V. Nourtier2, J. Foloppe2, P. Erbs2, B. Klonjkowski1. 1Ecole
Nationale Veterinaire d’Alfort, Universite Paris Est, Maisons-
Alfort, France, 2Transgene, Illkirch Graﬀenstaden, France
Oncolytic virotherapy with tumor selective viruses oﬀers a promis-
ing treatment modality for cancer. In human medicine, Vaccinia
virus (VV) has shown encouraging results on tumor explants. This
biotechnology is underused in veterinary oncology.
First objective of this study was to investigate the capacity of
various species cell lines to support infection by a replication-selec-
tive oncolytic VV (VVTG17990). Our second objective was to
assess replication potency of VVTG17990 on those cell lines.
A thymidine kinase and ribonucleotide reductase genes-deleted
VV expressing green ﬂuorescent protein (GFP) was designed
(VVTG17990).
Non tumoral canine (DKE1), feline (CrFK), porcine (PK-15)
and human (293) cell lines were used as well as tumoral canine
(A72) and human (HeLa) cell lines.
Susceptibility was evaluated 16 h after infection with
VVTG17990 using ﬂuorescence microscopy and ﬂow cytometry.
Multiplicity of infection (MOI) of 0.1, 0.01 and 0.001 were tested.
Virus titers were evaluated 4 days after infection at a MOI of
0.0001 and 0.00001, by standard plaque forming assay on culture
medium and cell lysate.
All experiments were performed in triplicate.
GFP expression was detected by ﬂuorescence microscopy 16 h
after infection for all cell lines even with low infective doses. Flow
cytometry allowed an assessment of a dose dependent infection of
cells. For all cell lines, more than 88% of cells were infected at a
MOI of 0.1. Equivalent percentage of infection was noticed for
HeLa, 293 and PK-15 at a MOI of 0.01. On the other hand, lower
infection was assessed for DKE1 (55%), A72 (27%) and CrFK
(21%). At a MOI of 0.001, higher percentage of infection was
observed for 293 (32%) and PK-15 (25%). For the others, less
than 13% of cells were infected. Tumoral status of cell lines didn’t
seem to inﬂuence susceptibility to VVTG17990.
Interestingly, 16 h after infection VVTG17990 proved eﬀective
lytic potency on cell lines. Lytic potency was more important with
higher viral doses.
A replication factor of 106 to 107 was determined 4 days after
infection for all cell lines, except for feline cell lines (about 103).
Tumoral status of cell lines didn’t seem to inﬂuence the replication
factor.
This study proves that canine, porcine and human cell lines sup-
port infection by VVTG17990 with a high replication factor. In
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comparison, susceptibility and replication potency were lower for
feline cell lines. An in vitro lytic potency was also noticed. These
promising results support the use of replication-selective oncolytic
VV on canine tumors.
Disclosures: Disclosures to report.
This study was support by Transgene.
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MULTIPLE COLORECTAL GRANULAR CELL TUMORS IN
A DOG. G.C. Ruiz, S. Gould, S. Warman. University of Bristol,
Langford, Bristol, UK
Granular cell tumors are uncommon soft tissue neoplasms believed
to arise from Schwann cells. Oral, ocular and neurological forms
have been reported in dogs, and various locations including the
gastrointestinal tract have been reported in humans. This latter
location has not been reported in dogs.
A four-year-old female neutered Jack Russel Terrier presented
with one-year history of hematochezia and intermittent diarrhea
that did not respond to dietary changes, and antibiotics. On pre-
sentation, the dog was bright and alert and in good body condi-
tion. Rectal examination revealed multiple (>20) nodular masses
(approximately 3–4 mm diameter) in the rectum. The remainder of
the examination was unremarkable.
Bloodwork revealed hypocobalaminemia (138 pmol/L, ref. 200–
408) and hypofolatemia (6.7 nmol/L, ref. 12–30) consistent with
diﬀuse small intestinal disease. Hematology and biochemistry were
unremarkable. A gastrointestinal endoscopy documented multiple
small masses in the rectum and the colon (>50 in total). These
masses were present on the last 20 cm of the large intestine. The
mucosa around the masses appeared irregular and swollen. The
ileum appeared mildly irregular. Histopathology of the masses
identiﬁed a population of large cells with granular cytoplasm mul-
tifocally expanding the lamina propria between the glands, consis-
tent with granular cell tumors. There was also a mild aggregation
of lymphocytes, plasma cells and sparse eosinophils in the colic
mucosa between the masses. There was minimal lacteal dilation in
the ileum, with no evidence of inﬂammation. Additional stains did
not yield signiﬁcant information. Bacterial and fungal cultures of
colic biopsies were negative.
Diet change to a hypoallergenic diet (Purina HA) and par-
enteral cobalamin supplementation led to resolution of the diar-
rhea. At the most recent follow-up one year after diagnosis, the
dog was still clinically well on hypoallergenic diet. The owners
reported intermittent hematochezia and very occasional tenesmus.
Rectal examination was similar to the initial visit.
Granular cell tumors are uncommon and predominantly benign
neoplasms in humans; 10% of the tumors develop in the gastroin-
testinal tract. Endoscopic surveillance is usually suﬃcient for small
and asymptomatic tumors. Surgical excision is recommended for
large, malignant and multifocal tumors. Endoscopic resection has
also been recently reported. No surgical excision was attempted in
our dog given the multiplicity of the masses and the absence of
signiﬁcant clinical sign. To our knowledge, this is the ﬁrst descrip-
tion of multiple granular cell tumors aﬀecting the gastrointestinal
tract in dogs, and these appeared to have a benign clinical course.
Disclosures: No disclosures to report.
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SPIROCERCA LUPI INDUCED ESOPHAGEAL NEOPLASIA:
PREDICTORS OF SURGICAL OUTCOME. P. Pazzi1, A. Kav-
kovsky2, A. Shipov2, G. Segev2, E. Dvir3. 1University of Pretoria,
Pretoria, South Africa, 2The Hebrew University of Jerusalem,
Rehovot, Israel, 3Tel Hai Academic College, Upper Galilee, Israel
Canine spirocercosis is caused by the nematode Spirocerca lupi.
Esophageal ﬁbro-inﬂammatory nodules may undergo neoplastic
transformation. No studies assessed pre- or post-surgical prognos-
tic indicators in dogs that undergo intervention.
This observational multi-center study aimed to assess the out-
come of dogs with neoplastic spirocercosis undergoing endoscopic-
guided ablation (n = 12) or surgery (n = 18), and identify prognos-
tic indicators. Parameters evaluated included: age, weight, body
condition score at diagnosis, gender, duration of clinical signs,
hematology, biochemistry, tumor size, placement of percutaneous
endoscopically-placed gastrostomy tube, histopathological mitotic
indices, days to discharge and chemotherapy administration.
Kaplan Meier survival curves showed no diﬀerence in survival
between ablation and surgery {(median: 68 days (range: 0–1550)
vs. 107 days (0–1511), respectively (P = 0.662)}. When only dogs
surviving the ﬁrst 21 days (T21) after ablation or surgery were
evaluated, the signiﬁcance in survival was borderline {79 days (45–
1550) vs. 250 days (80–1511), respectively, P = 0.082}. None of
the parameters measured were associated with survival advantage.
Intra-treatment-group survival analysis identiﬁed survival advan-
tage for chemotherapy within the surgical group (P = 0.021), this
became insigniﬁcant (P = 0.430) in T21. When the latter were eval-
uated, Ht >36% (P = 0.016) and white cell count <15.0 9 109/L at
presentation (P = 0.021) were associated with an improved out-
come. Ht <36% at presentation for all dogs and T21 showed a sig-
niﬁcant hazard ratio (0.960, P = 0.037 and 0.947, P = 0.022
respectively).
No clear beneﬁt was identiﬁed for surgery, when ablation is
technically possible. Prognostic indicators were only useful if the
dog survived the ﬁrst 21 days’ post-surgery. Chemotherapy post-
intervention made no diﬀerence to survival.
Disclosures: No disclosures to report.
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SURVIVAL OF DOGS DIAGNOSED WITH INFLAMMA-
TORY MAMMARY CANCER TREATED WITH A MULTI-
MODAL THERAPY. I. Clares Moral, L. Pe~na, P. Garcıa San
Jose, S. Gonzalez Sanz, D. Alonso Miguel, P.M. Garcıa Fernan-
dez, M. Suarez Redondo, M.D. Perez Alenza. Veterinary Teaching
Hospital Complutense of Madrid, Madrid, Spain
Inﬂammatory mammary cancer (IMC) is a speciﬁc type of locally
advanced mammary cancer in dogs. It is an uncommon tumor,
but the most aggressive type of mammary cancer in female dogs
with an extremely poor survival rate. No eﬀective treatment has
been reported for dogs with IMC and surgery is not indicated as
ﬁrst option. Based on the diﬀerent molecular features of these
highly angiogenic cancer, new therapies focused on speciﬁc targets
has been proposed.
The aim of this study was to evaluate the survival time in dogs
diagnosed with IMC treated with a multimodal therapy based on
an anti-COX2 drug (ﬁrocoxib), a tyrosine kinase inhibitor (to-
ceranib) and an androgen receptor inhibitor (ﬂutamide).
Ten dogs diagnosed with IMC presented to the Veterinary
Teaching Hospital Complutense of Madrid were included. Diagno-
sis was based on clinical features (edema, erythema, warmth and
ﬁrmness in the mammary glands) and histopathological conﬁrma-
tion. Immunohistochemical analysis (Ki-67 index, C-kit, COX-2
and androgen receptor) were performed. Five dogs received pallia-
tive treatment (antibiotics, corticoids) (control group or CG) and
the other 5 dogs were treated with a combination of ﬁrocoxib, ﬂu-
tamide and toceranib (treatment group or TG). One dog of the
TG refused treatment with toceranib due to economy matters. Sur-
vival time was deﬁned as the time from IMC diagnosis to euthana-
sia or death of the dog. Age at the time of IMC diagnosis,
reproductive status, previous history of mammary tumors and evo-
lution of IMC after treatment were also analyzed. A paired Stu-
dent’s t-test was performed for statistical analysis of parametric
variables with an alpha error of 0.05 and Chi Square test for no
parametric variables.
The mean survival time of dogs of TG was signiﬁcantly higher
than that of CG (34.6  15.0 and 10.6  13.4 days, respectively.
P = 0.028). Age at the time of IMC diagnosis (10.8  2.7 years in
TG and 11.0  1.9 years in CG ), reproductive status and
immunohistochemical proﬁle were no signiﬁcantly diﬀerent
between the 2 groups. In TG, a complete remission was obtained
in one case, stable disease in 2/5 dogs and progressive disease in 2/
5. In TG Grade 2 (n = 2) and grade 3 (n = 1) toxicities were
observed after 3–4 weeks, but an increase in quality of life was
referred in all cases after the initiation of the treatment.
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Despite of poor prognosis, the multimodal therapy increases
survival time in dogs diagnosed with IMC with an adequate qual-
ity of life.
Disclosures: No disclosures to report.
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EFFECT OF RADIATION THERAPY ON THE TREATMENT
OF INTRACRANIAL TUMORS IN DOGS: MENINGIOMA
AND GLIOMA. T. Magalh~aes1, J. Benoit2, S. Necova2, S. North2,
F.L. Queiroga1. 1University of Tras-os-Montes and Alto Douro,
Vila Real, Portugal, 2VRCC - Veterinary Referrals, Laindon, UK
Radiation therapy has been considered the treatment of choice for
many brain tumors in dogs, like glioma and intracranial
meningioma.
A retrospective study was carried out, with information about
patients treated between 2011 and 2015, in a veterinary referral
hospital. The goals were set to evaluate the eﬃcacy of this thera-
peutic approach and to search associations between diﬀerent epi-
demiological, clinical, diagnostic and therapeutic features with the
tumor type and the survival times. This study included 32 dogs
diagnosed with intracranial meningioma and glioma which under-
gone radiation therapy. The clinical reports were analyzed. Two
survival times were calculated: overall (OST) and post-treatment
(PTST), from the diagnosis or the end of radiation, respectively,
until death or end of the study period.
Sex and contrast enhancement exhibited statistically signiﬁcant
associations (P < 0.05) with tumor diagnosis. These results showed
a sexual predisposition of males for glial type and females for
meningeal type and a greater speciﬁcity of contrast enhancement,
observed on MRI, for meningioma. It was found that just the
breed and the sex are prognostic factors, as they were signiﬁcantly
associated (P < 0.05) with survival times. Boxer and labrador
retriever breeds and the female sex were considered as a survival
beneﬁt in these patients. Median values were 372 days for TSPT
and 446.5 days for the TST. The 1- and 2-year survival rates were,
respectively, 50% and 23.3%.
Thus, radiation therapy is an eﬀective treatment option for
these neoplastic cases, with better results than other therapeutic
approaches.
Disclosures: No disclosures to report.
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ULTRASOUND-GUIDED FINE-NEEDLE ASPIRATION OF
THE CANINE PROSTATE - A USEFUL SAMPLING
METHOD FOR MOLECULAR BIOLOGICAL ANALYSIS?. H.
Thiemeyer1, J.T. Schille1, L.K. Harder1, S.O. Hungerbuehler1, R.
Mischke1, M. Hewicker-Trautwein2, B. Brenig3, J. Beck4, E.
Sch€utz4, L. Taher5, H. Murua Escobar6, I. Nolte1. 1Small Animal
Clinic, University of Veterinary Medicine Hannover, Hannover,
Germany, 2Institute of Pathology, University of Veterinary Medi-
cine Hannover, Hannover, Germany, 3Institute of Veterinary Med-
icine, Georg-August-University G€ottingen, G€ottingen, Germany,
4Chronix Biomedical, G€ottingen, G€ottingen, Germany, 5Depart-
ment of Biology, Friedrich-Alexander-University of Erlangen-
N€urnberg, Erlangen, Germany, 6Department of Medicine, Clinic
III-Hematology/Oncology/Palliative Care, Rostock, Germany
Male dogs with prostate carcinoma are often diagnosed at a late
stage and therapeutic approaches are limited. Therefore, new diag-
nostic strategies for early detection are needed. Whereas prostate
speciﬁc antigen (PSA) as a biomarker is controversially discussed
for early detection in human medicine, potential biomarkers have
not yet been established for dogs. Gene expression data sets, gen-
erated by next generation sequencing, oﬀer new possibilities in can-
cer research for biomarker discovery, understanding of
carcinogenesis and development of therapeutic strategies. Since
ultrasound-guided ﬁne-needle aspiration biopsies (US-FNA) of the
prostate are routinely used for cytology in dogs, aspirated cells
can represent a source for gene expression studies. The aim of the
present study was to evaluate US-FNA material for routine
cytologic diagnosis and leftover cells for molecular biological anal-
ysis. US-FNAs were taken prospectively from 16 male dogs after
clinical examination. Collected cells were used for cytological
examination as well as molecular biological analysis. Prostate tis-
sue samples were taken from 18 euthanized dogs. All samples were
immediately frozen in liquid nitrogen. RNA was extracted from
US-FNA samples using the miRNeasyMicro Kit and RNA con-
centration was measured with Qubit. Prostate tissue samples were
classiﬁed histopathologically. RNA isolation from prostate tissue
was performed with AllPrepDNA/RNA/miRNA Universal Kit
and quantity was measured with the Synergy system. A bioana-
lyzer was used to determine RNA-integrity number (RIN). Whole
transcriptome next-generation sequencing (NGS) was performed on
an Illumina NextSeq500 system. Tissue samples were examined
histologically: Nine were diagnosed as malignant and nine were
classiﬁed as non-neoplastic. Cytological examination of US-FNA
was possible in 14 cases, eleven being diagnosed as normal to
hyperplastic and three specimens being classiﬁed as prostate carci-
noma. RNA concentration was detectable in all samples ranging
from 9 ng/µL to 99 ng/µL. RNA quantity was suﬃcient as start-
ing material for NGS. Transcriptome analyses from samples with
RIN value ≥5.5 were successful. Data sets of diﬀerentially
expressed genes (DEGs) were summarized in principal component
analysis and showed major variances in DEGs between non-neo-
plastic and malignant samples and minor diﬀerences between US-
FNA and tissue with comparable diagnosis. Globin genes were
identiﬁed and signiﬁcantly upregulated in US-FNA samples. Based
on isolated total RNA concentration and integrity, residual cells
from diagnostic US-FNA of the canine prostate can be considered
as an adequate sample source for gene expression studies, biomar-
ker research and a potential tool for advanced diagnostic of canine
prostatic diseases.
Disclosures: No disclosures to report.
ESVONC – P – 8
HISTIOCYTIC SARCOMA IS OVER-REPRESENTED IN
MINIATURE SCHNAUZERS IN THE UNITED KINGDOM. J.
Elliott, M. Rodriguez Blanco. Willows Referral Service, Solihull,
UK
Histiocytic sarcoma (HS) is an aggressive neoplasm of dogs. Over-
representation has been documented in several breeds, including
Bernese mountain dogs, ﬂat-coated retrievers, golden retrievers,
and Rottweilers. The purpose of this retrospective study was to
describe a series of miniature schnauzers (MS) diagnosed with HS
in the UK and assess whether they were over-represented when
compared to the hospital population.
Medical records of MS with a cytological or histopathological
diagnosis of HS between January 2010 and March 2017 were
reviewed. Breed predisposition was assessed with odds ratios, using
the total number of hospital admissions for each breed without
HS admitted during the study period as controls. This was also
performed where two or more cases with HS were recorded for a
particular breed.
Ten MS were diagnosed with HS during the study period, mak-
ing them over-represented among the hospital population (odds
ratio = 8.98 [95% CI 4.64–17.41]). Seven were diagnosed with pri-
mary pulmonary HS based on the presence of a large pulmonary
mass with or without evidence of intra-thoracic metastasis or
abdominal involvement, though only ﬁve exhibited overt respira-
tory signs. No patients had solitary HS. Five patients were treated
with chemotherapy (lomustine +/- epirubicin) but an aggressive
clinical course was found in all patients. Median survival time of
all patients was 54 days (range: 0–232 days). Several other previ-
ously reported breeds were also noted to be pre-disposed to HS.
MS, in addition to previously reported breeds, were over-repre-
sented amongst dogs with HS in this patient population. Primary
pulmonary involvement was common and patients presented with
advanced disease though some patients had no overt respiratory
signs. The prognosis appears to be poor despite chemotherapy.
Disclosures: No disclosures to report.
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SEROPREVALENCES TO ANAPLASMA PHAGOCY-
TOPHILUM, BORRELIA BURGDORFERI AND BABESIA
CANIS IN 2948 DOGS FROM GERMANY. D. Breu, J.
Guthardt, E. Mueller. Laboklin, Bad Kissingen, Germany
Dogs with exposure to ticks may contract multiple infections
simultaneously. Our study aimed (1) to ﬁnd seroprevalences to
Borrelia, Anaplasma and Babesia of the dogs with a suspected his-
tory of ‘vector-borne diseases’ and (2) to evaluate speciﬁc sero-
prevalences in ﬁve most common pedigree breeds. Antibodies to
Anaplasma were assayed by an IFAT-test and antibodies to Babe-
sia and Borrelia were tested using respective ELISA.
During the study period (2015/2016) involving 2948 dogs, over-
all seropositivity was 44% to = 1 pathogen(s). Single-positivity
accounted for 34.4% and was composed of Anaplasma (73.7%),
Borrelia (22.1%) and Babesia (4.1%). Double-positivity was 9.2%;
Anaplasma/ Borrelia (83.8%), Anaplasma/Babesia (11.8%) and
Borrelia/Babesia (4.4%).
Triple-positivity (Anaplasma/Borrelia/Babesia) was seen in 11 (=
0.4%) dogs.
Regarding the 868 dogs belonging to 5 pedigree breeds, overall
seropositivity to = 1 pathogen(s) was 49.5%; Bernese Mountain
Dogs (68.1% of 113) > Golden Retrievers (54.3% of 151) > Aus-
tralian Shepherds (50.5% of 105) > German Shepherds (47.7% of
174) > Labradors (41.5% of 325). For all breeds, single-positivities
ranged from 32% (Labradors) to 46% (Golden Retrievers). Except
for Bernese Mt-Dogs, the seropositivity to Anaplasma accounted
for 73–84% while the seropositivity to Borrelia accounted for 14–
27%. For Bernese Mt-Dogs, seropositivities to Anaplasma and
Borrelia were 36% and 64%, respectively.
Double-positivities were between 7% (Golden Retrievers) and
13% (German Shepherds), whereas they were 28% for Bernese
Mt-Dogs. With regard to speciﬁc combinations of pathogens, Ana-
plasma/Borrelia accounted for near 100% in Bernese Mt-Dogs,
Australian Shepherds and Golden Retrievers, whereas German
Shepherds and Labradors exhibited somewhat diﬀerent susceptibil-
ities: Anaplasma/Borrelia (68% and 80%, respectively) and Ana-
plasma/Babesia (27% and 20%), respectively.
Within the scope of this study, our data suggested a certain
dichotomy of seropositivity patterns depending on dogs of pedi-
gree breeds. Overall, single-positivities were seen in 32–46% of the
dogs and Anaplasma was the principal pathogen representing 73–
84% cases. Bernese Mt-Dogs were exceptional: Borrelia repre-
sented 64% and Anaplasma 36%. While double-positivities were
comparatively low (7–13%), Bernese Mt-Dogs were outstanding
with 28%. Furthermore, Anaplasma/Borrelia accounted for near
100% seropositivities in 3 breeds whereas Anaplasma/Babesia
accounted for 20–27% in 2 other breeds (German Shepherds, Lab-
radors). Under the circumstances where multiple factors - habitats,
ectoparasite controls among others - inﬂuence the occurrence and
prevalence of antibodies, our data showed certain breed-speciﬁc
patterns of diﬀerences in susceptibility/infectivity toward the
pathogens.
Disclosures: The authors Breu D and Guthardt J are employed
at Laboklin GmbH & Co.Kg Germany. Mueller E is owner/man-
ager of the Laboklin GmbH & Co.Kg, Germany.
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A PROSPECTIVE STUDY OF URINARY ADVERSE
EFFECTS OF ALLOPURINOL TREATMENT FOR CANINE
LEISHMANIOSIS. M. Planellas1, X. Roura2, Y. Espada1, R.
Novellas1, C. Anselmi2, L. Solano-Gallego1. 1Universitat
Autonoma de Barcelona, Bellaterra, Spain, 2Hospital Clinic
Veterinari, Universitat Autonoma de Barcelona, Barcelona, Spain
Canine leishmaniosis is a life threatening zoonotic disease with a
wide distribution and allopurinol is a parasitostatic drug used in
its long-term fashion treatment. Some retrospective reports indi-
cate that xanthinuria deposits can appear secondary to prolonged
therapy with allopurinol in dogs. The purpose of this prospective
study was to evaluate the incidence, characteristics and the time of
appearance of urinary adverse eﬀects in dogs with leishmaniosis
treated with allopurinol. Moreover, in dogs with xanthine deposits,
clinical response to low purine diet was also evaluated.
This study included 20 dogs with a new diagnosis of leishmanio-
sis under allopurinol treatment (10 mg/kg/12 h during 12 months).
Dogs were evaluated at time of diagnosis, one, six and twelve
months after diagnosis and treatment with allopurinol, addition-
ally 11/20 dogs were also evaluated at 3 months. Each clinical
evaluation included the following tests (physical exam, abdominal
ultrasound, UPC ratio, urinalysis, hematology, biochemical panel
and Leishmania serology). All dogs had an unremarkable urinary
ultrasound without urinary sediment before treatment. At one-
month control, 4/20 dogs had xanthinuria, 2/20 mineralization of
pelvic recesses (MPR) and 1/20 vesical urolithiasi. At three-month
control, 4/11 had xanthinuria, 4/11 bilateral MPR and 2/11
urolithiasis (located in renal pelvis and bladder in 1 dog and the
other in bladder). At 6-month control, 4/20 dogs had xanthinuria,
6/20 bilateral MPR, and 4/20 urolithiasis (located in renal pelvis
and bladder in 2 dogs and in renal pelvis in the other two). At 12-
months control, 7/20 dogs had xanthinuria, 7/20 bilateral MPR,
and 6/20 urolithiasis (located in bladder in 3 dogs and in renal pel-
vis in the other 3). Dogs that suﬀered from xanthinuria and renal
mineralization or urolithiasis were treated with low purine diet.
Reduction of xanthinuria and uroliths size was observed in 3 dogs
with compliant owners and strict diet treatment but MPR
persisted.
In conclusion, the present study describes an elevated and
prompt incidence of urinary adverse eﬀects associated with allop-
urinol treatment. A closer follow-up including urinalysis and
abdominal ultrasound is mandatory in dogs treated with allopuri-
nol. Moreover, according our results low purine diet seems to be
an option in reducing xanthine deposits. Further studies are
required to evaluate the eﬃcacy of dietary treatment. According to
authors’ knowledge, this is the ﬁrst prospective study that conﬁrms
previous suspicion of urinary adverse eﬀects of allopurinol treat-
ment in dogs with leishmaniosis.
Disclosures: No disclosures to report.
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DETECTION OF LEISHMANIA IN ARCHIVED CANINE
COLONIC INFLAMMATORY BIOPSIES IN AN ENDEMIC
AREA FOR CANINE LEISHMANIOSIS. L. Solano-Gallego1, I.
Casanova2, S. Martin1, A. Marco2. 1Universitat Autonoma de
Barcelona, Bellaterra, Spain, 2Servei de Diagnostic Patologia,
UAB, Bellaterra, Spain
Previous studies have demonstrated Leishmania infantum infection
in colonic samples with histiocytic or lymphoplasmacytic inﬂam-
mation from seropositive sick dogs. However, there are no studies
that have investigated the presence of L. infantum infection in dogs
diagnosed with inﬂammatory bowel disease (IBD) by clinical and
histopathological examination. The objectives of this study were to
retrospectively investigate the presence of Leishmania infection by
immunohistochemistry (IHC) in archived canine colonic biopsies
previously diagnosed with IBD in an area endemic for canine
leishmaniosis as well as to describe the main histopathological
ﬁndings. A total of 109 cases of canine colitis were retrospectively
retrieved from the archived of biopsies of Servei de Diagnostic de
Patologia of the Universitat Autonoma de Barcelona. Information
regarding clinicopathological data including signalment, histologi-
cal results and further diagnostic testing to detect Leishmania
infection such as Leishmania IHC staining was compiled from the
selected cases. Lymphoplasmacytic (n = 101), histiocytic (n = 5),
and lymphoplasmacytic with mild eosinophilic/neutrophilic com-
ponent (n = 3) colitis were diagnosed between January 1997 and
September 2015 performed by endoscopic colonic biopsies. Inter-
estingly, Leishmania IHC was only carried out in 13 out of 109
(11.9 %) colonic samples to conﬁrm or exclude Leishmania infec-
tion based on the diagnostic database. From those, 5 were diag-
nosed as granulomatous and 8 as lymphoplasmacytic colitis. Four
biopsies were classiﬁed as positive, two as unclear results due to
unspeciﬁc background staining and the rest were negative for
Leishmania IHC. Leishmania IHC was performed in 56 out of the
remaining 96 colonic samples with a diagnosis of lymphoplasmo-
cytic or histiocytic inﬂammation that were not previously tested to
conﬁrm or exclude this infection. Due to economical restrictions,
only 56 colonic samples retrieved could be investigated. Only one
out of 56 (1.8%) colonic biopsies examined was classiﬁed as
ECVIM Abstracts 601
positive by IHC. A total of 5 out of 109 (4.6%) dogs were diag-
nosed with Leishmania infection. Two dogs presented intense histi-
ocytic inﬂammation while three dogs showed mild to intense
lymphoplasmacytic inﬂammation. The number of amastigotes per
5 microscopic ﬁelds viewed at 409 assessed by IHC was variable
and ranged between 2 to countless. In conclusion, Leishmania
infection should be included in the list of diﬀerentials of inﬂamma-
tory colonic biopsies. Leishmania amastigotes are commonly not
visualized by routine histological staining. Therefore, IHC for
Leishmania should be routinely used as a diagnostic tool in ende-
mic areas of leishmaniosis, to exclude or conﬁrm an infection by
this parasite in patients with a diagnosis of IBD.
Disclosures: No disclosures to report.
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COMPARISON OF THE SEVERITY OF MYOCARDIAL
DAMAGE WITH THE QUANTITATIVE ESTIMATION OF
THE MYOCARDIAL PARASITIC LOAD BY REAL-TIME
PCR IN DOGS WITH CANINE VISCERAL LEISHMANIOSIS.
J. Duque1, D. Casamian-Sorrosal2, S. Belinchon-Lorenzo1, J. Sal-
ado-Tato1, L. Gomez-Gordo1, J.J. Real-Rıos1, L. Martınez-
Hernandez1, R. Barrera-Chacon1. 1Veterinary Teaching Hospital,
Caceres, Spain, 2Dick White Referrals, UK
It has been previously shown that canine leishmaniasis (CanL)
causes severe myocardial damage which leads to elevation of Tro-
ponin I (cTnI). It has also been previously shown that this
myocardial damage is likely to be primarily associated with the
severity of the protozoal disease and not with the degree of azote-
mia, anemia or systemic arterial hypertension. It remains to be
determined however whether this myocardial damage is directly
correlated with the cardiac parasitic load or the damage is primar-
ily indirect through other mechanisms such as systemic
inﬂammation.
The aim of this study was to evaluate and compare the concen-
tration of cTnI, histopathology severity and plasma creatinine con-
centration (Cr) with the parasitic load within cardiac tissue
samples in a cohort of dogs with CanL.
Ethical approval was granted by the University of Extremadura
committee. Five dogs without previous history of cardiac disease
and severe CanL and renal azotemia (Stage IV, LeishVet scheme)
were included in the study. All dogs underwent full physical exam-
ination hematology, biochemistry, urinalysis including protein-
creatinine ratio, ELISA serology for L. Infantum, cTnI measure-
ment, blood pressure, abdominal ultrasound, electrocardiography,
thoracic radiographs and echocardiographic examination. All dogs
were euthanized due to the severity of the disease and underwent
post-mortem examination. Myocardial samples were taken for
histopathology and were tested for L. Infantum by real-time-PCR
(RT-PCR) by detection and quantiﬁcation of Kinetoplast minicir-
cle DNA.
Elevation of cTnI (Dog 1: 0.36 ng/mL; Dog 2: 0.59 ng/mL;
Dog 3: 4.56 ng/mL; Dog 4: 7.69 ng/mL; Dog 5: 9.23 ng/mL; Med-
ian 4.56 ng/mL; IQR 0.59–7.56 ng/mL; normal <0.06 ng/mL) and
Cr (Dog 1: 2.7 mg/dL; Dog 2: 4.3 mg/dL; Dog 3: 15.5 mg/dL;
Dog 4: 3.8 mg/dL; Dog 5: 7 mg/dL; Median 4.3 mg/dL; IQR 3.8–
7 mg/dL; normal 0.7–1.2 mg/dL;) was detected in all dogs. Severe
lymphoplasmacytic myocarditis was observed in all myocardial
samples. L. infantum DNA was detected in the myocardial tissue
of all ﬁve dogs and RT-PCR assay was performed in the samples
to estimate the parasite load (Dog 1: 20,72 parasites/mg; Dog 2:
25.57 parasites/mg; Dog 3: 146.19 parasites/mg; Dog 4: 284.88
parasites/mg; Dog 5: 290 parasites/mg; Median 146.19 parasites/
mg; IQR 25.57–258.88 parasites/mg). A positive strong correlation
was observed between cTnI and the parasitic load (P < 0.001) but
no correlation (P > 0.05) was observed between cTnI and Cr
concentrations.
The results of this study shows for ﬁrst time an association
between the severity of myocardial damage in canine leishmaniasis
and the severity of myocardial parasitic load.
Disclosures: No disclosures to report.
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INVESTIGATION OF THE PRESENCE OF BACTEREMIA IN
PUPPIES WITH CANINE PARVOVIRAL ENTERITIS. L.
Kalogianni1, G. Kazakos1, Z.S. Polizopoulou1, K. Kontopoulou2,
V. Siarkou1, E. Triantafyllou3, S.C. Chaintoutis1, C.I. Dovas1, N.
Soubasis1, T.S. Rallis1. 1School of Veterinary Medicine, Faculty of
Health Sciences, Aristotle University, Thessaloniki, Greece, 2Gen-
eral Hospital of Thessaloniki, G. Gennimatas, Thessaloniki,
Greece, 3Vet Analyseis, Veterinary Diagnostic Laboratory, Larissa,
Greece
The aim of this prospective study was to investigate bacteremia in
puppies with enteritis attributed to canine parvovirus 2 (CPV-2)
infection.
Blood samples were obtained for culture from 17 puppies with
parvoviral enteritis (Group 1), aged 2–10 months, prior to treat-
ment on admission (time 1), 48 hours later (time 2), and on the
day of sudden deterioration or discharge (time 3). Thirteen healthy
puppies (Group 2), aged 2–6 months, were selected as controls
and sampled for blood culture once. Dogs were eligible for inclu-
sion in Group 1 according to clinical and clinicopathological
abnormalities, incomplete vaccination against canine parvoviral
enteritis, and presence of CPV antigens (rapid immunoassay) and
of CPV-2 DNA (real-time PCR) in feces. Group 2 dogs were
healthy on physical examination, complete blood count, serum
biochemistry, urinalysis, abdominal ultrasonography, buﬀy coat
cytology, and tested negative for CPV antigens and CPV-2 DNA
in feces. All animals had not received antimicrobials for 4 weeks
prior to inclusion in the study. Blood samples from all dogs were
aseptically obtained from both jugular veins at each time-point,
placed in pediatric culture bottles and shipped to the laboratory
immediately. Blood cultures were performed by BACTEC 9120
blood culture instrument (Becton Dickinson) using pediatrics
(PEDS) bottles. Isolates from positive blood cultures were identi-
ﬁed to the species level by the VITEK 2 automated system (Bio-
merieux, France). Standardized treatment included intravenous
administration of ﬂuids, maropitant, metoclopramide, ampicillin
and enroﬂoxacin.
In Group 1, 11/17 dogs survived to discharge. Escherichia coli
was isolated in 4/6 dead dogs, Klebsiella pneumoniae in 1/6, and
blood cultures were negative in 1/6. Nine out of 11 survivors were
blood culture-negative and 2/11 presented asymptomatic bac-
teremia on the day of discharge (K. pneumoniae and Enterobacter
cloacae, respectively). Repeat blood cultures in the latter 9 days
post-discharge, during which no antimicrobials had been adminis-
tered, were negative. Median duration of hospitalization for group
1 was 7 days (range 1–9 days). All blood cultures from group 2
were negative.
Limited data exist regarding blood culture results in puppies
naturally infected with CPV-2. E. coli, Enterobacter spp. and K.
pneumoniae have been previously reported in cultures from intra-
venous catheters in dogs with parvoviral enteritis, and E. coli has
also been recovered from blood in 3 cases. To the best of our
knowledge, this is the ﬁrst prospective study to monitor bacterial
blood cultures longitudinally in such dogs.
Disclosures: No disclosures to report.
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IDENTIFICATION OF SERUM BIOMARKERS IN DOGS
NATURALLY INFECTED WITH ANAPLASMA PHAGOCY-
TOPHILUM AND BORRELIA BURGDORFERI. Z. Yilmaz1, L.
Franco2, D. Escribano2, P. Schanilec3, P. Levent1, S. Martinez-
Subiela2, A. Tvarijonaviciute2, A. Saril1, N. Aytug4, J. Ceron2.
1Department of Internal Medicine, Faculty of Veterinary Medi-
cine, Uludag University, Bursa, Turkey 2Interdisciplinary Labora-
tory of Clinical Pathology, Interlab-UMU, University of Murcia,
Murcia, Spain , 3Faculty of Vetnary Medicine, University of
Veterinary & Pharmaceutical Sciences, Brno, Czech Republic,
4Department of Internal Medicine, Veterinary Medicine, Near
East University, Lefkosa, Cyprus
Anaplasmosis caused by Anaplasma phagocytophilum and Lyme
disease caused by Borrelia burgdorferi sensu lato (borreliosis) are
the most frequently diagnosed vector (tick)-borne disease (VBD)
in humans and dogs. To the authors’ knowledge, there are limited
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data of serum proteomics on these clinical animals and the modiﬁ-
cations in their proteome. Thus, the aim of the present study was
to identify the potential serum biomarkers of diagnosis of anaplas-
mosis and Lyme disease using a proteomic approach.
Pools of serum samples from dogs naturally infected with A.
phagocytophilum, B. burgdorferi, and infected with both agents
were collected before treatment, and compared with a control
group. Anaplasmosis and Lyme disease were diagnosed based on
speciﬁc IgG and IgM antibody titers. Serum C-reactive protein
and ferritin levels in infected dogs were higher (P < 0.05) than
those of controls. Two-dimensional electrophoresis (2DE) of
pooled samples was run in triplicate. 2DE image analysis showed
57 diﬀerentially expressed spots between infected animals and con-
trols. Compared to healthy controls, vitamin D-binding protein
decreased, while haptoglobin and Ig chains with diﬀerent spots
increased in both diseases. Serum apolipoprotein-A1 (Apo-A1)
level decreased in dogs with Lyme, but this did not express diﬀer-
entially in dogs with anaplasmosis. In dual infections, concentra-
tions of vitamin D-binding protein and albumin decreased,
whereas alpha glycoprotein, haptoglobin and Ig chain increased
compared to controls.
These study results showed that many proteins might be chan-
ged in the VBDs, and they could be useful biomarkers for diagno-
sis, pathophysiology and treatment strategies. Understanding the
role of these proteins in many biological processes such as acute
phase response, immunological reactions, transport, oxidative
stress, apoptosis, calcium, iron and lipid metabolism and blood
coagulation cascade provide advantages during diagnostic and
therapeutic approaches in clinical settings.
Disclosures: No disclosures to report.
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AT LEAST THREE YEARS OF PROVEN PROTECTION
AGAINST DISTEMPER, INFECTIOUS CANINE HEPATITIS
AND PARVOVIROSIS IN DOGS VACCINATED WITH THE
MULTIVALENT CANIGENTM DHPPI/L VACCINE. F. Sen-
seby, T. Butaud, P. Schreiber, L. Guegand, C. Fontaine, S. Gue-
guen. VIRBAC, Carros, France
Distemper, infectious canine hepatitis and parvovirosis are life-
threatening diseases due respectively to canine distemper virus
(CDV), canine adenovirus virus (CAV)-1 and canine parvovirus
(CPV). The maintenance of the serological response post vaccina-
tion is often used to evaluate the protective status of a dog. How-
ever, as live vaccines stimulate mainly the cell-mediated pathway
of the immune system, this method may underestimate the real
duration of eﬃcacy of these vaccines. The study aim was to evalu-
ate the eﬃcacy of the attenuated CDV, CAV and CPV strains of
the multivalent CanigenTM DHPPi/L vaccine (Virbac, France)
after experimental infections performed at three years after the
ﬁrst annual booster.
Forty seven SPF Beagle puppies, males and females, partici-
pated in the study. Puppies were allocated to either the vaccinated
group (Group 1, n = 23) or the unvaccinated group (Group 2,
n = 24). Puppies of Group 1 received CanigenTM DHPPi/L vac-
cine, formulated at minimum titer for the live components, for pri-
mary vaccination with two injections at a three-week interval
(respectively at 9 and 12 weeks of age) and for the ﬁrst annual
booster. Blood samples were taken on several occasions for sero-
logical follow-up. CDV, CAV-1, CPV-2 and CPV-2c antibody
titers were measured by seroneutralization tests (SN). After vacci-
nation, SN antibody titer ≥ 100.7 for both CDV and CAV-1 and ≥
101.17 for CPV-2 variants are considered as positive. At three years
after the ﬁrst annual booster, dogs of both groups were adminis-
tered either a pathogenic CDV (n = 10) or CAV-1 (n = 12) or
CPV-2c (n = 12) strain and followed for the appearance of any
typical sign of the related disease for 21 days. Vaccinated dogs
with the lowest SN titers were selected to receive the pathogenic
agents.
In Group 1, 23/23 puppies seroconverted after the primary vac-
cination course. At 3 years after the ﬁrst annual booster, SN anti-
bodies against CAV-1, CPV-2 and CPV-2c were still present in 23/
23 dogs and in 21/23 dogs for CDV. After the experimental infec-
tions, typical signs of distemper and infectious hepatitis leading to
death were observed respectively in 5/5 and 6/6 non-vaccinated
dogs and in none of vaccinated dogs (respectively n = 0/5, n = 0/
6). Typical signs of parvovirosis including CPV viral shedding
were observed only in the non-vaccinated dogs.
In conclusion, this experimental study demonstrated that the
protection against distemper, infectious canine hepatitis and par-
vovirosis lasts at least three years after any annual vaccination
booster with CanigenTM DHPPi/L vaccine.
Disclosures: Disclosures to report.
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COMPARATIVE KILLING OF CANINE URINARY PATHO-
GENS BY CEPHALEXIN (CP), MARBOFLOXACIN (MR),
PRADOFLOXACIN (PR) AND TRIMETHOPRIM/SUL-
FAMETHOXAZOLE (TMP/SMX). M. Blondeau, D. Shebelski.
Royal University Hospital, Saskatoon, Canada
Urinary tract infections are common in dogs necessitating antimi-
crobial therapy. In humans, short course therapy is used for
uncomplicated cases thereby questioning if shorter courses are pos-
sible in dogs. Rapid and complete killing of bacteria by antibiotics
aﬀects clinical cure and may inﬂuence shorter durations of
therapy.
The aim of this study was comparing killing of canine urinary
pathogens by 4 antimicrobial agents at clinically relevant drug
concentrations. Approximately 100,000 colony forming units/milli-
liter of canine isolates (3 strains each) of Escherichia coli (EC),
Enterobacter faecalis (EF), Proteus mirabilis (PM) and Staphylo-
coccus pseudintermedius (SP) were exposed to the maximum serum
(Cmax) and maximum urine (Umax) concentrations of each drug
and the log10 (LT) and percent (%) kill measured at 5, 10, 15, 20,
25, 30, 60, 120 and 180 minutes after drug exposure. All measure-
ments were in triplicate and averaged such that each data point
was based on 9 averaged values, i.e. triplicate and 3 strains. Expo-
sure of EC to the Cmax of CP, TMX/SMX, MR and PR resulted
in 22 (0.22 LT), 3 (0.01 LT), 94 (2.1 LY) and 99 (2.41 LT) % kill
following 30 minutes of drug exposure; at the Umax 23 (0.11 LT),
growth (+0.02 LT), 95 (1.6 LT) and >99 (2.5 LT) % kill following
5 minutes of drug exposure. Following 180 minutes of drug expo-
sure at the Umax, 82% kill was seen for CP and growth for TMP/
SMX. Exposure of PM to the Cmax of CP, TMP/SMX, MR, PR
resulted in 64%, >99%, 96% kill and growth respectively follow-
ing 60 min of drug exposure; at the Umax 42%, 4%, 96% and
>99% kill was observed following 15 min of drug exposure. Expo-
sure of SP to the Cmax of CP, TMP/SMX, MR, PR resulted in 3,
9, 53 and 93% kill following 30 minutes of drug exposure; at the
Umax 2, 3, 64 and 94% kill was seen respectively following 15 min-
utes of drug exposure. Exposure of EF to Umax for TMP/SMX,
MR, PR resulted in growth, 86 and 96% kill respectively following
120 minutes of drug exposure.
Killing of bacterial pathogens is necessary for clinical cure and
rapid and complete killing inﬂuence duration of therapy. MR and
PR more rapidly and completely killed urinary pathogens than did
CP and TMP/SMX. Such observations may be important clinically
for empiric antimicrobial treatment of canine urinary tract infec-
tions and is consistent with antimicrobial stewardship goals.
Disclosures: Disclosures to report.
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SNAP 4DX PLUS CORRELATES WELL WITH IFA FOR
DETECTION OF E. CANIS ANTIBODIES. J. Liu, H. Bewsey,
J. Drexel, M.G. Vrhovec, R. Chandrashekar. IDEXX Laborato-
ries, Inc., Westbrook, USA
Canine Monocytic Ehrlichiosis (CME) is a major tick-borne dis-
ease worldwide. Diagnosis of CME can be challenging, as the
patients may present with variable, often non-speciﬁc, clinical signs
associated with diﬀerent stages of the infection, or co-infections.
Ehrlichia canis is the etiological agent. Diagnosis of CME is gener-
ally supported by detection of E. canis antibodies either by indirect
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immunoﬂuorescence assay (IFA) and/or ELISA. Several rapid
point-of-care test kits are also available, but their relative accura-
cies have not been reported. The aim of this study was to evaluate
the performance of three point-of-care test kits for detection of E.
canis antibodies.
Three test kits evaluated included SNAP 4Dx Plus (IDEXX),
Speed Duo Leish K/EhrliTM (BVT/Virbac), and FASTest EHR-
LICHIA canis (MegaCor). Surplus samples were collected from
IDEXX Reference Laboratories (IRL) at Ludwigsburg, Germany,
and Phoenix, USA after requested diagnostic testing was com-
pleted. These were serum samples from suspected CME cases sub-
mitted by veterinarians for E. canis IFA and other testing. A total
of 104 positive (IFA titer ≥ 1:400) and 163 IFA negative samples
were included in this study. Samples were blinded and randomized
for testing with rapid tests. Each result was interpreted by 3 tech-
nicians. A test was considered positive when 2 or 3 technicians
called it positive; negative when 2 or 3 technicians called it
negative.
Compared to E. canis IFA, sensitivity/speciﬁcity was 95.2%/
100% for SNAP, 84.6%/82.0% for Speed Duo and 82.2%/84.0%
for FASTest, respectively.
The number of false positive results was surprisingly high on
Speed Duo and FASTest tests. To further conﬁrm these results, all
163 IFA negative samples were evaluated using a species-speciﬁc
ELISA (McBride et al. 2007) and they all tested negative. Of these,
118 were sourced from dogs living in Germany, non-endemic for
E. canis, yet, 21 (17.8%) were tested positive by the Speed Duo
test, and 16 (13.6%) positive by the FASTest test.
For E. canis, which has a reported prevalence rate of 1–5% in
the US and many European countries, tests with low speciﬁcity
could have a very low positive predictive value. Consistent with
previously published studies (Miro et al. 2013, Rene-Martellet
et al. 2015), results from this study suggest that SNAP 4Dx Plus is
an accurate point-of-care test useful for diﬀerential diagnosis or
screening.
Disclosures: Disclosures to report.
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SEROPREVALENCE OF INFECTIOUS DISEASES IN FERAL
CATS IN THE AMERICAN MIDWEST. J.S. Palerme, J.E. Olds,
E. Lamperelli, J. Gagne, C. Cazlan. Iowa State University, College
of Veterinary Medicine, Ames, USA
By the nature of their environment and behavior, feral cats have
an increased risk of exposure to a wide range of pathogens com-
pared to domestic cats. Consequently, feral cats can act as both a
reservoir for possible zoonotic diseases as well as a sentinel species
for seroprevalence in other animal populations. We assessed the
seroprevalence and risk factors associated with exposure to Lep-
tospira, Toxoplasma and Diroﬁlaria in a population of feral cats
from the American Midwest. Serum samples from a total of 140
cats were available for testing. Twelve cats (8.6%) were seroposi-
tive for leptospirosis based on a microscopic agglutination test
titer of 1:100 or greater. Bratislava was the most commonly
reported serovar, accounting for 6/12 positive titers. Forty-two
cats (30%) were seropositive for Toxoplasma based on competitive
ELISA testing and nine cats (5.3%) were seropositive for Diroﬁlar-
ia antibodies based on a lateral ﬂow immunoassay. All of the cats
for which a Diroﬁlaria antigen test was performed were negative.
Body weight and sexual status was not signiﬁcantly correlated with
seropositivity to any of the studied pathogens. Seropositivity to
one pathogen was not found to be a risk factor for seropositivity
to other pathogens. Seroprevalence for leptospirosis was signiﬁ-
cantly greater in spring than in fall (P = 0.023) and varied signiﬁ-
cantly between age groups (P = 0.014). Similarly, seroprevalence
for Toxoplasma varied according to age with cats between 73 and
120 months of age being signiﬁcantly overrepresented (P = 0.013).
Compared to previous seroprevalence reports of feline feral popu-
lations from the United States and abroad, this population of cats
from the American Midwest had a slightly lower seroprevalence of
Toxoplasma but higher seroprevalence of leptospirosis.
Disclosures: No disclosures to report.
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SERONEUTRALIZATION OF CANINE PARVOVIRUS BY
SERA OF CATS VACCINATED WITH EITHER LEUCOFELI-
GENTM FELV/RCP OR FELIGENTM CRP VACCINES. M.
Gillet, S. Arcidiaco, T. Almeras, C. Lesbros, S. Fournel, C. Fon-
taine, S. Gueguen. VIRBAC, Carros, France
Canine parvovirus (CPV)-2 has been isolated from cats presenting
with signs of panleukopenia. CPV-2c is reported as the most
pathogenic genetic variant in this specie. Few eﬃcacy data support
the ability of current feline parvovirus containing vaccines to pro-
tect cats against parvovirus from canine origin. As canine and
feline parvovirus seroneutralizing antibodies correlate with clinical
protection in each respective specie, the study objective was to
demonstrate the ability of both LeucofeligenTM FeLV/RCP and
FeligenTM CPR vaccines (Virbac, Carros, France) to protect cats
against parvovirosis due to CPV variants by serology.
In this retrospective study, kitten sera samples obtained within
the frame of two studies were used. In study A, sera were obtained
from 18 kittens, 9/18 vaccinated with LeucofeligenTM FeLV/RCP
and 9/18 unvaccinated kittens. From study B, sera were from
twenty-six kittens, vaccinated with either FeligenTM CRP (11/26)
or LeucofeligenTM FeLV/RCP (15/26). All vaccinated kittens had
received two sub-cutaneous vaccine injections three weeks apart
for primary vaccination, starting at 9–10 weeks of age. Sera were
taken prior vaccination and four weeks after the last vaccine injec-
tion, and used to assess the ability of the vaccines induced anti-
bodies to neutralize CPV-2 and CPV-2c antigens by
seroneutralization (SN) assays. SN titer below 101,17 was consid-
ered as negative. All results are expressed in mean  standard
deviation, in log10 units.
In both studies, none of the cat sera was able to neutralize
CPV-2 or CPV-2c antigen prior vaccination. At four weeks after
the last vaccine injection for primary vaccination, whatever the
study, kittens vaccinated with either LeucofeligenTM FeLV/RCP
(9/9 from study A and 15/15 from study B) or FeligenTM CRP
(11/11 from study B) were able to neutralize both CPV-2 and
CPV-2c antigens. After vaccination, SN titers against CPV-2 were
respectively 3.35  0.69, 4.02  0.54 and 4.03  0.86 for sera of
kittens vaccinated with LeucofeligenTM FeLV/RCP in study A,
study B and kittens vaccinated with FeligenTM CRP from study B.
CPV-2c SN titers obtained post vaccination were, for the same
groups, 3.35  0.65, 4.03  0.51 and 3.97  0.82. No signiﬁcant
diﬀerence could be demonstrated for any CPV-2 variant and for
any vaccine (P > 0.05).
Cats vaccinated with either LeucofeligenTM FeLV/RCP and
FeligenTM CRP vaccines developed an acquired immunity against
CPV variants. Based on the correlation between seroneutralizing
antibodies and protection for parvovirus, both LeucofeligenTM
FeLV/RCP and FeligenTM CRP vaccines protect cats against par-
vovirosis due to CPV variants.
Disclosures: Disclosures to report.
All authors are employees of Virbac.
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SEROLOGIC AND MOLECULAR DIAGNOSTIC SURVEY OF
BABESIA SPP. INFECTIONS IN HUNTING DOGS FROM
SOUTHERN ITALY. V. Veneziano1, D. Piantedosi1, B. Neola1,
N. d’Alessio2, M. Santoro2, L. Paciﬁco1, G. Sgroi1, L. Auletta3, C.
Leutenegger4, P. Tyrrell4, C. Genevieve4, J. Saucier4, J. Buch4, R.
Chandrashekar4. 1University of Naples Federico II, Napoli, Italy,
2Istituto Zooproﬁlattico Sperimentale del Mezzogiorno, Portici,
Italy, 3IRCCS SDN, Naples, Italy, 4DEXX Laboratories, Inc.,
Westbrook, Main, USA
Canine babesiosis is a potentially serious canine vector-borne dis-
ease (CVBD) caused by intraerythrocytic protozoan parasites of
the genus Babesia. Clinical signs of babesiosis include moderate to
severe hemolytic anemia, fever, anorexia, depression, pallor, and
splenomegaly. Infections are tick-transmitted and geographic dis-
tribution throughout Europe is expanding along with the spread
of the tick species Dermacentor reticulatus and Rhipicephalus san-
guineus. The present study aimed to perform a serological and
molecular diagnostic survey of Babesia spp. infections in hunting
dogs from southern Italy.
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Blood samples were collected from hunting dogs (n. 1,311) with-
out any speciﬁc signs associated to bebesiosis in the Avellino,
Napoli, and Salerno provinces of Campania region of southern
Italy. Signalment and history of tick infestation was recorded for
each dog at the time of blood collection. Serology testing was per-
formed by two enzyme-linked immunosorbant assays (ELISAs),
with one designed to detect canine antibodies to B. canis and B.
vogeli and the other designed to detect canine antibodies to B. gib-
soni. All samples were tested by real time polymerase chain reac-
tion (RT-PCR) assays for the presence of two large-form Babesias,
Babesia canis and Babesia vogeli, and one small-form Babesia,
Babesia gibsoni.
Nearly half (634/1311, 48.4%) of all hunting dogs had a history
of tick infestation. Seropositive rates were 14.0% (184/1311) for B.
canis/B. vogeli and 0.2% (3/1311) for B. gibsoni. PCR positives
rates for B. canis, and B. vogeli, were 0.2% (2/1311) and 1.1%
(15/1311), respectively. No dog tested positive by RT-PCR for B.
gibsoni. Salerno had the highest prevalence of Babesia spp. infec-
tions with 22.5% of dogs testing positive by either PCR or ELISA
followed by Avellino (15.7%) and Napoli (8.6%).
The present study represents the ﬁrst large-scale survey of Babe-
sia spp. infections in hunting dogs from southern Europe and
demonstrates that hunting dog populations in southern Italy are
at risk for babesiosis. Further studies are needed to determine the
prevalence of clinical babesiosis in this at-risk population and eval-
uate the relationship between hunting dogs and sympatric popula-
tions of wild animals in the epidemiology of Babesia spp.
Disclosures: No disclosures to report.
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ANTIBODY PRODUCTION AS REACTION TO FELINE
PANLEUKOPENIA VIRUS VACCINATION IN CATS WITH
FELINE IMMUNODEFICIENCY VIRUS AND FELINE LEU-
KEMIA VIRUS INFECTION. M. Bergmann1, S. Schwertler1,
A.L. Proksch1, S. Reese2, S. Speck3, U. Truyen3, K. Hartmann1.
1Clinic of Small Animal Medicine, M€unchen, Germany, 2Depart-
ment of Veterinary Science for Anatomy, Histology and Embryol-
ogy, LMU, Munich, Germany, 3Institute of Animal Hygiene and
Veterinary Public Health, University of Leipzig, Leipzig, Germany
So far, there are a few data, how immunocompromised cats, such
as cats infected with feline leukemia (FeLV) and immunodeﬁciency
virus (FIV), react to vaccination. Therefore, this study´s aim was
to measure feline panleukopenia virus (FPV) antibodies in FIV-
and FeLV-infected cats within a period of 28 days after FPV vac-
cination, and to compare the titer increase to that of healthy cats.
FIV- (n = 5), FeLV-infected (n = 5), and healthy cats (n = 112)
were vaccinated with a commercial FPV modiﬁed-live vaccine.
Pre- and post-vaccination antibody titers were measured by
hemagglutination inhibition (HI) on day 0, 7, and 28. An HI titer
≥1:40 was deﬁned as protective. An adequate immune response to
vaccination was deﬁned as a 4-fold titer increase. Diﬀerences
regarding titer increase between FIV-, FeLV-infected, and healthy
cats were analyzed using Chi-squared test.
Protective pre-vaccination FPV antibody titers were present in
80% (8/10; 95% CI: 47.9–95.4) of retrovirus-infected cats and in
64% (72/112; 95% CI: 55.1–72.6) of healthy cats. An adequate
titer increase was observed in 30% (3/10; 95% CI: 10.3–60.8) of
retrovirus-infected cats and in 48% (54/112; 95% CI: 10.3–60.8) of
healthy cats. There was neither a signiﬁcant diﬀerence in presence
of protective pre-vaccination titers (P = 0.491), nor in titer
increase (P = 0.335), or vaccination adverse eﬀects (P = 0.597).
FIV and FeLV infections did not negatively inﬂuence eﬃcacy
and safety of MLV FPV vaccination; thus, FPV vaccination can
be given to retrovirus-infected cats according to current guidelines.
Further studies should be performed involving larger numbers of
retrovirus-infected cats.
Disclosures: Disclosures to report.
The study was funded by Merial, Lyon, France. Merial played
no role in the interpretation of data, or in the decision to submit
the abstract for publication. There is no commercial conﬂict of
interest as the information generated here is solely for scientiﬁc
dissemination. The authors declare that they have no competing
interests.
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EVALUATION OF RAPID DIAGNOSTIC TEST KITS FOR
CANINE VECTOR-BORNE DISEASES. H. Bewsey1, J. Liu1, J.
Rodon Vernet2, R. Chandrashekar1. 1IDEXX Inc., Westbrook,
USA, 2IDEXX Laboratories, Inc., Barcelona, Spain
Canine vector-borne diseases (CVBD), including Leishmaniasis
(CanL), Canine Monocytic Ehrlichiosis (CME) and Anaplasmosis,
are prevalent in Mediterranean countries, South America, parts of
Asia and Africa. Diagnosis of CVBD is generally supported by
hematologic and serologic ﬁndings. Commonly used serological
tests include immunoﬂuorescence assay (IFA), and/or ELISA.
Rapid in-clinic tests are also available. The aim of this study was
to compare the performance of rapid tests with gold standard IFA
and/or ELISA for detection of canine antibodies to Leishmania
infantum, Ehrlichia canis and Anaplasma platys.
The rapid tests evaluated included SNAP Leishmania and
SNAP 4Dx Plus (IDEXX), Uranotest Leishmania and Uran-
otest Ehrlichia-Anaplasma (Uranovet). Study samples were col-
lected from IDEXX Reference Laboratories from samples
remaining after requested diagnostic testing was completed. These
samples were originally submitted by attending veterinarians for
detection of Leishmania antibodies using LEISCAN Leishmania
ELISA Test, or for detection of E. canis antibodies using E. canis
IFA. Positive samples for Leishmania were deﬁned for this study
as those with ≥1/160 equivalent titer (converted from OD ratio per
manufacturer’s instructions), negatives with ≤ 1/20 equivalent titer.
To control for potential cross-reactivity of E. canis IFA, a species-
speciﬁc ELISA (McBride et al. 2007) was used to conﬁrm E. canis
samples. Another species-speciﬁc ELISA (Qurollo et al. 2014) was
used to identify A. platys samples.
Compared to the respective diagnostic standards, the sensitivi-
ties of SNAP and Uranotest were 90.3% and 67.7% respectively
for Leishmania, 96.2% and 65.4% for E. canis, 83.0% and 48.9%
for A. platys. Speciﬁcities were high for all test kits.
This study revealed that the accuracy of in-clinic rapid tests for
CVBD varies signiﬁcantly. Consistent with previously published
studies (Ferroglio et al. 2007, Marcondes et al. 2011, Miro et al.
2013, Stillman et al. 2014, Rene-Martellet et al. 2015), this study
using clinical samples continued to demonstrate the high sensitivity
and speciﬁcity of SNAP tests for detection of Leishmania, E. canis,
and A. platys antibodies.
Disclosures: Disclosures to report.
All authors are employees of IDEXX Laboratories, Inc.
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ANTIMICROBIAL USE IN 44 DUTCH COMPANION ANI-
MAL CLINICS. N.E.M. Hopman1, I.M. van Geijlswijk2, D.J.J.
Heederik3, J.A. Wagenaar4, E.M. Broens4. 1Faculty of Veterinary
Medicine, Utrecht University, Utrecht, the Netherlands, 2Faculty
of Veterinary Medicine, Pharmacy Department, Utrecht Univer-
sity, Utrecht, the Netherlands, 3Faculty of Veterinary Medicine,
Utrecht University, IRAS, Utrecht, the Netherlands, 4Faculty of
Veterinary Medicine, Department I&I, Utrecht University,
Utrecht, the Netherlands
Antimicrobial use (AMU) in veterinary medicine is considered a
potential threat for public health and animal health as it selects
for antimicrobial resistance. Therefore a combination of compul-
sory and voluntary actions was implemented in the last 5 years to
reduce AMU in animals in the Netherlands. In food producing
animals, a considerable reduction in AMU has been accomplished
over the last years. Previous research in companion animals
showed that total AMU in companion animals is relatively low,
but large diﬀerences between clinics exist and especially in the
choice of antimicrobial agents there is room for improvement.
Therefore from the end of 2014 onwards, an antimicrobial stew-
ardship program (ASP) was developed and implemented stepwise
in 44 Dutch companion animal clinics.
Aims of present study are to calculate Deﬁned Daily Dosages
(DDDs) from these 44 clinics before start of the ASP implementa-
tion and to identify clinic related factors inﬂuencing AMU in these
Dutch companion animal clinics.
At the beginning of the ASP implementation, clinics ﬁlled in a
questionnaire and provided data on AMU from July 2012 till July
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2015. Questionnaires were used to study clinic related factors
which might inﬂuence AMU by companion animal veterinarians.
Antimicrobial usage data were converted to the number of Deﬁned
Daily Dosages (DDDs) with a standardized Dutch database built
for this purpose. A number of DDDs during a speciﬁed period
(mostly a year) represents the number of days during that period
that an average dog, cat or rabbit in a clinic is treated with AM’s.
DDDs were diﬀerentiated in ﬁrst (not selecting for ESBLs), second
(might select for ESBLs) and third choice AM’s (critically impor-
tant to public health; i.e. third- and fourth-generation cephalospor-
ins and ﬂuoroquinolones).
Results show that AMU decreased over the last years. There is
a signiﬁcant decrease in the use of third choice antimicrobials.
Further statistical analyses will be performed to explore associa-
tions between DDDs and clinic characteristics (e.g. number of vet-
erinarians working in a clinic, rural versus urban clinics and
number of dogs, cats and rabbits being treated in a clinic).
Disclosures: Disclosures to report.
This study was funded by ZonMW (Netherlands Organization
for Health Research and Development), project number:
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PREVALENCE AND RISK FACTOR FOR HARBORING
CAMPYLOBACTER JEJUNI IN YOUNG DOGS IN COPEN-
HAGEN. L.R. Jessen, S. Lund, C.K. Vøls, R. Langebæk, C.R.
Bjørnvad. University of Copenhagen, Frederiksberg, Denmark
Campylobacter jejuni (C. jejuni) is the most common cause of clini-
cal campylobacteriosis in people. In Denmark the incidence of
human campylobacteriosis is constant despite a signiﬁcant reduc-
tion in food borne cases over the last couple of years, indicating a
role for other sources of infection.
The aims of the study were as follows: 1) to examine the preva-
lence of C. jejuni in family dogs younger than 2 years of age in
Copenhagen, Denmark, 2) to identify risk factors associated with
carriage of C. jejuni and 3) to examine the association between
carriage of C. jejuni and clinical signs of diarrhea. A Cross-sec-
tional study in dogs younger than 2 years presenting to the
University Hospital for Companion Animals, University of Copen-
hagen, Denmark, was carried out from May to November 2016.
Samples were collected by rectal swabs and stored in a charcoal
medium at 4°C for a maximum of 32 h before culturing. Positive
samples were veriﬁed using phase contrast microscopy and Whole
Genome Sequencing. All dog owners completed a questionnaire
regarding the management of their dogs. Data was analyzed using
Chi-square tests, and multivariate analyses in SPSS Statistics 24.
P < 0.05 was considered signiﬁcant.
224 dogs were included. The prevalence of C. jejuni was 9.4%
(21/224). Primary feeding with “Bones and Raw Food” (BARF,
P = 0.008)) and regular feeding with dried meat (P = 0.01) were
signiﬁcant risk factors for Campylobacter carriage. Dogs younger
than 1 year of age fed with BARF and/or dried meat were at
greater risk of carrying Campylobacter than dogs older than
1 year of age with the same feeding routines. There was no associ-
ation between a positive C. jejuni status and concurrent diarrhea,
swimming in sea or lake water, having been abroad or living with
other pets or children in the family.
Dogs can act as a reservoir for C. jejuni and raw feeding
increases the risk. The carriage of C. jejuni in dogs may pose a
zoonotic risk to humans.
Disclosures: Disclosures to report.
The department of Veterinary Clinical Sciences, University of
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SURVEILLANCE OF BACTERIAL CONTAMINATION IN
STETHOSCOPES AND EFFECTIVENESS OF DIFFERENT
DISINFECTING PROTOCOLS. P. Sebastian1, D. Hermes2, M.
Sharman2. 1Hospital Veterinario Universidad de Murcia, Murcia,
Spain, 2Animal Health Trust, Newmarket, UK
Hospital acquired infections (HAIs) can be an important cause or
morbidity, and potentially mortality. There is increasing concern
for the role of multi-drug resistant (MDR) organisms in HAIs.
Surfaces, including stethoscopes, could act as fomites, however
there is no current consensus on decontamination protocols. Fur-
thermore, there is increasing concern regarding the development of
bacterial resistance to topically applied antiseptic agents, leading
to evaluation of innovative decontamination methods.
The purpose of this project was to evaluate the type, of bacte-
rial contamination of stethoscopes in a referral hospital setting,
and to compare the eﬀectiveness of three decontamination proto-
cols.
This study was prospective and interventional. Based upon
available information, a sample size of thirty stethoscopes per
group was calculated to be adequate to determine diﬀerences
between protocols. Three decontamination protocols were used in
a cross-over design across a six week period. Decontamination
protocols included 70% isopropyl alcohol, a quaternary ammo-
nium / biguanide disinfectant (Anistel) and exposure to UV light
(253.7 nm). For each, the diaphragm membrane of each stetho-
scope was sampled using a sterile cotton-tipped swab moistened in
PBS before and after . Colony numbers were determined, and bac-
terial identiﬁcation was performed. Between collection time points
stethoscopes were in regular clinical circulation.
For group comparisons, delta-change values in colony counts
were determined for each stethoscope. Diﬀerences between groups
were analyzed using a non-parametric analysis of variance (Krus-
kal-Wallis test). Where diﬀerences were returned between groups,
post-hoc analysis with Dunn’s multiple comparisons method was
performed to identify where diﬀerences occurred.
A variety of bacterial types were cultured across the course of
the study. No MDR bacteria were isolated. There was no diﬀer-
ence between delta change values when comparisons were made
between decontamination protocols (P = 0.07).
In this referral setting, stethoscope contamination with MDR
bacteria was not present. There was no diﬀerence between groups
regarding expected reductions in bacterial colony counts. UV light
appeared equivalent to other topical solutions in reducing contam-
ination rates of stethoscopes.
Disclosures: No disclosures to report.
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IDENTIFICATION OF ATTACHING AND EFFACING
ENTEROPATHOGENIC ESCHERICHIA COLI IN DOGS
WITH PARVOVIRAL ENTERITIS. J. Rubin, A. Carr, M.
Gaunt. University of Saskatchewan, Saskatoon, Canada
Canine parvovirus is a common cause of severe gastroenteritis in
young, incompletely vaccinated dogs. Concurrent infections with
gastrointestinal parasites and canine corona virus exacerbate clini-
cal disease, increasing mortality. The ability of bacterial pathogens
to potentiate clinical signs has not been thoroughly investigated.
Enteropathogenic E. coli, deﬁned by the presence of the eae gene,
produce characteristic attaching and eﬀacing lesions on the entero-
cyte brush border. These E. coli have been identiﬁed in up to 36%
of dogs with both acute and chronic diarrhea suggesting a patho-
genic role. Dogs with severe diarrhea infected with enteropatho-
genic E. coli have clinical signs and gross pathological lesions that
are indistinguishable from parvovirus infection. The aim of this
study was to identify the prevalence of eae positive E. coli in dogs
with parvoviral enteritis. Twenty ﬁve dogs admitted to the Veteri-
nary Medical Centre in Saskatoon, Canada were included in this
study if they met the following criteria: 1. Less than two years of
age, 2. Acute onset vomiting and/or diarrhea and 3. Incomplete
vaccination history. Feces were cultured and E. coli identiﬁed
using standard biochemical methods. Isolates were screened for
the eae gene by PCR, and amplicon identity was conﬁrmed by
DNA sequencing. Feces were evaluated for gastrointestinal
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parasites by ﬂoatation and for giardia and cryptosporidium by
immunoﬂuorescent antibody. Complete blood count, serum bio-
chemical proﬁle or venous blood gas, urinalysis and parvovirus
fecal ELISA were performed for each dog to identify other poten-
tial causes of gastroenteritis. E. coli were cultured from feces of
92% (23/25) of dogs, 8.7% (2/23) were eae positive. All dogs were
identiﬁed as Parvovirus positive including: 22/25 dogs by fecal
ELISA, 1/25 by immunohistochemistry and 2/25 by histopatholog-
ical examination. Fecal culture identiﬁed Clostridium perfringens in
17/24 and Campylobacter in 3/24 dogs. Salmonella were not identi-
ﬁed. Concurrent gastrointestinal parasitism was identiﬁed in 5/20
dogs tested, identifying Isospora (2/20), Sarcocystis (1/20), and
Toxascaris (1/20). Giardia sp. were identiﬁed in 2/20 by ﬂotation
or IFA. The role of these organisms as canine intestinal pathogens
is poorly deﬁned. The low prevalence of eae positive E. coli identi-
ﬁed among young dogs with parvovirus suggests that these organ-
isms are unlikely to be signiﬁcant gut pathogens in patients with
parvoviral enteritis. Further study is required to deﬁne the role of
these potential pathogens in canine enteric disease.
Disclosures: No disclosures to report.
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COMBINED THERAPY WITH CLINDAMYCIN, DOXYCY-
CLINE AND METRONIDAZOLE INDUCES COMPLETE
STERILIZATION OF BABESIA GIBSONI INFECTION IN
DOGS - A CASE REPORT. O. Sarpataki, A.R. Codea, M. Mir-
cean, I. Marcus, S. Bogdan, A.A. Daskalaki, B. Sevastre. Faculty
of Veterinary Medicine, Cluj Napoca, Romania
Canine babesiosis is a tick-borne protozoal disease, aﬀecting dogs
worldwide. According to previous studies, B. canis is considered as
the main species involved in canine babesiosis, but in recent years
more studies show the existence of Babesia gibsoni infected dogs
both in Europe and Romania. B. gibsoni infection in dogs is
mainly described in American Pit Bull Terriers, although the sig-
niﬁcance of this breed predisposition is not yet fully understood,
however the possibility of both blood-to-blood transfer and
transplacental infection has been considered as a possible modality
of host contamination. A 3 year old female, American Staﬀord-
shire Terrier was referred to our clinic, previously diagnosed with
Babesia canis infection and treated with one dose of imidocarb
dipropionate three days prior. The dog presented fever, pale
mucous membranes and hemoglobinuria. Complete blood count
revealed severe anemia (HCT 13%, Hg 4 g/dL, RBC 1.56 9 1012/
L), thrombocytopenia (PLT 32 9 109/L) and mild leukocytosis
with neutrophilia. Coomb’s test (Alvedia) and rapid test for Diroﬁ-
laria immitis antigen, Ehlichia canis antigen, Borrelia burgdoferi
antigen, Anaplasma phogocytophilum/Anaplasma platys antibody
(Rapid CaniV-4 Test Kit, Bionote) showed negative results.
Giemsa-stained blood ﬁlms were positive for small (1–2.7 µm)
pleomorphic inclusions. Babesia spp. DNA was detected by poly-
merase chain reaction (PCR) assay, further molecular characteriza-
tion of the sample showed the involvement of Babesia gibsoni
(Macrogen Europe, Amsterdam). Following molecular identiﬁca-
tion of Babesia gibsoni, combination therapy was initiated with
Clindamycin (25 mg/kg PO BID), Doxycycline (15 mg/kg PO
BID), and Metronidazole (5 mg/kg PO BID). Fourteen days after
therapy Hb, HCT, RBC and PLT values increased, but the blood
sample tested positive for B. gibsoni by PCR. Therapy was ceased
after 6 weeks, when HCT reached 40% and PCR showed complete
B.gibsoni infection sterilization of the patient. Blood samples tested
three and six months after the initiation of the treatment remained
negative for B. gibsoni. Since the female was 5 weeks post-partum
at the time of babesiosis diagnostic was established, four samples
from two diﬀerent litter pups were tested and found negative for
B.gibsoni, although transplancetal transmission is possible in B.gib-
soni infection. Accurate diagnosis is important in dogs presenting
hemolythic anemia, because B.gibsoni is resistant to traditional
anti-babesial therapy, but combination therapies may be eﬃcient
in order to reduce and eliminate parasitemia.
Disclosures: No disclosures to report.
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FIRST DOCUMENTATION OF CYTOCHROME B GENE
MUTATIONS ASSOCIATED WITH ATOVAQUONE AND
AZITHROMYCIN TREATMENT IN CYTAUXZOON FELIS.
A.N. Hartley, H.S. Marr, A.J. Birkenheuer. College of Veterinary
Medicine, North Carolina State University, Raleigh, USA
Cytauxzoon felis is an emerging tick-transmitted protozoan para-
site of domestic and wild felids. Cytauxzoonosis is typically fatal
in clinical cases without aggressive treatment. Combination treat-
ment with atovaquone and azithromycin (A&A) along with sup-
portive care has improved survival rates to over 60%; in contrast,
survival rates with imidocarb dipropionate are 26%. Parasite resis-
tance to atovaquone via a cytochrome b parasite gene (cytb) muta-
tion has been identiﬁed in other protozoans and is a concern for
C. felis. Speciﬁcally, mutations at the M128 amino acid position
of the putative atovaquone binding site on CYTB have been asso-
ciated with resistance.
We aimed to characterize the atovaquone binding region of cytb
in samples from a C. felis-infected domestic cat that remained para-
sitemic despite treatment with atovaquone and azithromycin. An
approximately nine-year female spayed domestic shorthair was pre-
sented for adoption assessment; the cat was anemic which persisted
despite fenbendazole and doxycycline treatment. Comprehensive
infectious disease testing detected C. felis via microscopy and poly-
merase chain reaction (PCR). Atovaquone (15 mg/kg PO
q8 h 9 10 days) and azithromycin (10 mg/kg PO q24 h 9 10 days)
treatment were administered and the PCV improved, but the cat
remained persistently infected with C. felis. Sequencing of the ato-
vaquone binding region of cytb over the course of infection (pre and
post-treatment samples) would reveal a transition from wild-type
(M128) to isoleucine and valine (M128I and M128V) at two and
four months post treatment. A repeat treatment course with A&A
using an increased atovaquone dose (25 mg/kg PO q8 h 9 10 days)
would fail to clear the C. felis infection and M128I and M128V
mutations persisted. The wild-type M128 cytb was not detected in
post-treatment samples up to 210 days.
This is the ﬁrst documentation of resistance of C. felis to ato-
vaquone associated with M128 cytb mutations. Additionally, this
carrier cat appears to be the ﬁrst chronically C. felis-infected felid
with persistent anemia. This case suggests that parasites with
mutations of cytb M128 can be selected and impart resistance to
A&A treatment even in the face of increased atovaquone dosing.
Disclosures: No disclosures to report.
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LETHAL POX DISEASE IN A CAT: CLASSICAL COWPOX
OR NOVEL ORTHOPOXVIRUS INFECTION?. N. Decaro1, G.
Dowgier1, F. Albanese2, G. Lanave1, E. Brogi3, A. Parisi4, M.
Losurdo1, M.L. Colaianni4, A. Lavazza5, V. Martella1, C. Buon-
avoglia1. 1University of Bari, Valenzano, Italy, 2Laboratorio Anal-
isi La Vallonea, Aradeo LE, Italy, 3Centro Veterinario
Montarioso, Siena, Italy, 4Istituto Zooproﬁlattico Serimentale di
Puglia e Basilicata, Putignano, Italy, 5Istituto Zooproﬁlattico Seri-
mentale di Lombardia ed Emilia Romagna, Brescia, Italy
Orthopoxvirus (OPXV) is a genus of the family Poxviridae, sub-
family Chordopoxvirinae, that includes several viruses infecting
humans and animals. Among these are Ectromelia virus (ECTV),
which infects only mice, and Cowpox virus (CPXV), which recog-
nizes wild rodents as reservoirs, while several species, including
humans and cats, are considered incidental hosts. Here, we report
a case of lethal infection in a cat that was caused by a putative
novel OPXV displaying an intermediate position between CPXV
and ECTV at the genomic level.
The cat, a European 6-month-old male, was presented with
wide alopecic and erythematous areas on the face and paws. After
few days the skin lesions spread to other areas of the body and
ulcers appeared on the tongue and palate. After the diagnosis of
OPXV infection, the cat was treated with antivirals (famciclovir
and subsequently aciclovir), but after an initial improvement the
animal rapidly worsened and was euthanized.
Bioptic samples, collected intra-vitam from the skin lesions, were
processed for histologic and virological investigations. By
histopathology, leukocyte inﬁltration and eosinophilic cytoplasmic
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inclusion bodies were evident in the skin punches. Diﬀerent PCR
approaches for detection and characterization of poxviruses showed
that the collected samples contained a poxvirus, but they were
unable to assign deﬁnitively the virus to a species within the genus
Orthopoxvirus. The OPXV strain, Italy-09/17, was isolated on Afri-
can green monkey kidney CV-1 cells and also on embryonated eggs,
as demonstrated by the development of the typical pocks in the
chorioallantoic membrane. A large amount of typical brick-shaped
virions, approximately 320 9 240 nm in size, morphologically
related to the genus Orthopoxvirus, were observed by negative stain-
ing electron microscopy. The nearly full-length genome of the virus
was obtained through a next-generation sequencing approach car-
ried out on the isolated virus. By sequence and phylogenetic analysis
of selected genomic regions, which are commonly used to classify
OPXVs, isolate Italy-09/17 was proven to form a separate cluster
from both CPXV and ECTV. Extensive epidemiological surveillance
in cats and wild animals, including rodents, will assess whether this
feline OPXV circulates in domestic cat populations and whether cats
are incidental hosts or represent the main reservoir of the virus.
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The dissemination of ESBL and Carbapenemase producing Kleb-
siella pneumoniae is a worldwide concern. Multidrug-resistant
(MDR) K. pneumoniae UTIs in companion animals raise great
concerns regarding their role as reservoirs and in the spread of
such bacteria. The aim of this study was to evaluate the within-
household sharing of ESBL-producing MDR K. pneumoniae from
a UTI infected cat.
Antimicrobial susceptibility testing of the uropathogenic bacte-
ria was conducted by microdilution methods according to CLSI
and screening for the presence of CTX-M ESBL was performed
by PCR and sequencing. Fecal samples from the infected cat
(ICat) and co-habiting pets (Cat-1, Dog-1, Dog-2) were collected
for detection and quantiﬁcation of colonization by the infection K.
pneumoniae strain. Environment swabs from the animals food/wa-
ter bowls and bedding were also collected. Samples were serially
diluted and cultured in MacConkey agar plates containing 1.5 lg/
mL cefotaxime (CTX). Negative samples were grown in enrich-
ment media prior to plating to detect low levels of colonization.
When positive, up to ﬁve K. pneumoniae colonies were obtained
for further analysis. Unique clones were resolved by PFGE-XbaI
macro-restriction using Dice/UPGMA clustering analysis.
A cat with history of urolithiases underwent a subcutaneous
ureteral bypass system (SUB) implantation. During SUB mainte-
nance a UTI by K. pneumoniae was diagnosed. The K. pneumoniae
was a CTX-M-15 producer with MDR phenotype. Fecal samples
from the infected cat (ICat) were positive for CTX-resistant K.
pneumoniae. Samples from Dog-1 and Dog-2 prior and after ICat
treatment were all negative, thus no colonization was detected.
Regarding Cat-1, only one sample collection was possible (during
ICat treatment), yet it revealed a high fecal burden of CTX-resis-
tant E. coli and K. pneumoniae. PFGE-XbaI analysis showed a
similarity index of 100% between CTX-resistant K. pneumoniae
from Cat-1 feces and K. pneumoniae from ICat urine, thus proving
the colonization/transfer. Furthermore, 100% similar CTX-resis-
tant K. pneumoniae was also detected from the cats bedding.
To our best knowledge this is the ﬁrst study reporting the sharing
of MDR K. pneumoniae between infected and healthy pets from the
same household. Same-species transfer of MDR K. pneumoniae was
likely due to sharing of litterbox and bedding, thus special control
measures should be implemented in these environments. The high
colonization with 3GCr Enterobacteriaceae of the co-habiting
healthy cat further increases the spread of MDR K. pneumoniae.
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The assessment of liver ﬁbrosis is of major importance for treat-
ment and prognosis of canine chronic liver diseases. A panel of
blood scores are currently used in human medicine and combine
several biochemical parameters in proprietary algorithms. These
tests help the clinician to stage and monitor liver diseases, thereby
decreasing the need for liver biopsy.
We already built a blood score using a training set of 58 dogs.
This score uses alanine aminotransferase, alkaline phosphatase,
total bilirubin, potassium, and gamma glutamyl transferase. This
blood score had a sensitivity and speciﬁcity of 81% and 68 %,
respectively (AUROC [95% CI] = 0.80 [0.67–0.92]).
The aim of the present study was to validate the blood score
performance in a new population.
Following Ethical committee approval and informed owner
consent, client-owned dogs ≥ 2 years old that underwent liver
biopsy to investigate abnormal liver enzyme activity were
included. Exclusion criteria were: focal liver lesion and/or extra-
hepatic cholestasis on abdominal ultrasound, previous medica-
tions or extrahepatic comorbid diseases that could have inﬂuence
liver enzymes activity, or diagnosis of neoplasia on histologic
examination.
Fasting blood sample were collected on the day of liver biopsy.
Liver ﬁbrosis was evaluated according to the criteria of the World
Small Animal Veterinary Association guidelines on canine liver
pathology. Dogs were classiﬁed as follow: no or only portal ﬁbro-
sis (group 1) and bridging ﬁbrosis or cirrhosis (group 2).
Thirty-eight dogs were recruited (53 % female, 47 % male): 20
in group 1 and 18 in group 2.
In this validation population, the blood score discriminates dogs
with signiﬁcant ﬁbrosis, with an AUROC curve of 0.83 [0.69–0.96]
(sensitivity 83 %, speciﬁcity 70 %) versus 0.68 [0.50–0.86] for ALT
and 0.59 [0.41–0.78] for ALKP.
The validation protocol demonstrated similar performances
between the training and the validation population. The blood
score developed in this study was designed to help clinicians to
screen for dogs with liver ﬁbrosis in order to guide further investi-
gations. This test provides accurate and reliable results in a fast,
simple and cost-eﬀective manner. An external validation protocol
is needed for further assessment of the robustness of the test.
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Increased serum bile acids (SBA) can be expected with hepatic, bil-
iary or portal disorders that limit hepatic portal blood ﬂow or
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hepatocellular uptake. Best clinicopathologic tests detecting those
disorders remain controversial.
Results of paired SBA (pre- and 2-h post-feeding) were retro-
spectively reviewed from samples obtained from animals undergo-
ing bile acid(BA) testing because of suspected liver disease from
two Veterinary Hospitals. The aim was to determine the frequency
of altered values of fasting, post-prandial and paired SBA, to eval-
uate if the clinical approach would be diﬀerent depending on the
selected test. SBA were sent oﬀ to an outside laboratory (Idexx
Barcelona) and measured by spectrophotometry with normal fast-
ing value <10 lmol/L (a diﬀerent cut-oﬀ of 25 lmol/L was also
evaluated) and postprandial value <25 lmol/L.
The study included 484 samples from 392 dogs and 12 cats (178
females and 226 males). Median age was 5.4 years (0.17–13).
Three feline breeds and 60 canine breeds were included.
Two-hundred ﬁfty-two paired SBA tests were considered as
abnormal; among them, 175(69.4%) fasting samples showed values
>10 lmol/L (70 samples were 10–25 lmol and 105 samples were
>25 lmol/L) and 201(79.8%) postprandial samples were
>25 lmol/L. In 131 tests (52.4%) only one BA value was altered;
abnormal value was detected only with fasting value in 51 tests
(20.4%) and only with postprandial value in 80 tests (32%). In
121 patients (48.4%) both fasting and postprandial values were
increased. Among 70 animals with fasting value in 10–25 range, 37
had increased postprandial value. In 380 tests fasting value was
lower than postprandial value, but 101 tests showed higher fasting
BA value.
Some authors have recently suggested that fasting BA can be a
useful screening test (Straten 2015), but this study corroborates the
higher value of paired SBA for this purpose, previously conﬁrmed
by others (Center 2011). If only fasting BA had been performed,
and a higher cut oﬀ had been selected (<20–25 lmol/L) as sug-
gested by some authors, 52.8% of cases with fasting values in 10–
25 range and abnormal postprandial values would have been
missed: therefore, normal fasting value <10 lmol/L seems appro-
priate. Moreover, post-prandial values were increased more often
than fasting values; therefore, if just one BA can be performed,
post-feeding could be the preferred test.
Fasting value exceeding the postprandial sample can occur, as
shown in 1 out of 5 tests of this study. Although spontaneous gall
bladder contraction may be responsible for it, if any value is
abnormal an hepatic abnormality is suggested (Lawrence 2017).
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